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I. Introduction 
A. General introduction 
The mucosal immune system in the female reproductive tract has evolved to meet 
the unique requirements of dealing with sexually transmitted bacterial and viral 
pathogens, allogeneic spermatozoa, and the immunologically distinct fetus. 
Despite years of immunologic investigation, the mechanisms that regulate this 
mucosal immune system in the human reproductive tract have received only little 
attention. This is due to the complexities of the immune and endocrine system and 
also to the difficulties of conducting experiments in this field. 
During the last years there has also been an increasing awareness of the need for 
further investigation of this area due to the continuously rising prevalence of 
sexually transmitted diseases (STDs), among them the pandemics caused by the 
human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). 
Also in another field of gynecology and obstetrics, the reproductive medicine, the 
knowledge of immunological mechanisms and disturbances has gained growing 
attention. 
However, recent progress in the field of genital tract immunology has shed light on 
some of the mechanistically most important functions of this immune system. Most 
importantly, we are beginning to understand how immune responses should best 
be stimulated at the genital tract mucosal level. On the basis of this information, 
the attempt to construct new mucosal vaccines specifically targeted to the genital 
tract is one of the ambitious goals of research in this field. 
B. Methods and goals of this study 
The objective of this work was to systematically review and discuss recent studies 
and articles dealing with the subject of the immunology of female genital tract 
tissue. 
To this purpose, a computerized search of PubMed databases was first performed 
on general terms such as “immunology of genital tract”, “mucosal immunology”, 
“mucosal immunity”, or “immunology in gynecology”. On the basis of references of 
these newer articles, other studies or older literature could be found as well.  
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To further explore studies on this topic, the comprehensive database of medical 
magazines (DocumentWeb) of the Ludwig-Maximilians-Universität München was 
used. Archives of relevant magazines dealing with immunology and/or gynecology 
were searched with the help of these general terms again. 
 
Particular attention was then given on a more specialized computerized search 
concerning the chapters on immunology of genital tract infections and immunology 
of reproductive medicine by using more defined keywords. 
 
Besides research via internet databases, I have used public institutions and 
libraries such as the Bayerische Staatsbibliothek München, Medizinische 
Universitätsbibliothek München Großhadern and the Deutsche Zentralbibliothek 
für Medizin Köln. 
 
After giving a brief introduction on the basic principles of human innate and 
specific immunity, and further of mucosal immunology, the overall goal of the first 
chapter is to define the mucosal immune system in the female reproductive tract. 
The focus is thereby to identify what is known about humoral and cellular factors of 
this particular mucosal immune system and to define the regulatory influences by 
sex hormones and cytokines. The unique immunologic characteristics of the female 
genital tract are then considered in respect to the design of mucosal vaccines for 
the protection against microbial disease.  
 
The second chapter deals with the most important infections of the female genital 
tract and describes the latest results on innate and adaptive immune responses 
and vaccine development for each infection. 
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These are the following: 
 
Viral infections 
Herpes simplex virus (HSV) 
Human immunodeficiency virus (HIV) 
Human papillomavirus (HPV) 
Bacterial infections 
Neisseria gonorrheae 
Chlamydia trachomatis 
Bacterial Vaginosis (BV) 
Mycoses 
Candida albicans 
Parasites 
Trichomonas vaginalis 
 
 
The third chapter then reports on different important fields of immunology in 
reproductive medicine. After describing immunologic principles at the fetomaternal 
interface during normal pregnancy and labor, another emphasis lies on different 
disturbances in maternal-fetal interactions and their immunologic background. 
These are: 
 
Preeclampsia 
Preterm labor/preterm birth 
Fetal growth retardation 
Early pregnancy loss 
 
 
Furthermore, the topic of infertility is further elucidated from an immunological 
point of view. The remarks on latest developments on immunocontraception 
conclude this chapter. 
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II. Immunology of the genital tract 
A. Fundamentals of immunology 
1. Concepts of innate and specific immunity 
The term immunity derives from the Latin word immunitas which stands for the 
privilege of the Roman senators to be protected from legal punishment or exempted 
from certain public duties (1). At all times immunity has been described as the 
protection against illness, especially infectious illness. In modern times immunity is 
more exactly defined as reaction of the body against unknown substances and the 
capability to distinguish infectious nonself and non-infectious self. 
 
The immune system has evolved to provide appropriate defense systems at various 
levels of innate or unspecific and acquired or specific immune responses (578). 
Innate immunity is the ancient part of the host defense mechanisms and lies 
behind most inflammatory responses. Acquired immunity can provide specific 
recognition of foreign antigens, an immunological memory of infection and 
pathogen-specific adaptor proteins. However, the adaptive immune response is also 
responsible for allergy, autoimmunity and the rejection of tissue grafts. 
 
In most cases, components of both systems interact to create an appropriate 
immune response to an infectious agent. But it is not only the protection from 
penetration by foreign or modified cells but also the elimination of old and deficient 
cells which characterizes a functioning immune system. 
a) The innate immune response to infectious agents 
Recognized as the first line of defense, innate immunity consists of different 
mechanisms which are already available before exposition with pathogens or 
unknown molecules and do not need prior activation or induction. Innate immune 
responses do not change in type or magnitude if there is more than one encounter 
with the same antigen and differences between unknown substances cannot be 
distinguished (302). In the following, a short overview of the different factors of 
innate immunity is given ( Table 1). 
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Mechanical and chemical barriers 
Skin, mucosal surfaces 
Enzymes (lysozyme), peptides (defensins), fatty acids, acidic pH, etc. 
Cellular factors 
Mononuclear phagocytes (blood monocytes/tissue macrophages) 
Granulocytes 
Dendritic cells 
Mast cells 
Natural killer cells 
Humoral factors 
Complement 
Acute-phase proteins 
Interferons 
 Table 1: Factors of the innate immune system 
Preventing microorganisms from gaining access to the body is achieved by 
mechanical barriers such as skin and surface epithelia (1019). These are also 
equipped with additional chemical features including fatty acids in the skin, low pH 
in the stomach or antibacterial enzymes in saliva, for example. Once the pathogen 
has crossed the epithelial barrier, cellular effector mechanisms involving 
granulocytes and mononuclear phagocytes are activated to eliminate the intruder 
by phagocytosis (1213).  
 
To recognize foreign structures that are not normally found in the host, the innate 
immune system relies on conserved germline-encoded receptors that recognize 
conserved pathogen-associated molecular patterns (PAMPs) found in groups of 
microorganisms (615). These are conserved products of microbial metabolism 
produced by microbial pathogens but not by the host, such as lipopolysaccharide 
(LPS) in the outer membrane of gram-negative bacteria. Recognition of these 
molecular structures allows the immune system to distinguish infectious nonself 
from non-infectious self (615, 909). 
 
Among receptors for PAMPs which are expressed on cells of the innate immune 
system, Toll-like receptors (TLRs) are of particular importance. Signaling through 
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TLRs in response to PAMPs leads to recruitment of other immune cells and 
production of antimicrobial factors that kill invading microbes as well as link innate 
and acquired immunity (16). Studies have found ten different subtypes of 
mammalian TLRs spread on the surface of different immune cells (534). 
Among the cells that bear innate immune or germline-encoded recognition are 
mononuclear phagocytes, dendritic cells (DCs), mast cells, granulocytes, and 
natural killer (NK) cells (615).  
(1) Cellular factors   
Phagocytic cells are located at strategically important spots in the organism (
 Table 2) and are all derived from pluripotent stem cells of the bone marrow.  
 
Localisation Phagocytic cells 
Blood 
Monocytes 
Neutrophils (Eosinophils, Basophils) 
Lung Alveolar macrophages 
Liver Kupffer cells 
Brain Microglia 
Bone Osteoclasts 
Kidney Mesangial cells in glomeruli 
Joint Synovia-A-cells 
 Table 2: Localisation of phagocytic cells 
Monocytes circulating in blood vessels and macrophages in other tissues like lung, 
liver and lymph nodes as well as granulocytes are capable of killing 
microorganisms. After activation by cytokines, especially interferon-γ (IFN-γ), 
macrophages produce toxic effector molecules as reactive oxygen intermediates 
(ROI) and reactive nitrogen intermediates (RNI) which are interactively able to kill 
the pathogen. RNI have proved to be the most effective defense mechanism in 
murine macrophages but also an increasing amount of studies supports RNI 
production of human macrophages (667). Lysosomal enzymes within the 
phagosome or depletion of intraphagosomal iron function as other mechanisms of 
phagocytic cells to kill intracellular pathogens (412, 817).  
 
The group of granulocytes consists of neutrophils, eosinophils and basophils but 
the uptake and intracellular killing of microorganisms is in the first place the task 
 Immunology of the genital tract 
 II-7  
of neutrophils. By expriming Fc receptors for immunoglobulin (Ig) G (CD16) and 
receptors for activated complement factors (C3b), neutrophils can phagocyte 
pathogens coated by antibodies or complement factors (1266). Neutrophils are able 
to release azurophil granule with myeloperoxidase and lysozyme, specific granule 
with lactoferrin or alkaline phosphatase as well as superoxid radicals, which leads 
to an inflammatory reaction of tissue (1266).  
Extracellular killing of large parasites such as helminths is performed by 
eosinophils. They also provide surface receptors for complement factor C3b and 
release their granule with major basic protein (MBP), cationic protein and anti-
inflammatory enzymes (1213).  
Basophils play an important role in allergic reactions and in immune responses 
against parasites where they release mediators such as histamine or heparine and 
chemotactic factors and therefore cause an anaphylactic reaction. They have 
surface receptors for both IgE and activated complement factors C3a and C5a 
(1266). 
 
Other cellular components of the innate immunity are NK cells which are large 
granular lymphocytes making out 5-10% of the peripheral lymphocytes in the blood 
(1266). They exprime surface receptors for IgG (CD16) as well as T cell markers 
such as CD8 and are able to mediate antibody-dependent cellular cytotoxicity 
(ADCC). Thereby, they are able to destroy target cells such as cancer or virus-
infected cells by binding these antibody-loaded cells to the Fc receptor of NK cells 
via the Fc region of the antibody (1266).  
(2) Humoral factors 
The complement system is a multicomponent triggered enzyme cascade (Figure 1) 
and is used to attract phagocytic cells to the pathogens. 
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                 Classical complement pathway          Alternative complement pathway 
                     Antigen-antibody-complex                       Surface of pathogens     
    ↓                                                            ↓ 
      C1                                                          D 
       ↓ ↓ 
      C4 C3 
       ↓ ↓ 
      C2 B 
                                                          C3-Convertase 
                                                                                    
                                      C3b       C3a, C4a, C5a 
                                                                                                       ↓ 
         Membrane attack        Binding to receptors                    Phagocytes 
              complex                     on phagocytes      
                    ↓                                     ↓ 
               C5 – C9                    Opsonization of 
                    ↓                              pathogens 
         Osmotic cell lysis 
Figure 1: Components and effector mechanisms of the complement system (616) 
Complement activation can start via the classical pathway with Igs in complex with 
antigens binding to complement protein C1. As it requires the presence of specific 
antibodies this way is delayed upon microbial infection (177). The alternative 
pathway beginning with the binding of complement factor C3b on different activated 
bacterial surfaces is initiated in the absence of antibodies and therefore is the more 
important one among the humoral mechanisms of the innate immune system (667). 
Both ways lead to the splitting and activation of factor C3 whose activated 
fragments enable the opsonization of antigens or bacteria surfaces. The terminal 
components C5-C9 form a membrane attack complex (1213) which enables the 
osmotic lysis of the pathogen. 
 
Other humoral factors of the innate immune system involve IFNs and acute-phase 
proteins (1266). IFN-α produced by leukocytes and IFN-β synthesized by fibroblasts 
and other cell types block viral replication in virus-infected cells. C-reactive protein 
as the most common representative of acute-phase proteins promotes the binding of 
complement to bacteria and facilitates their phagocytosis. 
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b) Specific acquired immunity 
If the intruding microorganism cannot be eliminated by the effector mechanisms of 
the innate immune system mentioned above, the components of the specific or 
adaptive immune system are activated. Specific immunity is characterized by an 
adaptation to the first reaction to an antigen (1213). The following responses to the 
same antigen are specific and quantitatively and qualitatively different from the 
primary response. This specificity is achieved through usage of clonally distributed 
antigen receptors, i.e. surface Ig on antibody-producing B lymphocytes and T cell 
receptors (TCR) on the surface of T lymphocytes. Another feature of the adaptive 
immune system is that it develops memory which allows a faster response of 
specific effector cells when encountering the relevant antigen a second time (667). 
 
Responding to antigens is either realized by producing specific antibodies (humoral 
immunity) or direct specific lymphocyte contact with host cells expressing foreign 
antigenic peptides (cell-mediated immunity). The cell-mediated response needs the 
cooperation of different subclasses of T cells, macrophages and perhaps NK cells. 
Humoral responses involve the interaction of B cells, T cells and antigen-presenting 
cells (APCs) (302). 
(1) The major histocompatibility complex (MHC) 
T and B lymphocytes need a system to be able to distinguish between “self” and 
“nonself”, which is done by the MHC (1482). This group of genes encodes for several 
proteins, also called human leukocyte antigens (HLA) (Table 3). MHC class I 
molecules, which include HLA-A, HLA-B and HLA-C, are being expressed by all 
nucleated cells whereas MHC class II molecules including HLA-DR, HLA-DP and 
HLA-DQ are being expressed by APCs, B and T cells (1266). 
 
MHC class Ia HLA-A, HLA-B, HLA-C 
MHC class Ib HLA-E, HLA-F, HLA-G 
MHC class II HLA-DP, HLA-DQ, HLA-DR 
MHC class III Complement components, TNF-α, TNF-β 
 Table 3: MHC classes with examples for encoding proteins 
 
 Immunology of the genital tract 
 II-10  
(2) B lymphocytes 
After the process of B cell differentiation in bone marrow each mature B cell bears a 
surface receptor, an Ig, which is different in its antigen specificity from all other B 
cells. These mature but naïve B cells circulate in the blood, lymph and secondary 
lymphoid organs waiting to encounter antigen. By interaction with antigen, B cells 
produce and secrete large amounts of antigen-specific memory B cells and effector 
plasma cells which generate large amounts of soluble but otherwise identical 
versions of the membrane-bound Ig (1). 
 
This clonal selection hypothesis (1387) explains why following responses to the 
same antigen are more effective and longlasting as in the initial response (302). In 
the first encounter with antigen, a primary antibody response is generated; later, a 
re-encounter with the same antigen causes a more rapid secondary response, 
producing high levels of antibodies with a high binding affinity for the target 
antigen. This process is also exploited in prophylactic vaccination. 
 
Characteristic for the primary immune response are primarily IgM class antibodies 
whereas the secondary and all subsequent responses to the same antigen may be of 
the IgG, IgE or IgA subclasses, depending on the location (302). Proliferation and 
differentiation of B cells as well as the Ig isotype class switching are driven by 
cytokines, especially by interleukins (IL)-4 and -5 (1266). The differences between 
the Ig subclasses shows Table 4. 
In addition to their unique role as antibody-producing plasma cells, B cells have the 
capacity to present antigen to T lymphocytes. Upon binding of antigen to 
membrane-bound Ig, antigen-antibody complexes are internalized and degraded. 
Antigen-derived peptides are then introduced to MHC-II-dependent pathways and 
can be presented to peptide-specific CD4+ T cells (1482) 
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 IgG IgA IgM IgD IgE 
Form Monomer 
Monomer 
Dimer 
Pentamer 
Hexamer 
Monomer Monomer 
Subclasses G1,G2,G3,G4 A1,A2 ― ― ― 
Percent of  
Ig 
75-85 7-15 5-10 0,3 0,019 
Binds to 
Macrophages 
NK cells 
Neutrophils 
 
Lymphocytes 
 
Lymphocytes ― 
Mast cells 
Basophils 
B cells 
Complement 
fixation 
Classical Alternative Classical ― ― 
Cross 
Placenta 
Yes ― ― ― ― 
Table 4: The different classes of immunoglobulins  
(3) T lymphocytes 
In contrast, T cells only recognize antigen when it is presented by appropriate MHC 
molecules on APC such as DCs or macrophages (667). 
During their differentiation in thymus, T lymphocytes learn to recognize MHC 
molecules and develop the cluster of differentiation (CD) 4 and 8 surface receptors 
which mark them as CD4+ T helper cells or CD8+ cytotoxic T cells (CTL). 
Antigenic peptides presented to T cells by MHC class I molecules stimulate the 
CD8+ T cells whose primary function is to destroy intracellular pathogens. Peptides 
presented by MHC class II molecules stimulate the CD4+ T cells which are able to 
eliminate both intracellular and extracellular pathogens. They produce various 
cytokines required for the activation of leukocytes and are therefore also termed T 
helper (Th) cells (667). 
 
Activation of T cells requires signaling mediated through both the TCR and 
costimulatory receptor-ligand interactions which involve the costimulatory 
molecules CD80 (B7.1) and CD86 (B7.2) on APCs (667). These can bind to T cell 
surface molecule CD28 and CD125 (CTLA-4). 
 
As CD4+ Th cells produce different cytokines upon antigenic stimulation to activate 
B cells and macrophages, they can be divided into the two subpopulations of Th1 
and Th2 cells (977). Th1 cells are characterized by secretion of INF-γ and IL-2, 
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whereas Th2 cells produce IL-4, IL-5 and IL-10 (977). Th2 cells are therefore 
important for the induction of humoral immune responses by controlling B cell 
activation while Th1 cells initiate cell-mediated immune responses by activating 
macrophages by IFN-γ and CD8+ T cells by IL-2 (667, Table 5). The differentiation of 
these subsets from Th0 precursor cells is driven by cytokines, especially by IL-
12/IL-18 and IL-4, respectively (667). 
 
 Th0 
                                      IL-12/IL-18                IL-4/IL-10 
       
     Th1        Th2 
 IFN-γ/IL-4 
 
 IL-2  IL-4 
 IFN-γ  IL-6 
 TNF-α  IL-10 
                Cell-mediated immunity                            Humoral immunity 
 
 Activation of cytotoxic T cells → 
Protection against viruses 
 Macrophage activation → Protection 
against intracellular microbes 
 Ig class switch to IgG (complement 
activation/opsonization) → 
Protection against extracellular 
microbes 
 Th1 activation → Protection against 
all microbes and viruses 
 B cell maturation → Protection 
against extracellular microbes, 
virions and helminths 
 Ig class switch to IgE (mast cell, 
basophil, eosinophil) → Protection 
against helminths 
 Ig class switch to IgG (neutralization) 
→ Protection against virions, toxins 
 Ig class switch to IgA (mucosa) → 
Protection against many pathogens 
 Eosinophil activation → Protection 
against helminths 
Table 5: The role of Th1 and Th2 cells in immunity, adapted from Kaufmann et al. 
(667) 
A third category of T cells, regulatory T cells (Tregs) with the phenotype 
CD4+CD25+, usually secretes IL-10 and tumor growth factor-β (TGF-β). Cells with 
this phenotype are thought to recognize self-antigens and function to prevent 
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autoimmunity, but they also regulate responses to exogenous antigens, and have 
been implicated in chronic and immunopathologic viral infections (1220). 
 
CTLs are able to eliminate virus-infected cells or tumor cells by lysis or apoptosis 
(1266). Cytotoxicity is mediated by pore-forming proteins (perforins) and enzymes 
(granzymes) that perforate the target cell. CTLs can also trigger apoptosis, i.e. 
programmed cell death, in target cells through receptor-ligand interaction (667). 
Upon activation, CTLs are induced to express Fas-ligand (FasL) which interacts 
with the corresponding receptor Fas expressed on virus-infected target cells. 
 
The division of the immune system into innate and specific immunity (Table 6) does 
not mean the strict separation of both when encountering pathogens. Instead, it is 
required that both systems closely cooperate and that components of both activate 
each other. Over the recent years, it has become increasingly clear that the two 
systems cannot be seen separately and that the innate immune system is even 
instrumental for the development of the adaptive immune response.  
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 Innate immune system Adaptive immune system 
General 
characteristics 
First line of defense 
No specificity and no 
adaptation following antigen 
exposure 
Specific recognition of 
foreign antigens 
Immunological memory 
Responsible for allergy, 
autoimmunity, rejection of 
tissue grafts 
Physical and chemical 
barriers 
Skin 
Mucosal membranes 
Immune systems of skin and 
mucosal membranes 
Antibodies in secretions 
Circulating molecules Complement Antibodies 
Cellular factors 
Macrophages/Monocytes 
Granulocytes 
Natural killer cells 
Lymphocytes 
Soluble mediators 
effective on other cells 
Cytokines like 
α- and β-interferons, 
tumor necrosis factor 
(derived from macrophages) 
Cytokines like 
γ-interferons 
(derived from lymphocytes) 
Receptors 
Genes encoded in germline 
DNA, no gene rearrangement 
Encoded in gene segments 
Rearrangement necessary 
Recognition 
Conserved molecular patterns 
(PAMPs) 
Details of molecular 
structure (proteins, peptides) 
Self-Nonself 
discrimination 
Perfect (selected over 
evolutionary time) 
Not perfect (selected in 
individual somatic cells) 
Response  
Immediate activation of 
effectors 
Delayed activation of 
effectors 
Table 6: The concepts of innate and specific acquired immunity, adapted from 
Janeway and Travers (616) 
2. Mucosal immunology 
The immune system can be divided into two compartments that display 
considerable functional independence; on the one hand, the systemic compartment 
represented by the bone marrow, spleen, and lymph nodes, and on the other hand, 
the mucosal compartment, represented by lymphoid tissues in mucosae and 
external secretory glands. Numbers and types of cells involved in immune 
responses and their soluble products, primarily antibodies, are remarkably different 
in the mucosal and systemic compartments of the immune system, which should 
be further elucidated here. 
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A particular immune system of mucosal surfaces in humans was first presumed 
during the times of Paul Ehrlich in the 19th century (1266). Further anatomical and 
biological studies of a common mucosa-associated immune system go back to the 
seventies where Tomasi started to describe the function of secretory (S)-IgA and 
cellular immune mechanisms of a common mucosal immune system as 
components of mucosa-associated immune system (1423).  
 
Several hundred square meters comprise the surface areas of mucosal membranes 
where antigens from ingested food or inhaled air and resident pathogens represent 
the most important exogenous stimulants (762). Due to the high antigen load of 
mucosal surfaces the mucosal immune system exhibits immunologic 
hyporesponsiveness or unresponsiveness to most antigens, on the other hand, it 
must also be capable of inducing effective cell-mediated and antibody-mediated 
immune responses towards selected antigens. To meet this task, mucosal surfaces 
possess a unique immune system that tightly controls the balance between 
responsiveness and non-responsiveness (tolerance). Besides mechanical barriers, 
humoral factors such as lysozyme, peroxidase and specific antibodies as well as 
cellular mechanisms contribute to the protection of mucosal surfaces (Table 7). 
 
Mechanical barriers and peristalsis 
Desquamation of epithelial cells with attached microorganisms 
Humoral factors: Mucin, acids, lysozyme, lactoferrin, peroxidase system 
antimicrobial proteins, interferon-α, complement 
Specific antibodies: IgA>>IgG>IgM 
Cellular factors: Phagocytic cells, T cells, NK cells 
Table 7: Protection of mucosal surfaces, adapted from Kutteh and Mestecky (762) 
Immune responses generated by organized lymphoid structures in the mucosa-
associated lymphoreticular tissue (MALT) result in the development of B cells 
capable of producing antigen-specific Igs that can reach the draining lymph nodes 
and other mucosal tissues where they differentiate into plasma cells (1018). A 
second major outcome of the entry of antigen and antigen presentation by DCs is 
the activation and differentiation of T cells that can subsequently migrate out of the 
MALT and reach mucosal as well as peripheral non-mucosal tissues.  
 
The mucosal immune system is structurally and functionally divided into sites for 
antigen uptake and processing at inductive sites on the one hand, and effector sites 
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engaging lymphocytes, granulocytes and mast cells on the other hand (1018). 
Besides the nasal-asssociated lymphoreticular tissue (NALT), the gut-associated 
lymphoreticular tissue (GALT) is the prototype of MALT and posesses APCs, T 
lymphocytes and IgA-committed B cells. 
a) S-IgA as the major Ig subclass in the mucosal immune system 
Igs of all isotypes have been detected in various human external secretions. The 
predominant Ig isotype in normal human serum is IgG, followed by IgA and IgM. In 
contrast to serum, the major isotype in human excretions such as saliva, tears, 
bile, urine and milk is IgA (762). 
IgA is the most important subclass of Igs that can actively and efficiently be 
secreted through epithelia (1). Due to the size of mucosal surfaces the total amount 
of daily IgA production was quantified by 66mg/kg body weight, which is more than 
twice the rate of IgG (247). Approximately 1500mg/day IgA are produced 
systemically in bone marrow, lymph nodes or spleen but twice as much IgA is 
released in the mucosal immune system. 
 
Most of the serum-IgA is found in a monomeric form with two heavy and two light 
chains whereas S-IgA is mainly polymeric with presence of a J chain and the so-
called secretory component (SC). IgA is produced by plasma cells in the lamina 
propria and combined with the SC, a glycoprotein expressed on the surface of 
mucosal epithelial cells (ECs). This protein then handles the active transport of 
polymeric IgA into the intestinal lumen where IgA is released by proteolytic cleavage 
again (1). Investigations concerning the origin of S-IgA have demonstrated that it is 
produced locally at the mucosal sites and is not derived to a significant degree from 
the circulation (764). 
 
The two different molecular forms also show different effector functions, which is 
illustrated in Table 8. 
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 Secretory-IgA Serum IgA 
Molecular form polymeric monomeric 
Subclass IgA1 ≥ IgA2 IgA1 >>>  IgA2 
SC-mediated transport into secretions Yes No 
J-chain expression Yes Mostly no 
Origin of precursor cells 
Bone marrow, no 
circulation 
Peyer`s 
patches, IgA 
cells in 
circulation 
Neutralization of antigens Yes Yes 
Inhibition of bacterial adherence Yes ? 
Loss of bacterial plasmid Yes ? 
Inhibition from antigen uptake from mucosa  Yes No 
Enhancement of innate factors Yes Yes (?) 
Suppression of inflammatory effects  
(phagocytosis, lysis, NK cell activity etc) 
Yes Yes 
Table 8: Effector functions of secretory and serum IgA (762) 
IgA can also be divided into two subclasses IgA1 and IgA2 which differ in primary 
structure, carbohydrate composition and their sensitiveness to bacterial proteases. 
Neisseria gonorrhoeae, for instance, is evidently a producer of IgA protease which 
constitutes its most important virulent factor.  
In serum, the monomeric IgA1 predominates over IgA2 whereas in external 
secrections almost exclusively polymeric forms of approximately equal proportions 
of IgA1 and IgA2 are found (925). Furthermore, specific antibodies to viral antigens, 
including HIV, are often found in the IgA1 subclass, whereas IgA2 antibodies in 
external secretions are associated with specificity for common structural microbial 
antigens as LPS and lipoteichoic acid (922).  
b) Inductive sites of the mucosal immune system, in the example of 
the GALT 
The primary inductive sites for mucosal immune responses are organized lymphoid 
aggregates such as Peyer`s patches placed in the wall of the intestine or tonsils in 
the upper respiratory tract. The Peyer`s patches of the GALT consist of a follicle-
associated epithelium with specialized ECs known as membranous epithelial (M) 
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cells, a subepithelial dome overlying B cell follicles, and interfollicular regions 
enriched in T cells (1528, Figure 2).  
Following ingestion, antigens and microorganisms are transported from the gut 
lumen to the dome region through specialized M cells (237) where they encounter 
APCs such as DCs leading to cognate interactions between APCs and T cells. DCs 
can also migrate to the interfollicular regions which are enriched with T cells and 
containing high endothelial venules (HEV) and efferent lymphatics to initiate 
immune responses upon antigen uptake. DCs as the APCs bind bacterial products 
with their TLRs, process antigen as relative immature cells and then migrate to the 
T cell region and present antigen to naïve T cells. There they have the properties of 
mature and immunogenic DCs with high surface expression of costimulatory 
molecules such as CD40, CD80, and CD86 and adhesion molecules such as CD44 
(843).  
 
Figure 2: Inductive site of the GALT, adapted from Neurath et al. (1018) 
After antigen uptake via M cells B cells are induced to switch into IgA-secreting 
cells. Following IgA switch and affinity maturation, B cells migrate from the Peyer`s 
patches to the mesenteric lymph node via efferent lymphatic vessels and finally to 
the lamina propria where they undergo terminal differentiation to plasma cells.  
Peyer`s patches are an enriched source of IgA precursor cells capable of lodging in 
the recipient`s gut as well as in other glands and mucosal tissue (762). Depending 
on the type of antigen and the duration of stimulation, ingestions of pathogens 
induce local and systemic immune responses with parallel appearance of specific S-
IgA in saliva, milk and tears, for example. The production of IgA is therefore 
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induced in lymphoid follicles such as the Peyer`s patches from where the cells 
recirculate through lymph and blood to diffusely populate other mucosal tissues 
and exocrine glands where terminal differentiation into IgA plasma cells under the 
influence of locally produced cytokines occurs.  
 
This provides the mucosal immune system with the ability to induce responses at 
sites that are distant from the immediate inductive environment, or even in different 
mucosal tissues. This has led to the concept of generalised functioning of mucosal 
tissues with some cross talk between them (857). Substantial dissemination of 
primed immune cells from GALT to exocrine effector sites beyond the gut is also the 
rationale for many desired oral vaccines. 
c) Effector sites of the mucosal immune system, in the example of 
the GALT 
Following induction in the MALT, mature lymphocytes leave the inductive sites and 
migrate to the effector sites such as the lamina propria where they can induce 
proinflammatory as well as suppressive immune responses. Effector mechanisms 
that protect mucosal surfaces include CTLs and effector CD4+ T cells for cytokine 
production and IgA response (1528).  
Lamina propria T cells are mainly CD4+ Th cells (60-70%), the majority of which 
also express the TCR, just as in peripheral blood. However, lamina propria T cells 
are in a more activated state than blood lymphocytes and have a mature or memory 
phenotype, indicated by the surface markers CD44high, CD62low, CD45RO+ (1264). 
 
Cytotoxic CD8+ T cells account for about 30-40% of T cells in the lamina propria. 
They control the level of viral infection and have a cellular memory (1266). A more 
restricted T cell population, the intraepithelial lymphocytes (IEL), mainly CD8+ T 
cells, may play a role in maintenance of epithelial integrity and in class switching to 
IgA (219, 1528). Zytologically, they are T lymphocytes but their function is 
equivalent to NK cells of the innate immunity. 
 
Besides an inflammatory phenotype T cells can adopt immunosuppressive function. 
These cells have been termed Th3 and Treg cells, and it is currently not clear if 
these cells are identical cell types or different immunoregulatory cells (537). Treg 
cells can actively inhibit activation or differentiation of other T cells and also 
 Immunology of the genital tract 
 II-20  
express the CD25 marker besides their CD4 marker (1266). Treg cells have been 
shown to produce large amounts of IL-10 and/or TGF-β and their immune-
suppressive properties are most likely explained by the ability of these cytokines to 
inhibit APC function and to mediate direct antiproliferative effects on T cells (866). 
 
Another task which is presumably done by T cells is the constant distinguishing of 
harmless antigens in food and on commensal bacteria from pathogenic microbes. 
Oral tolerance is defined as the induction of a state of systemic immune non-
responsiveness to orally administered antigen upon subsequent antigen challenge 
(1528). This mechanism seems to prevent the development of an immune reaction 
or allergy against intestinal intraluminal antigens. T cells appear to be the major 
target of tolerance and the reduction in antibody responses after antigen exposition 
are due to the reduction in T helper activity rather than to a tolerization of B cell 
directly. 
In addition to active suppression by Treg cells, tolerance is also maintained by 
deletion and anergy of T cells specific for luminal antigens (537, 1528). Deletion of 
specific T cells occurs by apoptosis whereas anergy of mucosal T cells is believed to 
be induced when cells are stimulated without proper costimulatory molecules. 
d) Cytokine regulation of the gut mucosal immune response 
The differentiation into different Th cells and Treg cells in the mucosa results in 
secretion of proinflammatory cytokines such as IFN-γ and TNF-α by Th1 cells; Th2 
cells secrete IL-4, IL-5, IL-6, IL-10, IL-13 and promote IgA expression, Th3 cells 
secrete TGF-β and Treg produce predominantly IL-10 (1266, Table 9).  
Several reports suggest that the level and type of costimulation a naïve T cell 
receives influences whether Th1 or Th2 cells develop. Further, different types of 
APCs may selectively trigger either Th1 or Th2 responses (824); however, the same 
APC cell can function equally well for inducing a Th1 or Th2 response.  
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Th 
subset 
Cytokine production Effect on IgA response 
Th1 
IL-2 
IFN-γ 
Lymphotoxin β 
Synergizes with IL-5/TGF-β → IgA synthesis 
Ig switch to IgG2a 
Development of Peyer`s patches 
Th2 
IL-4, IL-5 
IL-6 
IL-10 
Differentiation to plasma cells 
IgA synthesis 
IgA synthesis 
Th3 TGF-β IgA isotype switching 
TR1 IL-10, TGF-β 
Suppression of immune responses 
Downregulation of Th1 
Table 9: Cytokine help for the regulation of mucosal immunoglobulin response (1528) 
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B. General immunology of the genital tract 
1. Distinct features of the genital mucosal tissue 
Mucosal surfaces have evolved to handle potential pathogens against a background 
of selective physiological functions. The mucosal immune system of the female 
genital tract has developed to meet the unique requirements of dealing with the 
presence of a resident population of bacteria in the vagina with periodic exposure of 
antigens in the uterus and fallopian tubes as well as with the presence of sexually 
transmitted pathogens. It also has to balance allogenic spermatozoa and the 
longterm exposure of an immunologically distinct fetus which should also be part of 
this review later on.  
 
The lower genital tract in women is comprised of four discrete anatomical regions 
(1146): 
 The introitus, which is covered by a keratinized stratified squamous 
epithelium resembling skin 
 The vaginal mucosa, which is covered by an aglandular non-keratinized 
stratified squamous epithelium 
 The ectocervix, which is covered by a mucosal layer histological similar to 
that of the vagina 
 The endocervix, which consists of a simple columnar epithelium with 
numerous glands 
 
The transformation zone represents an abrupt transition between ectocervix and 
endocervix. The susceptibility of these regions to infectious organisms differs. The 
transformation zone is the main target of HPV infection whereas Candida albicans 
and Trichomonas vaginalis colonize the vagina, and the cervix is susceptible to 
infection by Chlamydia trachomatis and Neisseria gonorrhoea (1146).  
Among the tissues of the female reproductive tract, the upper genital tract 
consisting of the endometrium, the myometrium, the fallopian tube and the ovary 
needs to be investigated as well. These separate compartments have evolved to meet 
the different challenges and are precisely regulated by the endocrine system. 
  
The reproductive tract has various systems of defenses against the risk of infection, 
which appear complementary and synergistic. These defenses comprise non-
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immune strategies, namely passive factors such as pH, mucus, epithelial barrier on 
the one hand as well as active factors such as inflammatory reaction and secretion 
of humoral soluble factors on the other hand. Pre-immune humoral and cellular 
defense strategies are also possibly involved in rapid protection before antigenic 
stimulation. When these initial lines have been failed, a third strategy which is 
acquired and antigen-specific, occurs and associates humoral response with S-
IgA/IgM and locally produced IgG as well as cellular immune responses. The latest 
knowledge of these lines of defense should be reviewed here. 
 
Although the genital tract is considered to be a component of the mucosal immune 
system, it displays several distinct features not shared by other mucosal tissues or 
the systemic compartment. Differences include the endogenous flora, the 
predominance of IgG, hormonal fluctuations that may modify mucosal immunity, 
and the need to be tolerant to sperm and to a developing fetus but also the ability to 
respond to sexually transmitted bacterial and viral pathogens. 
 
Despite of the fact that genital and intestinal tract share a common embryologic 
origin and remain in anatomical proximity, these two compartments display distinct 
immunologic features that reflect their very different physiologic functions (Table 
10).  
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 Genital tract Intestinal tract 
Dominant Ig isotype IgG ≥ IgA IgA >>> IgG 
Hormonal regulation +++ - 
Contribution of Ig from 
the circulation 
++ (50%) - (1%) 
Inductive site for local 
and generalized humoral 
responses 
- to + ++ 
Effector site + ++ 
Expression of homing 
receptors on 
lymphocytes and ligands 
on ECs 
LFA-1, ICAM-1, 
VCAM-1, α4β1 
CCR9, CCR10, CCL25, 
CCL28, MAdCAM-1, 
α4β7, αEβ7 
Response after intranasal 
immunization 
++ + 
Dominant function 
Resident commensal 
flora in vagina vs 
exposure to sexually 
transmitted pathogens 
Acceptance of 
histoincompatible 
sperm/allogenic fetus 
Induction of effective cell-
mediated and antibody-mediated 
immune responses towards 
selected antigens  
Oral tolerance 
Table 10: Comparative characteristic features of humoral compartments of the human 
genital and intestinal tract, adapted from Mestecky et al. (924, 779) 
A major difference between the genital tract and the intestinal tract is that part of 
the genital mucosa is sterile, lacking the presence of a microbial flora. The female 
reproductive tract can thus be divided into two compartments, the vagina and 
ectocervix which host a commensal flora with predominantly lactobacilli which may 
play an important part in host defense, and endocervix, the uterus and fallopian 
tubes which are sterile (630). 
 
Sterility in the endocervix depends on the hormonal phases of the menstrual cycle, 
which should be discussed in further detail later (1151). The epithelium of the 
vagina and ectocervix therefore is required to provide a strong barrier whereas the 
epithelium of uterus and endocervix is less afflicted by microorganisms. A 
sophisticated barrier function is also given by the cervical mucus that filters 
bacteria but allows sperm to ascend to the uterus (630). Whether related to the 
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microbial flora or not, the vagina seems to be in a hypo-responsive state. This may 
be a protective measure as a result of the massive antigenic load in the lower 
genital tract. By contrast, the endocervix, uterus and fallopian tubes respond to 
bacteria with distinct patterns of cytokines and chemokines (1151). 
 
Several basic characteristics of mucosal immunity in the intestine and respiratory 
tract are absent in the genital tract. Mucosal lymphoid nodules and M cells for 
antigen uptake overlaying organized lymphoid tissue like in the intestinal tract are 
missing in the reproductive tract (630). There are lymphoid aggregates in the basal 
layers of the uterus but their presence and distribution strongly varies under the 
hormonal influence. Besides lymphoid aggregates, the genital tract mucosa 
contains APCs such as macrophages and DCs as well as genital ECs. Due to the 
specialized functions of the genital tract immune system it seems reasonable to 
assume that this system hosts unique regulatory cells. Both pregnancy and 
infection are associated with increased numbers or alterations of function of T cells 
which is discussed later on more specifically. 
 
The mucosal immune system of the female genital tract is under strong hormonal 
control that regulates the transport of Igs, the levels of cytokines, the distribution of 
various cell populations, and antigen presentation in the genital tissues during the 
reproductive cycle (1512). In addition to protecting against infectious agents, it 
must adapt to a spectrum of physiological events that includes fertilization, 
implantation, pregnancy, and parturition. A balance is maintained by sex hormones 
throughout the menstrual cycle to respond to the challenges of bacteria, yeast, and 
viruses without interfering with events that surround conception. 
The hormonal influence on the ability to respond to antigen is considerable, 
because vaginal immunization only in the follicular, but not in the luteal, phase 
gave strong local IgA antibody responses (745). Also the ability to present antigen is 
a property that is under strong hormonal control. 
 
Although sometimes disputed, several recent studies have revealed that human 
urine, seminal plasma, and cervicovaginal washings collected at various stages of 
the menstrual cycle contain IgG rather than IgA as the dominant isotype (764). In 
contrast to the predominance of IgA-producing cells in most mucosal tissues, the 
endocervix was found to contain a high proportion of IgG-secreting cells whose 
product, IgG, reaches the cervical fluid by a currently unknown mechanism (273). 
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2. Functions and regulations of innate immune responses in the 
human reproductive tract 
While much attention has been paid to innate immune function in other mucosal 
tissues like lung and intestine, very few studies have investigated presence and 
function of the innate immune system in the female reproductive tract. What is 
becoming clearer is that the innate immune system is present throughout the 
reproductive tract and functions in synchrony with the adaptive immune system to 
provide protection in a way that enhances the chances for fetal survival, while 
protecting against potential pathogens. 
 
The focus of the next chapter is on the different cells of the innate immune system 
defining the role of ECs, macrophages, DCs, neutrophils, and NK cells throughout 
the female reproductive tract, their functions and regulation during the menstrual 
cycle, and the ways in which these cells communicate with the adaptive immune 
system. 
a) Epithelial cells in mucosal immunity  
The epithelium of endocervix, uterus and fallopian tubes is composed of polarized 
ECs connected by tight junctions. This single cell layer was initially thought to 
reside in a sterile environment that was only infrequently exposed to bacteria 
constituitively present in the ectocervix and vagina (1514). However, studies 
demonstrate that polarized ECs of the reproductive tract are exposed to bacteria at 
a frequency not previously appreciated (1093). Furthermore, routine histological 
analysis has determined that uterus and fallopian tubes have a relatively low 
incidence of chronic infections (1514). 
 
Once thought to function only by providing a physical barrier between the lumen 
and internal tissue, mucosal ECs are now known to be a part of the mucosal 
immune system, protecting against the organisms present throughout the 
reproductive tract. They function as sentinels that recognize antigen and also 
respond in ways that lead to the production of antimicrobial molecules that either 
leads to killing or inactivation of the pathogen (1514). Their ability to signal to 
underlying immune cells when pathogenic challenge exceeds their protective 
capacity is also investigated. Estradiol and progesterone regulate their proliferation, 
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apoptosis, secretions and effects on pathogenic microbes. Finally, uterine ECs are 
involved, through their cytokine and chemokine secretions, in normal physiological 
processes such as menstruation and receptivity (1513). 
(1) The role of epithelial cells as mechanical barrier 
Throughout the reproductive tract ECs form an uninterrupted physical barrier 
between the lumen and underlying cell layers. This aims at preventing 
opportunistic and pathogenic microbes from infiltrating the body. However, they 
also permit the transport of sperm or ovum to the site of fertilization and 
implantation or support the conceptus through gestation (1512, 1514).  
 
Each site of the female reproductive tract has a unique morphological form of ECs. 
Whereas the vagina and the lower part of the cervix are lined with stratified 
squamous ECs, uterus and fallopian tubes have a columnar epithelium as well as 
the upper part of the cervix (1146). For the integrity of these cell formations the 
presence and maintenance of tight junctions is essential. Paracellular permeability 
is regulated by these most apical epithelial intercellular junctions which form a 
regulated, semipermeable barrier and act as a fence that segregates protein 
components of the apical and basolateral plasma membrane domains (1034). Built 
of several different proteins, tight junctions seal off the lumen from the basolateral 
compartment. However, this barrier is continuously regulated by calcium, 
cytokines, leukocytes and, above all, hormones (1034).  
 
When being established in culture, ECs from the female genital tract form polarized 
monolayers with distinct luminal and basolateral surfaces. They also establish an 
electrochemical gradient and a transepithelial resistance (TER) which illustrates the 
tightness of the epithelial barrier (372). Grant-Tschudy et al. demonstrated lately 
that estradiol significantly decreased TER within 24 hours when incubated with 
polarized uterine ECs from mice (474). ICI 182,780, an estradiol receptor (ER) 
antagonist, neutralized this effect whereas incubation with progesterone, cortisol, 
aldosterone and dihydrotestosterone had no effect on uterine epithelial TER. This 
demonstrated that epithelial monolayer integrity is directly influenced by estradiol 
via ER. 
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(2) Stromal cell regulation of epithelial cell function  
Stromal cells and ECs in the genital tract act as a single unit with each cell type 
producing factors to regulate each other (1514). The stroma is critically important 
for endometrial function by influencing epithelial development and differentiation. 
Conversely, ECs influence stroma cell function through soluble factors and cell-cell-
contact. Stromal cells from neonatal tissues are able to change the phenotype of 
adult epithelium (277). Regional differentiation in the reproductive tract epithelium 
is therefore directed by the inductive capability of the stroma. 
Uterine stromal cells also communicate with ECs via soluble factors to maintain 
epithelial barrier function, i.e. TER, and secretory activity. Previous studies showed 
that human uterine stromal cells modulate the barrier function of ECs by 
decreasing TER (372).  
 
Also the influence of stromal cells on the release of the cytokines TNF-α and TGF-β 
by ECs was object of studies. Mouse uterine ECs, which reach confluence as 
indicated by high TER, set free TGF-β into the basolateral compartment and TNF-α 
into the apical lumen. When brought together with mouse uterine stromal cells in 
culture, release of TNF-α of ECs went down whereas the amount of released TGF-β 
was not affected (473). This indicated that uterine stromal cells communicate with 
ECs via soluble factors to maintain uterine barrier function and epithelial secretory 
activity. They produce soluble factors that regulate EC` TER and release of TNF-α 
without effecting TGF-β release (473).  
 
The proliferation of ECs due to estrogen is also dependent on underlying stromal 
cells and their release of mediators. Several studies suggested that estrogen 
regulation of EC proliferation is mediated indirectly by uterine stroma (250, 595, 
1121). Also mediated by uterine stroma is the effect of estradiol on EC TNF-α 
release (476). While estradiol treatment on ECs alone led to a significant decrease in 
TER, the amount of released TNF-α did not change. But when ECs were cocultured 
together with stromal cells and treated with estradiol, apical TNF-α release was 
significantly decreased (476). However, the amount of released TGF-β was not 
altered by estradiol. One can conclude that estradiol directly influences epithelial 
electrical integrity whereas its effect on TNF-α release is dependent on the presence 
of uterine stromal cells.  
Further aim is to identify the mechanisms of stromal cell effects on uterine 
epithelium. Estradiol acts through the ER to regulate uterine growth and functional 
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differentiation. Studies detected that epithelial ER is neither necessary nor 
sufficient for estradiol-induced uterine epithelial proliferation. Instead, estradiol 
induction of epithelial proliferation appears to be a paracrine event mediated by ER-
positive stroma (250, 278).  
 
Stromal fibroblasts release soluble factors such as hepatocyte growth factor (HGF), 
insulin-like growth factor (IGF) and keratinocyte growth factor (KGF) as mediators 
of estrogen-induced proliferation of uterine ECs.  
HGF, a mesenchymal growth factor, is expressed by uterine stromal cells and 
mediates EC proliferation via HGF-receptor. HGF was shown to increase TER so 
that it was concluded that stromal cells act through HGF receptors on ECs to 
increase TER (475). At the same time, HGF was shown to decrease apical TNF-α 
release. Both effects could be blocked by incubating epithelial and/or stromal cells 
with anti-HGF or anti-HGF receptor antibody. HGF receptor, which is located at the 
basolateral surface of ECs, seems to mediate the effect of HGF on TER and TNF-α 
release. Moreover, as neutralization of stromal media failed to affect TNF-α 
secretion, these results suggest that other growth factors, in addition to HGF, affect 
EC cytokine production (475).  
(3) Production of antimicrobial molecules 
To encounter microbial pathogens, the genital tract ECs produce soluble factors of 
the innate immune system with microbicidal effects. Among these secretions of ECs 
that inhibit the growth of pathogens are the enzymes lysozyme and lactoferrin, 
defensins, secretory leukocyte protease inhibitor (SLPI) and the tracheal 
antimicrobial peptide (TAP) among other peptides (1512).  
 
Defensins 
Defensins, also called “natural antibiotics”, are small cationic peptides with proven 
effectiveness against bacteria, fungi and some viruses and contribute to mucosal 
immune responses at epithelial sites (436). Defensins are abundant in microbicidal 
granules of polymorphonuclear leukocytes and epithelia, including human 
intestinal Paneth cells or bovine tracheal epithelium (1436). Human defensins can 
be divided into two classes, the α- and β-defensins, which are both expressed in 
ECs and granulocytic white cells (325). The crucial step in defensin-mediated 
antimicrobial activity and cytotoxicity is the permeabilisation of target membranes; 
they seem to kill pathogens via creating pores in their membranes (436, 1271).  
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ECs at mucosal surfaces, and especially in the genital tract, are known to produce 
human β-defensins (HBD)-1 and -2.  
HBD-1 is an essential part of epithelial secretions in the genitourinary tract and 
was detected in the epithelial layers of vagina, cervix, uterus and fallopian tubes as 
well as in vaginal secretions (1436). The highest concentrations of HBD-1 were 
noted in the urine of pregnant women, intermediate concentrations in nonpregnant 
women, and the lowest concentration in men (1436). Exposure to microbial 
products, microtrauma and hormonal influences may regulate HBD-1 synthesis.  
HBD-2 was originally isolated from psoriatic skin lesions and is inducibly expressed 
in inflamed skin lesions and lung tissues upon treatment with bacterial LPS and 
cytokines (1023). It was shown that its expression is increased at infection or 
inflammation sites, for example the endometrium, and that HBD-2 is a potent 
chemoattractant of human neutrophils.  
 
The expression of these defensins may be regulated by cycle-associated changes in 
sex hormones. Fleming et al. demonstrated that HBD-1 expression was highest 
during the secretory phase while HBD-2 expression peaks during menstruation 
(415). The use of the oral contraceptive pill downregulates expression of both which 
may among other factors contribute to altered susceptibility to infection.    
Concerning HBD-3 and HBD-4, it was shown that HBD-3 messenger ribonucleid 
acid (mRNA) expression in the human endometrium is highest during the secretory 
stage of the menstrual cycle, HBD-4 mRNA expression peaks in the proliferative 
phase (707). Expression is altered due to hormonal contraceptive use which may 
contribute to differential infection rates in oral contraception users relative to non-
users. HBD-3 is also upregulated during infection allowing an increased immune 
response at that time. 
 
Concerning the α-defensins, leukocytes express human neutrophil peptides (HNP) 
1-4 whereas human defensin (HD)-5 and -6 are expressed mainly by intestinal cells. 
Lately, HD-5 was detected in female genital tract epithelia with variable expression 
in upper genital tract, but also in the lower genital tract (1152). It was also found in 
cervicovaginal lavages (CVL), with its highest concentration during the secretory 
phase of the menstrual cycle.  
In addition to their bactericidal activity, defensins have also been shown to have 
multiple functions in innate immunity. For example, β-defensins have been shown 
chemotactic for immature DCs and memory T cells by binding to the chemokine 
receptor CCR6 (1554). Uterine ECs also produce CCL20/macrophage inflammatory 
 Immunology of the genital tract 
 II-31  
protein (MIP) 3α, a chemokine ligand of CCR6, which has significant homology to 
defensins and has been shown to have significant antimicrobial activity (564). 
 
SLPI 
SLPI is a neutrophil elastase inhibitor which also has antibacterial and 
antiinflammatory properties (704). It is not only produced by macrophages but also 
by uterine and cervical ECs and is active against a variety of pathogens including 
gram-positive and gram-negative bacteria and HIV-1 (557).  
 
King showed that the primary site of its synthesis in the endometrium is the 
glandular epithelium and that secretory peaks are higher in the progesterone-
dominated late secretory phase than in the proliferative phase of the menstrual 
cycle (704). Expression of endometrial SLPI has been shown to be upregulated by 
estrogen in the rat (214) and by progesterone in the human (709). Studies also 
proved that uterine SLPI productions of premenopausal women were significantly 
higher than those of postmenopausal women (376). These results confirm the 
suggestions that expression of SLPI varies in cervical mucus during the different 
stages of the menstrual cycle and menstrual status.  
Furthermore, it increases in amniotic fluid during gestation and labor (323). This 
may be to modulate proinflammatory paracrine interactions for the maintenance of 
pregnancy and limit those occurring at parturition within the uterus. There is also a 
positive correlation between SLPI expression and implantation as well as early 
pregnancy which could be a benefit due to its antibiotic action and anti-
inflammatory effects of inhibiting elastase and nuclear factor- κB (NF-κB) (1512). 
NF-κB is responsible for the production of inflammatory cytokines in response to 
pathogens.  
 
Surfactant protein A and D 
Previous studies have demonstrated the essential role of Surfactant protein A (SP-
A), a member of the collectin family of proteins, in protecting the respiratory system 
from infections (811). MacNeill et al. have now identified SP-A in two layers of 
vaginal epithelium which makes SP-A an essential component of the host defense 
system in the genital tract as well (855). SP-A can facilitate phagocytosis by 
opsonizing bacteria, fungi and viruses. It can also modulate proinflammatory 
cytokine production by phagocytic cells and provides a link between innate and 
adaptive immunity by promoting differentiation and chemotaxis of DCs.  
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SP-D, originally detected in alveolar cells type II, was also recently demonstrated in 
cells lining the epithelium and secretory glands in the vagina, cervix, uterus, 
fallopian tubes and ovaries (809). Endometrial presence of SP-D varied according to 
stage of menstrual cycle with highest concentrations in the secretory phase. SP-D 
may play a role in preventing intrauterine infection at the time of implantation and 
during pregnancy.  
(4) Cytokine and chemokine production 
In the reproductive tract, growth factors and cytokines are synthesized in 
abundance at almost every level as partly mentioned above. There is evidence that 
they are not only regulators of immune function but also local modulators of steroid 
hormone action. Cytokines are small secreted proteins regulating immunity, 
inflammation and hematopoiesis by either acting on the cells that secrete them 
(autocrine action), on nearby cells (paracrine action) or distant cells (endocrine 
action). Although still considered a subclass of cytokines, chemokines are 
developing their own identity (674). Their hallmark is their ability to induce 
chemotaxis, but they are also involved in cellular proliferation and differentiation, 
angiogenesis and inflammation.  
The known chemokines form a large subsets of cytokines and basically consist of 
four families, CC, C, CXC and CXXXC, their receptors (-R) and ligands (-L) 
corresponding (674). The CC chemokines are functionally and structurally different 
from the CXC chemokines, stimulating multiple cell types such as monocytes, 
lymphocytes, basophils and eosinophils. In contrast, most of the CXC chemokines 
are specifically chemotactic for neutrophils with only minor effects on other cells 
(1249). 
 
Cytokines are the mediators of communication between ECs as first line of defense 
and other immune cells and therefore guarantee a successful interactive immune 
response. They are produced by ECs, macrophages and T lymphocytes and act 
through different receptors in the reproductive tract to regulate differentiation, 
maturation and recruitment of lymphocytes (1514). Cytokine and adhesion 
molecule expression are also decisive for endometrial growth in preparation for 
fertilization, implantation and successful pregnancy but also for the renewal of the 
uterus during each menstrual cycle.   
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Several studies described the production of numerous cytokines including 
granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-
stimulating factor (G-CSF), TNF-α, IL-1, IL-6, leukaemia inhibitory factor (LIF), TGF-
β and of chemokines such as MIP-1β, monocyte chemoattractant protein-1 (MCP-1), 
RANTES (regulation upon activation, normal T cell expressed and secreted) and IL-8 
by endometrium ECs (374, 672, 673, 674).  
They are constitutively produced by the polarized ECs, preferentially secreted 
apically and contribute to the resident and temporary populations of immune cells 
in the subepithelial layers of the endometrium, for example by recruiting 
neutrophils, monocytes and T cells (374).  
Besides HBD-2 (1023), another chemokine of uterine ECs, MIP3α/CCL20, attracts 
B cells, memory T cells and immature bone-marrow derived DCs. Its levels 
significantly increased together with levels of TNF-α by the presence of Escherichia 
coli and PAMPs (265, 264). Chemokines could also account for the influx of 
leukocytes and lymphocytes that form lymphoid aggregates observed during the 
secretory phase of endometrium (1560). 
Kayisli et al. stated that IL-8 and MCP-1 among others produced by endometrial, 
myometrial and trophoblast cells also display specific roles in endometrial 
angiogenesis, apoptosis, proliferation and differentiation (674). IL-8 takes part in 
cervical ripening and parturition and is also found at high levels in the peritoneal 
fluid of women with endometriosis. Besides mesothelial cells that form the majority 
of the peritoneal cells, macrophages and endometrial cells are potential sources of 
this chemokine. It was found that there are menstrual cycle-dependent changes in 
IL-8 mRNA in the endometrium (48). IL-8 mRNA levels in the late secretory and 
early to midproliferative phase samples are higher than the level observed in the 
middle of the cycle. It can be speculated that IL-8 may modulate the timely 
recruitment of neutrophils and lymphocytes into the endometrium.  
 
Endometrial stromal and ECs produce IL-6 in response to hormones and other 
activators. Besides its role in inflammation and cell differentiation of 
immunocompetent cells, it also regulates ovarian steroid production, 
folliculogenesis, and embryo implantation. Endometrial stromal cell IL-6 protein is 
induced by IL-1β or IL-1α, TNF, platelet-derived growth factor (PDGF) and INF-γ. IL-
6 is said to inhibit the proliferation of human endometrial stromal cells, dependent 
on cell density, which suggests that IL-6 may play a role in epithelial-stromal 
interaction in the normal uterus (1574).  
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IL-6 fluctuations during the menstrual cycle reflect an inverse relationship to 
estrogen action; IL-6 levels are high during the secretory phase and low during the 
proliferative phase (1382). Yoshioka et al. observed that IL-6 has no effect on the 
growth of endometrial stromal cells from the proliferative phase, but it inhibits 
proliferation of endometrial stromal cells from the secretory phase (1564). 
 
Concentrations of cytokines and chemokines vary in the endometrium during 
physiological processes as well as pathological conditions. Many cytokines such as 
GM-CSF, TNF-α, TGF-β and LIF show temporal release patterns and are regulated 
by sex hormones.  
Four different patterns of cytokine expression related to the menstrual cycle were 
identified in CVL obtained from healthy ovulating women (880):  
 LIF, RANTES, and MIP-1α are detectable at menses only 
 IL-8, IL-6, TGF-β, and IL-1β are detected throughout the cycle but at highest 
levels at menses 
 M-CSF and epidermal growth factor (EGF) are found throughout the cycle 
but peak during the late proliferative phase 
 IFN-γ and TNF-α are detectable in a subpopulation of women during non-
menses stages of the cycle and may be associated with inflammatory events 
 
For example, progesterone withdrawal results in upregulation of MCP-1 and IL-8 
leading to chemotaxis and activation of monocytes and neutrophils (268). A 
correlation between high levels of IL-6, IL-8 and MCP-1 and amniotic microbial 
infections has been found in cervicovaginal fluids and amniotic fluids from women 
in preterm labor (610, 1512). However, low cervicovaginal concentrations of IL-6 
and IL-8 were found in patients with chorioamnionitis in early pregnancy (1307). 
The conclusion was that low concentrations of multiple cytokines indicated a broad 
immune hypo-responsiveness that could create a permissive environment for 
infection whereas high levels correlated with a dangerous infection.  
 
Among other cytokines, GM-CSF, which regulates granulocyte and macrophage 
proliferation, is released by ECs of the pregnant and non-pregnant uterus, which 
Robertson et al. have shown in mice (1205). They also demonstrated that GM-CSF 
synthesis and release by uterine EC cultures is stimulated by estrogen and 
moderately inhibited by progesterone (1204). GM-CSF can synergize the effect of IL-
8 of attracting neutrophils (1292). 
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TNF-α plays a dominant role in inflammatory processes and had been demonstrated 
in both normal pregnancies and conditions of pregnancy loss (470). It is also 
promoted by estrogen in uterine mast cells whereas studies in macrophages 
suggested that TNF-α expression is unaffected by estrogen but inhibited by 
progesterone (580). 
TGF-β seems to regulate cellular proliferation, migration, differentiation and protein 
expression. Diethylstilbestrol, a synthetic estrogen, was proved to increase TGF-β 
mRNA expression and protein for TGF-β1, -2 and -3 in the immature mouse uterus 
(1386).  
(5) Regulation of Ig secretions into the lumen  
At genital tract mucosal surfaces, the polymeric Ig receptor (pIgR), a 
transmembrane glycoprotein created by ECs, is responsible for transporting 
polymeric IgA across ECs (1514). It was shown that SC as the external part of the 
pIgR was synthezised by ECs and tended to accumulate in the apical compartment, 
especially in endocervix and ectocervix. It binds polymeric IgA at the basolateral 
surface of ECs and builds a receptor-ligand-complex which is internalized and 
transported to the apical surface. There the ectoplasmic portion of the receptor is 
cleaved from the transmembrane and cytoplasmic part.  
 
The female sex hormones estradiol and progesterone influence the local production 
and Ig transport in ECs in the reproductive tract (1519). During the estrous cycle 
and after the administration of estradiol in rats, IgA, SC and IgG accumulation are 
stimulated in the uterine lumen and are inhibited in cervicovaginal secretions (CVS) 
(1519, 1520).  
In the uterus, estradiol increases vascular permeability, which results in serum 
transudation of IgA and IgG into the uterine tissues. In contrast, movement of IgA 
and IgG in CVS is inhibited by estradiol and progesterone. Estrogen increases 
expression of pIgR and therefore IgA transport into the lumen when ECs were 
cultured with IL-4 and IFN-γ (918). IgG, however, moves down a concentration 
gradient from blood to uterine lumen under the influence of estrogen. 
 
Other data demonstrated that Ig levels in cervical mucus corresponded to hormonal 
fluctuations during the human menstrual cycle (423). Peak concentrations of IgA 
and IgG occurred approximately one day before the estradiol peak around ovulation 
and decreased from the time of ovulation in cervical mucus secretions of normal 
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ovulating women (423, 764). The decrease of Ig levels could represent an effect of 
dilution secondary to the increased volume of cervical mucus and estradiol 
produced at the time of ovulation. When compared with women on birth control 
pills, the mean peak of IgA detected was about one third less in normal ovulating 
women. This supports the general agreement that reproductive hormones enhance 
immunity. 
(6) Antigen presentation 
As mentioned in the last chapters, the role of APCs throughout the body as well as 
at mucosal surfaces, is central to the generation of immune protection. An effective 
immune response requires that exogenous antigen has to be internalized, processed 
and returned to the cell surface of APCs in association with MHC class II for 
recognition by CD4+ T cells. It can also stimulate MHC class I-restricted T cell 
activation after uptake by APCs via a phagocytic pathway. After antigen 
presentation, lymphocyte effector functions including cytokine production, 
cytotoxicity and antibody synthesis are activated. 
 
Previous experiments investigated mixed cell suspensions from throughout the 
genital tract and found cells capable of presenting foreign antigen to autologous T 
cells, independent from menstrual status (373). Isolated uterine ECs expressed 
MHC class II antigen and were able to process and present tetanus toxoid to T cells, 
as well as cells from basolateral subepithelial stroma (1470).  
Lately, this was supported by the finding that preparations of endometrial ECs 
without being contaminated with professional APCs such as DCs or macrophages 
presented tetanus toxoid to autologous T cells (375). ECs also had the ability to 
express CD1d and CD40 which shows that these cells interact with CD8+ T cells. In 
addition to MHC class II molecules, CD40 and CD1d proteins are another family of 
antigen-presenting molecules that bind bacterial and lipid antigens for presentation 
to T cells.  
 
Antigen presentation in the female reproductive tract is supposedly regulated by 
sexual hormones and soluble factors of stromal cells. Isolated uterine and vaginal 
cells from ovariectomized rats treated with estrogen were incubated with sensitized 
T cells. ECs from animals treated with estrogen presented more antigen than ECs 
from saline controls did. In contrast, uterine stromal and vaginal cells from 
estrogen-treated animals presented fewer antigens than the saline control group. 
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Estradiol enhances antigen presentation by ECs of rat uterine at a time when 
uterine and vaginal stromal antigen presentation is inhibited (1515, 1516).  
More recent studies demonstrated that stromal antigen presentation is regulated by 
cytokine production by ECs. In response to estrogen, uterine ECs produce TGF-β 
which suppresses underlying APCs in the stroma (1517). 
 
It can be concluded that uterine ECs as well as APCs in the uterine stroma and 
vagina are capable of presenting antigen which initiates an immune response in the 
female reproductive tract. Moreover, sex hormones play a principal role in 
regulating antigen presentation in the genital tract. 
(7) TLRs on epithelial cells 
As mentioned above, TLR are a newly discovered family of integral membrane 
receptors which can stimulate cytokine and chemokine production after ligand 
recognition. First, a Drosophila Toll receptor made up of a type 1 transmembrane 
protein with a cytoplasmatic protein was described (520). Then, Medzhitov et al. 
described a human homologue of this receptor which was similar to the IL-1 
receptor (910). The Drosophila Toll and human TLR both act through the NF-κB 
pathway.  
The eleven known TLRs in mammals comprise a family of structurally related 
receptors that recognize specific products of pathogens referred to as PAMPs as well 
as endogenous ligands associated with cell damage. Just as TLRs are conserved 
from one species to another, PAMP ligands are repeated in a high variety of 
pathogenic microbes. An overview of TLRs and their ligands gives Table 11.  
 Immunology of the genital tract 
 II-38  
Receptor Ligand Origin of ligand 
TLR1 
Lipopeptides 
Soluble factors 
Bacteria/mycobacteria 
Neisseria meningitides 
TLR2 
Lipopeptides 
Lipoteichoic acid 
Peptidoglycan 
Zymosan 
Lipoarabinomannan 
Various pathogens 
Gram-positive bacteria 
Gram-positive bacteria 
Fungi 
Mycobacteria 
TLR3 Double-stranded RNA Viruses 
TLR4 
Lipopolysaccharide 
Taxol 
Fusion protein 
Gram-negative bacteria 
Plants 
RS-Virus 
TLR5 Flagellin Bacteria 
TLR6 
Diacyl lipopeptides 
Lipoteichoic acid 
Zymosan 
Mycoplasma 
Gram-positive bacteria 
Fungi 
TLR7 Single-stranded RNA Viruses 
TLR8 Single-stranded RNA Viruses 
TLR9 CpG-containing DNA Bacteria and viruses 
TLR10 ? ? 
TLR11 ? Uropathogenic bacteria 
Table 11: Toll-like receptors and examples for their ligands (15)  
Stimulation of different TLRs induces distinct patterns of gene expression which not 
only leads to the activation of innate immunity but also instructs the development 
of antigen-specific acquired immunity. TLRs are expressed on immune cells such as 
lymphocytes or APCs as well as on ECs (1514). 
 
Human uterine EC lines express TLR that are capable of recognising specific 
structural components of bacterial, fungal and viral pathogens.  
Young et al. first examined the expression of TLRs in the endometrium and 
detected TLR1-6 and TLR9 mRNA in both whole endometrium and separated 
endometrial ECs (1567). Both whole endometrial samples and purified epithelium 
lacked detectable TLR 7, TLR 8 and TLR 10. Since B cells are the predominant cell 
type for expressing TLR 10, the absence of TLR 10 is consistent with data 
suggesting that B cells are rare in the endometrium.  
Constitutive expression of TLR1-6 was observed throughout the female genital tract 
by Pioli et al. (1126). They also described the differential expression of TLR2 and 
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TLR4 in the human reproductive tract tissue. TLR2 mRNA levels were highest in 
fallopian tube and cervical tissues, followed by endometrium and ectocervix. In 
contrast, TLR4 expression declined along the tract with highest levels in fallopian 
tubes and endometrium. TLR4 is expressed in primary endometrial ECs but not in 
cervicovaginal epithelium. This is maybe because gram-negative bacteria in the 
upper genital tract are likely to be associated with infection whereas bacteria are 
usually found as commensal organisms in the lower genital tract. 
Another study showed that TLR1-9 were expressed by the uterine EC line EEC1 
and that PAMP agonists of TLR2, TLR4 and TLR9 stimulated expression of IL-6, IL-8 
and MCP-1 (1261). However, it is not known if changes in sex hormones affect TLR 
expression (91). 
 
More recently, studies were undertaken to examine the expression of TLRs on 
human primary uterine ECs and to determine if exposure to the TLR agonist 
poly(I:C) would induce an antiviral response. The ligand for TLR3, dsRNA, is 
produced by virtually all viruses at some point in their life. When investigating 
exposure of poly(I:C), a synthetic dsRNA which binds TLR3 to uterine ECs, the 
expression of the proinflammatory cytokines IL-6, G-CSF, GM-CSF and TNF-α, of 
the chemokines IL-8, MCP-1 and MIP-1β as well as of MIF and HBD1/2 was 
induced (1262, 1263). Also the uterine ECs initiated an antiviral response when 
inducing IFN-β and IFN-β-stimulated antiviral genes myxovirus resistance gene 1 
and 2`,5`-oligoadenlyate synthetase mRNA.  
This also suggests that ECs in the female reproductive tract are sensitive to viral 
infection and possess the capability to respond to RNA viruses.  
 
To conclude, the following figure shows the multiple functions carried out by 
uterine ECs as sentinels of immune protection in the female reproductive tract. 
Acting as the first line of defense, ECs provide host protection in a number of ways 
that includes providing a mechanical barrier, secreting antimicrobial molecules, 
transporting IgA, processing and presenting antigen and communicating with 
underlying immune cells by secreting cytokines and chemokines. Sex hormone 
regulation of EC function is both direct via ER in ECs and indirect via ER located in 
the underlying stromal cells (Figure 3). 
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Figure 3: Different immunoregulatory functions of ECs in the female reproductive 
tract, adapted from Wira et al. (1514)  
b) The role of macrophages in the female genital tract 
As mentioned above, monocytes and tissue macrophages are important effector 
cells of innate immunity. The phenotypic characteristics of tissue macrophages 
reflect the unique tissue environment including cytokines, extracellular matrix and 
cellular components. They are identified in tissues by their expression of cell 
surface receptors and can execute diverse functional activities, including 
phagocytosis of foreign antigens, matrix dissolution and tissue remodelling, and 
production of cytokines, chemokines and growth factors. 
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(1) Distribution and function 
Concerning distribution in the female reproductive tract, macrophages can be found 
throughout all tissues and represent about 10% of the total number of leukocytes 
(459). Macrophages in mouse, rat and human uteri are distributed throughout the 
endometrial stroma and myometrial connective tissue with myometrial 
macrophages usually larger in size than endometrial macrophages (584).  
 
A large accumulation of endometrial leukocytes occurs in the periimplantation 
phase and during early pregnancy as well as a dramatic influx in the premenstrual 
phase and during menses. Pregnancy-associated leukocytes are predominantly a 
subpopulation of macrophages and uterine-specific NK cells whereas in the 
perimenstrual period there is a dramatic influx of inflammatory-type leukocytes: 
neutrophils, mast cells and macrophages (638). Immediately after implantation a 
redistribution of uterine macrophages takes place. Macrophages are reported to flee 
from the implantation site and are entirely absent from the primary decidua in mice 
and rats. They continued to be excluded from the decidua as pregnancy progresses 
and are only present in small numbers in maternal blood near the placenta (584). 
 
Besides their role in the regulation of inflammation, macrophages have also been 
identified as important effector cells of ovarian function. The distribution of ovarian 
macrophages differs during the various stages of the menstrual cycle. The highest 
level of macrophages is in the vascular connective tissue and the theca-lutein areas 
of the corpus luteum during the periovulatory period (1538).  
Their specific localization and variations in distribution in the ovary during different 
stages of the cycle as well as their presence in periovulatory human follicular fluid 
suggest that they play diverse roles in the folliculogenesis, tissue restructuring at 
ovulation and corpus luteum formation and regression. Ovarian macrophages 
secrete several cytokines such as TNF-α, IFN-γ, IL-1, IL-6, IL-10, IL-12 to regulate 
inflammation, as for example the state of ovulation (920). 
(2) Regulation by sex hormones 
Multiple studies have been examining the influence of estrogen on infectious 
diseases where results showed that physiologic levels of estrogen influence 
macrophage proliferation and function as well as cytokine production (1512). It 
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appears that the ability of estrogen to induce either pro- or antiinflammatory 
mediator production is concentration- and cell-context dependent.  
Human peripheral blood monocytes and human macrophages have similarly shown 
expression of both receptor isoforms, ERα and ERβ (1114, 964). Although 
macrophages have been showing an effect to progesterone, nuclear progesterone 
receptor (PR) was rarely detected on macrophages with the work of Vegeto et al. as 
only exception (1451). This paradox between macrophage progesterone 
responsiveness and lack of PR expression is explained by cross binding of 
progesterone to the glucocorticoid receptor (1495). 
 
There is high evidence that steroid hormones regulate the recruitment of uterine 
macrophages throughout the menstrual cycle due to regulation of cytokine and 
chemokine expression. The total uterine leukocyte population increased 
significantly on treatment with estrogen. This rise in leukocytes was due to a 
significant increase in both uterine macrophage populations and NK cells (318).  
Human studies have demonstrated that macrophages selectively aggregate into 
premenstrual endometrial stroma, concurrent with depression of estrogen and 
progesterone levels as the result of luteolysis (639, 656).  
 
One cytokine that controls macrophage migration and activation is MCP-1, which 
has also been shown on human uterine ECs (926). Highest levels of MCP-1 in the 
endometrium were detected perimenstrually at low estrogen levels and lowest levels 
around the time of ovulation when estrogen levels are high. This was coincident 
with macrophage accumulation and depletion. Arici et al. have demonstrated that 
treatment of endometrial stromal cells with estradiol significantly inhibits 
expression of MCP-1, which correlates with suppression of macrophage migration 
(48). 
 
Estrogen also plays an important role in the modulation of MIF expression by 
macrophages. MIF is produced by monocytes and macrophages as a consequence of 
bacterial LPS stimulation and mediates lymphocyte activation and nitric oxide 
synthesis as proinflammatory functions (168). As a counterpart of glucocorticoid-
regulated antiinflammatory effects, it stimulates monocyte production of IL-6, IL-8 
and IL-1β (1211). Estrogen was demonstrated to downregulate MIF expression by 
LPS-activated human monocytes, directly mediated by ER (54). 
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c) Dendritic cells in the female genital tract 
The APCs of the vaginal mucosa include the intraepithelial CD1a+, MHC class II+, 
fascinbundling protein (p55)+, CD11c+, CD123-, DCSIGN-, CD4+ Langerhans cells 
(LC), and CD1a- MHC II+ p55+, DC-SIGN+, and CD4+ DCs in the lamina propria of 
the mucosa. LCs are abundant in the epithelial layer of the vaginal and ectocervical 
mucosa of women (119), whereas DCs are predominant in the submucosal layers. 
These immune cells detect pathogenic invasion and/or damage of epithelial 
surfaces. Migration of LCs from epithelial surfaces is triggered by inflammatory 
cytokines induced either by pathogen invasion of mucosal surfaces, and/or by 
epithelial damage. 
 
DCs as bone marrow-derived professional APCs are initiators and modulators of the 
immune response via stimulation of B and T lymphocytes (73). Immature DCs 
reside in peripheral lymphoid tissues, acquire antigen by phagocytosis, 
macropinocytosis or adsorptive pinocytosis and mature on pathogen stimulation, 
for example through LPS. This leads to the upregulation of MHC class II and the 
costimulatory molecules CD80 and CD86. After migration to T cell areas of 
secondary lymphoid tissue, they undergo terminal maturation through ligaturing of 
CD40 with CD154 (CD40L) on antigen-specific T lymphocytes. Terminally mature 
DCs are characterized by production of IL-12 which facilitates production of IFN-γ-
producing Th1 cells (196).  
DCs express mRNA for both ER isoforms at all stages in their differentiation. Data 
suggest that nonsteroidal anti-estrogens such as tamoxifen inhibit the 
differentiation of immature DCs and therefore the development of inflammatory Th1 
responses (737). Anti-estrogens can act as estrogen agonists or antagonists 
depending on the target cells and are therefore called selective estrogen receptor 
modulators. Human monocytes incubated with GM-CSF and IL-4 in the presence of 
anti-estrogen fail to differentiate into immature DCs; however, this was not 
mediated by ER (737).  
Others illustrated that estradiol promoted the differentiation of functional DCs from 
murine bone marrow precursor cells via ER (1060). Ex vivo DC differentiation was 
inhibited in steroid hormone-deficent medium and was restored by addition of 
physiological amounts of estradiol, but not dihydrotestosterone.  
 
Estrogen has also been demonstrated to modulate the expression of cytokines and 
chemokines in human monocyte-derived DCs. Their treatment with estradiol 
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increased production of IL-6, IL-8 and MCP-1 (106). Moreover, mature DCs treated 
with estradiol had an increased ability to stimulate naïve CD4+ T cells.  
d) Natural killer cells in the female genital tract 
NK cells are large granular lymphocytes that utilize receptors encoded in the 
germline DNA to become specifically activated or inhibited and are thus part of 
innate immunity. NK cell function can be classified in three categories (Table 12): 
 
Cytotoxicity 
NK cells can kill virally infected cells and tumor target cells regardless of their MHC 
expression via their cytolytic granules containing perforin 
Cytokine and chemokine secretion  
Besides production of IFN-γ, NK cells also secrete TNF-α, GM-CSF, IL-5, IL-13, MIP-1 and 
RANTES. Killing and cytokine secretion seem to be mediated by different subsets of NK 
cells characterized by the intensity of expression of the CD56 marker on their surface 
Contact-dependent cell costimulation 
Serving as a bride between innate and adaptive immunity, NK cells express several 
costimulatory ligands including CD40L which allow them to provide a costimulatory 
signal to T cells or B cells  
Table 12: Different functions of NK cells (1051) 
Human NK cells are found in the blood, lymphoid organs, liver and various mucosal 
tissues including lung, intestine and uterus. They comprise about 15% of all 
lymphocytes and are defined phenotypically by their expression of CD56 and lack of 
expression of CD3 (252).  
Human blood NK cells can be divided into two major subsets based on the density 
of CD56 expression (252, 1051, 1512). CD56dim cells comprise the majority of 
peripheral blood NK cells (about 95%) and express high levels of the Fc-γ receptor 
CD16 and killer cell Ig-like receptors (KIRs) as well as perforin. Thus, they have a 
high spontaneous lytic activity. CD56bright NK cells express low levels of CD16, KIRs 
and perforin but high levels of cytokines and are thought to be an important 
inflammatory subset. This is the primary NK cell subset found in lymph nodes. 
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(1) Distribution and characteristics 
Distribution  
In the female reproductive tract, NK cells can be found in all tissues. Their numbers 
as a percentage of leukocytes vary in the different regions from 10 to 30% in 
nonpregnant women (459). NK cells account for a substantial presence in the 
uterus, and altered NK cell numbers and activity have been associated with a 
variety of clinical conditions involving reproductive organs and reproductive failure. 
Reduced NK cell activity is associated with an increase in the incidence of ovarian 
and endometrial malignancies (848) while higher NK cell activity has been 
associated with recurrent pregnancy loss (338).  
In the human endometrium, NK cells localize in large numbers especially following 
ovulation and account for almost 70% of leukocytes prior to menstruation (459, 
584) which again suggests the involvement of sex hormones in regulation of this NK 
cell migration. 
 
Phenotype 
Closer characterization of NK cells in reproductive tract tissues besides the 
endometrium has been performed rarely. McKenzie found CD3+, CD8+, CD16+, 
CD56-positive NK cells in the ectocervical epithelium which increase in number in 
relation to cervical intraepithelial neoplasia (CIN) (902). In fallopian tubes, cervix 
and ectocervix there seem to be up to 20% of all leukocytes of the CD45+, CD56+, 
CD3- cell type (1512).  
Endometrial NK cells also have a unique cell-surface phenotype compared with 
peripheral blood NK cells. They have been previously described as endometrial 
granulocytes, endometrial stromal cells or decidual NK cells (1512). Uterine NK cells 
express CD56 and CD94, few express CD16 and none express CD8 or CD57 (370). 
A large amount express KIRs on their surface but unlike blood NK cells, uterine NK 
cells express also CD9 and CD69 on their surface (370).  
 
Decidual NK cells were investigated more closely and it was revealed that they differ 
in 278 genes from blood NK cells (740). It was indicated that decidual NK cells were 
more similar in their gene expression profile to CD56bright N cells than to CD56dim 
NK cells.  
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Chemokine receptors 
Blood NK cells express a variety of chemokine receptors such as CXCR3, CXCR4, 
CCR5 and CCR7 and specific migration of NK cells has been induced by 
chemokines in vitro (598, 858). Uterine NK cells demonstrated expression of CXCR3, 
CCR5 and CCR7 (1275). Kitaya et al. investigated the expression of chemokines in 
the human endometrium throughout the menstrual cycle (715). The expression of 
CCL4, CXCL9 and CXCL10 increases during the menstrual cycle which correlates 
with the increasing number of NK cells in the endometrium.  
Sentman et al. showed that estrogen and progesterone were able to induce 
expression of the CXC chemokine ligands 10 and 11 (CXCL10 and CXCL11), which 
suggests that sex hormones induce specific chemokines in nonpregnant human 
endometrium that can activate NK cell migration (1275).  
 
Several potential chemokine receptor-ligand pairs have been described in decidua 
that could be involved in the leukocyte trafficking during pregnancy. In the 
maternal decidua, CD16- NK cells are found in direct contact with the fetal 
extravillous trophoblasts. It is yet unknown which factors contribute to the specific 
homing of this unique NK subset to the decidua. Hanna and colleagues reported 
that CXCL12, a ligand for CXCR4, which preferentially recruits CD56bright NK cells, 
was shown to be expressed in the trophoblast (504). CD56brightCD16- NK cells, 
which are the predominant type in decidual leukocyte population, have been 
reported to express chemokine receptor CCR5 and that its ligand CCL4 acts as a 
strong chemoattractant for these cells (1180).  
(2) Functions and hormonal regulation 
Functions 
Large amounts of NK cells are populating the human decidua, often close to 
trophoblasts. These uterine NK cells have several functions in pregnancy (1512): 
 Help shield trophoblasts bearing paternal antigens from the maternal 
immune system 
 Protect the mother from trophoblast invasion and limit their expansion 
 Be involved in regulation and restructuring of maternal spiral arteries 
 Be a part of the innate immune system, protecting against infection in 
the uterus 
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NK cells are capable of amplifying an inflammatory response and promoting 
macrophage activation and generation of cytotoxic T cells by producing cytokines 
and chemokines. Uterine NK cells have been proved to secrete IFN-γ, CSF-1, GM-
CSF, and TNF-α, IL-8, IL-10, and TGF-β1 (370, 634). Human NK cells cultured in 
the presence of IL-12 or IL-4 differentiate into cell populations with distinct patterns 
of cytokine secretion similar to Th1 and Th2 cells. NK cells grown in IL-12 produce 
IL-10 and IFN-γ while NK cells grown in IL-4 produce IL-5 and IL-13 (1107).  
These cytokines may have significant effects on decidualization and trophoblast 
invasion. Uterine NK cells also produce other cytokines than blood NK cells such as 
angiogenic growth factors and LIF which constitutes the hypothesis that uterine NK 
cells may play a role in endometrial angiogenesis (815).  
 
In the first trimester of pregnancy uterine NK cells accumulate as a dense infiltrate 
around the trophoblast cells and spiral arteries (156). With further progression of 
pregnancy these cells disappear from the decidua and are absent at term which 
suggests that specific signals are involved in the recruitment and localization of NK 
cells within the uterus. Shao et al. found that trophoblast cells induce a subset of 
regulatory CD8+ T cells during the first trimester which suggests that these cells 
probably regulate T cells as well as NK cell function at the maternal fetal interface 
(1288).  
Also the general effects of human NK cell deficiency were investigated (1052). These 
deficiencies were correlated with an increase in infections, especially viral herpes 
infections. But the role of NK cell function alone is difficult to determine as many of 
the NK cell deficiencies involve other immune function as well. NK cells have also 
been shown to actively recognize fungal infections and to play a role in the immune 
response against Cryptococcus. 
 
Regulation through cytokines 
NK cells can be activated by several cytokines including IL-2, IFN-α/β as well as by 
prolaktin and IL-15 or IL-18 in combination with IL-12 (252, 387, 716). IL-15 and 
prolaktin are both produced by endometrium and influence NK cell differentiation. 
Uterine NK cell were shown to express prolaktin receptors (1371). 
IL-15 is present during the whole menstrual cycle with increasing levels during the 
mid-secretory phase and early pregnancy and is produced by endometrial and 
decidual stromal cells (209, 348). The role of IL-15 seems to be determined for 
survival, proliferation and attachment of uterine NK cells. Perhaps expression of IL-
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15 by decidual endothelium is important for specific localization of NK cells close to 
spiral arteries (30).  
Another immunoregulatory molecule which has been observed to influence NK cell 
is TGF-β. Inhibition of uterine NK cell cytokine production by locally produced TGF-
β is a likely mechanism to regulate NK cell function in the human endometrium 
(370). 
      
Regulation by sex hormones 
There is strong evidence that uterine NK cell numbers and migration are regulated 
by sexual hormones. NK cells are found widely within the nonpregnant 
endometrium and are associated with other leukocytes in small aggregates (1560). 
NK cell numbers are low in the early proliferative phase and increase as the 
menstrual cycle progresses (459, 702).  
In the late secretory phase prior to menstruation NK cells account for up to 70% of 
the leukocytes in the endometrium and are often seen as loose aggregates in the 
Stratum functionalis lying next to the upper endometrial glands and the luminal 
epithelium. The cyclic nature of uterine NK cell appearance and the role of sex 
hormones in modifying changes in endometrium suggest hormonal regulation of NK 
recruitment and expansion in the endometrium.   
(3) NK cell recognition and interactions 
NK cells can distinguish between healthy cells and abnormal cells by using a 
sophisticated repertoire of cell surface receptors that control their activation, 
proliferation and effector functions (783). There is the hypothesis that NK cells co-
evolved with T cells given that they share common killing mechanism using perforin 
and granzymes and a similar pattern of cytokine production. Both of these 
lymphocytes are focused on recognition of MHC molecules and in this regard, NK 
cells distinguish themselves from phagocytes which rely on conserved pattern-
recognition receptors such as TLRs.  
 
NK cell recognition includes the initial binding to potential target cells, interactions 
between activating and inhibiting receptors with ligands available on the target, and 
the integration of signals transmitted by these receptors, which determines whether 
the NK cell responds or detaches again (783).  
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Three families of cell surface receptors, KIR, Ly49 and CD94/NKG2, are expressed 
on NK cells which all recognize MHC I ligands and contain both activating and 
inhibitory isoforms (1177). They all share a common immunoreceptor tyrosine-
based inhibitory motif (ITIM) in their cytoplasmatic domains and provide protection 
for all cells that express normal amounts of MHC I on the cell surface. The MHC-I-
binding inhibitory receptors recruit tyrosine phosphatases which are believed to 
counteract activating receptor-stimulated tyrosine kinases. KIRs recognize epitopes 
on HLA-A, HLA-B and HLA-C classes while the CD94/NKG2 receptor recognizes 
human HLA-E (1177). Many of these receptors or related proteins are also found on 
NKT cells, memory T cells and other immune cells (905).  
 
Downregulation of MHC I due to viral infection or transformation of cells would 
alleviate inhibition of NK cell positive signaling and may result in initiation of 
cytotoxicity and cytokine production. It appears that there is not a single antigen 
receptor responsible for NK cell activation but an activity of several receptors 
triggering effector function. Activating receptors on NK cells include molecules with 
immunoreceptor tyrosine-based activation motifs (ITAM) such as NKG2D that 
recognizes MHC-like proteins MICA and MICB as well as 2B4 which binds to CD48 
(784). MICA and MICB are expressed by epithelial tumor cells and stressed cells; 
CD48 is significantly upregulated in B cell infected with Epstein-Barr-Virus (EBV), 
for example (483, 784). NKG2D triggering can induce NK cell lysis of tumor cells 
and cytokine secretion.        
 
The invading trophoblasts express HLA-G and can interact with the KIR receptors 
on uterine NK cells. Membrane-bound HLA-G has been shown to stimulate uterine 
NK cells and IFN-γ production and to suppress mononuclear cell effector functions 
(1438). NK cell-derived IFN-γ seems to be necessary for vascular remodelling of 
spiral arteries and placental formation so that the recognition of HLA-G on 
trophoblasts by uterine NK cells may be important for placental development. 
Uterine NK cell-deficient mice demonstrated failure to sustain decidual integrity 
and loss of spiral artery modifications (481). 
 
NK cell interactions with DCs are seen as an important part of forming an initial 
immune response. NK cells have been demonstrated to kill immature DCs (313). 
DC-derived IL-2 is essential for induction of NK cell production of IFN-γ during 
bacterial infection. Moreover, IFN-α helps activating NK cell cytotoxicity, and DCs 
are a good source of IFN-α after infection. NK cells can interact with endothelial 
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cells through adhesion molecules and chemokine receptors. NK cells are able to 
recognize and kill endometrial endothelial-derived cell lines, and ECs can produce 
cytokines upon exposure to pathogens that can activate NK cells. However, the 
interactions of NK cells with these cells are poorly understood so far.        
(4) TLRs 
Like other innate immune cells, NK cells also express various TLRs. Human blood 
NK cells were positively tested for the expression of mRNA of TLR1 to TLR10 (568). 
Agonists of TLR2, TLR3 and TLR9 are able to trigger IFN-γ production of NK cells 
while CpG DNA as the agonist of TLR9 is not certain to activate NK cells directly or 
via cytokines such as IL-12, IL-8, IL-15 or TNF-α (749).  
Recent data suggest that uterine NK cells express several TLRs such as TLR2, TLR3 
and TLR4 whose agonists can trigger these cells to produce IFN-γ (1512). The 
hypothesis is therefore that microorganisms may initially activate ECs which 
produce cytokines and these cytokines in combination with PAMPs will activate NK 
cell cytokine production, resulting in further activation of innate immune 
responses.   
e) Neutrophils in the female genital tract 
Neutrophils comprise 40 to 70% of circulating white blood cells and have always 
been considered as a first line of defense against pathogens (1266). They have a 
relatively short lifespan of about 6 hours circulating in blood before being removed 
by macrophages of the reticuloendothelial system (RES). When pathogenic 
microorganisms infect the host, neutrophils rapidly migrate to the site of infection 
during the first 1 to 4 hours.  
Produced in bone marrow, they enter the blood stream by inflammatory signals 
originating from the infection sites, adhere to the vessel wall at the sites of tissue 
damage and transmigrate through endothelial cells to the infection site (600). When 
moving with the blood stream they roll along the vessel wall and continuously 
interact with the capillary walls to search for inflammation signs, what is called 
margination (812).  
 
Tissue cell injury and infection result in increased expression of the adhesion 
molecules E- and P-selectins by endothelial cells as well as expression of 
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sialomucins which interact with L-selectins on neutrophils. When rolling across the 
endothelial surface the integrin molecules on the neutrophils` surface are activated, 
which leads to firmer adhesion. IL-8 is secreted by endothelial cells which induces 
shedding of integrins and L-selectin and therefore starts transmigration of 
neutrophils (576). By crossing the endothelial barrier neutrophils unpack their 
granules with tissue-degrading enzymes and microbicides which facilitate this 
passage (382).  
Neutrophils follow both endogenous and bacterial chemoattractant signals to arrive 
at a site of infection (536). The presence of pathogens are detected by germline-
encoded receptors that recognize PAMPs; human neutrophils express TLR 2 to 10 
except TLR3 (525). The final elimination of pathogens is completed either by 
phagocytosis or production of toxic oxidate compounds by the cytoplasmatic and 
membrane-bound nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
system. Other possible mechanisms are the release of microbicides such as 
defensins and serine proteases from intracellular granules (1512). The neutrophils 
themselves produce several cytokines, for example IL-1β, IL-8, TNF-α, TGF-β1 
(182), that attract more neutrophils, macrophages and other immune cells helping 
to initiate the adaptive immune response. 
(1) Distribution 
Neutrophils can be found in all tissues of the female reproductive tract. Given the 
fact that the vagina is colonized by a mixture of commensal microorganisms one 
would expect the highest level of neutrophils in these lower regions of the female 
genital tract where the most pathogens can be found. However, the highest amount 
of neutrophils is recovered from fallopian tube with consistently decreasing 
numbers down through the lower genital tract (459).  
Patton and colleagues examined vaginal tissue of ovulating and non-ovulating 
women during three phases of the menstrual cycle for the number of cell layers and 
epithelial immune cells (1098). The number of EC layers underwent a small 
reduction from days of menses to the postovulatory phase and non-ovulating 
women had a thinner vaginal epithelium than ovulating women which suggests a 
hormonal influence on vaginal EC growth. However, the numbers of neutrophils as 
well as these of T cells and macrophages remains constant throughout the cycle.  
 
In mice, a large number of neutrophils infiltrate into the vaginal epithelium 
accompanied by an increased number of neutrophils in vaginal lavage fluid after 
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ovulation (1327). Correspondingly, concentrations of a functional IL-8 homologue, 
murine MIP-2 were significantly increased. This indicates the regulation of 
neutrophil migration into the vagina by MIP-2 in a sexual cycle-dependent manner.  
 
IL-8 is a potent chemotactic and activating factor for neutrophils and high levels of 
IL-8 correlate with high levels of neutrophils in the female vagina (192). This 
corresponds with the findings that neutrophils cannot cross the epithelial barrier 
unless they are under the influence of a chemokine gradient of IL-8, for example 
(692). The same study showed no difference between the number of neutrophils or 
concentration of IL-8 in healthy women compared to women with bacterial vaginosis 
(BV). When women were experimentally infected with Candida albicans, either a 
commensal or a pathogen, there was no neutrophil infiltration in the vagina when 
the infection was asymptomatic or did not take place (400). In case of vaginal 
infection there was neutrophil infiltration and inflammation. Production of 
chemokines that attract neutrophils and neutrophil infiltration seem to occur only 
after infection of the vaginal epithelial layer. Vaginal lavage fluid from women with 
symptomatic infection, but not those asymptomatically colonized, promoted the 
chemotaxis of neutrophils (400).       
In animals, a rapid subepithelial influx of neutrophils in the vagina occurs not only 
due to insemination but also to sterile liquid solution brought into the vagina (888). 
Similar results were produced in women after insemination, although more in 
association with the cervix (1074).    
 
Cervix 
Compared with other leukocytes, neutrophils represent the highest population with 
83% of all leukocytes in human cervical secretions (1414). Both insemination with 
increased local production of IL-8 and infection of the cervix increase the number of 
neutrophils in the cervix significantly (125). In case of infection, cervical cells 
secrete IL-8 to promote neutrophil invasion in response to pathogen-associated 
substances such as LPS (1481) but human cervical tissue is generally capable of 
producing IL-8 in vitro with decreasing activity postmenopausal (125).  
 
Uterus 
The complex cycle of the endometrium is regulated by hormonally controlled 
interactions between cytokines, chemokines, endometrial cells and leukocytes. 
During most phases of the menstrual cycle the numbers of neutrophils are low. 
However, prior to menses a decrease in progesterone levels is responsible for a rise 
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in IL-8 production in perivascular cells, epithelia and glands (47, 267). At this time, 
there is also a significant increase in endometrial neutrophils which comprise up to 
15% of all tissue cells (1249), which serves to guard against infection at this time of 
lower epithelial defenses.  
Neutrophils may aid in endometrial breakdown as neutrophil granules release 
elastase and membrane-type matrix metalloproteinase (MT1-MMP) by chemotaxis 
which both are able to activate MMP 2 and 3 (1579). The degranulation of 
neutrophils also releases antimicrobial contents such as defensins, SLPI or the 
neutrophil protease inhibitor and microbicide related to SLPI, elafin, which also 
peaks at menses (706).  
Endometrial neutrophils are also capable of producing IFN-γ both in vitro and in 
vivo (1559), especially in the endometrial stromal layer. This production of IFN-γ 
also shows no variation during the menstrual cycle. By altering the local cytokine 
environment, neutrophils seem to be able to biase immune responses in the 
endometrium.  
 
Fallopian tube 
The fallopian tubes represent the tissues with the highest number of neutrophils in 
the female reproductive tract (459) with most of them distributed in the lamina 
propria and a few in the epithelium (1529). The expression of IL-8 is highest in the 
late proliferative phase around ovulation (1067). This may suggest a greater influx 
of neutrophils at this time but there seem to be no studies on neutrophil number 
variation in the fallopian tubes during menstrual cycle (1512). IL-8 was also present 
in greater amounts in the distal compared with the proximal tube. The degradative 
enzyme aminopeptidase N is found in tubal stromal tissue at the epithelial stromal 
border and may limit the effect of epithelial IL-8 in recruiting neutrophils. However, 
the exact role of neutrophils in the fallopian tubes as part of the local immune 
system remains quite unclear.  
 
Ovary 
Also in the ovary neutrophils are present throughout the menstrual cycle. It has 
been show that low numbers of neutrophils infiltrate ovarian stroma but high 
numbers are present in the wall of the developing ovarian follicle (144). At 
ovulation, there was a marked increase in the density of these cells in the follicle 
wall, especially in the thecal layer, where they accumulate particularly around the 
point of imminent rupture. This suggests an active role for neutrophils in tissue 
remodelling during the ovulatory process.  
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Following rupture of the follicle and release of the ovum, the empty follicle becomes 
the corpus luteum. In the corpus luteum there is a higher density of neutrophils in 
the theca lutein area compared with the granulosa lutein area (144). There are no 
significant changes in the density during early and late luteal phase.  
IL-8 concentrations in follicular fluid vary over the menstrual cycle and have their 
peak around ovulation which is consistent with the peak of neutrophil influx 
(1225). Exposure to follicle-stimulating hormone (FSH) and luteinizing hormone 
(LH) but not estradiol or progesterone increased the IL-8 secretion from granulosa 
cells.  
(2) Characteristics and functions 
The different numbers and distribution of neutrophils in the female reproductive 
tract explains the need for investigating the distribution of neutrophil 
chemoattractants in the different regions of the genital tract (1512).  
It was found that cervical tissue expressed the highest amount of RNA for Gro-γ 
(CXCL3), ENA-78 (CXCL5), GCP-2 (CXCL6) and IL-8 (CXCL8). Fallopian tube 
expressed the second highest amount of IL-8, but ectocervix was the second to 
highest in expression of ENA-78 and NAP-2. Endometrium expressed the least 
amounts of RNA for Gro-γ, GCP-2, NAP-2 and IL-8. These findings do not correlate 
with neutrophil recovery from tissues by enzyme digestion (1512). The cervix should 
contain the greatest number of neutrophils if CXC chemokine expression was 
proportional to recruitment of neutrophils. Moreover, one would expect a higher 
amount of microorganisms at the cervix than in higher regions of the reproductive 
tract, resulting in greater need for innate immune protection by neutrophils.  
 
In studies with EC cultures of the reproductive tract the high neutrophil 
chemoattractant activity of these cells was the result of synergistic action between 
IL-8 and GM-CSF secreted by ECs (1292).  
This suggests that relatively low concentrations of GM-CSF can potentiate the 
activity of CXC chemokines in induction of neutrophil chemotaxis. Moreover, one of 
the many actions of GM-CSF on neutrophils could also be to downregulate 
responses when they are no longer necessary (1512). If neutrophils have entered 
the lumen of the genital tract after encountering high GM-CSF levels in the 
epithelium, a response to IL-8 which might attract the cells back into the tissue 
would be counterproductive.    
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Concerning neutrophil crossing of the epithelial barrier, it is known that they prefer 
to cross monolayers of cultured ECs from the basal to the apical side provided that 
an IL-8 gradient exists from apical to basal (692). Wira and colleagues presumed 
that unstimulated ECs in the female genital tract secrete chemokines basally to 
attract neutrophils to the epithelium. In addition, they produce a higher amount of 
chemoattractant on the luminal side that might serve to induce neutrophils to cross 
the epithelium and enter the lumen (1512). 
Shen and colleagues have concentrated lately on the investigation of neutrophils of 
the fallopian tubes as this tissue has the highest numbers of neutrophils per gram 
(1512). Fallopian tube neutrophils compared with blood neutrophils expressed 
higher levels of the adhesion molecule CD31 (PECAM-1) and CD15. 
CD31 is expressed on leukocytes and endothelial cells and is increased on 
transmigrated neutrophils (844), which suggests that fallopian neutrophils have 
crossed the endothelial barrier and are not only part of the marginated pool 
associated with the luminal surface of blood vessels. CD15 is a carbohydrate 
antigen involved in the binding of neutrophils to the endothelial lectins, E-selectin 
and P-selectin. When stimulated with chemotactic peptides during neutrophil 
migration, for example, CD15 is brought to the surface from intracellular pools. 
Another point is that CD15 ligation is reported to induce a release of granule 
content; the high CD15 expression may be important for innate immune responses 
in the fallopian tube.     
Fallopian neutrophils have also shown lower amounts of specific granule-associated 
molecules which suggests that they have undergone some kind of degranulation. 
Furthermore, they also demonstrated high levels of intracellular VEGF and IFN-γ 
(1512). As VGEF plays an important role in vasodilatation and vascular 
permeability (86) it would make a leukocyte infiltration of tissues possible.  
In summary, neutrophils in the reproductive tract seem to be regulated by the 
hormonal cycle as well as chemokines and cytokines.       
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3. Functions and regulations of adaptive humoral and cell-
mediated immunity in the female genital tract 
a) Immunoglobulins in the female genital tract 
(1) Distribution of immunoglobulin classes and subtypes 
Highly variable information has been reported about the presence of different Ig 
classes in human female genital secretions. Such discrepancies seem to reflect both 
the differences in the applied sampling method and individual variability such as 
age and stage of menstrual cycle (1090). The dominance of IgA in the majority of 
external secretions, such as intestinal and nasal fluids, saliva, tears and milk, has 
for decades been considered a cardinal characteristic of the humoral arm of the 
mucosal immune compartment.  
Waldman et al. found in 1971 already that S-IgA was the predominant Ig class 
(45%) in normal CVS; the remainder consisting of monomeric IgA (20%) and IgG 
(30%) (1467). In the same study, IgA levels were found to decrease with age in 
contrast to IgG which increases.  
In more recent studies results partly differ from those findings. Latest studies have 
revealed that humane urine, seminal plasma and cervical or vaginal washings 
collected at various stages of the menstrual cycle contain a higher proportion of IgG 
than IgA (608). Some studies showed a predominance of IgG in cervical secretions 
but a higher proportion of specific IgA antibodies in secretions from women with 
colonized group B streptococci in their cervix or rectum (566). Hocini et al. came to 
the result that IgG is also predominant in normal vaginal fluid (556) which fits to 
the findings of Quesnel et al. with IgG dominating in vaginal fluid and IgA in 
mucus mostly from endocervix (1155). However, Kutteh et al. showed in 1996 with 
the method of cervical washing the predominance of IgG also in cervical mucus with 
a peak before the time of ovulation together with smaller preovulatory peaks of IgA 
and IgM (764). Parr and Parr reported in their article that in several reports IgG 
appears to be the predominant Ig in CVS, but the ratios of IgG to IgA vary from 2:1 
to 10:1 (1090). Measurements of Ig in humane uterine fluid also indicated the 
predominance of IgG; nevertheless, the uterus may be the primary source of IgA in 
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vaginal fluid since the concentration of IgA in vaginal fluid from hysterectomized 
women was only about 10% of normal (612).  
 
IgG occurring in genital secretions was deemed to be mainly serum-derived, but a 
significant enrichment of the IgG1 subclass suggested also some local influence 
(556). However, the mechanisms involved in the appearance of IgG in cervical 
secretions remain unclear. There are strong suggestions that specific activity of IgG 
antibodies in genital tract secretions often correlates with that in serum which 
shows that part of IgG originates from circulation. Others discuss that part of IgG is 
secreted by plasma cells residing in genital tissues (1227). How IgG reaches the 
lumen whether by active transport or passive diffusion remains unknown.  
Concerning IgM antibodies, very little is known so far. A short-lived IgM response 
has been found during herpes simplex infection.   
 
Concerning the IgA subclasses, female genital tract secretions resemble secretions 
of the lower intestinal tract rather than the upper intestinal or respiratory tract 
where IgA antibodies mostly belong to the IgA1 subclass (922). Both IgA1 and IgA2 
are found in equal proportions in the female genital tract as well as in the rectum 
and the large intestine (Figure 4).  
 
Figure 4: Distribution of IgA1- and IgA2 producing cellls in systemic and mucosal 
tissues in humans (925) 
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With respect to the molecular forms of IgA, the female genital tract secretions are 
again unique. In contrast to plasma in which monomeric IgA constitutes 90-99% of 
total IgA or to saliva and milk in which 95% of IgA is polymeric, cervical mucus 
contains about 70% polymeric IgA and vaginal secretions contain almost equal 
proportions of polymeric and monomeric IgA.  
The ratios of IgA1 and IgA2 and the predominance of polymeric IgA in cervical 
secretions indicate that much of the IgA originates from local production, not from 
plasma (764). However, the high representation of the serum monomeric form of IgA 
in the vagina clearly demonstrates that, contrary to other mucosal surfaces, the 
genital tract relies heavily on antibodies derived from serum and systemic 
immunity. Because of the intrinsic resistance of IgA2 to IgA1 proteases of many 
pathogenic bacteria, the increased proportions of IgA2 may provide functional 
advantage to certain specific antibodies (763). 
 
To conclude, antigen-specific IgA, IgG and IgM antibodies and SCs can be detected 
in the external secretions of the human genital tracts. IgG levels in the lower genital 
tract secretions seem to equal or even exceed the levels of S-IgA whereas the 
dominant isotype of other mucosal secretions is S-IgA (763). IgG and IgA are under 
hormonal influence and are derived from the systemic compartment, as well as 
being locally produced. 
(2) Production of immunoglobulins in female genital tract tissue 
Cervix, fallopian tubes and vagina  
IgA and IgG antibodies in genital tracts can be transported from peripheral blood 
and can also be produced by resident Ig-secreting cells. Studies showed that the 
presence of antibody-containing and antibody-secreting cells is higher in the 
uterine endocervix than in the ectocervix, fallopian tubes and the vagina (273, 759). 
IgG and IgA-secreting plasma cells are abundant in the lamina propria of the 
endocervix and almost all IgA-producing cells contain J chain, a marker of 
synthesis of polymeric IgA. The immunocyte class proportions were similar to those 
reported for small intestine mucosa, with a striking predominance of IgA-producing 
cells.  
Immunohistochemical examinations by Mestecky and Kutteh (759) found out that 
the number of Ig-producing cells of IgA, IgG and IgM is different at various spots in 
the female genital tract (Table 13). The endocervix and the ectocervix displayed the 
highest accumulation of Ig-forming cells and that such cells predominantly produce 
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antibodies of the IgA subtype, among that almost equal proportions of IgA1 and 
IgA2 subtypes.  
 
Tissue IgA IgA1 IgA2 IgM IgG 
Fallopian 
tube 
67 55 45 22 11 
Endocervix 73 57 43 12 15 
Ectocervix 79 59 41 10 11 
Vagina 79 45 55 14 7 
Table 13: Distribution of immunoglobulin-producing in different tissues of the female 
genital tract in percentage of total Ig-containing cells, adapted from Kutteh et al. 
(759)   
However, in a study by Crowley-Norwick et al. on cervical cells with ELISPOT, at 
least four times more IgG- than IgA-producing cells were detected (89% versus 17%) 
(273). Brandtzaeg proposed that immunohistochemical studies have 
underestimated the IgG class because of interstitial staining (141). Moreover, the 
quantification of Ig-producing cells is difficult to perform due to their uneven 
distribution.  The actual quantities of Ig-producing cells were measured as density 
by number of cells/10 low-power fields without any accurate definition of the 
evaluated tissue compartment. The endocervix was found to have the largest 
number followed by ectocervix, fallopian tubes and vagina (761).  
While the expression of both CD19 and CD20 is lost in terminal differentiation of B 
cells, CD38 is strongly expressed by plasma cells. Johansson et al. could not 
detect any CD19- or CD20-expressing cells in cervix and vagina which agrees with 
the results of Crowley-Norwick et al. (626). CD38 plasma cells were abundant and 
scattered in subepithelial stroma reinforcing that the genital tract contains 
antibody-producing cells.  
 
Mestecky et al. also found out that the ECs of fallopian tubes, uterus, endocervix 
and ectocervix express the pIgR, the extracellular part of which is called the SC 
(923). Thus, all components for an active transepithelial transport of polymeric IgA 
are present which takes place in the same manner like in other mucosal tracts.  
As the pIgR is not distributed equally throughout the genital tract, secretion of S-
IgA takes place primarily in the cervix and to a lesser extent in the fallopian tubes 
and uterus. Uterine expression of polymeric IgA is under the control of hormones, 
in a way that estradiol elevates whereas progesterone partly reverses this effect. 
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Moreover, in case of infection or inflammation its expression is also increased, 
possibly by cytokines such as IFN-γ, TNF-α and IL-4 (1227). 
Table 14 shows an overview of the presence and frequency of IgA, IgG, J chain and 
SC in different female genital tract mucosa. Data suggest that the endocervix is 
likely to be a focal point for mucosal immunity in the genital tract.  
   
 IgA J chain SC/sIgA IgG 
Myometrium ― ― ― ― 
Fallopian tube + + + + 
Ovary ― ― ― ― 
Endometrium +/― +/― + + 
Endocervix +++ +++ ++ +/+++ 
Ectocervix ++ + +/― + 
Vagina + + +/― ++ 
Table 14: Summary of results form different studies concerning relative distribution 
of IgA, IgG, SC, and J chain in the tissues of the female reproductive tract (conflicting 
results exist for IgG production in cervical mucosa), adapted from Brandtzaeg (141)     
Endometrium 
Studies have reported that only quite rare and scattered Ig-producing cells are 
present in the normal human endometrium (759). Others reported the 
predominance of IgG-containing cells in the human endometrium regardless of the 
stage in menstrual cycle (141), followed by IgM and IgA-containing cells.  
When evaluated without the prefixation washing procedure, the endometrium`s 
stroma contained scattered IgG and less IgA but there was an accumulation of IgA 
within the glandular lumina and apically in the epithelium without the presence of 
IgA immunocytes (140). This strongly suggested selective external transport of 
serum-derived polymeric IgA, which was supported by staining for J chain. 
Monomeric IgA without co-localization of J chain was detected in vessel lumina, 
which supports this hypothesis.  
Also the preferential epithelial localization of IgM compared with IgG supported the 
idea that polymeric Igs derived from serum can actively be transported externally 
through endometrial glands. This was underlined by the general appearance of SC 
throughout the endometrial epithelium, particularly in the glands (141). Glandular 
uptake of antibody molecules from the interstitial fluid therefore seems to be 
dependent on SC acting as pIgR with additional paracellular diffusion of IgG (141).  
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SC-expression and IgA uptake in the endometrium proved to be dependent on the 
phase of the menstrual cycle, showing a rise from the proliferative to the mid- and 
late secretory phase (118). The same study showed that the endometrial glands 
contained significantly more of all components of the secretory immune system in 
the mid- and late luteal phase than in the early half of the menstrual cycle (Figure 
5). 
 
   
Figure 5: Scatter diagram displaying the percentage distribution of human 
endometrial glands containing different humoral immune components throughout the 
menstrual cycle; each thin line representing one specimen, thick lines connecting 
medians, adapted from Bjerke and Brandtzaeg (118) 
(3) Regulation of Ig levels by sex hormones 
Sex steroid hormones may be important in regulating both the systemic and 
secretory immune system. Estrogens, progesterone, and androgens directly and 
indirectly modify numerous immunological functions (1408).  
Estrogens drive differentiation of CD4+ helper T cells toward Th2 regulation, 
increase production of Igs, and downregulate cell-mediated immunological 
processes. In contrast, androgens, such as dehydroepiandrosterone (DHEA), drive 
differentiation of CD4+ helper cells toward Th1-regulated functions and antagonize 
certain estrogen-mediated immunological effects. Progesterone increases the activity 
of suppressor T cells. 
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There is clear sexual dimorphism in the immune responses of males and females 
which is shown by higher Ig levels in females as compared with males. Together 
with more vigorous antibody responses to exogenous antigens of females this 
indicates a higher humoral immunity in females than in males (929). In addition, 
females seem to have a reduced incidence of tumors, a better resistance against 
viral and parasitic infections and seem to reject allograft more rapidly as compared 
with males which also suggests a higher cellular immunity in females (135). 
 
From an endocrine point of view, each organ in the female genital tract acts like a 
discrete reproductive organ whose contribution to reproductive success is 
controlled by the ovarian release of estradiol and progesterone. They also enhance 
or suppress immunocompetency of the genital tract. 
IgA and IgG levels in uterine secretions in rats were shown to change markedly 
during the reproductive cycle with highest levels at ovulation (1518). When 
ovariectomized rats were treated with estradiol, IgA and IgG levels in uterine 
secretions were elevated compared to saline controls (1519). In CVS, however, levels 
of IgG, IgA and SC were lowered in response to hormones (1520). This suggests that 
changes in hormone levels may have different effects on immune responses in 
different regions of the female reproductive tract. 
Estradiol also upregulates the expression of pIgR on uterine ECs and thereby 
increase the transcytosis of polymeric IgA into the uterine lumen of intact and 
ovariectomized rats (1518, 1519). 
Kutteh et al. demonstrated that Ig levels of IgA, IgG and IgM in cervical mucus are 
dependent on the stage of menstrual cycle reaching a peak before the time of 
ovulation (764). Previous experiments on IgA concentrations in cervical mucus and 
cervicovaginal secretions also show a decrease at ovulation from preovulatory peaks 
(1467). This relationship between estrous cycle and specific antibody levels likely 
reflects the changes that occur in the female reproductive tract during the course of 
the estrous cycle. Preovulatory until the time of ovulation, or at the time of mating, 
the female genital tract is subjected to numerous pathogens (1144). In fact, sperm 
has been shown to be a vector for bacteria, whereby the bacteria attach to the tails 
of sperm as they move up the reproductive tract. 
 
Estrogen has been shown to increase total IgG and IgM production by human 
peripheral blood mononuclear cells (PBMCs) from normal individuals (1058, 661). 
In the former study, the Ig-enhancing effects of estradiol were due to inhibition of 
CD8+ suppressor cells (1058), while in the latter study the effect of estradiol was 
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neutralised by anti-IL-10 antibody (661) and the authors suggested that the 
increased IgG production was mediated by secretion of IL-10 by monocytes in the 
PBMC cultures.  
b) Prevalence of T lymphocytes  
Givan et al. estimated that leukocytes represent 6 to 20% of the total number of 
cells in fallopian tubes, endometrium, cervix and vaginal mucosa with greater cell 
numbers in the upper tract (459). B cells are present in low but measurable 
numbers but T cells accounted for about 50% of all leukocytes, with CD8+ T cells 
predominating over CD4+ T cells.  
This was confirmed some years later in a study by Johansson and colleagues who 
also showed a characteristical distribution of immune cells (626). They found that 
both CD4+ and CD8+ T cells were concentrated in a band beneath the epithelium 
and dispersed in epithelium and lamina propria. They also found several lymphoid 
aggregates consisting of T cells and B cells in one cervical sample.   
Also another study detected aggregates consisting of an inner core of B cells 
surrounded by mainly CD8+ T cells and an outer halo of macrophages in the 
human endometrium (1560). Size was found to vary with the stage of menstrual 
cycle with larger size during secretory stage than those at proliferative stage. The 
absence of these aggregates in uteri of postmenopausal women provided further 
evidence that these aggregates are under hormonal control (1560). These aggregates 
had multiple features of inductive lymphoid tissue, for example aggregated 
lymphocytes in follicle-like structures, lymphocyte invasion of overlying epithelium 
and the presence of HEV. This suggests that these structures represent an 
organization of immune cells that are not dependent on the presence of infection or 
malignancy.    
White et al. used hysterectomy specimens cocultured with IL-2 that contained 
CD3+CD8+ T cells to demonstrate cytolytic activity in the genital tract (1497). 
Cytolysis by CD3+ CD8+ T cells was found throughout the reproductive tract and 
appeared to be hormonally regulated, since in the uterine endometrium, the 
capacity for CD3+ T cell cytolytic activity was present during the proliferative phase 
of the menstrual cycle and absent during the subsequent secretory phase. In 
contrast, in postmenopausal women the entire reproductive tract, including the 
uterus, retains the capacity for strong CD3+ T cell cytolytic activity (1497). 
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A study by Pudney et al. showed that in women without inflammation, T cells and 
APCs were most prevalent in the cervical transformation zone and surrounding 
tissue (1146). Intraepithelial lymphocytes were predominantly CD8+ T cells; most 
CD8+ cells in the transformation zone and endocervix, and a proportion of cells in 
the ectocervix, expressed T-cell internal antigen-1, a marker of cytotoxic potential.  
In contrast, the normal vaginal mucosa contained few T cells and APCs. Cervicitis 
and vaginitis cases had increased numbers of intraepithelial CD8+ and 
CD4+lymphocytes and APCs. The menstrual cycle and menopause had no apparent 
effect on cellular localization or abundance in any of the lower genital tract tissues. 
These data indicated that the cervix, especially the transformation zone, is the 
major inductive and effector site for cell-mediated immunity in the lower female 
genital tract (1146).  
 
Other data demonstrated that changes in circulating levels of estrogen can regulate 
the recruitment of bone marrow-derived cells to the uterine endometrium. In a 
study by DeLoia et al., the total uterine leukocyte population increased 
significantly when the women received oral estrogen, which resulted in higher 
serum estrogen levels (318). This rise in leukocytes was due to a significant increase 
in both the uterine NK cells and the macrophage populations whereas T-cell 
numbers did not change relative to circulating estrogen levels. 
While further studies will be required to determine the effects of sex hormones on T 
cell function, receptors for estradiol have been demonstrated on both CD8+ and 
CD4+ T cell populations whereas the presence of progesterone receptors on T 
lymphocytes remains controversial (91). 
 
 
 
To conclude, the human systemic and mucosal compartments of the immune 
system, especially the female genital tract, display a remarkable degree of 
independence. In contrast to other mucosal systems, the genital tract mucosal 
system is characterized by a significant contribution of the systemic compartment 
with respect to Ig isotype distribution, unique distribution and phenotypes of B and 
T cells, strong hormonal dependency and lack of typical lymphoepithelial inductive 
sites (Table 15).  
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Humoral immunity Cellular immunity 
 
Ig-
producing 
cells 
J 
chain 
pIgR 
T cells 
CD4 - CD8 
NK 
cells 
MA DC N 
Myometrium – – – –         – – – – – 
Fallopian tube + + + ++       ++ + + + +++ 
Ovary – – – +         +  – +/– +/– + 
Endometrium +/– +/– ++ ++       ++ ++ + – ++ 
Endocervix +++ ++ +++ ++       ++ + + ++ ++ 
Ectocervix ++ + + +++     +++ + + ++ ++ 
Vagina + + – +++     +++ + + ++ ++ 
Table 15: Components of humoral and cellular immunity at different sites of the 
female reproductive tract; MA=macrophages, N=neutrophils, adapted from Kutteh et 
al. (763) 
4. Immunization studies  
Based on the concept of a common mucosal immune system through which a 
fraction of lymphocytes activated at one mucosal site can disseminate immunity not 
only at this specific site, but also to other mucosal tissues, there has been much 
interest in the possibility of developing vaccines against mucosal infections in the 
genital tract (287).  
Although the concept of the common mucosal immune system has been the 
dominant paradigm in mucosal immunology for more than two decades, it has 
become increasingly clear that there is a substantial degree of 
subcompartmentalization with the human reproductive tracts representing a 
component of this system with unique features, as discussed in the last chapters in 
detail. Indirect evidence suggests that female genital tract tissues may be 
preferentially supplied by cells from inductive sites located in intestine, rectum and 
nasal cavity.  
 
It has been well established that the dissemination of cells from the inductive to the 
effector site is regulated by characteristic homing receptor-ligand interactions 
operational in mucosal tissue. In order to recruit leukocytes to mucosal tissue, the 
endothelium of the vessels expresses adhesion molecules, or addressins, that serve 
as ligands for homing receptors on the cells. Johansson et al. described the 
expression of intercellular adhesion molecule-1 (ICAM-1), VCAM-1, vascular 
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adhesion protein-1 (VAP-1) and P-/E-selectins in cervical and vaginal tissue (626). 
However, none of the samples expressed mucosal addressin cell adhesion molecule-
1 (MAdCAM-1). MAdCAM-1 has been shown in the gut-associated lymphoid tissue 
and is the only known vascular adhesion molecule that specifically directs 
lymphocytes to mucosal tissue via binding to the lymphocyte integrin α4β7 (1364).   
Immunization that produces secretory immunity in the female reproductive tract 
against STDs could have important practical applications. Investigators have 
attempted to elicit secretory immunity in the genital tract by using different routes 
of immunization. These local, remote and parenteral routes should be briefly 
outlined here.  
a) Vaginal immunization 
Earlier studies of immunization in the human uterine lumen with sperm, for 
example, failed to detect immune responses in the reproductive tract (966). 
Comparative studies have demonstrated that antibody titers in luminal fluids of the 
mouse female tract after intravaginal immunization are low in comparison with 
titers produced by systemic immunization (1410). Adjuvants increased local 
immune responses to intravaginal immunization in mice as they are likely to 
damage the uterine epithelium thus allowing antigen to reach lymphoid cells and 
vessels in stroma (1409).  
However, in 1973, Ogra and Ogra observed that immunization with inactivated 
poliovirus placed in the uterine lumen resulted in IgG antibodies in uterine 
secretions but not in serum (1041).  
More recent studies with the potent mucosal immunogen cholera toxin (CT) B 
yielded analogous results. In one study by Kozlowski et al. women were 
immunized three times either orally, rectally, or vaginally with a cholera vaccine 
containing the recombinant CTB subunit with or without killed Vibrio cholerae cells 
(743, 744). All three immunization routes increased levels of specific IgG in serum 
and specific IgA in saliva to similar extents. Only vaginal immunization significantly 
increased both specific IgA and specific IgG in both the cervix and the vagina but 
did not generate antibodies in the rectum (743, 744). As the quality of humoral 
immune response is significantly influenced by the time of immunization during the 
menstrual cycle, it may be necessary to administer vaccine during the follicular 
phase of the menstrual cycle in case of the vaginal route (745).  
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b) Rectal immunization 
Follicular structures analogous to Peyer`s patches are also found in the appendix 
and the large intestine, with especially pronounced accumulations in the rectum. 
The fact that the distribution of plasma cells produces almost equal amounts of 
IgA1 and IgA2 subclasses in the large intestine and female genital tract suggests 
that rectal lymphoid tissue may be an important source of IgA precursor cells 
destined for the genital tract.  
The potential importance of rectal lymphoid tissues as an inductive site for 
stimulation of humoral immune responses in the human female genital tract has 
been subject of several studies (272, 743, 744, 745, 760).  
 
In the studies by Kozlowski et al., rectal immunization was superior to other 
routes for inducing high levels of specific IgA and IgG in rectal secretions but was 
least effective for generating antibodies in female genital tract secretions (743, 744). 
In the trial of Crowley-Norwick et al. with influenza virus, rectal immunization 
induced significant increases in the concentration of flu-specific IgA but not of IgG 
found in cervical secretions within 28 days after vaccination (272). Rectal 
administration did not induce significant IgA responses, and only small flu-specific 
IgG increases in serum. Six months after administration, IgA and IgG flu-specific 
antibody concentrations were significantly higher than baseline levels in 
vaginal/cervical secretions.  
c) Nasal immunization 
Animal studies also emphasized the importance of the inductive sites in the nasal 
cavity for the generation of mucosal, including genital, and systemic immune 
responses that may exceed in magnitude those induced by oral immunization 
(1227).  
Limited studies on nasal immunization performed on women suggested that 
intranasal immunization with CTB or CTB-Vibrio cholerae vaccines induced 
respectable titers of anti-CTB IgA and IgG antibodies in vaginal washings and 
cervical fluid (111, 625, 1222).  
The results of another study comparing nasal and vaginal immunization with CTB 
showed that both resulted in significant IgA and IgG anti-CTB responses in serum 
(627). Only vaginal vaccination given on days 10 and 24 in the cycle induced strong 
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specific IgG and IgA antibody responses in the cervix whereas modest responses 
were seen after nasal vaccination. Nasal vaccination was superior in inducing a 
specific IgA response in vaginal secretions, giving a 35-fold increase, while vaginal 
vaccination only induced a 5-fold IgA increase. It was concluded that a combination 
of nasal and vaginal vaccination might be the best vaccination strategy for inducing 
protective antibody responses in both cervical and vaginal secretions, provided that 
the vaginal vaccination is given on optimal time points in the cycle (627).  
 
When mice were immunized intravaginally with a bacterial protein antigen coupled 
to CTB subunit plus CT as adjuvant, weak specific antibody responses in both IgA 
and IgG isotypes were detected in vaginal wash fluids 7 days after the last of three 
immunizations (1537). No antibodies were detected in saliva and only low levels of 
IgG antibodies were found in the serum. In contrast, when the same immunogen 
was administered without adjuvant intranasally, mice developed substantially 
greater levels of IgA and IgG antibodies in vaginal fluids, and also IgA antibodies in 
saliva as well as IgG and IgA antibodies in serum. Analysis of the molecular forms 
of IgA antibodies in murine vaginal washes indicated that these were predominantly 
polymeric and similar to those found in saliva, consistent with S-IgA, although 
smaller amounts of possibly monomeric IgA were also present (1537). 
d) Systemic immunization 
Systemic immunization is of unique relevance to the induction of the humoral 
immunity in the female genital tract. The significant contribution of IgG from the 
circulation to the pool of antibodies in the genital tract secretions clearly indicates 
that parenteral immunization may be of considerable value (1227). Indeed, systemic 
vaccination with the inactivated influenza virus TT elicited specific IgG antibodies in 
vaginal and cervical secretions (272). Thapar et al. immunized female mice at two 
parenteral sites in the pelvis which generated significant IgG and IgA titers in 
vaginal fluid (1410). 
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5. Immunology of menstruation – menstruation as an 
inflammatory process 
In order to be prepared for implantation, the endometrium undergoes predictable, 
sequential phases of proliferation and secretory changes. Menstruation results from 
partial breakdown of the superficial or functionalis layer of the endometrium and 
ends in almost complete loss of the functionalis due to a fall in estrogen and 
progesterone. Re-epithelialization occurs simultaneously with the tissue destruction 
and is followed by regeneration of the stromal components (1248).  
This also occurs by withdrawal of exogenous hormones as in the case of 
contraceptive use or by administration of progesterone receptor antagonists such as 
mifepristone at the appropriate stage of cycle (424). However, although levels of 
these hormones fall significantly with corpus luteum degeneration in all mammals 
with oestrous cycle, only women and some primates menstruate. The molecular 
mechanisms by which steroids induce these changes involve interactions between 
the endocrine and immune system.  
a) Classic concepts of menstruation 
Markee examined the morphological changes in autologous endometrium 
transplanted to the eye of the rhesus monkey in the year 1940 (873). Prior to 
menstruation there was vasoconstriction of the spiral arterioles followed by 
vasodilatation. His thesis was that the tissue destruction occurred by necrosis 
coming from anoxia.  
Already 1961 it was observed that menstruation still occurred in primate atrophic 
endometrium without such coiled arteries (553). Overall endometrial blood flow is 
not reduced just prior to menstruation and the thesis of the presence of anoxia has 
not been demonstrated in human endometrium.   
 
Later on it has been demonstrated that the onset of bleeding is clearly not the first 
significant event in the process. Prior to bleeding as the first outward sign of 
menstruation, one can see degeneration in the basal lamina supporting the 
decidualized endometrial cells and the endothelium of blood vessels in the late 
luteal phase of the cycle (1201). Small lesions in the luminal epithelium have been 
observed on day 28 of the cycle followed by degeneration of the functionalis layer 
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(838). The first event in menstruation seems to be the degradation of extracellular 
matrix which leads to a loss of blood vessel integrity resulting in bleeding. The 
disruption of luminal epithelium then allows the escape of blood into the uterine 
lumen.  
 
Since the 1980s the concept of menstruation as the result of an inflammatory event 
has been coming up (413).  
Several features during the late secretory phase involving the presence of tissue 
oedema and decidual cells and the influx of migratory cells have been observed as 
well as leukocyte invasion and subsequent production of inflammatory mediators. 
The more recent identification of a variety of types of inflammatory cells using 
specific markers and also of chemokines and MMPs in premenstrual and menstrual 
tissue strongly supports this hypothesis.  
Current views of the mechanism of menstruation fall in two different categories, 
that supporting a key role for vasoactive substances and that proposing a central 
role for tissue destruction. Both theories fit the concept that menstruation is 
initiated at the stage when cells bearing proinflammatory molecules dramatically 
increase in number in the tissue (1249). During the immediate premenstrual phase 
the progesterone withdrawal induces expression of uterine cytokines that attract 
leukocytes into the uterine environment and the expression of MMPs by both 
endometrial and leukocytic cells. However, the knowledge of the exact local 
mechanisms involved is still incomplete.  
b) Distinct features of endometrium during menstruation 
During the secretory phase one of the characteristic features is a progressive rise in 
the number of apoptotic cells within the endometrial glands (1381). Withdrawal of 
factors such as ILs as well as of steroid hormones leads to apoptosis in steroid-
sensitive tissues. Estrogen regulates proliferation and apoptosis in endometrium as 
studies on animals showed; its withdrawal inducing apoptosis (1384).   
Secretory epithelium loses its integrity during the menstrual phase. The loss of key 
proteins in cell-cell adhesion may be responsible for the loss of integrity of the 
epithelial lining in endometrium during menstruation.  
Menstruation is also associated with a compromise in vascular integrity. (1384).    
Progesterone withdrawal also involves a severe constriction of the spiral arteries 
with consequent hypoxia in the regions closest to uterine lumen (873). There have 
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been proposed other endometrial vasoconstrictors besides prostaglandins such as 
endothelins and angiotensin II whose activity was increased in perivascular stromal 
cells around spiral arterioles in the secretory phase (12).  
Kelly has proposed two different phases of menstruation (686). Vasoconstriction 
and cytokine changes at the onset of menstruation are initiated by progesterone 
withdrawal and probably reversible. Subsequent activation of lytic mechanisms due 
to hypoxia is then inevitable. This latter phase seems to be progesterone 
independent and involves cells that may not express progesterone receptor such as 
uterine leukocytes. 
Hypoxia stimulates local mediators such as the angiogenic vascular endothelial 
growth factor (VEGF) in endometrial stromal cells. VEGF, a heparin-binding 
glycoprotein, is a very potent mitogen for endothelial cells, and induces vascular 
permeability and acts as a chemoattractant for monocytes. It is also one of the most 
potent angiogenic factors and is produced by monocytes, macrophages and smooth 
muscle cells. It has been shown that VEGF protein is localized predominantly in 
endometrial glands (1299). Estradiol increases the expression of VEGF gene in 
normal human endometrium. Hypoxia, IL-1, PDGF and TGF-β, EGF, and 
prostaglandin E2 are other factors known to up-regulate VEGF expression. VEGF 
also induces expression of certain MMPs in the endometrium (268).       
Endometrium repair starts as early as 36 hours after the beginning of menstrual 
bleeding while tissue breakdown is still in progress. Macrophages are partly 
responsible for the removal of detritus (1248). Cytokines and growth factors 
produced by inflammatory cells induce the process of wound healing. Macrophages, 
for example, express TGF-α, TGF-β, fibroblast growth factors, PDGF, VEGF and 
activin βB (877).  
(1) Non-resident cellular components of human endometrium 
Both the extracellular matrix composition and the cellular components of the 
human endometrium change parallel with the hormonal changes during the normal 
menstrual cycle (1248).  
Recently, the contribution of infiltrating cells of lymphomyeloid origin has been 
recognized. The population of various lymphomyeloid cells varies with the different 
phases of the cycle and has their highest levels during the premenstrual and 
menstrual phases. The distribution of inflammatory cells in the endometrium at 
three stages of the normal menstrual cycle shows Table 16. 
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Proliferative phase 
(days 10-12) 
Secretory phase  
(days 22-23) 
Menses 
(days 26-28) 
Macrophages + ++ +++ (6-15%) 
Eosinophils - - ++ (3-5%) 
Neutrophils - - +++ (6-15%) 
Mast cells ++ ++ ++ (3-5%) 
T lymphocytes + + + (1-2%) 
B lymphocytes +/- +/- + 
NK cells - +/++ +++ (5-6%) 
 Table 16: Relative distribution of specific inflammatory cells in the functional 
endometrium at three stages of the normal menstrual cycle, with their percentage of 
total endometrial cells at menses (1249) 
Evidence has emerged that at any time subsets of these cell types, represented by 
different phenotypes, are present in the endometrium and that apparently similar 
cells in the endometrium can be functionally different from those in the blood of the 
same individual (1497). Thus at least some of the cells which traffic into the 
endometrium must change in phenotype in response to the new environment.  
However, there is no doubt that during the perimenstrual and menstrual phase 
there is a significant influx of inflammatory cells into the endometrium comprising 
up to 40% of total cell number within the functional endometrium. 
 
Leukocyte population in the endometrium is dynamic. Fluctuations in the number 
of cells are probably a consequence of migration from the blood, cellular 
proliferation within the tissue, apoptosis and cell loss during the shedding of the 
functionalis. Eosinophils and neutrophils become apparent in the endometrium 
during the premenstrual phase only whereas increased numbers of macrophages 
and NK cells can be found earlier in the cycle (Table 16, 1250).  
 
Neutrophils 
Neutrophils, the most abundant leukocytes in the human, are closely related to 
tissue damage in inflammatory disorders.  
During most of the cycle, neutrophils are barely detectable in normal endometrium 
but the amount raises perimenstrually, comprising about 6-15% of the total cell 
number at this time (1249). Densities compared to those seen during menses are 
also reached in areas of endometrial breakdown in patients treated with progestins 
(1326).  
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Neutrophils may aid in endometrial breakdown as neutrophil granules release 
elastase and membrane-bound MT1-MMP by chemotaxis which both are able to 
activate MMPs 2 and 3 (1579). The degranulation of neutrophils also releases 
antimicrobial contents such as defensins, SLPI or the neutrophil protease inhibitor 
and microbicide related to SLPI, elafin which also peaks at menses (706). However, 
not all neutrophils have been observed to be immunopositive for MMP-9, activin βA 
which is responsible for cellular differentiation and MT11-MMP (1248) which 
suggests that there is more than one phenotype.  
Endometrial neutrophils are also capable of producing IFN-γ both in vitro and in 
vivo (1559), especially in the endometrial stromal layer. This production of IFN-γ 
also shows no variation during the menstrual cycle.  
 
Eosinophils 
Eosinophils have been detected in the human endometrium by immunolocalization 
of eosinophil cationic proteins (ECP) 1 and 2. They are also absent from normal 
endometrium during most of the cycle but immediately prior to menstruation 
increase dramatically in their numbers. Most of them are found in aggregates and 
the extracellular localization of the ECP suggests activation of the cells (623). Also 
some eosinophils are positive for MMP-9 and also the eosinophil chemoattractant, 
the chemokine eotaxin, and its receptor CCR3 were localized in the endometrial 
cells (1580). 
 
Macrophages 
Macrophages (CD68+) are present throughout the cycle with an increase in the 
early secretory phase and a further increase in the late secretory phase (1250). On 
days 27 to 28 their numbers are similar to those of neutrophils comprising 
approximately 6-15% of all cells in the functionalis at this time (1249). These cells 
are distributed throughout the tissue with some aggregates and some concentration 
around endometrial glands. Increased numbers of macrophages are found in 
progestin-exposed endometrium, particularly in association with abnormal uterine 
bleeding (236). Macrophages also show phenotypic differences concerning the 
expression of MMP-9, activin βB and MT1-MMP (1248). 
 
Mast cells 
Mast cells secrete many vasoactive and proinflammatory molecules and participate 
in inflammation through vasodilatation and enhancing leukocyte infiltration as well 
as causing direct tissue damage through their proteases.  
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Mast cells are to be found in endometrial tissue throughout the cycle without any 
changes in their number or distribution. However, by detecting the mast cell-
specific proteases tryptase and chymase one can tell that there are defined phases 
of mast cell activation. Activated mast cells are seen in the mid-proliferative (days 
10-12) and mid-secretory phase (days 20-23) phase and immediately prior to and 
during menstruation coinciding with the phases of tissue oedema (623). The mid-
secretory activation occurs at a time when implantation would be initiated in a 
fertile cycle.  
Two different phenotypes have been detected in the endometrium; those in the 
functionalis are positive for tryptase and negative for chymase while those in the 
basalis contain both mast cell-specific proteinases.  
Thus, tryptase, more than chymase, seems to have an important function in the 
process of shedding of the functionalis (1249). It can activate proMMP-3, a key 
enzyme in the activation cascade of MMPs, and could be an important factor in 
degradation of the interstitial matrix through its actions on collagen type VI. 
Endometrial interstitial stroma contains a matrix composed of collagen type I, III, V 
and VI and fibronectin whereas basement membrane structures are composed of 
laminin and collagen type IV. As compositional changes during menstruation 
includes the depletion of collagen VI during periimplantation period and at times of 
oedema (623), tryptase seems to be of immediate relevance to the stromal 
disruption and oedematous changes that apparently coincide with endometrial 
mast cell degranulation.  
Mast cell products histamine and heparine mediate changes in endometrial 
vasopermeability, bleeding and angiogenesis. Mast cell activation also has the 
potential to stimulate the production of matrix-degrading metalloproteinases 
through their expression of ILs and TNF-α.  
 
NK cells 
NK cells are among the most numerous haematopoietic cells in perimenstrual 
endometrium. Only few can be detected during the proliferative phase but numbers 
increase during the secretory phase and their numbers rise up to 15% of the total 
number of cells in the stroma perimenstrually (1249). They are found distributed 
throughout the stroma and in intraepithelial locations. They are present during the 
decidual changes and the very large number of these cells found in the decidua of 
pregnancy suggests an important role in the decidualization process (703). In 
contrast, the death of uterine NK cells could be an early event in the onset of 
endometrial breakdown at menstruation. In premenstrual endometrium, NK cells 
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undergo morphological changes with their nuclei becoming pyknotic and 
fragmented. Probably they influence the critical decision that the mid- to late 
secretory endometrium has to make either to decidualize or to undergo 
menstruation.  
Due to their expression of CD56bright, they seem to be relatives of the CD56dim 
CD16+ NK cells in peripheral blood (697). Compared to peripheral NK cells, EGLs 
have cytotoxic activity from the late proliferative phase on (637). At this phase the 
proportion of ELGs expressing the activation antigens CD69 and HLA-DR is highest 
and decreased during the menstrual phase (727) suggesting anti-infectious abilities. 
EGLs contain perforin, granzyme A, T cell intracytoplasmatic antigen-1 granules 
and MT1-MMP (1248) which all can contribute to cell and tissue degradation. 
 
Lymphocytes 
CD3+ T lymphocytes are present in the endometrium throughout the menstrual 
cycle and their numbers increase prior to menstruation. Their total numbers are 
much less than those of other leukocytes with only 1-2% of the total number of 
cells (1249). Concerning their distribution they are found as basal lymphoid 
aggregates, in intraepithelial sites and scattered throughout the stroma.  
The CD4+ to CD8+ ratio in endometrium is inverted when compared with peripheral 
blood T cells (66% of CD8+ to 33% CD4+ in endometrium) (1248). The cells are 
cytolytically active during the proliferative phase but not in the same manner in the 
secretory phase which could mean that progesterone may downregulate its activity 
(1497). T cell activity may be related also to local secretion of cytokines such as IFN-
γ, which is apparent in lymphoid aggregates in the stratum basalis but less 
consistently in functionalis throughout the cycle. Other T cell activation markers as 
CD69 and DR are similar in both proliferative and secretory phase and suggest that 
T cells are in a state of persistent activation in the activation (213). At the time 
when cytolytic activity is low in these cells in the endometrium it is high in such 
cells within the blood, indicating that endometrial CD3+ cells are functionally 
different. Subsets of endometrial T cells also express MMP-9 (1248).   
 
CD45RA+ B lymphocytes can also be detected in low numbers during the entire 
cycle and are present in perimenstrual tissue in clusters among stromal cells 
(1249). So far Ig synthesis or its specificity at this site remains unknown. 
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(2) Regulation of leukocytes in endometrium 
Steroid hormones 
Although there is also the possibility of leukocyte regulation by estrogen, the 
greatest chances in leukocyte numbers and activation occurs during the changes in 
progesterone level. Leukocyte numbers are negatively regulated by progesterone in 
an ovine endometrium (471) while the influx is coincident with the fall in 
progesterone.  
It seems to be the PR-expressing cells such as stromal, epithelial and endothelial 
cells that regulate the influx and activation of leukocytes. These act as effector cells 
that mediate the destruction and remodelling of the endometrial tissue together 
with factors produced by resident endometrial cells (1248).  
The question arises how inflammatory cells differentiate to different phenotypic 
subsets in the endometrium and how are they activated to release their mediators 
at appropriate time and place for menstruation. Besides entering the endometrium 
from the blood, some leukocytes, especially granulocytes, have been observed to 
proliferate in the endometrium, mostly during the secretory phase (1383). CD45+ T 
cells, macrophages and CD56+ NK cells express the proliferation markers Ki67 and 
BrdU within endometrium throughout the menstrual cycle with a marked increase 
in the secretory phase. 
 
Endometrial receptors of both hormones are upregulated during the follicular phase 
by ovarian estrogen and subsequently downregulated in the luteal phase by 
progesterone (268). The predominant form of the ER in all cell types in the uterus is 
ERα with only weak expression of ERβ (883). ERα expression in the functionalis 
increases in both glandular and stromal cells in the proliferative phase and declines 
in the secretory phase due to progesterone suppression (266). ERβ, however, has 
also been detected in vascular endothelial cells, which suggests a direct influence of 
estrogen on endometrial blood vessels. Such direct effects may be involved in 
endometrial angiogenesis and vascular permeability changes during the cycle.  
The PR isoform PRA is present in human glandular and stromal cells during the 
proliferative phase but is present only in stromal cells by the end of the secretory 
phase (1474). The other isoform PRB is also detected in both cellular compartments 
in the proliferative phase and absent in the late secretory phase.  
 
In rodents, however, steroid hormone receptors have been identified on several 
immune cell types with low binding affinities but numerous steroidal effects which 
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would support direct actions (940). Studies in sheep suggest that endometrial 
leukocytes are negatively regulated by progesterone, either directly or indirectly 
(471).  
The finding of PR on leukocytes would confirm this hypothesis but most studies 
show a lack of evidence for PR or ER expression on endometrial leukocytes which 
suggests that effects of steroid hormones on human leukocytes may only be indirect 
(708, 1356). Except the study of Paldi and colleagues (1065) there was also no 
evidence for PR-encoding mRNA in peripheral blood lymphocytes. However, there 
are PR-independent effects of progesterone which still have to be investigated in the 
case of endometrial leukocytes. 
 
Cytokines and adhesion molecules 
Leukocyte migration into the endometrium is likely to be mediated by chemokines, 
which bind a large family of G-protein-coupled receptors on their target cells. In 
addition to their role in cell migration, they also stimulate degranulation and 
promote angiogenesis.  
Most of these intercellular mediators are multifunctional and synergistic as well as 
antagonistic properties exist for specific cytokine combinations. Different 
chemokine receptors expressed on the same cell can induce specific signals, giving 
weight to the theory that the receptors couple to distinct pathways (1412). Steroid 
hormones could modulate the influx of inflammatory cells via actions on 
chemokines.  
Most chemokines are stimulated by IL-1 and inhibited by glucocorticoids (105). 
Glucocorticoid receptors are similar to PRs; both belong to a superfamily of 
homologous transcription factors. Therefore it is highly likely that progesterone 
could act in progesterone-dependent tissues in a similar manner than 
glucocorticoids in other tissues.  
Each of the non-resident cells in the endometrium described above is able to 
synthesize and release a variety of cytokines and growth factors. The distribution 
pattern of chemokines in the normal endometrium (Table 17) supports their role in 
the influx of inflammatory cells prior to menstruation although there are partly 
inconsistent data.  
 
IL-8 was detected in the surface epithelium and glands but not in stromal cells (47) 
whereas others demonstrated the presence of IL-8 in perivascular cells of blood 
vessels increasing in the late secretory phase (639).  
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MCP-1 was also detected in perivascular cells of blood vessels and was increased in 
both late secretory and proliferative phase (639) while other studies localized MCP-1 
in ECs (635). Kelly and colleagues demonstrated that progesterone inhibited the 
synthesis of MCP-1 from cell lines (684) and synthesis of IL-8 from endometrial 
explants (685). Progesterone withdrawal thus can stimulate the premenstrual rise 
in these chemokines. 
RANTES production from endometrial stromal or ECs was stimulated by IL-1 and 
TNF-α in vitro, but not by sexual hormones (567).  
Eotaxin, a chemoattractant for eosinophils which is only detectable in the late 
secretory phase, was found in eosinophils, perivascular and decidualized stromal 
cells at this stage (1580). The highest concentrations were seen in luminal and 
glandular ECs throughout the proliferative and secretory phases of the cycle. Its 
CCR3 receptor was expressed not only by eosinophils but also by endometrial ECs. 
Therefore the role of eotaxin and its receptor is not limited to recruitment of 
eosinophils premenstrually but they may also have additional functions due to their 
overall expression by ECs. 
These results may give the conclusion that chemokines modulate the recruitment of 
leukocytes into the endometrium and their expression is stimulated by the 
withdrawal of progesterone at the end of cycle.  
 
Adhesion molecules are necessary for the attachment of leukocytes to endothelium 
and for their extravasation and trafficking through tissues.  
ICAM-1 has been demonstrated in the stroma of the functionalis during the 
menstrual phase of the cycle (1413). This molecule was also expressed by CD3+ 
cells in the lymphoid aggregates in the basalis layer and was present on vascular 
endothelium throughout the cycle with an overall peak in expression at 
menstruation. ICAM-2 expression was just detected in vascular endothelium 
without changes during the menstrual cycle. Platelet endothelial cell adhesion 
molecule (PECAM) was also stained in stroma during menstruation and in 
endothelial cells of all vessel types (1397). VCAM-1 and E-selectin appeared in 
stromal cells in the upper functionalis in the secretory phase (1380). It seems likely 
that unique cell and site-specific expression of adhesion molecules in the 
endometrium may account partly for the distinct distribution of leukocytes. 
 
 Immunology of the genital tract 
 II-79  
 Localization in endometrium Cyclic expression 
Chemokines 
IL-8 (47, 639) Surface epithelium, glands, perivascular 
Increase in late secretory 
phase 
MCP-1 (501) Epithelial>stromal>vascular 
Proliferative and secretory 
phase 
MCP-2 (501) Epithelial 
Proliferative and secretory 
phase 
RANTES (567) Stromal  
Eotaxin (1580) 
Epithelial>decidualized stromal 
cells/perivascular/eosinophils 
Proliferative and secretory 
phase 
MIP-1α (17) Epithelial 
Proliferative and secretory 
phase 
Adhesion molecules 
ICAM-1 (1413) Epithelial, vascular, stromal 
Entire cycle, peak at 
menses 
ICAM-2 (1413) Vascular endothelium Entire cycle 
PECAM (1397) Vascular endothelium, stromal Peak at menses 
VCAM/ 
E-selectin 
(1380) 
Glands 
Vascular endometrium, 
Stromal 
Entire cycle 
Secretory phase 
Secretory phase 
Table 17: Distribution of different chemokines and adhesion molecules in 
endometrium during the menstrual cycle 
(3) Matrix metalloproteinases 
The integrity of endometrial tissues is maintained by cell-cell and cell-matrix 
interactions and binding as well as an intact fibrovascular meshwork. Shedding of 
the endometrium seems to require participation of factors that display the ability to 
cause the breakdown of these cell-cell and cell-matrix adhesions and compromise 
the integrity of the fibrovascular stroma. 
 
MMPs are a family of highly homologous endopeptidases that degrade components 
of both interstitial and basement membrane extracellular matrix (117). The MMPs 
can be divided into major subfamilies; collagenases, gelatinases, stromelysins and 
MT-MMPs. Most of them are secreted as zymogens that can be activated in vitro by 
a number of natural proteases and can be inhibited by specific inhibitors of 
metalloproteinases (TIMPs) by the formation of 1:1 complexes (117).  
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The sources of various MMPs and TIMPs in the human endometrium gives Table 
18.  
 
Most of the MMPs such as MMP-1, -2 and -3 are produced by endometrial 
stromal/decidual cells except MMP-7 which is an EC product and MMP-9 which is 
mainly produced by leukocytes including eosinophils, neutrophils and macrophages 
(1209). MMP-2 and MT1-MMP are distributed more widely and are found in almost 
all cells in endometrium (1579).  
 
MMPs are regulated at the transcriptional level by a variety of cytokines, growth 
factors and steroid hormones by tissue and cell-specific mechanisms. The patterns 
of expression of MMPs during the menstrual cycles are different in normal human 
endometrium. MMP1, MMP-3, MMP-7, MMP-9 and MT1-MMP mRNA and protein 
are all substantially increased immediately prior to and during menstruation (1209, 
1579) which let regard them as the mediators of tissue breakdown at menstruation. 
TIMPs have been demonstrated to be present throughout the cycle and can be 
localized in most cell types (1582). 
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MMP Localization in human endometrium Cyclic expression 
Collagenases 
MMP-1 
(1209) 
Stroma, connective tissue cells 
Increase prior and during 
menses 
MMP-8 Neutrophils  
Gelatinases 
MMP-2 
(1209) 
Stroma, most cells Entire cycle 
MMP-7 
(1209) 
Glandular epithelium 
Increase prior and during 
menses 
MMP-9 
(1209) 
Neutrophils, macrophages 
Increase prior and during 
menses 
Stromelysins 
MMP-3 
(1209) 
Stroma 
Increase prior and during 
menses 
MMP-10 
(1209) 
Stroma  
MMP-11 
(1209) 
Stroma, epithelium  
Others 
MT1-MMP 
(1579) 
Epithelium, most cells 
Increase prior and during 
menses 
MT2-MMP 
(1579) 
Most cells 
Increase prior and during 
menses 
TIMPs 
TIMP-1 
(1582) 
Epithelium, stroma, vascular smooth muscle Entire cycle 
TIMP-2 
(1582) 
Epithelium, stroma, vascular smooth muscle Entire cycle 
TIMP-3 
(1582) 
Epithelium, stroma, vascular smooth muscle Entire cycle 
Table 18: Distribution of MMPs and TIMPs mRNA or protein in human endometrium 
during menstrual cycle 
Leukocytes can produce MMPs and other enzymes with the potential to degrade 
components of the extracellular matrix (Table 19). These factors produced by 
leukocytes have the potential to stimulate the production of latent MMP produced 
by adjacent cells or participate in MMP activation.  
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Leukocyte Protease Potential substrate 
Mast cell 
Tryptase 
Chymase 
Chymotrypsin 
Plasminogen activator 
proMMP-3 
proMMP-1, pro-MMP-3 
broad spectrum 
plasminogen 
Neutrophil 
Elastase 
MMP-8 
MMP-9 
MT1-MMP 
Heparanase 
Cathepsin G 
Elastin, proteoglycans, collagens 
Collagens 
Collagens, elastin 
ProMMP-2, proMMP13 
Proteoglycans 
Elastin, proteoglycans, collagens 
Eosinophil 
MMP-1 
MMP-9 
β glucoronidase 
aryl sulphatase 
Collagens 
Collagens 
Proteoglycans 
Proteoglycans 
Macrophage 
MMP-9 
Metalloelastase 
MT1-MMP 
Plasminogen activator 
Proteoglycans 
Elastase, collagens 
Elastase, collagens 
Elastase, collagens 
T lymphocyte 
MMP-2 
MMP-9 
Elastase, collagens 
Elastase, collagens 
NK cells MT1-MMP Elastase, collagens 
Table 19: Leukocyte production of proteases relevant to menstruation (1248) 
For example, when MMP-3 is present, a cascade of MMP activation can be initiated 
(1248). Besides production of plasminogen activator and chymotrypsin, mast cells 
produce tryptase which can activate proMMP-3 and chymase which can activate 
proMMP-1 and proMMP-3. Neutrophil elastase acts directly on substrates elastin, 
proteoglycan and collagen but they also produce MMP-8, MMP-9 and MT1-MMP 
themselves. Eosinophils can produce MMP-1 and MMP-9 while macrophages can 
generate MMP-9 and MT1-MMP. Thus activation of leukocytes at any site can result 
in substrate-degrading enzyme or activators of such enzymes being released into 
the surrounding tissue.  
Studies have examined the regulation of MMP production and activation by 
endometrial cells in vitro. Endometrial stromal cells were put in culture with the 
human mast cell line (HMC)-1, or with peripheral blood neutrophils (1581). HMC-1 
produces the mast cell products tryptase, IL-1 and TNFα. The HMC-1 cells 
stimulated stromal cell proMMP-1 and proMMP-3 and to a lesser extent also 
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proMMP-2, with an increasing stimulation as mast cell numbers increased. When 
cultured with peripheral blood neutrophils, proMMP-2, proMMP-3 and proMMP-9 
were activated while TIMP-1 and TIMP-2 produced by stromal cells were degraded.  
Withdrawal of progesterone may contribute to the recruitment and activation of 
leukocytes by inducing the production of cytokines and chemokines by endometrial 
and ECs of the endometrium. Furthermore, withdrawal of progesterone may directly 
promote MMP production by resident endometrial cells. Several in vitro studies 
demonstrate that progesterone is a potentially important player in regulation of 
MMPs in the endometrium.  
Physiological concentrations of progesterone co-cultured with endometrial explants 
almost completely inhibited the release of both latent and active MMPs (868). 
Salamonsen demonstrated the upregulation of MMP-1, -2 and -3 productions by 
withdrawal of progesterone in a cell culture model (1247). There are several 
arguments for indirect actions of progesterone withdrawal accounting for the 
upregulation of MMPs at menstruation (1249). Menstruation exclusively happens in 
women and some primates while all mammals undergo demise of the corpus 
luteum in a nonfertile cycle. Furthermore, withdrawal of progesterone is an 
endocrine mechanism and would result in systemic actions whereas MMP 
production happens very focal.  
There are also many local mediators in endometrial cells that modulate MMP 
production which are maximally produced during the late secretory and menstrual 
phase. These include TGF-β, TNF-α, IL-1, LIF, GM-CSF and prostaglandins (1249). 
In vitro studies support their potential for MMP regulation in the endometrium. For 
example, TNF-α and IL-1 are both products of epithelial and stromal cells and 
increase MMP-1 and MMP-3 production by stromal cells (1178). 
Prostaglandins are present in high concentrations in endometrium where synthesis 
and metabolism of prostaglandin is regulated via estrogen and progesterone. 
Increased production of prostaglandin F2α induces myometrial contractions and 
vasoconstriction whereas other prostaglandins are vasodilatators that work together 
with bradykinin to increase pain and oedema (268). Cyclooxygenase 2 (COX2) is the 
inducible form of prostaglandin synthetase and is present in human endometrium, 
particularly in the menstrual phase (639).  
Finally, a summary of the latest hypotheses of menstruation gives Figure 6.  
 Immunology of the genital tract 
 II-84  
 
Demise of corpus luteum 
Progesterone withdrawal 
                                
                              +                                                          +     COX2 
 
             
     MCP-1                     IL-8                Hypoxia             Prostaglandins  
                                                                                                    PGE2, PGF2α 
 
 
Chemotaxis/activation        Neutrophil            VEGF            Vascular permeability 
          of monocytes         influx/activation                                      changes 
 
 
 
Cytokines, prostaglandins,               Release of 
     IL-8, MCP-1, IL-1 etc.   MMPs              
       proMMPs 
 
 
 
Initiation of menstruation 
Figure 6: Summary of menstruation hypothesis (268) 
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C. Immunology of genital tract infections 
The understanding of the immune system in the genital tract is of critical 
importance when considering the increasing prevalence of STDs. The World Health 
Organisation (WHO) estimated a global incidence of 340 million curable STDs in 
1999 compared to 250 million cases in 1990 (1532). Especially in the developing 
world limited access to diagnosis and treatment causes STDs to be the second 
leading cause of healthy years of life lost by women of reproductive age (336).  
In the United States, it is estimated that approximately 18.9 million new cases of 
STD infections occurred in the year 2000, of which 9.1 million (48%) were among 
young persons aged between 15 and 24 (1487). Among them, three STDs, HPV, 
trichomoniasis and chlamydia, accounted for 88% of all new STI cases (1487).  
The epidemiology of each STD is different and dependent of many factors including 
individual behaviour, social conditions, pathogen characteristics and access to 
treatment. In the following, the latest developments and current studies on the 
most essential STDs should be discussed with an emphasis on immune responses 
and chances for vaccination.   
1. Viral infections of the genital tract 
a) Herpes simplex virus 
The family of human herpesviridae includes the herpes simplex virus type 1 and 2 
(HSV-1 and HSV-2) which are of essential clinical importance in gynecology and 
obstetrics (Table 20).  
 
Alpha-herpesviridae 
Herpes simplex virus 1 
Herpes simplex virus 2 
Varicella zoster virus 
Beta-herpesviridae 
Cytomegalovirus 
Human herpes virus 6 
Human herpes virus 7 
Gamma-
herpesviridae 
Ebstein-Barr-Virus 
Human herpes virus 8 
     Table 20: Overview of human herpesviridae (790) 
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HSV is an enveloped, linear, double-stranded DNA virus whose only known hosts 
are humans. HSV-1 and HSV-2 are distinguished by antigenic differences in their 
envelope proteins. There are 11 glycoproteins in HSV, which are inserted into the 
envelope of the virus and perform different biological functions (Figure 7).  
 
    
Figure 7: Structural elements and their biological functions of a HSV virion, adapted 
from Cunningham and Mikloska (279)  
Typically, HSV infects ECs at mucosal surfaces or abraded skin. HSV-1 normally is 
associated with oral infections and HSV-2 with genital infections, but either type 
can infect a person anywhere on the skin. HSV-2 is usually sexually transmitted 
and is clinically manifested in the genital or adjacent area as primary or recurrent 
infection. HSV-1 is becoming an increasingly common cause of primary genital 
infection but is less commonly a cause of recurrent infection. 
 
The natural history of HSV infection includes an acute or subclinical first-episode 
mucocutaneous infection, establishment of viral latency in the dorsal root ganglion, 
and subsequent reactivation. With reactivation, the virus travels back down the 
nerve root to create a mucocutaneous outbreak, or it may produce no detectable 
symptoms (1499).  
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Genital herpes infection caused by HSV-2 is one of the most prevalent STDs 
worldwide and is the most common cause of genital ulcers. The percentage of HSV-
2 infections varies between 6% and 50% among different populations (1337). 
Genital herpes is more common in women than in men, with approximately one in 
four women versus one in five men having specific antibodies to HSV-2 (416).  
Subclinical viral shedding has been documented in more than 80% of HSV-2-
seropositive persons who report no lesions (1465). Only 10 to 25% of persons who 
are HSV-2 seropositive report a history of genital herpes, which suggests that most 
infected persons have unrecognized symptomatic or completely asymptomatic 
infections. However, once patients are told of their positive antibody status, more 
than 50% identify clinically symptomatic recurrences that previously were ascribed 
to other conditions. It is thought that viral shedding in persons who are unaware of 
their infection is responsible for at least 70% of HSV transmission (1465). 
There is a concerning relationship between HIV and genital HSV infection because 
the interaction of HSV-2 and HIV-1 may result in more efficient transmission of 
HIV-1 and an increased rate of HIV replication during HSV reactivation (1466).  
 
Although oral treatment with aciclovir can reduce the severity of infections, 
development of a vaccine to prevent or control HSV-2 infections in the genital tract 
would greatly contribute to preventive health care. To achieve this goal, it is 
important to understand the host defense mechanisms that are available at genital 
mucosal sites to protect against this STD. 
(1) Innate immune responses in genital herpes infections 
The role of immune factors in the control of HSV infection, especially recurrent 
lesions after viral reactivation, appears complex. There is a general difference 
between immune responses to primary and recurrent disease, which is clinically 
demonstrated in the much longer median duration of lesions and viral shedding in 
initial infection. There is a mean of 21 days for lesions and 10 days for viral 
shedding in primary infection compared to 10 days for lesions and 4 days for viral 
shedding in recurrent infections (279).  
Extensive studies have identified responses that are important in limiting viral 
replication and spread to uninfected cells (347). These include IFN type 1 responses 
which are produced within hours after infection, and neutrophils which are found 
within 24 hours after vaginal infection and secrete TNF-α. Moreover, there are 
macrophages, NK cells and submucosal DCs which have been shown to capture 
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HSV-2 antigen and stimulate T cell activation in regional lymph nodes (1584). 
Before, basic factors of innate immune responses have also been implicated in the 
protection against genital HSV infection. 
 
Acidic pH 
The acidic environment of the healthy human vagina with a pH of 4.0 to 4.5 
contributes to the first line of innate immune defenses in the genital tract. 
Therefore, earlier studies already developed acid-buffering compounds as candidate 
microbicides and tested anti-HSV activity provided by acidic pH (1218).  
MasCasullo and colleagues found out recently that acidic buffers with a pH ≤ 4.5 
irreversibly inactivated HSV-1 or HSV-2 and reduce viral yield at least 1000-fold in 
vitro whereas exposure to pH of 5.0 has only little effect (880).  
In the next step, a vaginal acid-buffering formulation with pH 3.5 named AmpHora 
was tested in a murine model (440). AmpHora significantly protects mice from 
genital herpes when challenged with the virus delivered in human seminal fluid 
compared to mice that received a placebo gel.  
 
Antimicrobial peptides 
Antimicrobial peptides with their subgroups α- and β-defensins and cathelicidines 
have a broad spectrum activity against different microorganisms and are also 
presumed to contribute to antiviral activity in the genital tract.  
HNP1-3 have been demonstrated to protect human cells from HSV in vitro (1557). 
Further studies indicated that synthetic HNP-4 is less active than HNP1-3 in 
protecting against HSV and that the EC defensins HD-5 and HD-6 also inhibit HSV-
2 infection (880).  
Data showed lately that CVS obtained from healthy women by CVL inhibits HSV 
infection (633). There was a reduction of HSV-2 infection of at least 90% if cells 
were cultured with CVL from healthy women compared to a control group. The anti-
HSV activity of CVL was independent of age, vaginal pH and the presence of HSV 
antibodies in serum which suggests that CVS contribute to innate resistance to 
HSV-2 infection. The same study indicated that this anti-HSV activity correlated 
with the concentration of HNP1-3 in the fluid (633). Both CVL samples and HNP1-3 
interacted with virus and prevented virus entry after binding.  
Preliminary work failed to demonstrate any in vitro anti-HSV activity for synthetic 
HBD-1 and -2 but further studies are needed to assess whether HBD in cervical 
secretions contribute to intrinsic anti-HSV activity. The only known human 
cathelicidin, LL-37, has also not been tested for its anti-HSV activity (880). 
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These findings suggest that CVS contribute to innate resistance to HSV-2 and 
identify defensins as contributors to this activity (Table 21).  
 
α-defensins Antiviral activity against HSV-2 References 
HNP1-3 Yes 1557, 633 
HNP-4 Less 880 
HD-5 Yes 880 
HD-6 Yes 880 
β-defensins   
HBD1-2 No; further studies needed 880 
Cathelicidins   
LL-37 Not tested 880 
Table 21: Antiviral activity of antimicrobial peptides against HSV-2  
Although SLPI is known to protect human macrophages and CD4+ T cells from HIV-
1 infection (907), not much has been found out about the influence of SLPI in 
protection against HSV. Preliminary studies showed that SLPI inhibits HSV-2 
infection in vitro, but HSV-2 significantly decreases SLPI in cervical cell culture 
supernatants, implying that the virus may downregulate this antiviral protein (880). 
 
Lactoferrin was shown to inhibit HSV-1 infection in vitro by interfering with the 
binding of glycoprotein C to cell surface heparin sulphate receptors (869). This may 
explain only little anti-HSV-2 activity of lactoferrin as binding of HSV-2 to cells is 
primarily mediated by glycoprotein B (221). SP-D was lately demonstrated in the 
genital tract mucosa, and may play a role in inhibiting HIV transmission as well as 
in protecting against other STDs (921).  
 
Complement 
As another factor of innate immunity, complement recognizes infectious agents 
using three different molecules. These are C1q, mannose binding lectin (MBL), and 
C3, which trigger the classical, lectin, and alternative pathways of complement 
activation, respectively. All three of these molecules are detected in vaginal 
secretions from healthy women (1104).  
Notably, HSV has evolved several strategies to evade immune attack by the classical 
and alternative complement pathways, which include inhibiting activities mediated 
by C3, C5, and properdin. Specifically, glycoprotein C binds C3 and its activation 
products, C3b, iC3b and C3c, and accelerates the decay of the alternative 
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complement pathway C3 convertase (429). In a murine genital tract model, viruses 
deleted in HSV-1 glycoprotein C are less virulent (835). 
Less is known about the role played by MBL and the lectin pathway as a host 
defense against genital herpes infection. Recent studies indicate that MBL binds to 
HSV-2 in vitro (432). Interestingly, MBL deficiency increases the generalized 
susceptibility of an individual to infectious diseases (432), and increased 
susceptibility to HIV infection in MBL-deficient individuals has been described 
(441). 
 
DCs 
HSV-1 has been shown to productively infect immature DCs with progressive loss of 
DCs and is associated with downregulation of CD1a, CD40, CD54 (ICAM-1) CD80 
and CD86, which may lead to delayed activation of T cells and allows more time for 
replication of HSV type 1 in epidermal cells. Thus, this may be yet another novel 
strategy of immune evasion (932).  
In contrast, Linehan et al. showed in a murine model that HSV-2 infection of the 
epithelium induces activation of the phenotype and function of the neighboring 
uninfected submucosal DCs (821). Intravaginal inoculation of mice with HSV-2 led 
to a rapid recruitment of submucosal DCs to the infected epithelium.  
Subsequently, DCs harboring viral peptides emerged in the draining lymph nodes 
and were found to be responsible for the stimulation of IFN-γ secretion from HSV-
specific CD4+ T cells (1584).  
These results demonstrate a role for submucosal DCs in the generation of protective 
Th1 immune responses to HSV-2 in the vaginal mucosa, which is also supported by 
work from King et al. (711). LCs from the vaginal epithelium did not migrate to the 
draining iliac lymph nodes after intravaginal HSV-2 infection. LCs may be inhibited 
from performing antigen-presenting functions as a result of the lytic destruction of 
the epithelial layer. This notion is supported by the progressive reduction of the 
number of LCs in draining lymph nodes after HSV-2 infection (1584). 
MasCasullo et al. have recently obtained similar results using immature human 
monocyte–derived CD11c+ DCs which showed limited productive viral replication 
and increased expression of CD86, CD83, and HLA DR as well as release of 
proinflammatory cytokines and chemokines after exposure to HSV-2 (880).  
A recent study by Nordström et al. showed that blood DCs infected with HSV-2 
activated CD8+ T cells which again blocked CD4+ T cell proliferation (1027). These 
DC can transform CD25- CD8+ T cells into Treg cells that block both antigen-
specific and allogeneic CD4+ T cell activation in vitro.   
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NK cells 
Several recent studies have also shown a role for NK cells, NK T cells and IL-15 as 
regulatory factor in an innate immune response to HSV.  
Mice lacking IL-15 or NK/NK T cells are significantly more susceptible to 
intravaginal HSV-2 infection than control mice (58). The lack of NK and NK T cells 
in these mice, and as a result, lack of early IFN-γ response impairs the innate 
immune response against HSV-2. A following study by the same group indicated 
that IL-15 also has direct antiviral activity independent of NK/NK T cells in 
mediating innate defense against HSV-2 infection (453).  
A number of examples of NK cell deficiencies in humans have been reported and are 
associated with an increase in herpes virus infections as well (1053). 
 
Neutrophils 
The role played by neutrophils in the innate immune response to genital herpes in 
human beings is not exactly known.  
In a murine model, depletion of neutrophils before HSV-2 intravaginal inoculation 
did not increase the incidence of infection, suggesting that the small population of 
resident neutrophils was ineffective in preventing infection by a viral pathogen 
(946).  
However, neutrophils did help in virus clearance from the genital mucosa after 
primary infection. The mechanisms by which neutrophils mediate antiviral activity 
are not well understood. They bind HSV virions or HSV-infected cells in vitro and 
kill them by oxygen-dependent or -independent systems (880). Furthermore, 
neutrophils may mediate antiviral activity through release of antiviral cytokines 
such as TNF-α, IFN-α, IFN-γ or oxygen and nitrogen metabolites (182). 
 
TLRs 
As mentioned earlier, the recognition of infectious pathogens like HSV-2 by the 
innate immune system relies on TLRs. TLR2 and TLR9 seem to be involved in cell 
signaling in response to HSV. TLR9 mediates HSV-2 induced IFN-α secretion from 
DCs (840) and HSV-1 also elicits inflammatory cytokine secretion through TLR2 
(756).  
 
A summary of the innate immune responses of the female genital tract against HSV 
shows Figure 8.  
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Figure 8: Mucosal innate immune response to HSV in the female genital tract. Viral 
particles may be inactivated by acidic pH and substances secreted into the vaginal 
lumen including defensins, SLPI, or complement. Resident immune cells including 
ECs, DCs, NK cells, and PMNs respond to viral exposure by killing virus or virally 
infected cells directly or by releasing cytokines and chemokines. These initial 
responses trigger the recruitment of additional immune cells, notably monocyte-
derived CD11c+ DCs which endocytose viral antigens, mature, and then migrate to the 
draining lymph node to stimulate CD4+ T cells and initiate the adaptive immune 
response. Adapted from MasCasullo et al. (880) 
(2) Specific immune responses in genital herpes infection 
T lymphocytes 
For decades, the questions about T cell subtypes and the specific role of 
neutralizing antibodies in HSV infection have been the dominating issues. 
The longer prevalence of herpetic lesions in AIDS patients as well as the high 
frequency in patients after organ transplantation in the 1980s indicates the 
dominant influence of T cell responses rather than the persistence of neutralizing 
antibodies in recurrent infections (1301). Moreover, only very high levels of 
neutralizing antibodies can prevent the axonal spread of HSV-1 to epidermal cells in 
vitro contributing to control of HSV spread and shedding (936).  
Mice depleted of CD4+ and CD8+ T cells prior to genital HSV-2 infection shed virus 
for a prolonged period, confirming a role for T cells in virus clearance (1087).  
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Early murine studies of the immunology of HSV infection suggested that IFNs and 
macrophages were an important part of the initial immune response and that the 
most important protective specific T-lymphocyte response was mediated by CD8+ 
lymphocytes. However, immunohistology of biopsies of human recurrent herpetic 
lesions revealed a sequence of immune cell infiltration beginning with CD4+ 
lymphocytes and macrophages in the first 2 days around the infected epidermal 
cells which also develop strong HLA-DR expression (281). This was followed by an 
influx of CD8+ lymphocytes, which normalized the balance between CD4+ and 
CD8+ lymphocytes. The CD4/CD8 ratio is not restored to that of the blood until 
after 2 days, indicating an early CD4+ and a later CD8+ lymphocyte influx (281).  
 
A murine model of genital HSV infection by Milligan et al. was utilized to examine 
the local T cell response in the genital mucosa and the draining genital lymph 
nodes (944). HSV-specific T cells with a higher rate of CD4+ and Th1-like T cells 
were first detected four days after vaginal HSV inoculation in the genital lymph 
nodes, followed by their appearance in the genital tract one day later. Also 
experiments by Kuklin et al. with T cell subtype knockout animals and depletion 
with T cell subset-specific monoclonal antibody indicated that immunity following 
vaginal HSV challenge was principally dependent on the function of CD4+ T cells 
(753). 
 
It was found out that HSV is able to downregulate MHC class I on the surface when 
infecting epidermal keratinocytes, which is a mechanism of immune evasion that 
allows the infected cell to escape scrutiny by cytotoxic CD8+ lymphocytes (733). The 
immediate-early viral protein of HSV, infected cell protein 47 (ICP 47), complexes 
with and inhibits the human transporter associated with antigen presentation (TAP) 
on the surface of the endoplasmic reticulum in humans but not in mice (1424). TAP 
is responsible for transporting small antigenic viral peptides into the lumen of the 
endoplasmic reticulum, where it assembles into the MHC class I peptide complex 
before transport to the cell surface. Inhibition of TAP inhibits the assembly of MHC 
class I peptide and recognition by CD8+ cytotoxic T lymphocytes (544).  
However, IFN-γ, which is produced by CD4+ lymphocytes in the lesion, partly 
restores MHC class I expression on the surface of infected cells by the cellular 
production of TAP and also stimulates MHC class II expression (1427). Specific 
activated CD4+ lymphocytes are able to recognize infected epidermal cells and 
probably uninfected cells expressing MHC class II. This may result in the 
production of more IFN-γ or destruction of infected cells by CD4 T lymphocytes, 
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which is normally mediated by CD8 lymphocytes (281). The restoration of MHC 
class I expression on infected epidermal cells allows recognition by CD8 cytotoxic T 
lymphocytes, which are then apparently able to destroy the remaining infected 
epidermal cells.  
A study by Posavad et al. demonstrated HSV-specific CD8+ precursor CTL in HSV-
1 and -2 seropositive persons with recurrent genital herpes (1140). 
 
A summary of the adaptive immune mechanisms with T cell priming in genital 
herpes infection gives Figure 9. 
 Immunology of the genital tract 
 II-95  
 
Figure 9: T cell priming in genital herpes infection, adapted from Iwasaki (604) (1) The 
virus replicates within the infected keratinocytes which results in the induction of 
signals necessary for the recruitment of the CD11b+ DCs to the submucosa beneath 
the infected ECs. (2) This signal likely involves chemokines, since pertussis toxin 
treatment of mice at the time of infection prevents DC accumulation at the infected 
sites. Once recruited, submucosal DCs can take up virus antigens from the infected 
keratinocytes and migrate to the draining lymph nodes. (3) By the time the CD11b+ 
DCs enter the lymph nodes, they assume an activated phenotype, expressing higher 
levels of costimulatory molecules such as CD80 and CD86. Within the lymph nodes, 
the virus antigen-loaded CD11b+ DCs can stimulate CD4+ T cells, which undergo 
differentiation to Th1 cells. It is possible that CD8+ T cells are also stimulated within 
the lymph nodes, by a separate group of DCs expressing CD8a. Once activated, the 
effector Th1 and CTLs exit the lymph nodes and migrate back to the vaginal mucosa, 
where they mediate clearance of infected keratinocytes. (4) The IFN-γ secreted from 
the Th1 cells has multiple effector functions, including upregulation of MHC class II 
molecules on the infected keratinocytes, making these cells susceptible to recognition 
by CD4+ effector cells. Some of these CD4+ T cells may act as CTLs, and eliminate 
infected cells. The IFN-γ secreted from the effector Th1 cells may also activate 
phagocytes such as tissue macrophages and neutrophils directly or via chemokines, 
resulting in the clearance of infected cells.  
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B lymphocytes 
Studies among B cell-deficient mice have been used to further illustrate the 
contributions of humoral and cellular immunity in protection against vaginal 
infection in the HSV-2 mouse model (509, 1088). In this model, progesterone-
treated adult mice are inoculated intravaginally with a thymidine kinase (TK)-
deficient, attenuated strain of HSV-2. The deletion in the TK gene, which is required 
for the reactivation of the latent HSV-2, renders the virus only infectious during the 
primary mucosal infection without the neurovirulence associated with the wild-type 
(WT) virus. 
Although B cell-deficient mice in these studies developed an early transient genital 
inflammation upon primary infection with TK-deficient-HSV-2 (509), during 
secondary challenge of immune mice with the WT-HSV-2, all of the mice cleared the 
infection completely (1088). Further, mice immunized with TK-HSV-2 were 
completely protected from subsequent WT-HSV-2 challenge (509, 1088). These 
results also indicate that B cells are not the critical APCs required to activate T cells 
following TK– HSV-2 infection. 
 
Igs 
Despite the fact that S-IgA was the predominant Ig in progestin-treated mouse 
vaginal mucus, nearly all specific viral antibody in HSV-immune mice was of the 
IgG isotype (1079). This is in agreement with the findings of Milligan et al. who 
also found predominantly IgG antibodies to the virus (943). However, these 
observations did not eliminate the possibility of contribution of vaginal IgA in 
immune protection against HSV-2, since ELISA titers of specific antibodies do not 
necessarily predict functional virus neutralization (1092). 
 
The protective role of antibodies in vaginal secretions of mice that were immune to 
vaginal challenge with HSV-2 was further investigated by neutralization and passive 
transfer (1082). These neutralization studies were carried out by incubation of WT-
HSV-2 in antibody preparations in vitro, followed by inoculation into vaginae of 
nonimmune mice.  
The results showed that HSV-2 was effectively neutralized by both unfractionated 
antibody and by purified IgG from immune vaginal secretions, but not by purified 
S-IgA from immune secretions or by unfractionated antibody from nonimmune 
mice. The protective effect of IgG in vivo was further investigated by passively 
transferring purified serum IgG from immune and nonimmune donors to 
nonimmune recipients before vaginal challenge infection (1082). Immune IgG 
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significantly reduced the percentage of vaginal epithelium infected, shed virus 
protein concentrations in the vaginal lumen, and illness scores, even though the 
viral antibody titers in the serum and vaginal secretions of recipient mice at the 
time of challenge, were only 29% and 8%, respectively, of those in actively 
immunized mice.  
Although Igs do not play a critical role during secondary challenge with HSV-2 in 
mice immunized with TK-HSV-2, passive transfer of immune IgG can significantly 
reduce local virus replication (1082). Further, neutralizing antibodies may be 
important in the prevention of viral shedding from neuronal axons to the epidermis 
during reactivation (936). The importance of IgG in HSV immunity is evidenced by 
the immune evasion mechanism employed by the virus. The HSV genome encodes 
glycoprotein E and I, which together comprise a high-affinity Fc receptor expressed 
by infected cells for the purpose of absorbing and inactivating anti-HSV IgG (998). 
Data indicate that IgG antibody in vaginal secretions of immune mice provides early 
protection against vaginal HSV challenge infection whereas S-IgA contributed very 
little to protection (1082, 1085). 
 
Concerning the origin of IgG, observations suggest that the titer of viral IgG in 
vaginal secretions of mice that were intravaginally immunized with HSV-2 may be 
higher than can be accounted for by passive transudation from serum (1079). 
The relative contributions of humoral and cell-mediated adaptive immunity against 
HSV-2 infection in the mouse model have recently been studied. Antibody is 
supposed to mainly act early during immune resistance to challenge infection, 
whereas cell-mediated immunity primarily acts later (1088). An early role for 
antibody is consistent with the presence of neutralizing IgG in vaginal secretions of 
immunized mice (1082) whereas memory T cells, on the other hand, require several 
hours to secrete substantial amounts of IFN-γ in the vagina in response to the 
challenge antigen and may require even longer developing cytolytic activity (1091). 
     
Women with symptomatic genital herpes have antibodies to HSV-2 of both IgA and 
IgG isotypes, as well as IgM in CVS (59). Another study aimed at detecting HSV 
antibodies and neutralizing activity in CVS of women seropositive for both HSV-1 
and HSV-2 and to stratify the HSV-2-specific antibody activity according to their 
HSV-2 DNA genital shedding status (894). HSV-specific binding antibodies were 
detected at rates of nearly 70% (IgG) and 51% (IgA), with similar proportions of Igs 
to HSV-1 and HSV-2. The presence of detectable HSV-specific antibodies was 
inversely associated with HSV-2 DNA genital asymptomatic shedding and a subset 
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of these women (17%) had functional neutralizing activity against HSV-2 in their 
CVS. 
(3) The role of cytokines 
Both HSV-specific CD4+ and CD8+ T cell cytotoxicity have been demonstrated in 
vitro and in lymphocytes cloned from recurrent herpetic lesions ex vivo (728). In 
vivo, CD8+ lymphocyte cytotoxicity is presumably dependent upon upregulation of 
MHC class I by IFN-γ secreted from earlier infiltrating CD4+ lymphocytes.  
Furthermore, the mechanism for the enhancement of CD8+ T cell cytotoxicity by 
adjuvants in this system appears to be via increased levels of IL-12 (935). The 
specific infiltration of monocytes and CD4+ and CD8+ lymphocytes in sequence 
associated with few B lymphocytes suggests a leukocyte-specific chemotactic 
stimulus rather of β-chemokines than of α-chemokines which are chemoattractant 
for neutrophils but not for monocytes and lymphocytes.   
 
Parr et al. have shown in the mouse model that after HSV-2 inoculation a rapid 
synthesis of IFN-γ by lymphocytes and macrophages was observed which occurred 
only in immune/challenged but not in non-immune/challenged mice indicating 
that it required memory T cells (1092). Data indicate that virus-specific memory T 
cells in vagina of immune mice encounter challenge virus antigen, rapidly secrete 
IFN-γ, leading to T and B cell recruitment into the vagina. Thus, IFN-γ seems to be 
an early and important mediator of T cell immunity in the HSV-2 infection. 
 
The high concentration of IFN-γ in herpetic lesion fluid also suggests a Th1 pattern 
of cytokine response (934). The Th2 pattern leads to predominantly neutralizing 
antibody secretion by B cells whereas a Th1-pattern leads to production of the 
antiviral cytokines, IFN-γ and TNF-α, and the activation of cytotoxic CD8+ 
lymphocytes, through IL-12 and IFN-γ. A Th1 pattern of cytokine induction is 
important in the control of persistent virus infections since only CTLs are able to 
eradicate infected cells, and IFN-γ and TNF-α can purge infected cells of viral 
proteins (487). A Th2 pattern leading to neutralizing antibody production may 
prevent cell-to-cell transmission of the virus. 
 
Concerning the presence of cytokines, on the first day of the lesion, high 
concentrations of IL-1β and IL-6, moderate concentrations of IL-1α and IL-10, and 
low concentrations of IL-12 and β chemokines were found; levels of MIP-1β were 
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significantly higher than levels of MIP-1α and RANTES. At day 3, the concentrations 
of IL-1β, IL-6, and MIP-1β were lower, whereas the levels of IL-10, IL-12, and MIP-
1α remained similar, and the level of TNF-α was now detectable (934).  
These cytokines may play a role in early recruitment, activation, and IFN-γ 
production of CD4+ cells in herpetic lesions. β-chemokines attract monocytes and T 
lymphocytes into the lesions, in particular, MIP-1β for CD4+ lymphocytes and IL-12 
entrains CD4+ lymphocyte secretion to a Th1 pattern. Macrophages probably also 
secrete IL-12, IFNs and other cytokines within the lesion. Immune processes in a 
recurrent herpetic lesion show Figure 10. 
 
     
Figure 10: Immune processes and in vivo secretions of cytokines and chemokines in 
herpetic lesions; M=macrophage, K=keratinocyte, adapted from Cunningham and 
Mikloska (279)   
(4) New immunologic therapeutic aproaches  
Resiquimod 
Current treatment of genital herpes focuses on the direct inhibition of viral 
replication. The nucleoside analogs, in particular aciclovir, dominate the treatment 
recommendations for genital herpes (240). Most antiviral therapy is aimed at the 
treatment or suppression of recurrent episodes. Both episodic and long-term 
suppressive therapies are prescribed, but nucleoside analogs have no long-term 
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effect on the disease; genital herpes episodes recur at the pretreatment rate if 
therapy is stopped.  
However, given the limitations of current therapy directed against viral replication, 
a regimen utilizing an immune modulator may be more acceptable to patients. 
Therefore, the development of the immune response modifiers (IRMs) as a potential 
new treatment option for genital herpes should be briefly presented.  
IRMs, as for example Imiquimod and Resiquimod, are synthesized ring-structured 
nucleoside structures (942). They induce certain immune cells to produce cytokines 
and thus, initiate the immune response which can result in antiviral or antitumor 
effects. Especially Resiquimod was shown to stimulate the development of Th1 
immune responses in guinea pig models of genital herpes (942). Resiquimod 
stimulates the secretion of IFN-a, TNF-a, IL-6, IL-8 and IL-12 from various cells 
including DCs, monocytes and macrophages. Resiquimod induces the functional 
maturation of DC, LC and B lymphocytes into effective APCs and it promotes the 
development of B lymphocytes into plasma cells (Figure 11).  
  
    
Figure 11: Stimulation of immune responses by the IRM Resiquimod, adapted from 
Miller et al. (942) Resiquimod stimulates the secretion of IFN-a, TNF-a, IL-6, IL-8 and 
IL-12 from various cells including DCs, monocytes (mono) and macrophages (macro). 
Resiquimod induces the functional maturation of DC, LC and B lymphocytes into 
effective APCs and promotes the development of B lymphocytes into plasma cells and 
the subsequent secretion of IgG2a. Resiquimod also stimulates nitric oxide (NO) 
production from macrophages 
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Resiquimod was shown to inhibit herpetic lesions and delays genital herpes 
recurrency in the guinea pig model (112). The decrease in recurrency was correlated 
with an increase of the in vitro IL-2 produced by peripheral mononuclear cells in 
response to HSV antigen but not with IFN levels or circulating anti-HSV-2 
antibodies.  
The rationale for the use of resiquimod as a treatment for genital herpes is to 
stimulate the secretion of certain key cytokines, e.g. IFN-a, IL-12 and TNF-α from 
specific cell types of the innate immune response in order to establish the HSV-
specific Th1 acquired immune response.  
In a randomized vehicle-controlled Phase II clinical study on 52 patients with a 
history of six or more recurrences per year, topical application of resiquimod 
reduced recurrences of genital herpes even after cessation of dosing (1333). The 
median time to the next recurrence was 169 days in the resiquimod-treated group 
in comparison to 57 days in the vehicle-treated group. The percentage of patients 
without a recurrence during the 6-month observation period after dosing was 6% in 
the vehicle-treated group compared to 32% in the resiquimod-treated group.  
 
This apparent continued post-treatment benefit of resiquimod could be an 
important improvement to current treatments for recurrent genital herpes, such as 
oral anti-HSV nucleosides, which do not appear to have post-treatment benefit. 
However, Phase III clinical trials were suspended due to the lack of efficacy of 
resiquimod gel in recurrent genital herpes lesions (1333). It may have a comeback 
as a vaccine adjuvant for viral infections that require a strong Th1 immune 
response.  
 
CpG oligodeoxynucleotides 
Also recently, local vaginal delivery of CpG containing oligodeoxynucleotide (ODN), a 
synthetic mimic of bacterial DNA and TLR9 agonist, holds substantial promise as a 
strong inducer of innate immunity against genital herpes infections in the animal 
models of the disease.  
As mentioned, TLRs are responsible for recognition of conserved molecular 
structures named PAMPs such as LPS, bacterial DNA and viral double-stranded 
RNA in microbes. Interaction between CpG motifs in microbial DNA and TLR9 in 
APCs stimulates the responding cells to produce proinflammatory cytokines such as 
IFN-γ and IL-12 through the Toll/IL-1-receptor signaling pathway and to activate B 
cells for proliferation and antibody production (748). Among PAMPs, synthetic 
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analogues of bacterial DNA, termed CpG ODN, have shown a great promise in 
mobilization of protective immunity against different pathogens (508).  
Harandi et al. demonstrated in a mouse model that a single intravaginal dose of 
CpG ODN induces production of Th1-type cytokines IFN-γ, IL-12 and IL-18, CC 
chemokines RANTES, MIP-1α and MIP-1β and CXC chemokines IP-10 and MIP-2 in 
the genital tract mucosa as well as a dramatic increase in the total cell numbers of 
B cells, NK cells, NKT cells and T cells in the genital lymph nodes (507).  
Studies have proven a protective effect of prophylactic delivery of CpG ODN against 
primary genital herpes in mice and have showed that the observed protection can 
lead to the development of a HSV-2 specific memory response affording sterilizing 
immunity against reinfection (55). Also a therapeutic effect of topical application of 
CpG ODN on genital herpes was demonstrated in both mouse and guinea pig 
models of the disease (1149).  
(5) Vaccination strategies  
Despite antiviral therapy, HSV-2 is a suitable target for a vaccine because the virus 
causes lifelong infection and significant medical morbidity. A vaccine has the 
potential to reduce HSV acquisition, disease severity and the number of neonatal 
herpes cases. However, efforts to develop vaccines to protect women against HSV-2 
and other sexually transmitted pathogens would be facilitated by a better 
understanding of the immune mechanisms that protect the female reproductive 
tract against such infections. 
 
Vaginal versus nasal/parenteral immunization 
In the progestin-treated adult mouse model by Parr and Parr (1092), intravaginal 
inoculation of WT-HSV-2 caused infection of the vaginal epithelium followed by 
lethal neurological illness. Intravaginal inoculation of an attenuated strain of TK-
depleted HSV-2 caused epithelial infection but did not lead to neurological illness 
(1086). Importantly, vaginal infection with the attenuated strain induced protective 
immunity to subsequent lethal challenge with WT-virus. These observations 
indicated that intravaginal immunization with the attenuated virus induced 
mucosal immunity in the vagina that prevented reinfection.     
 
However, many have studied immunization at IgA-inductive sites including the 
intestine, nasopharynx, and pelvis at least partly with a view toward the induction 
of S-IgA responses in the female genital tract. Parr compared nasal and vaginal 
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immunization using attenuated HSV-2 for protection against vaginal infection with 
WT-HSV-2 (1081). Compared to vaginal immunization, nasal immunization neither 
increased IgA plasma cell numbers in the vagina nor elicited a higher IgA titer in 
vaginal secretions. Vaginal immunization increased the number of vaginal IgG 
plasma cells and the secretion/serum titer ratio of IgG, indicating a local 
production of virus-specific IgG.  
Both T and B lymphocyte numbers were rapidly increased by about 20-fold in the 
vagina after virus challenge in immune mice but not in nonimmune mice and 
lymphocyte recruitment was mediated by IFN-γ (1091). Data clearly indicate that 
the IFN-γ secreted by memory T cells in the vagina of immune mice after virus 
challenge was responsible for rapid recruitment of large numbers of additional T 
and B lymphocytes to the vagina (1091).  
Also the expression of endothelial addressins in the vagina and their regulation by 
IFN-γ in immune mice after vaginal inoculation with HSV-2 was investigated (1089) 
as lymphocyte recruitment into tissues requires the presence of adhesion molecules 
on vascular endothelial cells. ICAM-1 and VCAM-1 may be involved in the rapid 
IFN-γ-mediated recruitment of lymphocytes to the vaginal mucosa of immune mice.  
 
Another aspect is that the titer of viral IgG in vaginal secretions of mice that were 
immunized in the vagina with attenuated HSV-2 may be higher than can be 
accounted for by passive transudation from serum (1079). The number of IgG 
plasma cells in the vaginae of immunized mice was markedly higher than in 
nonimmune mice, suggesting that IgG may be produced locally in vaginae of 
immune mice (1086).  
This is also an important issue considering the route of immunization in 
vaccination strategies that would best protect against reinfection. The results 
summarized above indicate that vaginal immunization of mice with attenuated 
HSV-2 elicits a strong protective immune response in the vagina consisting of cell-
mediated immunity, IFN-γ, and viral IgG antibody in vaginal secretions.  
 
The question is if parenteral immunization with attenuated HSV-2 would protect 
against vaginal challenge infection as effectively as vaginal immunization. One of 
the paradigms of mucosal immunity is that immunization at a mucosal surface 
provides stronger immunity against challenge at that surface than does parenteral 
immunization. However, the basis of enhanced immune protection at sites of 
mucosal immunization is generally thought to be the local production of specific S-
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IgA antibody, and vaginal immunization with HSV-2 induces mainly IgG viral 
antibody.  
Parr and Parr have therefore compared immunity resulting from local 
immunization in the vagina to that induced by parenteral immunization with 
attenuated HSV-2 [1083]. Interestingly, vaginal immunization induced sterilizing 
immunity against challenge with a high dose of WT-virus, whereas parenteral 
immunizations protected against neurologic disease but did not entirely prevent 
infection of the vagina.  
Vaginal immunization caused 86-fold and 31-fold increases in the numbers of IgG 
plasma cells in the vagina at 6 weeks after immunization, whereas parenteral 
immunizations did not increase plasma cell numbers in the vagina (1083). Vaginal 
secretion/serum titer ratios and specific antibody activities in vaginal secretions 
and serum indicated that IgG viral antibody was produced in the vagina and 
released into vaginal secretions at 6 weeks and 10 months after vaginal 
immunization but not after parenteral immunizations. In contrast to plasma cells, 
the numbers of T and B lymphocytes in the vagina were increased similarly by 
vaginal challenge with HSV-2 in both vaginally and parenterally immunized mice.  
Thus, local vaginal immunization with attenuated HSV-2 increased the number of 
IgG plasma cells in the vagina and increased vaginal secretion/serum titer ratios 
3.0- to 4.7-fold higher than in parenterally immunized groups but appeared to 
cause little if any selective homing of T and B lymphocytes to the vagina. 
 
HSV protein targets for vaccine construction 
As mentioned above, studies have shown that recurrent disease is prevented by 
virus-specific Th1 cytokines, i.e. IFN-γ, and activated innate immunity. Th2 
cytokines, i.e. IL-10, and regulatory (suppressor) T cells downregulate this immune 
profile, thereby allowing unimpeded replication of reactivated virus and recurrent 
disease. Accordingly, an effective therapeutic vaccine must induce Th1 immunity 
and be defective in Th2 cytokine production, at least of IL-10 (66).  
In different approaches the most immunogenic HSV proteins were tried to be 
identified as possible targets for vaccines (Figure 12). 
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Figure 12: HSV protein targets for CD4 and CD8 T cells as potential vaccine 
candidates; ICP=infected cell protein, g=glycoprotein, UL=unique long, VP=viral 
protein, adapted from Cunningham and Mikloska (279) 
One approach was directed at identifying the Th2-polarizing proteins so that they 
can be deleted from a potential vaccine. The functionally independent protein 
kinase (PK) domain of the HSV-2 large subunit of ribonucleotide reductase which is 
known as ICP10 has Th2-polarizing activity. In infected cells, ICP10PK upregulates 
the Th2 cytokines IL-6, IL-10, and IL-13, and downregulates RANTES, which is a 
chemoattractant for Th1 but not Th2 cells (66).  
Significantly, ICP10PK is required for virus replication and latency reactivation 
(1318), suggesting that its deletion will interfere with virus replication and latency 
establishment while reducing or eliminating Th2 polarization and toleragenic 
potential.  
Therefore, the vaccine candidate ICP10∆PK with deleted ICP10PK was developed. It 
was shown to be growth and latency compromising (1318) and in the mouse, 
ICP10∆PK vaccination inhibited HSV-2 replication and provided virtually absolute 
protection from fatal and cutaneous HSV-2 disease (65).  
 
Other approaches using blood lymphocytes taken from infected patients and 
restimulated with whole virus in vitro identified the viral glycoproteins gD and gB as 
key targets for the activation of CD4+ T cells (933) and viral ICP27, a protein 
present only at early stages in infected cells, as the key target for activation of CD8+ 
T cells (74). Another method is to clone T lymphocytes out of current herpes simplex 
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lesions and react them against B lymphocytes infected with HSV-1 and -2 and 
combinations thereof. With this method, several tegument proteins were identified 
as major T cell targets (730).  
 
Based on these targets, the original goal was to develop a prophylactic vaccine 
that induces local mucosal and systemic immunity which prevents infection and, 
thereby, virus transmission. The objective of a prophylactic vaccine is to induce 
sterilizing broad and durable immunity effective at all portals of HSV entry.  
A vaccine providing effective immunity against HSV must produce a response more 
powerful than the response produced by natural infection. This goal was predicated 
on the belief that neutralizing antibody and activated T cells at mucosal surfaces 
are the likeliest means to prevent infection, and its construction targets the viral 
glycoproteins D and B, which are involved in cell entry. However, it is becoming 
increasingly evident that the original vaccination goals may be unrealistic. 
Accordingly, the more recent goals of prophylactic vaccination are to prevent or 
reduce the clinical symptoms of primary infection and to shift the titer of virus 
necessary to give a primary infection and establish latency (1339). In this context, 
efforts focus on the selection of ideal adjuvants and the definition of optimal 
immunization route and protocol (66). 
 
Sununit HSV-2 vaccines 
Subunit HSV-2 vaccines using glycoproteins B and D prepared from infected cells 
(1336) or immune-stimulating complexes (ISCOM) consisting of glycoproteins (956) 
provided protection from lethal HSV infection and decreased severity and frequency 
of disease in animal models.  
In humans, a vaccine consisting of glycoproteins B2 and D2 with the adjuvant MF-
59 by Chiron was only transiently effective in two double-blind, placebo-controlled 
phase III studies that assessed prevention of HSV-2 infection. The first enrolled 531 
persons and the second 1862 individuals who were at high risk for HSV-2 infection. 
During the first 5 months of the studies, the acquisition rate of HSV-2 among 
vaccine recipients was 50% lower than in the placebo group, but after one year the 
overall efficacy was only 9% (254).  
In both studies, the vaccine failed to reduce the likelihood or severity of 
symptomatic disease. Interestingly, the HSV-2 antibody titers did not differ between 
vaccinated, uninfected and vaccinated, finally infected individuals. These results 
suggest that neutralizing antibody alone is not sufficient to protect against genital 
HSV-2 infection and that the vaccine failed to induce critical cell-mediated immune 
 Immunology of the genital tract 
 II-107  
responses against HSV-2 infection. Possible explanations for the loss of efficacy 
could be that the protective immune response was only short time or that initial 
protection was lost with frequent exposure to the virus (1339). 
 
In another trial, a vaccine consisting of glycoprotein D and a mixture of alum and 3-
deacylated monophosphoryl lipid A (3-dMPL) as adjuvant by GlaxoSmithKline was 
tested (1338). In a phase I trial, the vaccine was well tolerated and induced both 
cellular and humoral immune responses (1339). In two double-blind, placebo-
controlled trials with 847 and 2491 partners of HSV-2 infected individuals, 
respectively, the vaccine`s efficacy was 38% in seronegative male and female in 
study 1 and 42% in seronegative females of study 2 (1338). This vaccine was 
effective in preventing symptomatic genital HSV-2 disease in women in about 73% if 
they were initially HSV-1 and HSV-2 seronegative. The vaccine was shown to induce 
both gD-specific neutralizing antibodies and a Th1 cell-mediated immune response.  
 
This is the most promising approach of creating a vaccine preventing genital herpes 
which is currently further investigated in another trial on 7550 HSV-2 seronegative 
women.  
The partial effectiveness of this vaccine compared to the Chiron vaccine suggests 
that the adjuvant may be critical in facilitating the induction of protective immune 
responses (Figure 13). The MF59 adjuvant induces a Th2-pattern of response 
(1313), whereas the MPL adjuvant induces a Th1-pattern of cytokine response. 
However, in vitro studies have shown that MPL alone is not sufficient to induce 
CD8-lymphocyte cytotoxicity. MPL plus the Quil A derivative, QS21, significantly 
enhanced cytotoxicity, via induction of IL-12 from APCs and IFN-γ from T 
lymphocytes (935). 
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Figure 13: Postulated mechanisms of action of adjuvants for HSV vaccines, adapted 
from Cunningham and Mikloska (279) 
Live attenuated HSV vaccines 
Attenuated live virus vaccines cause a primary infection but do not reactivate after 
establishing latency in ganglia. Two strategies were used to develop live HSV-2 
vaccines. The first strategy used viral vectors that express HSV glycoproteins. 
R7020, constructed from a HSV-1 strain by replacing a deleted portion with a 
fragment of HSV-2 genome encoding glycoproteins D, E, G and I, was poorly 
immunogenic and caused adverse events in clinical trials despite reduced latency 
results in animal models (912).  
 
Viral DNA vaccines 
Concerning viral DNA vaccines, results are inconsistent. Plasmid DNA encoding 
glycoproteins D and/or B or the immediate-early protein ICP27 induced protective 
immunity in some animal models whereas immunity was incomplete in other 
models (136, 449). 
 
Therapeutic vaccines aim to prevent HSV recurrence or minimise disease severity 
and duration and reduce transmission. A vaccine must augment the host`s specific 
immune responses but as immune mechanisms controlling outbreaks seem to be 
different from those required to prevent initial infection, therapeutic vaccines will 
have to boost different immune responses to that of a prophylactic vaccine (1339).  
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Therapeutic vaccines probably need to stimulate strong virus-specific cell-mediated 
immune responses. The challenge in developing a therapeutic vaccine is to identify 
the HSV antigens that induce a greater protective response than infection with the 
whole virus. Therapeutic vaccines could be an alternative to antiviral therapy as 
well.  
 
The above mentioned ICP10∆PK has shown therapeutic activity in phase I and 
phase II clinical trials with a reduced recurrency rate, total days of disease and 
disease severity compared to placebo group (179). At 6 months after treatment, 
HSV-2 recurrences were completely prevented in 37.5% of the vaccinated patients 
but were prevented in none of the placebo-treated patients. Vaccinated patients 
who experienced disease had a significantly lower frequency of episodes, reduced 
severity of episodes and a lower mean total illness days relative to the placebo 
group. 
 
The second strategy used to develop live vaccines was to generate mutants rendered 
nonvirulent by the deletion of one or more genes while retaining the viral 
glycoproteins previously identified as immunogenic targets. 
An HSV-2 mutant deficient in glycoprotein H, known as DISC (disabled infectious 
single cycle), reduced HSV-2 replication and provided protection from HSV-2-
induced disease (904). DISC also caused a 36% reduction in recurrent lesions in 
the guinea pig when given systemically but not when administered by the mucosal 
route (904). In phase I clinical trials done by Cantab, now Xenova/GSK, DISC was 
well tolerated and induced neutralizing antibody and lymphoproliferative T-cell 
responses. 83% of the vaccine recipients also developed HSV-specific CTL. However, 
clinical endpoints were not met in phase II trials to assess DISC’s efficacy as a 
therapeutic vaccine, and further development was halted (66). 
 
An overview of double-blind placebo-controlled clinical trials on different 
therapeutic HSV vaccines gives Table 22. 
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Therapeutic 
vaccines 
n 
(vaccine/ 
placebo) 
Results  
Non-specific live vaccines 
Bacillus Calmette-
Guerin (BCG) (339) 
83/72 
Mean rate of recurrence 0.528/month vs 
0.392/month (placebo) 
No influence on duration of lesions 
Whole inactivated virion vaccines 
Whole virus, 
formalin-inactivated 
(689) 
16/23 Fewer recurrences in 70% vs 76% of placebo group 
Whole virus, heat-
killed (Lupidon 
G/H) (1490) 
28/34 
Cure/reduced disease severity/prolongation of 
interval length in 80% vs 30% of placebo group 
Whole virus, heat-
killed (Lupidon 
G/H) (881) 
142/50 
Reduced number and duration of recurrences 
Increased interval length and reduced length of active 
disease  
Inactivated subunit vaccines 
Subunit, lectin-
purfied (758) 
18/24 Fewer recurrences in 43% vs 35% of placebo group 
Skinner vaccine, 
formalin-inactivated 
(1315) 
148/144 
Reduced number of recurrences in women 
Reduced number of lesions per recurrence in men 
Recombinant glycoprotein vaccines 
gD2-alum vaccine 
(1360) 
98 
24% fewer clinical and 36% fewer culture recurrences 
per month vs placebo group 
gD-gB-MF59 
vaccine (1361) 
101/101 
No effect on recurrence rate 
Reduced symptom duration/new lesion 
formation/lesion duration 
Disabled infectious single cycle (DISC) virus vaccines 
TA-HSV2 vaccine 
(1339) 
483  
No significant differences between vaccine and 
placebo group 
Table 22: Results of therapeutic human HSV vaccination trials     
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b) Human immunodeficiency virus  
HIV-type 1 is the etiological agent of AIDS, a disease characterized by progressive 
immune deterioration and disappearance of CD4+ T cells from peripheral blood and 
lymphoid organs.  
It is estimated that over 40 million people currently live with HIV-1, most of them in 
sub-Saharan Africa and Asia, and that about 28 million have already died of the 
pandemic. As the mean incubation period from seroconversion to AIDS is about 8 to 
10 years and many HIV-infected persons are unaware of their infection status, the 
chance for them to further disseminate HIV through sexual contact is very high. 
Therefore, HIV/AIDS has the potential to become an even more serious health 
problem than it already is today.  
 
On the African continent, women living with HIV/AIDS make up 60% of the number 
of HIV-infected people (1531). Heterosexual transmission of HIV-1 is the major 
route of infection on a worldwide basis and accounts for 70-80% of new infections. 
Although female-to-male transmission of HIV can occur, the vast majority of cases 
of 80% involve transmission of virus or virus-infected cells from male to female 
(571). Nonetheless, only one in 200 to one in 1000 encounters results in productive 
infection which emphasize the effectiveness of structural and cellular barriers to 
virus entry (479). Genital tract infection may also be linked to mother-to-child 
transmission of HIV.  
 
As the genital mucosa is the site of initial contact with HIV-1 for most exposed 
individuals, study of the virus from the genital tract is critical for the development 
of vaccines and therapeutics. It is currently not clear which factors contribute to 
the establishment of HIV-1 infection within the female reproductive tract. The 
establishment of HIV-1 infection seems to be dependent on the virus amount, the 
presence of other genital tract infections and the effectiveness of immune systems 
in the reproductive tract. 
  
In recent years, significant progress has been made in understanding anti-HIV 
immunity in the vagina by using the simian immunodeficiency virus (SIV)/rhesus 
monkey model of heterosexual HIV transmission (937).  
Both HIV and SIV are retroviruses of the lentivirus family. They have a high degree 
of nucleotide sequence homology and similar organization of viral genes. It has been 
shown that vaginal inoculation of SIV in rhesus macaque results in systemic 
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infection (937). The reproductive physiology of rhesus monkeys is remarkably 
similar to that of humans with both having menstrual cycles with an average length 
of 28 days. Also, the similarity of the immune cell populations of the human and 
rhesus macaque lower female reproductive tract suggest that the biology of the 
closely related SIV and HIV viruses is likely to be very similar in their respective 
species. Thus, the rhesus macaque has become a widely accepted animal model for 
studying anti-HIV immunity in the female genital tract. 
(1) HIV transmission and shedding in the genital tract 
HIV-1 is present as free virus and virus-infected cells in semen from HIV-1 infected 
men (1101) and is deposited within the vagina in close proximity to the cervix 
during sexual intercourse. Which cells become infected and how the virus replicates 
is still not exactly clear. Also the mechanisms of viral transmission within the 
female reproductive tract and the mode of viral spread to the periphery are not well 
understood.  
Although HIV can be recovered from the vagina of women who have had a total 
hysterectomy, most genital virus arises from the cervix and possibly the upper 
genital tract (378, 251). The proximity to the vaginal lumen of cervical stroma 
lymphocytes, which compose the genital-associated lymphoid tissue, probably 
contributes to both HIV shedding and to susceptibility to mucosal transmission. 
The ectocervix is seen as a likely first site of contact with HIV-1 following 
heterosexual transmission, and expression of HIV receptors and coreceptors is 
likely to correlate with susceptibility to viral infection. 
 
HIV receptors 
The envelope glycoprotein gp120 of HIV-1 binds to cell-surface receptors on target 
cells. The primary receptors are CD4, which is mainly expressed on a subset of T 
cells and on macrophages (614), and galactosyl ceramide (GalCer) (249).  
 
Furthermore, it is evident that the chemokine receptors CCR5 and CXCR4 which 
are expressed by most leukocyte subsets and ECs function as HIV-coreceptors and 
are important for HIV infection of cells (110).  
There are T cell line-tropic strains of HIV which are specific for CXCR4 and can 
infect continuous CD4+ T cell lines and primary CD4+ T cells. Macrophage-tropic 
strains are specific for CCR5 and can infect primary macrophages and primary 
CD4+ T cells (110). The CCR5 ligands MIP-1α, MIP-1β and RANTES block infection 
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by macrophage-tropic strains of HIV-1 and similarly, the CXCR4 ligand stromal 
cell-derived factor-1 blocks infection by T-tropic strains of HIV-1 (110). However, the 
designation of HIV-1 phenotype is revised to indicate coreceptor usage. Accordingly, 
HIV-1 variants are designated as either X4 (CXCR4-specific) or R5 (CCR5-specific).  
 
It has been shown that HIV-1 infects viable tissue sections and isolated cells from 
both the lower and upper female genital tract suggesting that both ECs and 
submucosal leukocytes may be targets for initial HIV-1 infection (571). Moreover, it 
was also demonstrated that uterine EC lines can be productively infected with X4 
strains of HIV-1 and that these cells express CD4, GalCer and CXCR4, but not 
CCR5. CCR5 and CXCR4 expressing primary human uterine ECs are able to 
internalize both X4 and R5 strains of HIV, but can only become productively 
infected by X4 strains (61).  
HIV-1 strains that utilize the CXCR4 chemokine receptor for infectivity are able to 
undergo reverse transcription, integration, viral DNA transcription and viral release 
whereas viral strains that utilize CCR5 do not undergo these early replicative events 
and are only released unmodified from these cells (570).  
 
Therefore, Asin et al. suggest three potential mechanisms of virus transmission in 
the female genital tract (61). One mechanism seems to occur only with X4-tropic 
strains of HIV-1 and supports the development of a productive viral infection by the 
EC. Infection with the R5 strain of HIV-1 in which replication is not supported 
appears to lead to a gradual release of unmodified infectious virus. In addition, HIV-
1 infection is transmitted after cell-to-cell contact between the infected ECs or 
stromal fibroblasts and the susceptible target cell. An alternative mechanism of HIV 
infection of the lower female genital tract involves the transcytosis of endosome-
internalized HIV through the epithelium barrier, without EC infection (558). This 
approach may allow HIV to transverse directly to the submucosa, where it can 
infect susceptible immune cells.  
 
To characterize the frequency of potential targets of HIV infection within the female 
genital tract, a study of the expression of HIV receptors and coreceptors on ECs and 
leukocytes from the ectocervix was performed (1558).  
Results demonstrated expression of CCR5 and CD4 on basal and parabasal 
epithelium, and a clear compartmentalization of chemokine receptor expression 
between the squamous mucosa and submucosal stroma (Figure 14, Table 23). 
CCR5- and CXCR4-expressing leucocytes were found exclusively in the submucosal 
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stroma adjacent to the basal lamina. GalCer was expressed by cells of the parabasal 
and cornified layers, and as such is likely to be the only HIV receptor readily 
accessible to virus. Moreover, studies show that CD4+ and chemokine receptor-
expressing cells are proximal to the lumen in the dermal papillae. Given the 
phenotypes present in the papillae, it is proposed that these structures serve as a 
potential first site of encounter with infectible leucocytes and, given the large 
number of HLA-II positive macrophages within the stromal papillae and HLA-II 
positive DCs as APCs present, may represent an antigen sampling structure for the 
ectocervix and vaginal mucosa. 
 
 
Figure 14: Structure of squamous epithelium in the ectocervix; adapted from Yeaman 
et al. (1558) 
HIV receptor/coreceptor expression on ectocervical ECs in proliferative 
phase/secretory phase of menstrual cycle, respectively 
 Basal Parabasal Midzone Superficial 
CCR5 ++/+ +/+ ― ― 
GalCer ― +++/+++ +/+ +++/+++ 
CD4 ++/+ ++/+ ― ― 
CXCR4 ― ― ― ― 
Table 23: HIV receptor/coreceptor expression in the human ectocervix in different 
phases of the menstrual cycle (1558) 
The lack of CCR5-, CXCR4- and CD4-expressing cells accessible to HIV in the 
lumen of the ectocervix contrasts with previous findings of HIV-1 receptor and 
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coreceptor expression in the uterus where all three of these receptors are expressed 
on the luminal aspect of the glandular and columnar epithelium (1561).  
 
Mediators of HIV transmission 
Enhanced detection of HIV in CVL is often correlated with decreased CD4+ count 
and increased viral load (979). Additional correlates of enhanced HIV in the female 
genital tract include oral contraceptive use, pregnancy, cervical ectopy and STDs 
(Table 24).  
The exact mechanism of STD-mediated enhanced shedding of HIV is still unknown. 
Enhanced recruitment of activated immune cells, disruption of the epithelium 
barrier, reduction of T-helper and CTL function, which are all associated with STDs, 
may contribute to this STD-mediated enhancement of HIV detection in the female 
genital tract (27). Inflammation associated with STDs may also lead to increased 
proinflammatory cytokine production such as IL-1, IL-6 and TNF-α, which can 
potently upregulate HIV replication (1130).  
 
Associations between HIV and STDs 
Increased shedding/replication of HIV as a result of the local inflammation produced by 
the STD 
 Recruitment of activated (HIV-susceptible) immune cells (e.g. CD4+ T cells) 
 Increase of proinflammatory cytokine production 
Increased susceptibility to HIV as a result of the macroscopic/microscopic breaks in 
mucosal barriers caused by the STD 
Higher prevalence of STDs among HIV infected individuals as a result of common risk 
factors for both infections 
Increased susceptibility to STDs due to immunosuppression associated with HIV infection 
Table 24: Causes for increased predisposition of individuals with other STDs to HIV 
and vice versa 
Bacterial vaginosis (BV) is also associated with increased transmission of HIV. 
Cultured bacteria such as mycoplasma or streptococci from CVL of HIV-positive 
women with BV have been shown to induce HIV-1 expression in vitro (28). These 
studies point to a direct role of BV-associated microorganisms in the induction of 
HIV replication, which may increase genital tract viral load and possibly impact 
horizontal and vertical transmission of HIV. BV also causes an increased vaginal 
pH, which may prolong the survivability of HIV in this lower genital tract 
microenvironment.  
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Additional mediators of HIV transmission may also exist. There has been described 
an HIV-inducing factor isolated from the CVL of women, independent of HIV-
serostatus, that potently upregulated the expression of HIV (29). This factor 
induced HIV-LTR transcription in a NF-κB-dependent pathway and is closely 
correlated with abnormal vaginal pH and BV (1046). This HIV-inducing factor in the 
genital tract of women may have a role in enhanced replication or horizontal or 
vertical transmission of HIV.  
 
Compartmentalization 
One of the main questions in understanding HIV replication in the genital tract is 
whether HIV is locally produced within the female genital tract or whether the virus 
is circulated through peripheral/tissue-infected cells to the genital tract. Therefore, 
the question of compartmentalization, the occurrence of distinct, yet 
phylogenetically related HIV-1 genotypes within different anatomic sites, is a very 
important one. Mucosal-associated lymphoid tissues may provide a source of HIV 
infection in the female genital mucosa but limited studies have addressed this 
compartmentalization question.  
 
Viral sequence analysis of HIV isolated from the periphery and the genital tract of 
infected women in one study indicates that these viruses are similar between the 
blood and the CVL (1282).  
However, other studies supported compartmentalization between genital tract and 
periphery (1588). Zhu and colleagues demonstrated that HIV-1 variants in genital 
secretions of chronically infected transmitters differed from those in the blood and 
variants in cells differed from those in cell-free plasma, indicating sequence 
heterogeneity as well as compartmentalization of the virus in different body sites. 
Some of those differences can be attributed to differences in the techniques used to 
detect HIV-1 in the lower genital-tract compartment and the significantly higher 
short-term variations in HIV-1 load in the genital tract compartment than in that of 
blood. Another study documented significant differences in the mean number of 
glycosylations on viruses derived from the genital tract and plasma, underscoring 
the importance of considering HIV-1 and immune response in the genital tract 
when designing vaccines (688).  
In addition, by quantifying the proportion of R5 and X4 viruses in each site, it was 
found that coreceptor usage often varied significantly between genital tract and 
plasma. Moreover, the study demonstrated a significant association between higher 
CD4+ cell counts and compartmentalization of both viral genomes and density of 
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gp120 glycosylation sites, suggesting that the immune response influences the 
development of viral genotypes in each compartment. 
(2) Innate immune responses in HIV infections 
Antimicrobial peptides  
HNP1-3 inhibited both laboratory and clinical isolates of HIV in vitro (1476) and 
notably, although it is not as well characterized, HNP-4 shows even greater anti-HIV 
activity than HNP1–3 and was more effective in protecting human PBMC from 
infection by both R5 and X4 HIV-1 strains (1539). 
HBD-2 and -3 inhibited HIV-1 replication and downregulated CXCR4 expression 
(1157). Interestingly, a recent study showed a significant correlation between a 
single-nucleotide polymorphism in the untranslated region of the DEFB1 gene, 
which probably regulates the gene expression of HBD-1, and the risk of perinatal 
HIV infection supporting a potentially important role for defensins in innate 
immunity of HIV infection (138). However, further studies have to further elucidate 
their role in HIV immunity in the female genital tract. 
 
Another factor that is likely to control HIV infection within the female reproductive 
tract is SLPI. SLPI protects human macrophages and CD4+ T cells from HIV-1 
infection (907), and more recent studies demonstrated that SLPI blocks HIV 
infection through interactions with a cellular target, annexin II, a cofactor for 
macrophage HIV-1 infection (849). There is mounting evidence suggesting that SLPI 
may be an important host defense. Higher SLPI concentrations in vaginal fluid 
samples correlate with a reduced rate of perinatal HIV transmission (1123). 
 
DCs and macrophages 
Several reports have identified DC, NK cells, resting and activated CD4+ T cells and 
macrophages as the earliest cell populations to become positive for SIV- and HIV-
RNA following a nontraumatic exposure to the virus (1558). DCs are considered 
important target cells in HIV infection and transmission. In SIV-infected rhesus 
macaques, infected DCs appear first in the mucosa and within 18 hours they are in 
the draining lymph nodes where they efficiently transmit the virus to CD4+ T cells 
(574).  
Cervical biopsies from HIV-positive women have shown significantly reduced levels 
of LCs but increased numbers of macrophages (13). The epithelium of the cervix 
from HIV+ subjects showed a significant increase in both numbers of macrophages 
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(CD68+) and proportions of activated macrophages (CD68+ HLA-DR+) compared to 
healthy persons which could act as APCs for lymphocytes. The stroma contained 
increased proportions of inductive (D1+) and suppressive (D1+ D7+) macrophages 
but decreased effector phagocyte (D7+) proportions and LCs. 
In HIV-infected individuals, viral infection of DCs isolated from peripheral and 
lymphoid tissues has been demonstrated (1317). Immature DCs (iDCs) as well as 
LCs express both CD4 and the HIV chemokine coreceptors CCR5 and CXCR4 at 
their surface. Their surface receptor DC-SIGN is also thought to be one of the 
receptors to bind and internalize virus prior to its transmission to CD4+ T cells 
(442). However, they are infected with lower efficiency than CD4+ T cells and 
macrophages. In contrast, mature DCs (mDCs) do not efficiently replicate the virus 
and may therefore represent an important reservoir of latent virus infection (1317). 
Once bound, HIV is internalized and retains its infectivity for several days, a time 
also required for migration of DCs to regional lymph nodes, their differentiation to 
mDCs and the transfer of virions (transinfection) of CD4+ T cells (770).  
However, several functional impairments and a reduction of DCs have been 
reported. Ex vivo cultured DCs from HIV-infected persons are impaired in their 
ability to stimulate T lymphocyte proliferation (420). NK cell function and numbers 
are also impaired in terms of cytolytic activity, mainly by the capacity to secrete 
CCR5-binding chemokines. This results in impaired elimination of infected cells 
and limited virus replication (420). However, further studies need to be done to 
evaluate these findings and if they can also be transferred to the genital tract 
mucosal immune system. 
(3) Specific immune responses in HIV infection  
CTLs 
CTLs have been shown to be the major means by which an immune response 
eliminates systemic viral infections. In studies with mice, it has been shown that 
virus-specific CTLs, generated in the genital lymph nodes, can participate in 
effective genital immune responses against a sexually transmitted viral pathogen, 
for example HSV (897).  
Systemic HIV-1 specific CD8+ T lymphocytes have been associated with protection 
against HIV-1 infection and improved host control immune control of HIV-1 (906). 
In the acute phase of infection, the CTL response initially follows the rise of HIV in 
the blood and when that response reaches a peak the virus level falls (Figure 15). In 
the following, there is an inverse relationship between CTL response and virus load 
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(1040). Quantification of the early T cell response can be made with HLA tetramers 
(Figure 15). HIV-specific CTLs produce cytokines such as IFN-γ, TNF-α, and the 
chemokines MIP-1α, MIP-1β and RANTES which can suppress viral replication 
(906). However, less than 15% of HIV-specific CTLs contained perforin which may 
result in poor target-cell death. Analyzing their surface glycoproteins compared to 
CMV-specific T cells, HIV-specific CD8+ T cells may be immature rather than end-
stage effectors.  
The cellular immune response to HIV, mediated by T lymphocytes, thus seems 
strong but fails to control the infection completely. HIV undermines this control by 
infecting key immune cells, thereby impairing the response of both the infected 
CD4+ T cells and the uninfected CD8+ T cells. The failure of the latter to function 
efficiently facilitates the escape of virus from immune control and the collapse of the 
whole immune system (741). 
 
     
Figure 15: Early CTL responses (mauve line) and virus load (red line) – further 
observations were influenced by the initiation of antiretroviral drug therapy (blue 
bands); adapted from McMichael and Rowland-Jones (906) 
However, animal models have suggested that it may be mucosal CD8 lymphocytes 
that play a particularly important role in protecting against mucosal virus 
challenge. Therefore it is important to assess the function as well as the frequency 
of HIV-1-specific CD8+ cell responses in the genital tract. 
A study showed that SIV-specific CTL activity is present in the CD8+ T cell 
population in the vaginal epithelium of SIV-infected animals (827). The SIV-specific 
CTL in the vaginal epithelium may be recognizing SIV-infected DCs present in the 
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vaginal epithelium of acute and chronically infected rhesus macaques (574). The 
generation of antiviral CTL activity in vaginal IEL appears to be part of the normal 
immune response to infection with SIV and HIV.  
It is also possible that SIV-specific CD8+ CTL are homing to the vaginal epithelium 
as part of a normal pattern of lymphocyte recirculation, unrelated to the presence of 
virus infected cells (938). The immune cell population in the ectocervical and 
vaginal epithelia are immunophenotypically similar, and it is likely that similar CTL 
activity is present in the CD8+ T cells in the ectocervical squamous epithelium.  
 
A similar population of anti-HIV CD8+ CTL has been found in brushings of the 
endocervical canal from HIV-infected women (993) and in the genital tract of highly 
exposed persistently seronegative sex workers (668). Genital HIV-1-specific CD8+ 
cell responses of HIV-positive women were present at similar or higher levels than 
in the blood (669). In a study by Ahmed et al., HIV-positive women had 
significantly increased numbers of CD8+ lymphocytes resulting in reversal of the 
CD4/CD8 ratio compared with the control group which is in keeping with systemic 
events (13). However, the elevated numbers of CD8+ cells seen in the ectocervix of 
HIV-positive women demonstrates the active recruitment of nonresident CD8+ 
lymphocytes rather than an expansion of the resident intraepithelial population. 
 
As elsewhere, these cells do not appear to be capable of mounting an adequate 
immune response to the virus. There was a significant increase in the proportion of 
activated CD8+ HLA-DR+ and CD4+ HLA-DR+ lymphocytes, but not in CD8+ TIA-1+ 
cells (13). The monoclonal antibody TIA-1 identifies cytotoxic granules in cells. 
Although the majority of CD8+ T cells express TIA-1 in low-risk women, the lack of 
a significant increase in the proportions of CD8+ TIA-1+ cells in HIV-infected 
women provides circumstantial evidence that there is no increase in the cytotoxic 
capacity of these CD8+ cells. The increased proportion of activated CD4+ HLA-DR+ 
cells seen in the female genital tract despite declining CD4 T-cell numbers suggests 
that this mucosal immune system of HIV-positive women exists in a more activated 
state than that in seronegative individuals. 
 
Anti-HIV antibodies in genital tract secretions 
Anti-HIV antibodies in vaginal washing samples include antibodies from serum 
transudates, local vaginal production and cervical mucus. Anti-HIV antibodies have 
been found in CVS of seropositive individuals. Cervicovaginal Igs were significantly 
increased with IgG as the predominant isotype of anti-HIV antibodies in CVS of 
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HIV-1 infected women (101) and SIV-infected rhesus macaque (939). Low levels of 
anti-HIV-1 IgA associated with large increases in anti-HIV-1 IgG in CVS are 
common in HIV-infected women. Lü found a significantly higher HIV-1-specific IgG 
activity than that of IgA in CVS, saliva and breast milk of HIV-infected individuals 
(833). Correlation studies suggested that IgG, IgM, and HIV-1-specific IgG in CVS is 
mostly serum derived. CVS IgA seems to be both locally produced and serum 
derived, while IgA, IgM, and HIV-1-specific antibodies in saliva and breast milk are 
mostly locally produced. 
 
In the rhesus macaque, the relative levels of anti-SIV IgG and IgA in the serum 
seem to reflect the relative levels of anti-SIV IgG and IgA in vaginal secretions (939). 
This is most easily interpreted as an indication that the bulk of anti-SIV antibody in 
vaginal secretions is due to serum transudation. However, the results in 
hysterectomized animals are consistent with anti-SIV Ig production in the vaginal 
mucosa. Thus it seems that both local production and transudation of serum 
antibodies are sources of anti-SIV antibodies in the vaginal secretions.  
 
There is the hypothesis that in frequently HIV-exposed but uninfected individuals, 
HIV-specific mucosal antibody responses may exist and play a role in resistance to 
HIV. It has been published that HIV-1-resistant sex workers show the presence of 
HIV-specific IgA in their genital secretions (670) whereas other studies described 
the absence of HIV-specific antibodies in genital secretions of HIV-resistant sex 
workers (337). So far, a condition that mimics the reports of HIV infections that 
produce genital anti-HIV antibodies without exposures of a systemic immune 
response could not be reproduced in monkeys (938).  
(4) Cytokine profiles 
Proinflammatory cytokines may stimulate replication and spread of HIV.  
Belec et al. determined TNF-α, IL-1β and IL-6 concentrations in paired serum and 
CVL from 45 HIV-negative and 50 HIV-positive women to evaluate to what extent 
the female genital tract represents a source of proinflammatory cytokines in normal 
conditions and during the course of HIV infection (102). Expression of cytokine 
mRNA in cervicovaginal fluid and proportion of inflammatory cells was increased in 
advanced stages of HIV infection. Levels of TNF-α and IL-6 correlated positively with 
the homologous serum cytokine levels in HIV-infected women. A transudation of 
cytokines from serum to the cervicovaginal fluid may have occurred in HIV-infected 
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patients, but local production of cytokines was assessed by the detection of 
cytokine mRNAs (102).  
Anderson et al. also described elevated levels of IL-1β and MIP-1α in genital 
secretions of HIV-infected persons compared to uninfected women which suggest an 
inflammatory state of the genital tract (35).  
Corwley-Norwick and colleagues evaluated IL-2, IL-10 and IL-12 concentrations in 
cervical secretions of female adolescents in order to determine how cytokine levels 
are influenced by infection with HIV and coinfection with other sexually transmitted 
pathogens (271). Compared with HIV–negative patients, HIV-positive patients had 
higher concentrations of IL-10. Coinfection of HIV and HPV predicted the highest 
IL-10 concentrations; coinfection of HIV, human papillomavirus, and other sexually 
transmitted pathogens predicted the highest IL-12 concentrations. In contrast, HIV 
infection, HPV infection or infection with other STDs is not associated with 
differences in IL-2 concentrations.  
The data indicate that concomitant infection of the genital tract with HIV and other 
viral, bacterial, or protozoan pathogens influences the local concentrations of some 
immunoregulatory cytokines. 
In the review of Fauci, he summarized that IL-2, TNF-α, IL-1, and IL-6 can 
upregulate HIV replication, whereas INF-α, TGF-β, IL-10, and β-chemokines (MIP-
1α, MIP-1β, RANTES) can downregulate HIV (380). The balance between HIV-
inducing and HIV-inhibiting cytokines may impact the viral load in the mucosa and 
subsequently, the sexual transmission of the virus. 
(5) Impact of hormones and menstrual cycle on HIV 
Female hormones may impact HIV replication not only in the genital tract but also 
in the periphery. Steroid hormones can bind to hormone-responsive elements 
within the long terminal repeat (LTR) of HIV which leads to an upregulation of HIV 
transcription (450). Recent studies using the SIV-macaque model of vaginal 
infection indicated that progesterone implants enhanced HIV transmission, 
presumably by thinning of the vaginal wall (878), whereas estrogen inhibited HIV 
infection, inversely, by thickening of the vaginal wall (1320). 
 
The impact of the menstrual cycle on genital tract shedding of HIV is controversial. 
Reicheldorfer et al. reported that genital tract HIV-1 RNA levels from CVL fluid 
and endocervical cytobrush specimen were highest during menses and lowest 
immediately thereafter (1183). The menstrual cycle had no effect on blood levels of 
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HIV-1 RNA. Benki et al. investigated the association between hormone fluctuations 
during the menstrual cycle and HIV-1 RNA shedding in cervical and vaginal 
secretions (108). A significant positive correlation between serum levels of 
progesterone and serum levels of HIV-1 RNA was detected. The lowest levels of 
cervical virus levels were present at the midcycle surge in LH, which was followed 
by an increase in virus levels that reached a maximum before start of menses.  
However, other studies were unable to detect a menstrual cycle pattern to HIV 
genital tract shedding (978). Variation in assay methods and small number of 
women sampled in previous studies may account for this discrepancy. The length of 
the menstrual cycle also seems to be independent of HIV serostatus (511). 
 
Wang et al. investigated the influence of hormonal contraception on genital tract 
shedding of HIV-1 (1473). Women demonstrated a significant increase in the 
prevalence of HIV-1 infected cells and a slight increase in HIV-1 RNA detection in 
CVS after initiating hormonal contraception whereas no changes were observed in 
concentrations of HIV-1 RNA. This may have implications for the HIV-infectivity of 
women using hormonal contraception. 
 
Expression of HIV-1 receptors and coreceptors in the female genital tract varies as a 
function of menstrual cycle stage, suggesting that sex hormone levels may influence 
a women`s susceptibility to HIV-1 infection. The expression of HIV-receptors and -
corecptors was evaluated on uterine epithelia at different stages of the menstrual 
cycle (1561). CD4, CCR5 and CXCR4 were found on glandular and luminal ECs. 
Both CD4 and CCR5 expression on uterine ECs was high throughout the 
proliferative phase of the menstrual cycle; CXCR4 expression increased gradually 
during the proliferative phase. During the secretory phase of the cycle, CD4 and 
CCR5 expression was reduced whereas CXCR4 expression remained elevated. 
Expression of GalCer on endometrial glands is higher during the secretory phase 
than during the proliferative phase.  
This variation in receptor expression suggests that receptors are regulated by 
estradiol and progesterone and that a woman`s susceptibility to HIV infection may 
vary due to this hormonal regulation of HIV receptor expression. Progesterone also 
causes a decrease in IL-2-mediated induction of the two main coreceptors for HIV 
entry, CCR5 and CXCR-4, on activated T cells, leading to reduction in HIV infection 
(1449).  
The results presented by Yeaman et al. suggest that, in contrast to the uterus, 
expression of CD4, CCR5, CXCR4 and GalCer in leukocyte populations from the 
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ectocervix do not greatly vary with the stage of the menstrual cycle (1558). 
Moreover, ECs from tissues at early and mid-proliferative stages of the menstrual 
cycle express CD4, although by late proliferative and secretory phases, CD4 
expression was absent or weak. In contrast, GalCer and CCR5 expression on 
ectocervical ECs was uniform in all stages of the menstrual cycle (Table 23).  
A study among 55 HIV-positive women with CD4 count <350 cell/µl examined over 
the course of 8 consecutive weeks has found that vaginal IL-1β, IL-2, IL-4, IL-6, IL-
10, MIP1β, TGF, and TNFRII are all increased during menses whereas peripheral 
cytokines were not altered (26). Increased cytokine levels during menses of HIV-
positive women may be correlated with the increased numbers of granulocytes and 
macrophages in the genital mucosa at menses (102) which in the case of HIV may 
be hyperactivated, leading to enhanced cytokine production. 
In HIV-seropositive women with advanced HIV disease and a CD4 count <200 
cells/µl, TNFα, IL-1β and IL-6 are enhanced in comparison to patients with early 
HIV disease and a CD4 count >500 cells/µl or HIV-seronegative women (1280). 
Phenotypic and functional analysis of systemic lymphocytes was not altered by the 
menstrual cycle as evaluated from HIV-positive or HIV-negative women (26). 
c) Human papillomavirus 
HPV is a heterogenous group of DNA viruses from the Papovaviridae family. With its 
at least 100 different genotypes it can infect and replicate in skin epithelium 
(cutaneous HPV) and in mucuos membranes (mucosal HPV), and induce epithelial 
proliferation resulting in warts (1055). More than 40 anogenital genotypes have 
been associated with STD, which makes HPV the most common viral STD in the 
world.  
 
Two out of three people having sexual contact with an HPV-infected partner will 
develop an infection within the next months which will be asymptomatic in almost 
three out of four cases (1417). Most HPV infections regress spontaneously with HPV 
DNA persisting for about 6-12 months in the genital tract and spontaneously 
disappearing in the majority of patients. 
 
The correlation between genital HPV infections and cervical cancer was first 
documented in the early 1980s by the study group of Harold zur Hausen, a 
German virologist (458). HPV infection is now generally accepted as being involved 
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in the development of anogenital precursor neoplasia, i.e. cervical, cervical 
glandular, vulval, vaginal and anal intraepithelial neoplasia. Approximately 30% of 
high-grade CIN will progress to invasive cervical carcinoma over a period of 10-20 
years which makes persistent HPV infection the major risk factor for developing 
cervical carcinoma (867, Figure 17).  
HPV types 16, 18, 31, 33, 35, 45, and 58, and about eight to ten other minor types, 
are oncogenic and are found in almost all cervical cancer biopsy samples and in 
90% of high-grade intraepithelial precursor lesions (Figure 16). HPV types 16 and 
18 are the most commonly detected HPV types in biopsy samples (1340). 
 
      
Figure 16: Prevalence of different HPV types in cervical cancer biopsies, adapted from 
Stanley (1340)  
HPV types which infect the genital tract can be classifed into three groups (831, 
Table 25).  
The low-risk group includes HPV 6 and 11 which are commonly associated with 
condylomata accuminata and low-grade squamous intraepithelial lesions (LSIL or 
CIN I).  
The high-risk group includes HPV 16, 18, 45 and 56 which are commonly found in 
patients with high-grade squamous intraepithelial lesions (HSIL or CIN II/III) or 
invasive carcinoma of the cervix, vulva, anus or penis.  
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The intermediate risk group is associated with high-grade CIN but less commonly 
with invasive cancer; this group includes HPV 31, 33, 35, 51 and 52 (867). Low risk 
types remain extrachromosomal or episomal whereas the genomes of high risk HPV 
types 16 and 18 are found integrated into the cellular host DNA in most human 
cervical carcinomas (1359).  
 
Risk type HPV type Association with 
Low risk  HPV 6 / 11 / 41 / 42 / 43 / 44  
Condylomata accuminata 
Low-grade CIN (CIN I)/LSIL 
Intermediate 
risk  
HPV 31 / 33 / 34 / 35 / 39 / 51 / 
52 
High-grade CIN (CIN II-III)/HSIL 
High risk  
HPV 16 / 18 / 45 / 51 / 52 / 56 / 
58 / 59 / 61 / 62 / 64 / 66 / 67 / 
68 / 69 / 70 
High-grade CIN (CIN II-III)/HSIL 
Invasive carcinoma of cervix, 
vulva, anus or penis 
Table 25: Classification of HPV types according to oncogenic potential and clinic 
 
 Transmission via genital skin-to-skin contact 
 
      Low-risk types                                                                  High-risk types 
 
 Transient HPV infection Persistent HPV infection 
 
 
Asymptomatic              CIN I/LSIL CIN II-III/HSIL 
   infection 
 
 Benign genital warts 
  Invasive cervical carcinoma 
  Cofactors: smoking, STDs, 
  oral contraceptives, parity (1418) 
Figure 17: Etiology of cervical carciogenesis as the result of HPV infection  
Cervical carcinoma constitutes a major public health problem worldwide with 
500,000 new cases per year. It is the most common female malignancy in 
developing countries and second most common in western countries following 
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breast cancer. The latest cancer statistics for the year 2006 reported 9,710 
estimated new cases and 3,700 estimated deaths of cervical cancer in the USA 
(620). Despite optimal management with options like radical surgery, radiotherapy 
and chemotherapy, the overall 5 year survival for patients with cervical carcinoma 
is still only 58% (867). This suggests a need to develop novel approaches not only to 
treatment, for example immunotherapy, but also the strong need to develop 
prophylactic or therapeutic vaccines. 
(1) Composition and mechanism of HPV infection 
The HPV genome 
The HPV genome can be divided into a coding and a noncoding region. The 
noncoding region, the long control region (LCR), contains the origin of viral DNA 
replication and the enhancer/promoter elements regulating the viral transcription. 
The coding region consists of open reading frames (ORFs) and encodes the early (E) 
and late (L) viral proteins.  
The late genes encode structural proteins, the viral capsid proteins (L1 and L2) 
which selfassemble into the viral capsid interacting with a receptor of the target cell 
facilitating entry of the viral DNA. 
The early proteins E1 and E2 are involved in regulation of viral transcription and 
DNA replication. The E6 and E7 genes of high-risk HPV types encode for 
oncoproteins that can immortalize human keratinocytes (1102). This potential 
appears to be limited to high-risk types, because E6 and E7 from HPV6 or HPV11 
are nontransforming. 
E6 will bind, inactivate, and degrade the host`s oncosuppressor protein p53, which 
results in loss of p53-induced apoptosis and G1 arrest of the cell cycle (691). The 
binding of E7 to retinoblastoma gene product (Rb) will lead to the transcriptional 
deregulation of cell-cycle control and results in uncontrolled cell proliferation (210). 
When viral DNA integrates into the host genome (malignant transformation), it will 
cause successively the disruption of the E2 ORF, loss of E2 protein expression, the 
overexpression of E6 and E7, uncontrolled cell proliferation, and in the end 
oncogenic transformation of the cell (1417). 
HPV genome is usually present in an episomal (circular and nonintegrated) 
configuration in CIN, whereas in invasive cervical cancer the genome is commonly 
integrated into the host DNA (572). HPV DNA integration appears to be the critical 
event in the development of cervical neoplasia, since HPV E6 and E7 are conserved 
intact and show persistent and increased expression in carcinomas. 
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Molecular pathogenesis 
HPV penetrates the suprabasal cells in the cervical epithelium and tightly 
maintains a program of viral transcriptional repression of its late genes L1 and L2, 
which are potentially the most powerful immunogens that HPV synthesizes (1059). 
This repression allows escape from immune surveillance and recognition. This is 
different from certain animal models where papillomavirus infections are rapidly 
eradicated due to the expression of L1 and L2 in all layers of the infected 
epithelium, which attracts more immune effector cells to the infected area. 
As HPV progresses through the layers of the epithelium, the replicative program of 
its genes changes in an orderly fashion. The HPV early proteins E6 and E7 are 
produced through most of the phases of the HPV life cycle, making them better 
candidates for therapeutic vaccines. On the other hand, the HPV L1 and L2 late 
proteins are not produced until the virus is located in the most superficial layers of 
the epithelium, correlating with the assembly of infectious virions and their release 
from the epithelium with the desquamated infected superficial cells (1059). 
 
Human HPV infections are exclusively intraepithelial and, theoretically, HPV attack 
should be detected by the APC of squamous epithelia, the LC. The activated LC 
should then migrate to the draining lymph node, processing HPV antigens en route, 
and present antigen to naïve T cells in the node. The T cells should then 
differentiate into armed effector cells, migrate back to the infected site, and destroy 
the infected keratinocytes (1342).  
(2) Mechanisms of HPV to evade the immune response 
HPVs, unlike other recurrent or persistent human viruses such as influenza or 
Epstein-Barr-Virus, do not provoke strong humoral or cellular immune responses 
(328). The diagnosis of HPV still relies on the cytological detection of cellular 
abnormalities and the histopathological confirmation of epithelial lesions. Also the 
chronic nature of HPV infection, especially with oncogenic types, suggests that the 
virus has apparently evolved to avoid the mammalian immune response.  
 
A number of immune evasion mechanisms have been proposed (427, Table 26). 
 
Low profile 
HPV infection per se does not elicit any major damage likely to evoke the principle 
innate immunity danger signals (1351). The virus infects only ECs, encodes non-
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secreted proteins expressed at low levels, with virus production in cells, which are 
sloughed off at the end of their lifespan. There is no viraemia and the infected cells 
are not lysed, limiting the production of antigens for systemic presentation. 
The infectious cycle of HPV is itself an immune evasion mechanism inhibiting host 
detection of virus. The virus replication cycle is conducted within the maturing 
keratinocyte (KC) and mature virions escape from the infected epithelial surface 
within desquamating KCs, so there is little local or systemic presentation of HPV 
antigens to the immune system by professional APCs during infection.  
HPV replication and release do not cause cell death, since the differentiating KC is 
already programmed to die which does not present a danger signal to the immune 
system. Thus, for most of the HPV infectious cycle, there is little or no release of the 
proinflammatory cytokines important for DC activation and migration into the local 
milieu, and the essential signals required for immune responses in squamous 
epithelia are absent (755). 
Another level of immune evasion derives from the tropism of genital HPVs for KCs. 
Unlike so-called professional APCs such as DCs, KCs have low levels of HLA class I 
and class II molecules, and costimulator molecules such as B7.1 (427). Exposing 
CD4+ T-cells to KCs in vitro has lead to non-responsiveness, a mechanism which 
could be operating in vivo to render HPV-specific T-cells functionally inert (427). 
 
Immunosuppression by early proteins 
However, even in the absence of viral-induced cytolysis and cell death, HPV-infected 
KCs should activate secretion of type 1 IFNs, IFN-α and IFN-β. As most DNA 
viruses, HPVs have evolved mechanisms for inhibiting IFN synthesis and signaling 
by downregulating IFN-α-inducible gene expression (1016). HPV 16 E6 and E7 
oncoproteins directly interact with components of the IFN signaling pathways (78, 
814). 
It is also apparent that these viral genes regulate other factors likely to influence 
the survival of virus infected cells including TGF-β2 as important components of 
any local inflammatory response (1017). Another strategy for immune evasion 
stems from the ability of HPV 16 E6 to downregulate the IFN-promoting factor IL-18 
(224). Other immunosuppressive actions of HPV early proteins include the 
inhibition of EC interactions with DCs by E6 (884). E6 and E7 further inhibit the 
activity of the important MCP-1 (722). 
Thus, activity of E6 and E7 provides the molecular basis for promoting viral 
persistence and avoiding innate immunity and the consequential activation of 
adaptive immunity. 
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E5, another early protein of HPV, prevents the efficient pH-dependent processing of 
peptidic antigens (171). Other relevant influences include the modulation of antigen 
processing pathways through E5-mediated MHC expression (1578) 
 
Downregulation of HLA 
The further level of immune evasion is also related to the KC in the aspect that HLA 
class I molecules on HPV-transformed cells are often expressed at a low level or are 
absent altogether (248). It is not known if this is of functional consequence for 
CTLs, but the downregulation of certain HLA-B alleles does correlate with a poorer 
prognosis for some patient populations with cervical dysplasia (130).  
The MHC molecular expression is usually upregulated by cytokines associated with 
an inflammatory response, so this will be suboptimal in an HPV infected target cell. 
However, the genetics of HLA may also influence susceptibility to HPV infection or 
ability to clear the virus and thus avoid persistence, which is the key risk factor for 
progression (543). 
 
Activation of T cell subsets 
Another potential mechanism of immune evasion is the suppression of immune 
responses by HPV-transformed KCs, through the production of either inhibitory 
cytokines (238) or proteins that can inactivate stimulatory cytokines (1319). HPV-
transformed KCs might resist CTL-killing either by producing proteins that interfere 
with CTL-lytic mechanisms or by inducing apoptotic cell death in the CTLs 
themselves (1570). 
It is possible that HPV has evolved to exploit the endogenous tissue responses 
utilized by innate immunity to disfavour induction of a more threatening Th1 
response which would favour the development of CTLs. Indeed, it has been shown 
that in CIN lesions there is a relative downregulation of TNF-α by the epithelium 
and upregulation of the Th2 cytokine IL-10 compared to normal cervix (980). The 
migrating LC may thus be inappropriately activated, skewing any subsequent 
immune activation of T cells, which might include the induction of anergic or Treg 
cells. 
Recent studies have documented a predominant Th2 polarity of tumor infiltrating 
lymphocytes in human cervical cancer (1294) and the draining lymph node in 
cervical cancer appeared to have an increased proportion of Treg cells (379). 
Immune evasion by HPV-transformed cells can also be considered at the level of the 
effector T-cells. Immune responses in patients with advanced cancer are often 
diminished as a result of disease or treatment. One mechanism that has been 
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proposed for their decreased immune responsiveness is the downregulation of 
signaling components of the TCR such as CD3 zeta chain (739). These alterations 
were associated with reduced cellular functions such as the production of TNF. 
 
Suppression of LCs 
Disturbances in the afferent phase of the immune response are suspected. The 
analysis of inflammatory infiltrates in cervical dysplasia has revealed reduced 
numbers of LCs in CIN II and III lesions (1454). This may result in changes in cell 
surface E-cadherin expression in the basal and suprabasal layers. For example, E6 
can down regulate epithelial E-cadherin expression, which could modulate their 
contacts with LCs not allowing optimal antigen capture or activation necessary for 
the initiation of anti-viral T cell responses (884). In addition, the change in tissue 
architecture is more permissive for the expansion and spread of immortalized 
and/or transformed cells (1351). 
  
Fausch et al. explored the interaction of HPV with LCs which are the first APCs 
that the virus comes into contact with during infection (384). In contrast to DCs, 
LCs are not activated by HPV virus-like proteins (VLPs), which is illustrated by the 
lack of upregulating activation markers, secreting IL-12, stimulating T cells in a 
mixed lymphocyte reaction and inducing HPV-specific immunity and migrating from 
epidermal tissue. Since DCs or LCs are generally accepted as being the most 
efficient APCs of the immune system their lack could probably result in an 
inefficient primary immune response (1418). 
Moreover, capsid entry is usually an activating signal for DCs, but there is evidence 
that LCs, unlike stromal DCs, are not activated by uptake of HPV capsids, a 
phenomenon that would inhibit both LC migration and maturation, and the priming 
of the immune response against the capsid proteins (385). 
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Mechanisms of HPV to evade host`s immune 
response 
Results in 
Low 
profile 
KC as priviledged site for HPV infection 
 Low HLA I/II expression 
 No lysis of infected cells 
 No viraemia 
Little local/systemic HPV 
antigen presentation by APCs 
Little release of proinflammatory 
cytokines 
Resistance to CTL-mediated 
lysis 
Early  
proteins  
 Interference with IFN pathways 
 Downregulation of activity of  
      MCP-1/IL-18/TGF-β2 
 Interference with MHC II  
      antigen maturation on KC 
Limitation of HPV antigen 
presentation by LC 
Inhibition of cytokine release 
T cells 
 Downregulation of TCR signaling 
components 
 Predominance of Th2 lymphocytes 
and Treg cells 
 Downregulation of TNF-α 
 Upregulation of IL-10 
Resistance of KC to CTL-
mediated killing 
Reduction of cell-mediated 
immunity 
LCs 
 Reduction in number 
 Inhibition of EC-DC interaction 
Interference with antigen 
presentation 
Table 26: Mechanisms of HPV to evade the host`s immune responses, resulting in 
increasing viral persistence 
(3) Cell-mediated immunity in HPV infection 
As HPV transmission and subsequent infection is a local event in the lower female 
genital tract, local immunity seems to be of crucial importance in the outcome of an 
HPV infection. The local immune status might determine whether the virus 
infection will be cleared or will be persistent, finally resulting in the development of 
cervical neoplasia.  
Although a very high percentage of young sexually active women are positive for 
genital HPV (555), most HPV infections are subclinical in immunocompetent 
patients or manifest intermittently as self-limiting warty lesions. Most HPV 
infections are transient with a median duration of about 8 months which means 
that HPV is successfully attacked by the immune system after transmission (549). A 
small fraction of the lesions, however, will progress to CINs and if left untreated, to 
invasive and metastatic carcinomas (899).  
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The peak prevalence of genital HPV infections is soon after the onset of sexual 
activity in women. Thereafter, the prevalence declines, indicating that long-term 
protection can be acquired. Supportive to this is the fact that up to 65% off all CIN1 
lesions in women between 15 and 34 years of age will regress (1260). 
Cell-mediated immunity is likely to be important as in immunocompromised 
individuals like HIV-infected women and organ transplant recipients, the presence 
of HPV infections and anogenital neoplasia is higher than in the general population 
(32). In addition, HIV-1-infected patients have lesions that progress more rapidly 
(390). Furthermore, the regression of HPV-induced warts is associated with 
lymphocytic infiltration in both patients with genital warts (245) and animal 
papillomavirus models (1273). 
 
Clues to the nature of the cellular immune response to HPV infection have come 
from immunohistologic studies of spontaneously regressing genital warts (245).  
Nonregressing genital warts are characterized by a lack of immune cells at the site 
of infection; the few intraepithelial lymphocytes are CD8+ cells, and mononuclear 
cells are present mainly in the stroma.  
Histologic examination of regressing genital warts reveals a large infiltrate of both 
CD4+ and CD8+ T cells and macrophages in the warts` stroma and epithelium. The 
infiltrating lymphocytes express activation markers, the cytokine milieu is 
dominated by proinflammatory cytokines such as IL-12, TNF-α, and IFN-γ, and 
there is upregulation of the adhesion molecules required for lymphocyte trafficking 
on the endothelium of the wart capillaries (245). This is characteristic of a Th1-
based immune response.  
 
Moreover, the detection of HPV-specific circulating T cells in healthy individuals 
substantiates the role of a cell-mediated response (1492) as well as the detection of 
anti-HPV IgG1 and IgG2, IFN-γ and IL-4 in individuals with cleared infection (316).   
The role of specific or nonspecific cell-mediated immunity in the clearance of HPV is 
not exactly known, largely because immune parameters after primary HPV infection 
have not been studied to a large extent.  
In women with preinvasive cervical neoplasia, the spontaneous regression of lesions 
occurs in approximately 30% of cases (867). The question if HPV-specific immunity 
influences this process and if the development of cancer results from a failure of the 
immune system is still unclear.  
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The investigation of the role of natural immunity to HPV infection is problematic as 
HPV infections can be transient and often asymptomatic. Studies have been carried 
out largely on patients with established HPV-associated disease and have focused 
on the oncogenic HPV types, in particular responses against the viral transforming 
proteins, E6 and E7, the only viral antigens constitutively expressed in transformed 
cells. Also studies have focused on systemic rather than mucosal immunity, so a 
substantial component of the host response against HPVs could be missed (867). 
 
The link between HPV16 and cervical carcinoma opens up the possibility of immune 
T-cell intervention, either against the preinvasive lesions from which tumors arise, 
or against the virus antigen-positive tumor cells themselves. This requires a better 
understanding of the spectrum of T-cell responses induced by HPV16 antigens 
during the course of natural infection, and of their role in disease clearance and 
progression. 
 
CD4+ T cell responses 
There are several studies providing information about CD4+ T-cell responses to 
HPV16 where proliferative responses to either peptides or soluble HPV proteins 
have been demonstrated in patient groups.  
In early studies, PBMCs from patients with a history of skin warts were able to 
proliferate in vitro against crude wart antigen preparations but also PBMCs from 
individuals with no history of warts responded specifically to the same wart antigen 
preparations (276).  
 
Serological T cell responses against peptides derived from HPV 16 E7 and HPV 16 
L1 were not, however, significantly associated with HPV disease as T cell responses 
were also seen in healthy asymptomatic controls (846, 845). It is not clear if the 
results in healthy control group represent in vitro artefacts or memory responses 
based on a prior exposure to HPV.  
However, results suggested that a Th1 pattern of response was predominant among 
healthy adults but reduced in women with cervical dysplasia (845). Indeed, 
immunohistological studies have indicated that regression of HPV-infected lesions 
is associated with a Th1 response (1343). 
 
De Gruijl et al. examined T cell proliferative responses to HPV16 E7 peptides in 
women with mild dyskariosis and demonstrated the strongest T cell responses in 
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women with persisting HPV infection and progressive disease (99% reactive) 
compared to those who cleared the infection (44% reactive) (314).  
Other studies on HPV 16 E7 peptides have shown that the T cell responses 
correlated with both the stage of disease and the presence of HPV 16 DNA (643). A 
following study by Kadish et al. on women with CIN I or II found out that cell-
mediated responses to E7 peptide significantly correlated with disease regression 
and resolution of viral infection within 12 months (644). 
In summary, these studies suggest a relationship between T cell responses against 
HPV and cervical disease, with a decreased response in cancer patients and an 
increased response in women with high-grade CIN and viral persistence.  
 
De Jong et al. showed that failure of immune system to eliminate HPV was 
reflected by the absence of type 1 T cell immunity against HPV 16 E2 and E6 in 
patients with cervical lesions (307).  
 
CD8+ T cell responses 
The role of naturally occurring CTLs in mediating the regression of HPV-related 
disease has not been proven. There has been an increasing interest in CD8+ CTLs 
as vehicles for immunotherapy in human cancers, using either vaccines capable of 
inducing CTLs or adoptive therapy protocols which has been based on clear 
demonstrations of anti-tumor immunity (867). The expression of E6 and E7 
proteins by HPV-transformed cells provide attractive tumor-specific targets for 
immunotherapy.  
 
The search for human memory CTL responses was initially difficult because of the 
lack of well-defined viral reagents for in vitro testing.  
HPV16 E2-, E6- and E7-specific CTLs can be detected in patients with previous 
(1000) or ongoing HPV infections (1022) using whole HPV proteins to restimulate 
CTL responses, either in a soluble form or expressed by recombinant viral vectors. 
Results suggest that naturally occurring HPV E6- and E7-specific CTLs do exist in 
patients with HPV-associated disease, for example HPV16 E7-specific CTLs that 
exist in the peripheral blood of women with high-grade CIN and cervical carcinoma, 
but are extremely rare (1565).  
 
The difficulties of obtaining memory T-cell responses from patients have resulted in 
the use of DCs to generate primary responses. HPV-specific CTL responses could be 
generated from healthy asymptomatic donors (990) and cervical cancer patients 
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(1255) using DCs pulsed with recombinant HPV 16 or HPV 18 proteins. The 
successful processing and presentation of exogenous HPV antigens in vitro raises 
the possibility that antigens released from HPV-infected cells during the disease 
process or by surgical procedures could be stimulating HPV immunity in vivo (867). 
 
CTL responses in asymptomatic subjects appear to be rare, suggesting that CTL 
responses are associated with HPV-induced disease.  
Preliminary studies have not, however, addressed whether CTLs have a role in the 
prevention, control or treatment of disease. Furthermore, although CTLs have been 
operationally defined as HPV specific, based on their reactivity against recombinant 
HPV proteins, few as yet have been shown to recognize tumor cells. 
(4) Antibody responses in genital HPV infection 
Circumstantial evidence suggests a role for the serologic immune system, for 
example antibodies to capsid proteins, besides the cellular immune system in the 
clearance of HPV infections.  
 
The generation of serum neutralizing antibody is observed in most, but not all, 
infected individuals (714) and is directed against conformational epitopes on the L1 
protein displayed on the outer surface of the intact virus particle. Serum 
neutralizing antibody levels following natural HPV infections, even at peak titers, 
are low (1456). This probably reflects the exclusively intraepithelial infectious cycle 
as well as the production of virus particles in the superficial ECs distant from APCs 
and patrolling macrophages. These factors limit antigen uptake, delivery to the 
lymph node, and presentation to naïve B and T cells.  
 
As mentioned, the majority of women with cervical HPV-16 infections generate a 
systemic IgG Ab response to the major HPV-16 capsid protein as detected by ELISA, 
using VLPs as antigens (714). Systemic IgA and IgG responses against HPV-16 VLP 
were more frequently observed in women with HPV DNA than in the controls and 
the presence of HPV-16 VLP-specific IgG in plasma is correlated with persistent 
viral infection (131).  
In contrast, systemic IgG response to HPV-16 E7, as determined by peptide-based 
ELISA, is correlated with viral clearance in a subset of CIN (131). However, the 
presence of serum Abs to HPV-16/18 VLP L1 as well as antigens E6 and E7 is not 
correlated with occurrence or prognosis of cervical cancer (800, 1303).  
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So far, few studies have been reported on the local antibody response to HPV.  
IgA antibodies against HPV capsids from HPV 6, 11, 16, 18, 31, 33 and 35 could be 
demonstrated in cervical mucus from patients with cervical neoplasia and controls 
(1478).  
In other studies, local antibodies have been detected against E2, E7, L1, and L2 of 
HPV 16 in cervical secretions and in CVL of patients with cervical neoplasia, 
patients with condylomata and women with normal cervical cytology (342). IgA 
against HPV 16 E2 was found in 49% of the cervical secretions from patients with 
CIN whereas IgA against E2, E7, L1, and L2 from HPV 16 was observed in 15-32% 
of the secretions in healthy women. Local IgG against HPV 16 E2 was reported in 
46% of patients with CIN and in 15% of healthy controls (342).  
A recently published study showed IgA, IgG, and S-IgA antibodies to HPV 16 
capsids in cervical samples in, respectively, 11%, 24%, and 9% of the subjects 
(496).  
Bard et al. quantified IgG, IgM, IgA and S-IgA in CVS of healthy and HPV-infected 
women (76). IgG, IgA and S-IgA were significantly higher in CVS of HPV-infected 
patients with a lower S-IgA/IgA ratio compared to the control group which suggest 
that HPV could be responsible for an increase in local production of non-secretory 
IgA.  
 
Another study by Nguyen et al. analyzed systemic as well as mucosal IgA and IgG 
responses to HPV-16 oncoprotein E7 in women who underwent radical 
hysterectomy for cervical cancer (HCC) compared to those in women who 
underwent loop excision for cervical dysplasia or had hysterectomy for other 
reasons (1020).  
It was demonstrated that the levels of HPV16 E7-specific IgA and IgG were 
relatively, but not significantly higher in sera of patients undergoing HCC as 
compared to those determined in patients of other noncancerous groups. These 
results indicate that serum antibodies to oncoprotein E7 were not a specific marker 
for diagnosis or prognosis of cervical cancer which is in agreement with other 
studies on large populations (800). 
Another interesting finding in this study was that the local mucosal immune 
response, as determined by levels of HPV-16 oncoprotein E7-specific IgA in genital 
tract of women with cervical cancer, was downregulated (1020). Gene expression 
profiling also indicated downregulation of genes associated with Ig synthesis 
including gene encoding the heavy chain of IgA2 in cervical tumor tissue as 
compared to that in the normal tissue of the same patient. 
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(5) Vaccination strategies 
Compared to developing countries, considerably lower incidences of cervical cancer 
are observed in West Europe, USA and Japan probably due to the widely available 
screening in these regions. Screening methods comprise the conventional 
Papanicolaou test, liquid cytology and HPV DNA testing (641, 1417).  
Unfortunately, no trials have shown reduction of cancer incidence in populations 
where HPV-testing was added to cytologic screening and currently, despite all the 
screening and treatment facilities, the incidence of invasive cervical cancer remains 
stable or even increases (550).  
 
The role of HPV in cervical carcinogenesis and their cellular immune response have 
created expectations for prevention. A primary preventive strategy which also 
includes vaccination aims to reduce the incidence of disease and generally targets 
the entire population without symptoms or disease. 
 
Two types of HPV vaccines are currently being developed. First, there are 
therapeutic vaccines which induce cellular immunity targeted against ECs infected 
with HPV and induce regression of precancerous lesions or remission of advanced 
cervical cancer. Second, there are prophylactic vaccines inducing virus-neutralizing 
antibodies protecting against new but not against established infections. The 
prophylactic vaccines are focused on the generation of neutralizing antibodies 
against L1 and in a lesser extent on L2. In therapeutic chimeric vaccines, the 
targets are E6 and E7, which have no share epitopes with human cellular proteins; 
therefore, the risk of inducing an autoimmune response is theoretically eliminated 
(1349). 
 
Prophylactic vaccines 
Most viral vaccines are based on an attenuated form of the virus. But the 
development of an attenuated HPV vaccine is not possible, as there is no effective 
culture system. Secondly, such a vaccine would be ethically unacceptable, because 
it would expose healthy subjects to potentially harmful viral oncogenes.  
The observation that the major papillomavirus capsid protein L1 has the intrinsic 
ability to selfassemble into VLPs when expressed in specific expression vector 
systems in the absence of other gene products has provided a major technical 
advance in the field (713).  
 Immunology of the genital tract 
 II-139  
VLPs contain empty virus capsids containing the major HPV capsid antigen and, 
possibly, the minor capsid antigens, but lack viral DNA. Therefore, they mimic the 
natural structure of the virion and are immunogenic but not harmful as they do not 
contain the viral genome.  
VLPs were found to bind very well to human and mouse immune cells that 
expressed markers of APCs such as MHC class II, CD80 and CD86, including DCs, 
macrophages and B cells (289). DCs were found to internalize and present VLP-
derived antigens to CD4+ and CD8+ T cells in vitro, suggesting that DCs initiate 
immune responses to the VLP in vivo (805). 
In a study by Lenz et al. results showed that both monocyte-derived DCs and 
plasmacytoid DCs bind and acquire papillomavirus VLP, but only monocyte-derived 
DCs undergo phenotypic activation after exposure to the VLP and induce primary T 
cell responses (804).  
Together with the observation that cutaneous LCs are not activated by 
papillomavirus VLP (385), these findings underscore the heterogeneity of DC 
populations and strongly suggest that monocyte-derived DCs are the principal cells 
in the T cell response to VLP observed in individuals vaccinated with VLP (1125). 
However, HPV16 VLP induced plasmacytoid DCs to secrete IFN-α and IL-6, both 
cytokines that play a role in the generation of antibody responses, as well as TNF-α 
and IL-8 (804). 
 
In several animal papillomavirus models the parental injection of VLPs elicited high 
titres of type-specific neutralizing antibodies and subsequent protection against 
virus challenge (823) which made L1 VLPs clear candidate immunogens for 
prophylactic vaccination in humans.  
Other studies have shown oral, intranasal, or intravaginal vaccination to be more 
effective in inducing mucosal immunity and also in producing serum IgG antibodies 
of higher affinity than parental vaccination routes (300).  
At present, several vaccines have been developed and tested in clinical trials. The 
vaccines are generally well tolerated and highly immunogenic. Current clinical data 
indicate that prophylactic vaccines are very effective against new persistent 
infections and the development of cervical intraepithelial lesions. The protection is 
type specific but the follow-up of the vaccination trials is still short. 
So far, there have been several published phase I/II clinical trials using HPV VLP 
vaccines which present encouraging results (Table 27).  
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Authors 
Trial phase 
/patients 
Vaccine Results 
Evans et al. 
(2001) (371) 
Phase I 
n=65 
HPV11 L1 VLP 
Well tolerated; induction of 
neutralizing antibodies and T cell 
response  
Harro et al. 
(2001) (513) 
Phase I 
n=72 
HPV16 L1 VLP 
Well tolerated; highly 
immunogenic  
Koutsky et al. 
(2002) (742) 
Phase II 
n=1533 
HPV16 L1 VLP 
Overall infection rate 0.6 vs 6.3 in 
placebo group 
Ault et al. 
(2004) (63) 
Phase I 
n=40 
HPV18 L1 VLP 
Induction of neutralizing 
antibodies  
Harper et al. 
(2004) (512) 
Phase I 
n=1113 
HPV16/18 L1 
VLP 
Well tolerated; high efficacy in 
incident and persistent HPV16/18 
infections 
Villa et al. 
(2005) (1456) 
Phase II 
n=277 
HPV6/11/16/18  
L1 VLP 
High efficacy in persistent 
HPV6/11/16/18 infection  
Table 27: Clinical phase I/II trials on prophylactic HPV vaccines  
The overall trial results show a good safety profile and an almost universal 
induction of high titers of virus-specific antibody by VLP-based vaccines. The 
dominant antibody responses induced by VLP vaccines are of the IgG1 subclass and 
have been shown to be neutralizing by a variety of surrogate neutralization assays. 
100% of vaccinees in the per-protocol cohort were protected against persistent 
infection with the homologous HPV type, whereas the placebo group had persistent 
infections with both HPV and CIN (512, 742). 
The most important characteristics of the two clinical trials on HPV VLP vaccines by 
GlaxoSmithKline and Merck are shown in Table 28. 
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Features GlaxoSmithKline Merck 
Vaccine type Bivalent HPV 16/18 VLP L1 Monovalent HPV 16 VLP L1 
Concentration 20µg HPV 16, 20µg HPV 18 40µg HPV 16 
Application 
0,5ml i.m.  
0, 1 and 6 months 
0,5ml i.m.  
0, 2 and 6 months 
Vaccinees/ 
placebo 
560/533, age 15-25years 768/765, age 16-23years 
Requirements 
No history of cervical lesions 
Few sexual partners 
No history of cervical lesions 
Few sexual partners 
Duration Up to 27 months Up to 48 months 
Efficacy 
 
Prevention of incident infection 
92% 
Prevention of persistent infection 
100% 
Prevention of pre-invasive lesions 
100% 
Prevention of incident infection 
91% 
Prevention of persistent infection  
100% 
Prevention of pre-invasive lesions 
100% 
Seroconversion 100% 100% 
Specific titers 
50 times greater for HPV 16 
80 times greater for HPV 18 
(compared to natural infection) 
60 times greater 
(compared to natural infection) 
Reference Harper et al. (512) Koutsky et al. (742) 
Table 28: Characteristics and results of two large randomized, placebo-controlled 
trials on HPV VLP vaccines by GSK and Merck, adapted from Franco et al. (421) 
Further follow-up is needed to see whether the antibody levels remain after decades 
or whether booster vaccination is needed (1417). The duration of protection of 
vaccine-induced immunity measured by antibody titers has not been evaluated and 
needs to be established. Encouraging data presented on the antibody response to 
HPV L1 VLP vaccines suggests only a slight decline in the high serum antibody 
titers over a 6-to-8-months evaluation period (1417). There is also the possibility 
that vaccinations could lead to selection of HPV types, subtypes, or variants that 
would be unaffected by the vaccine. 
In a study by Pinto et al., innate and adaptive immune system cytokine responses 
induced by HPV-16 L1 VLP in whole blood cultures from individuals receiving the 
vaccine or placebo before and after vaccination were evaluated (1124). Cytokine 
profiles from whole blood samples clearly discriminated between vaccine and 
placebo recipients and between pre- and post-vaccination responses. Significant 
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increases in Th1-, Th2- and inflammatory cytokines were observed in whole blood 
assays following vaccination. 
 
Arising problems in HPV vaccine development 
Some further problems should be briefly discussed here.  
Nardelli-Haefliger et al. determined whether HPV immunization results in specific 
antibody levels in cervical secretions of women who had been immunized with 
HPV16 VLPs (1004). They additionally examined the influence of the menstrual 
cycle and oral contraceptive use on these levels.  
All participants developed detectable titers of anti-HPV16 VLP IgGs in their cervical 
secretions after immunization; however, cervical titers of specific IgG and total IgGs 
and IgAs among participants in the contraceptive group were relatively constant 
throughout the contraceptive cycle. In contrast, the cervical titers of specific IgG 
and total IgGs and IgAs among participants in the ovulatory group varied during 
the menstrual cycle, being highest during the proliferative phase and decreasing 
approximately ninefold around ovulation (1004). 
 
Another consideration is the preferred delivery route for vaccine administration in 
order to induce effective mucosal immune responses (1349). 
The vaccination should induce a local mucosal immunity in form of S-IgA in the 
lower genital tract in addition to systemic immunity to adequately prevent HPV 
infection (300). Mucosal antibodies are induced by systemic delivery of VLPs. 
Obviously, a single dose with mucosal delivery would be the preferred route for 
vaccine delivery; if nasal or oral delivery can induce antibodies still has to be 
further investigated.  
In another study by Nardelli-Haefliger et al. women were vaccinated with 
escalating doses of HPV16L1 VLPs via nasal nebulisation, bronchial aerosolisation, 
or a combination of intramuscular and aerosol vaccination (1003).  
The alternative routes of vaccination were well tolerated and many of the volunteers 
who received aerosol vaccinations exhibited serum antibody titers that were 
comparable to those induced by intramuscular vaccination. A mucosal immune 
response was induced by aerosol vaccination as demonstrated by the induction of 
anti-HPV16 VLP IgA secreting cells in PBMC and S-IgA in secretions. 
 
The choice and the number of HPV types included in the vaccine is an important 
issue as there are geographic differences in the prevalence of HPV types involved in 
CIN and cancer.  
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In order to be effective for at least 80% of the population, the vaccines should 
theoretically consist of VLPs of the four or five most common types of HPV of that 
country or region but combining multiple types in one vaccine may be problematic 
(989, 1417). A pentavalent vaccine with VLPs of HPV types 16, 18, 45, 31, and 33 
would potentially prevent 83% of all cervical carcinomas whereas a heptavalent 
vaccine that also included types 52 and 58 could potentially prevent 87% of the 
overall cervical cancer burden internationally (989).  
 
Villa and colleagues presented results of a double-blind, placebo-controlled 
efficacy trial of a quadrivalent (HPV types 6, 11, 16, and 18), aluminium-adjuvant 
vaccine in young women negative for HPV (1456). As in the previous reports, peak 
antibody concentrations were much higher in vaccinees than in seropositive non-
vaccinated individuals at seroconversion, and these concentrations remained higher 
36 months after vaccination, when antibody titres in the vaccinees had decreased. 
In this study, no patients in the vaccinated group had CIN, whereas in the placebo 
group, seven had CIN and four had external genital warts. 
 
Finally, all trials to date of HPV vaccines have enrolled women, but genital HPV 
infections are mainly sexually transmitted and men will also need to be vaccinated 
if the whole population is to develop immunity. 
 
Therapeutic vaccines 
Therapeutic vaccines for HPV are at a much earlier stage of development than their 
prophylactic counterparts. In contrast to preventive vaccines, HPV therapeutic 
vaccines would need to include some antigenic determinants derived from the early 
HPV proteins as E6 or E7 rather than the late proteins that VLPs use to self-
assemble (1059).  
For therapeutic vaccines L1/L2 would be a poor target because of its restricted 
expression in patients already having cervical neoplasia whereas both E6 and E7 
proteins are continuously expressed in cervical lesions and tumors. This has proved 
to be a much more challenging task in terms of biodelivery and response.  
 
E7 is probably the best studied; it induces protective cellular immunity against 
cervical dysplasia (644) and prevents tumor growth in animal models (14). Anti-E7 
antibodies have been correlated with more advanced stage of disease (414) and 
worse prognosis (1455), but do not seem to denote an effective host immune 
response against cervical cancer. Indeed, it seems that immune responses in 
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patients with cervical cancer are marginal and functionally ineffective, making this 
a less attractive group for immunomanipulative strategies. Given that E6 and E7 
expression increases as the HPV infection progresses in establishing a dysplastic 
process, they seem ideal targets for immune attack (1059). 
Therapeutic vaccines consisting of E6 and/or E7 have been tested in patients and 
have proven to be safe and effective against benign warts, however, they have had 
limited therapeutic effect so far in cases of cervical cancer (425). 
 
In general, there are several broad categories of therapeutic vaccine strategies: 
chimeric VLPs, peptides, proteins, nucleic acid–based, and cell-based. 
The major challenge in infected patients remains the targeting of already infected 
basal cells that do not express capsid antigens. Therefore, chimeric VLP vaccines 
with structural viral L1 or L2 proteins and functional E proteins are being 
developed (986).  
In preclinical data, these chimeric VLP vaccines elicited both neutralizing antibodies 
to the VLP and T cell responses to L1 and E7. Chimeric VLP comprised of a fusion 
of HPV16 E7 to the L1 or L2 capsid proteins have been shown to initiate a potent 
E7-specific CTL response in vaccinated mice. The vaccine was found to be sufficient 
to protect mice against challenge with an E7-containing tumor cell line (288).  
The reason behind this vaccine`s high immunogenicity is a result of the interaction 
of chimeric VLPs with potent APC residing at or near the vaccination site which are 
able to induce an efficient antigen-specific immune response after interaction with 
naïve CD8+ T cells (1223). 
These vaccines could therefore be prophylactic and therapeutic and would eliminate 
any breakthrough infection that escaped antibody neutralization (435).  
 
Nieland et al. reported on the results of a randomized, double-blind, placebo-
controlled, clinical trial with HPV16/E7 chimeric VLPs (1341). HPV DNA was 
cleared in vaccinees and placebo group although there were more responders in the 
vaccinees. Serum IgG to HPV16 L1 developed in all vaccinees but not in placebo 
recipients whereas only some vaccinees showed CTLs. Antibody responses and CTL 
generation, however, did not correlate with clinical outcome.  
Chimeric capsomeres may be more stable and less expensive than chimeric VLPs 
and Gissmann et al. showed that HPV16 L1/E7 capsomeres were immunogenic, 
generating both anti-L1 antibody and E7-specific CTLs in mice (1341).  
In another study, DCs and LCs are activated by three different therapeutic 
vaccination strategies including heterologous papillomavirus VLPs and HPV VLP 
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immune complexes (383). DCs and LCs incubated with these VLP upregulated 
surface activation markers and increased secretion of IL-12 p70 and IL-15. The 
activated cells are then able to initiate an immune response against chimeric VLP-
derived antigens.  
This shows that also other therapeutic vaccination strategies based on using 
heterologous chimeric VLP or chimeric HPV VLP immune complexes may be more 
effective in generating an immune response against HPV-induced diseases such as 
cervical cancer. 
 
In animal models, CTLs can be generated using E6 and E7 peptide-based vaccines 
that are protective against subsequent challenge with lethal doses of E6- and E7-
containing tumors (389). Stimulation of peripheral blood lymphocytes from patients 
with HPV16-positive cervical cancer with synthetic HPV-16 E7 peptide generates 
specific CTLs capable of tumor recognition and lysis of cervical cancer cells (25). 
A clinical trial using a peptide-based vaccine was performed on 18 patients with 
high-grade dysplasia. Ten of 16 subjects mounted primary CTL responses to the E7 
peptides, and a complete clinical response was observed in three subjects (984). 
 
Protein-based vaccinations have been used in early-phase clinical trials. A 
randomized, placebo-controlled phase I study with E6/E7 fusion protein plus 
adjuvant was tested in women with CIN (426). Antibody and CD8+ T cell responses 
were significantly greater in immunized subjects than in placenbo recipients. 
 
DNA vaccines usually involve intramuscular injection of plasmid DNA or DNA 
delivery into the epidermis via gene gun (853). Polynucleotide and recombinant viral 
vaccines encoding non-structural viral proteins show therapeutic efficacy in animal 
models and are candidate immunotherapies for established low-grade benign 
genital infections.  
Immunization of rabbits with with the non-structural viral proteins E1 and E2 
induced a CD4+ T cell response; fewer papillomas developed and they regressed 
more rapidly than those in non-vaccinated animals (1277). The canine oral 
papillomavirus (COPV) model has provided evidence that immunization with codon-
modified early proteins will be effective in preventing the development of lesions 
postexposure to virus. Animals challenged orally with COPV and immunized 
subsequently with with a COPV E2 polynucleotide vaccine remained free of oral 
warts (962). Immunization of rabbits with established papillomas with an E1, E2, 
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E6, and E7 gene cocktail reduced the development of carcinoma by 75% and 
suppressed papilloma growth substantially (502).   
In high grade intraepithelial lesions there are only two possible antigenic targets, E6 
and E7. Tolerance to viral antigens, modulation of cytokine milieu and 
downregulation of MHC class I alleles on the neoplastic KCs are associated with 
progressive CIN and possibly invasive cancer, which pose strong barriers for 
immunotherapies (1344).  
It is possible and also supported by few studies that there is a spectrum of 
responses to therapeutic vaccination ranging from complete through partial up to 
no regression of the clinical disease.  
For example, studies with a recombinant vaccinia virus encoding modified E6/E7 
genes of HPV 16 and 18 in patients with high grade vulval intraepithelial neoplasia 
showed complete clearance in only less than 10% of the patients, partial regression 
in at least 50% and no clinical change in 10-30% (299). Lesion regression did not 
correlate with T cell responses in all cases. This method for delivering antigenicity 
using a DNA vaccine involves the use of viral vectors as delivery carriers into the 
body. 
 
Vaccines designed to elicit CTLs specific for the HPV oncoproteins E6 and E7 show 
immunogenicity and inhibition of tumor growth in transplantable tumor models in 
rodents (1344). However, human HPV-induced tumors have been largely refractory 
to the approaches successful in rodents. All the vaccines tested have been safe, 
well-tolerated and have induced T cell responses which did not necessarily correlate 
with clinical responses (666, 1191). 
 
A previous trial with a L1 DNA vaccine evidenced only weak immune responses to 
HPV (350). Recently, a modified version DNA vaccine targeting HPV6 L1 and L1-E7 
was constructed and tested, to determine if this DNA vaccine would elicit an 
immune response in mice (822). 
 
In summary, other potential delivery systems for HPV immunogens besides 
recombinant viral vectors (666, 139) include recombinant bacterial vectors such as 
Listeria monocytogenes (1279), viral DNA (229), proteins (426, 1277) and peptides 
alone (984) or tagged to immune adjuvants such as CpG oligonucleotide (215) and 
DCs (1026); some of these experimental strategies have already even been tested 
clinically with promising results (1351). 
 Immunology of the genital tract 
 II-147  
An overview of the different strategies with candidate biologics for HPV vaccines 
gives Table 29. 
 
Virus-like particles (L1 based) Prophylactic 
Chimeric virus-like particles  
(both late and early proteins expressed) 
Prophylactic/Therapeutic 
Viral DNA Therapeutic 
Fusion proteins Therapeutic 
Recombinant viral vectors Therapeutic 
Recombinant bacterial vectors Therapeutic 
Peptides (alone or with adjuvants such as CpG 
oligodeoxynucleotide) 
Therapeutic 
Dendritic cells Therapeutic 
Table 29: Candidate biologics for HPV vaccines, adapted from Padilla-Paz (1059) and 
Steller (1349) 
2. Bacterial infections of the genital tract 
a) Gonorrhea 
Gonorrhea is another example for a STD and is caused by Neisseria gonorrheae, a 
gram-negative diplococcus. It is an exclusive human pathogen that primarily infects 
the urogenital epithelia but can also lead to infection of other EC surfaces.  
Gonococcal infection is with over 60 million cases a major global health problem 
with highest incidences in less developed countries (444). However, more than 
300,000 cases are reported to the Centers for Disease Control and Prevention in the 
United States each year but an estimated 600,000 people are infected (197). 
 
Gonococcal infections usually remain localized to the sites of primary infection, the 
male urethra and the female cervix. Gonococcal cervicitis often remains 
asymptomatic but subsequently tends to spread to the upper genital tract inducing 
chronic complications (353). Ascending infection occurs in up to 45% of infected 
women and can result in pelvic inflammatory disease (PID) which can cause 
infertility and ectopic pregnancies due to fallopian tube blockage (1330). Repeated 
infections are rather common, which suggests antigenic variations in the organisms 
or an ineffective immune respose to infection. 
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Furthermore, the gonococcus-induced increase in the local expression of viral RNA 
together with the loss of mucosal integrity due to an acute inflammatory response is 
associated with increased susceptibility to HIV-1 infection (211). Despite the 
presence of effective antibiotic treatment these health concerns demand the need 
for further investigation on the mechanisms of the infection in order to develop a 
vaccine against gonorrhea.  
(1) Mechanisms of N. gonorrheae to evade the immune response 
Virulence factors 
Only recently it has been shown that N. gonorrheae can invade mucosal ECs and 
are intracellular during human infection (39).  
A repertoire of virulence factors have been identified and allow this bacterium to 
successfully adapt to variable microenvironments within its sole human host and 
are thought to play a role in EC invasion. These virulence factors are responsible for 
gonococcal evasion of the human immune system and explain the tendency to 
chronificate. These factors consist of outer membrane constituents such as porin, 
pili, opacity-associated outer membrane proteins (Opa), reduction modifiable 
protein (Rmp) and lipooligosaccharides (LOS) (353). 
 
Pili seem to modulate host cell signaling mechanisms to aid gonococcal epithelial 
invasion and participate in forming an initial attachment with host cells (1372). 
They may also provide a mechanism by which nonmotile gonococci are able to 
colonize and to ascend mucosal surfaces through their ability to exhibit twitching 
motility (1469). The transmembrane protein CD46 involved in regulation of 
complement activation has been demonstrated to serve as a receptor for gonococcal 
pilus in human cells (653). 
 
Opa proteins are thought to contribute to the cellular trophisms exhibited by 
gonococci and are divided into two classes based on their ability to differentially 
recognize host cell surface molecules (353). Opa50 recognize host cell heparin 
sulphate proteoglycans and Opa52 recognize carcinoembryonic antigen-related 
family of cell adhesion molecules (CEACAM or CD66). 
 
LOS play a role in attachment of the pathogen to epithelial tissues and is a target 
for bactericidal antibodies found in normal human serum (160). Variations of LOS 
molecule structure in the outer membrane of N. gonorrheae are observed within and 
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between strains which results in constant antigenic variation. This spontaneous 
conversion of oligosaccharide determinants can change the manner in which the 
gonococcus associates with host tissues and, hence, can potentially alter the course 
of gonococcal disease. 
 
Porin, a water-filled channel through which small molecules traverse the gonococcal 
outer membrane, is thought to play multiple roles in potentiating disease caused by 
N. gonorrhoeae. Porin molecules trigger variable functional responses within host 
cells depending upon the particular porin and the host cell type under study. A 
unique feature of gonococcal porin is its ability to translocate into eukaryotic cell 
membranes and form a voltage-gated channel (1484).  
By demonstrating the ability of porin to induce apoptosis in ECs (985) it is proposed 
that porin plays a role in the cytotoxicity observed in fallopian tube organ culture 
and in the shedding of ECs which occurs in vivo during mucosal infection (353). In 
contrast, gonococcal infection of primary human male urethral ECs results in 
antiapoptotic events (116). It is hypothesized that the enhanced survival of the 
urethral EC may allow the bacterium to proliferate within an intracellular, 
protective environment and, consequently, promote gonococcal colonization. Porin 
may also facilitate the cytoskeletal rearrangements required for actin-mediated 
entry of the gonococcus into its target host cell (1493).  
 
These virulence factors together with the high heterogeneity and adaptability with 
repeated phase and antigenic change may be a way to downregulate the functional 
immune response of the host. Pathogens use at least two basic strategies to survive 
the host`s immune response. Some avoid provoking specific host defenses and 
others induce immune responses but possess the ability to evade the consequences. 
The high rate of reinfection despite the presence of antigonococcal antibodies leads 
to the assumption that N. gonorrhoeae evades the host’s immune response. 
Indeed, N. gonorrhoeae possess several mechanisms which could potentially thwart 
the effects of immune responses directed toward this organism in vivo, including 
hypervariation of surface antigens, resistance to complement- mediated 
bacteriolysis, and the production of IgA1 protease (530).  
 
Resistance to complement-mediated bacteriolysis 
Gonococci possess several potential mechanisms to avoid complement-mediated 
bacteriolysis, including sialylation of LOS, induction of blocking antibody to Rmp 
and binding of complement downregulating proteins such as C4bp to particular 
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porin domains (1229). However, it seems unlikely that complement-mediated, IgG-
dependent bacteriolysis operates at mucosal surfaces, where a fully functional 
complement system is not usually present (1396) and IgA may interfere with 
complement activation. Both IgA and IgG in genital secretions have been shown to 
inhibit adherence of gonococci to ECs (1428). 
 
IgA1 protease 
Vaginal washes from patients infected with N. gonorrhoeae have been found to 
contain IgA1 protease activity demonstrable in vitro and were able to cleave 
exogenous IgA1 in a manner suggestive of IgA1 protease activity (120). However, 
despite the presence of substrate, and contrary to expectations, Hedges et al. did 
not detect any evidence of IgA1 cleavage fragments by gonococcal IgA1 protease in 
cervical mucus or vaginal wash samples (530). Nevertheless, all of the clinical 
isolates of N. gonorrhoeae infecting these patients produced IgA1 protease in vitro. 
 
These apparently contradictory results may be explained by two linked hypotheses. 
First, N. gonorrhoeae may not be present in the lumen or on the mucosal surface in 
sufficiently high numbers but rather may colonize a subepithelial niche (530). This 
hypothesis is supported by the lack of significant local immune or cytokine 
responses in women infected with N. gonorrhoeae. Therefore, the lack of detectable 
IgA1 protease activity in cervical mucus, in addition to the lack of local host 
responses, may simply be due to small numbers of bacteria at that site.  
Secondly, N. gonorrhoeae may require IgA1 protease for survival within as well as 
outside the host tissues. 
In addition, there is recent evidence that the lysosomal-phagosomal protein LAMP-1 
on ECs is cleaved by neisserial IgA1 protease (820). Growth of gonococci within ECs 
was enhanced by cleavage of LAMP-1 which may contribute to intracellular 
gonococcal survival and facilitate escape from antibodies and complement. 
 
Differences of gonococcal infection in male and female 
Interestingly, there are important differences between gonococcal genital infection 
in men and women and N. gonorrhoeae has evolved variable pathogenic 
mechanisms to ensure its survival in the distinctly different microenvironments 
found within the male and female (uro)genital tracts (353). 
In male urethral epithelium, the interaction of gonococcal LOS with the 
asialoglycoprotein receptor present on the urethral EC mediates invasion and 
results in production of the cytokines IL-1, IL-6, IL-8 and TNF-α (516, 514).  
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Cytokine release contributes to the usually symptomatic nature of gonococcal 
disease in men and is accompanied by a large influx of PMNs, which in turn 
contribute to the observed cytokine release and inflammation. The interaction of 
gonococci with PMNs is mediated by the interaction of Opa gonococcal proteins and 
CEACAM host cell proteins (1192). The specific interactions occurring between 
these two families of proteins may dictate specific host cellular responses and the 
survival or death of phagocytosed gonococci. The PMN response to gonococci is 
further modulated by gonococcal porin, which inhibits PMN degranulation and the 
production and release of toxic oxidants from the host cell to the extracellular 
milieu. Transmission of gonococci to a sexual partner is then partly aided by the 
ability of gonococci to bind to human sperm which also were found to express 
asialoglycoprotein receptor (515).  
 
In contrast to the inflammatory response generated predominately with gonococcal 
infection of the male urethra, 50 to 80% of women with lower genital tract N. 
gonorrhoeae infection are asymptomatic, and 70-90% of women with disseminated 
infection lack signs of genital tract involvement (1330).  
The clinical findings that there is neither an antibody response nor elevated local 
cytokine levels in women with gonococcal infection are consistent with the ability of 
the gonococcus to evade and subvert host immune function (531).  
Cervical epithelia provide a source of alternative pathway complement activity, yet, 
at a level comparable to only approximately 10% of that observed for human serum 
(1440). 
Within minutes of infection of primary cervical ECs, complement protein C3b is 
deposited on the lipid A portion of gonococcal LOS and is rapidly inactivated to iC3b 
(354). This is supported by the predominance of iC3b in comparison to C3b on the 
surface of clinically isolated gonococci (1460). 
Analysis of clinical biopsies obtained from women with culture-documented 
gonococcal cervicitis and infection studies performed with primary human cervical 
ECs indicate that complement receptor 3 (CR3) on female genital epithelia serves as 
the primary receptor for N. gonorrhoeae adherence to and invasion of the ectocervix 
and endocervix (355). 
Binding of gonococcal pilus to the I domain of CR3 probably allows the gonococcus 
to overcome the electrostatic repulsion between its own cell surface and that of the 
cervical cell and may juxtapose the gonococcus at the cervical cell surface, where 
complement concentrations would be expected to allow efficient opsonization for the 
subsequent intimate adherence of iC3b, i.e. converted C3b, and gonococcal porin to 
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the I-domain. Binding of the gonococcus to CR3 requires the cooperative action of 
iC3b bound to the gonococcal surface in conjunction with gonococcal porin and 
pilus (355). This ligand binding to the I-domain of CR3, however, does not invoke a 
proinflammatory response in professional phagocytic cells and cellular fate of 
gonococci is not clear (353).  
Interestingly, menses is associated with an increased risk to women for PID and for 
disseminated infection (1373). C3 production by the cervical epithelium exhibits 
cyclic variability, and the highest levels of C3 are detected during menses (521). 
Additionally, a correlation can be made between the presence or the absence of Opa 
and the site of gonococcal infection. Opa- gonococci are predominate within the 
fallopian tubes and in the cervix at the time of menses while Opa+ gonococci are 
found predominately within the male urethra and within the cervix at the time of 
ovulation (353). 
Ascent to the upper female genital tract might be facilitated through the ability of 
gonococci to exhibit twitching motility, in conjunction with hormonal changes 
which influence the mucosal epithelium and the expression of complement and 
molecules serving as gonococcal receptors within the female genital tract (353).  
Microscopic analysis of tissue biopsies indicates that the expression of CR3 
progressively decreases in an ascending manner from the ectocervix to the fallopian 
tubes (354). But expression of the lutropin receptor (LHr) which might serve as 
gonococcal receptor in upper genital tract epithelia (1331) increases in an ascending 
manner to fallopian tubes with highest levels at menses (521). The presence of LHr 
on the human uterus, placenta, decidua, and fetal membranes may partly 
contribute to the fact that the increased risk of spontaneous abortion associated 
with N. gonorrhoeae infection is due to a gonococcus-LHr interaction occurring on 
deciduas and placental membranes (1190). 
(2) Immune responses to gonococcal infection 
Igs 
Early studies using enzyme immunoassay determined the presence of IgM, IgA and 
IgG antibodies to gonocoocal pili antigens in serum (930). In all Ig classes, a 
significantly higher mean antibody activity and a higher percentage of positive sera 
were found in men and women with N. gonorrhoea than in controls. The magnitude 
of antibody response was higher among infected women than men, especially in the 
IgM class. Another study found serum and local IgG and IgA to be produced against 
 Immunology of the genital tract 
 II-153  
several antigens during goncoccal infection, although the quantity of antibody was 
greater in serum (601). 
 
As mentioned earlier, recent preliminary evidence indicated, however, that while 
antigonococcal antibodies were detected in infected patients, the levels of both 
serum and antigonococcal antibodies in genital secretions were surprisingly low 
(532).  
A following study measured the concentrations of total IgA1, IgA2, IgG, and IgM in 
cervical mucus, vaginal wash, and serum samples from volunteers without 
demonstrable infection, from volunteers in whom only N. gonorrhoeae was detected, 
and from volunteers infected with other pathogens (C. trachomatis or T. vaginalis) 
with or without N. gonorrhoeae (531).  
There were no differences between the concentrations of total IgA1, IgA2, IgG, and 
IgM in genital tract secretions in patients with different STDs compared with non-
infected women. Moreover, levels of IgA1, IgA2, IgG, and IgM antibodies specific for 
N. gonorrhoeae MS11, a widely studied gonococcal strain, in female mucosal 
secretions and serum were found at low levels in both uninfected and infected 
women. IgA1 antibody levels in serum, but not in secretions, were higher in female 
patients infected with N. gonorrhoeae than in noninfected patients while the levels 
of IgG and IgM antibodies in serum and secretions were not different between 
gonococcus-infected and noninfected patients (531). 
 
A history of previous infections with N. gonorrhoeae did not alter the antibody levels 
in patients with a current infection except for arising levels of serum IgA1 antibody. 
These results further support the possibility that repeated infections with N. 
gonorrhoeae are common because there is little development of immune memory 
and therefore only minimal levels of protective immunity. 
One potential explanation for the paucity of antibody responses to N. gonorrhoeae in 
uncomplicated genital tract infections may be related to the absence of organized 
mucosa-associated lymphoid tissue, such as the Peyer`s patches of the small 
intestine, which are recognized as major sites for the uptake and processing of 
antigens leading to generalized disseminated mucosal immune responses as 
described earlier.  
Although in some studies local vaginal antibody responses were recorded, 
intravaginal immunization in humans appeared to be inefficient in inducing either 
circulating or generalized mucosal antibody responses compared to oral or nasal 
immunization (743). In contrast to the genital tract, the rectum contains lymphoid 
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follicles resembling Peyer`s patches that likely serve as an inductive site of the 
common mucosal immune system. In addition, it has been suggested that these 
sites may preferentially supply specific antibody-secreting cell precursors to the 
adjacent genital tract which shares the same lymphoid drainage (272). Therefore, it 
seemed likely that persons infected at both the rectum and genital sites might be 
expected to display enhanced antibody responses to the infecting organism, both in 
the genital tract and perhaps also in remote secretions.  
Due to the prevalence of rectal infections with N. gonorrhoeae in the mentioned 
study it could be examined whether more pronounced antigonococcal antibody 
responses were generated by gonococcal infection at a site known to contain 
organized inductive lymphoid tissue.  
There was a small effect of rectal infection on the levels of isolate specific IgG in 
cervical mucus but overall only little difference in antibody levels in patients with 
cervical compared with cervical and rectal infections was found, suggesting that 
rectal infection was no more efficient than the genital tract infection for inducing 
humoral responses to N. gonorrhoeae (531). 
A recent study by Pantelic et al. demonstrated that N. gonorrheae via their Opa 
protein has the ability to suppress antibody production by killing CEACAM1-
expressing B cells (1075). 
 
Cytokines 
This relative paucity of antibody response provokes the question as wether there is 
a cytokine response to gonococcal infection as it is seen in female urinary tract 
infection and experimentally infected men (1166).  
Therefore, the levels of IL-1, IL-6, IL-8, IL-10, and TGF-β in sera and genital tract 
secretions from women with gonococcal cervicitis and other genital infections were 
examined (532). Surprisingly, the local levels of all these cytokines in genital 
secretions were not elevated in women with gonococcal cervicitis compared with 
levels of uninfected persons. In contrast, serum IL-6 levels, but not IL-8 and IL-1 
levels were significantly elevated in gonococcus-infected women.  
Serum, but not local, IL-1 and IL-6 levels were elevated in patients concomitantly 
infected with Trichomonas vaginalis or Chlamydia trachomatis in addition to N. 
gonorrhoeae compared with levels in patients infected with any single organism 
(532).  
 
However, in contrast, Fichorova et al. have reported increased IL-1, IL-6, and IL-8 
expression in similar studies performed with immortalized vaginal, endocervical and 
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ectocervical epithelia (396). Experiments with whole gonococcal lysates revealed 
that the IL-8 and IL-6 response by cervical and vaginal ECs was not restricted to 
the interactions with viable gonococci.  
Similarly, a recent study has shown that viable N. gonorrhoeae is not essential for 
proinflammatory response by innate immune cells, since mature human 
macrophages generate an array of cytokines and chemokines in response to purified 
gonococcal surface antigens (861).  
These findings suggest that gonococcal components can stimulate proinflammatory 
responses, which are independent of either gonococcal metabolic activity i.e. 
viability or entry into the host cells. 
 
T lymphocytes 
Gonorrhea typically correlates with a transient reduction in T cell counts in blood, 
and these populations recover when gonococcal infection is resolved. Opa proteins 
have been shown to bind CEACAM1 expressed by primary CD4+ T cells and 
suppress their activtion and proliferation (134).  
 
On the basis of the absence of cytokines and the low levels of antigonococcal 
antibody detected during uncomplicated cervical infections by N. gonorrhoeae it is 
proposed that in addition to their ability to evade the consequences of immune 
responses, gonococci either fail to induce, or possibly actively suppress, the host`s 
immune and inflammatory responses.  
(3) Development of vaccines 
As N. gonorrheae is an obligate human pathogen, the development of a vaccine has 
been hampered by the unavailability of a convenient and simple animal model. 
Attempts to infect or colonize the genital tracts of different animal species have been 
unsuccessful (49).  
Certain vaccines have been evaluated in human males but earlier prototype 
gonococcal vaccines have shown limited or no protection against reinfection with N. 
gonorrhoeae despite the generation of serum antibody responses against the vaccine 
antigens. A trial with gonococcal pilus vaccine, which has been shown to be safe as 
well as antigenic and resulted in the production of specific antibodies, failed to 
protect men (1429, 132). 
A second vaccine consisted of porin protein as a systemic immune response to 
porin protein was shown after endocervical and urethral infection (244). This 
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vaccine failed to provide protection (1193) but it was later recognized that the 
vaccine was contaminated with Rmp. Rmp leads to production of blocking 
antibodies capable of preventing the function of bactericidal antibodies against 
porin.  
This suggests that vaccination endeavors should therefore be directed toward 
exploiting novel concepts and strategies of mucosal or systemic immunizations. 
Examples include nasal immunization, which has been shown to generate antibody 
responses in genital secretions, and which has been studied to determine if it could 
elicit an immune response capable of preventing vaginal colonization of gonococci in 
a mouse model (1127). Bacterial clearance was significantly faster for mice 
immunized intranasally with gonococcal outer membrane preparations than control 
mice. The development of systemic and local vaginal antibodies directed mainly 
against a number of these outer membrane proteins was induced. 
However, Jerse has developed a more improved mouse model of gonococcal female 
genital tract infection (621) which will facilitate testing of topical microbicides and 
experimental vaccines for mucosal gonococcal infection (1332). 
b) Chlamydia trachomatis 
Chlamydia trachomatis is one of three major species within the genus Chlamydia 
and an etiologic agent for several common genital tract syndromes such as 
urethritis, cervicitis and PID in women as well as urethritis and epididymitis in 
men. Genital tract infection with C. trachomatis is often chronic and is associated 
with few symptoms and a scant inflammatory exudate.  
 
Despite continous improvement of screening and treatment programs, genital 
chlamydial infection is with approximately 4 million new infections per year the 
most common bacterial STD in the United States and with about 90 million new 
cases per year worldwide a major health problem (1543). The prevalence rates for 
chlamydial infection among sexually active individuals range from 3% to 25% (683). 
The highest rates of chlamydial infection occur among adolescent women who are 
also at the greatest risk to develop complications arising from untreated infection. 
 
It is an obligate intracellular bacterium and therefore, efficient antimicrobial 
therapeutics have to achieve adequate intracellular concentrations. Most patients 
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are free from infections after a 2 or 3 weeks treatment with tetracyclines or 
macrolides (443).  
However, approximately 70% of initial chlamydial infections remain asymptomatic 
(187), which results in the lack of seeking medical help and in further spreading of 
the disease. Chlamydia specifically infects ECs in the reproductive tract where the 
organism ascends from the cervix to the fallopian tubes (1527). The lack of 
antibiotic treatment and the ability of Chlamydia to evade immune defense 
mechanisms results in persistent fallopian tube infection. An ongoing infection 
eventually leads to scar formation and occlusion of the fallopian tubes which 
consequently results in pregnancy loss, infertility or ectopic pregnancy.  
 
In order to fully appreciate the development of a local immune response against 
Chlamydia, it is important to understand its life cycle with respect to host-parasite 
interactions.  
Chlamydiae have a unique developmental cycle among obligate intracellular 
bacteria that involves two distinct morphological forms called the elementary body 
(EB) and the reticulate body (RB) (90).  
The infectious but metabolically inactive EB particle enters host cells by first 
binding to a number of proposed ligands on Chlamydia which induces the 
internalization of the pathogen. EBs are finally differentiated to RBs within the cell 
and start replication. After the developmental cycle is completed after 40 to 72 
hours, RBs differentiate into infectious EBs which are released from the host cell 
and infect neighbouring cells after having reached a certain density (1527). The 
most common cellular host in the reproductive tract is the superficial columnar EC.  
 
With exception of the Chlamydia serovars L causing lymphogranuloma venereum, 
infections are mainly local. Chlamydia exits the apical end of the EC preventing the 
spread of infection to cells underlying the basement membrane. Currently there 
have been detected 18 serovars of C. trachomatis based on immunoepitope analysis 
using monoclonal antibodies directed against the major outer membrane protein 
(MOMP) of chlamydiae (1475).  
Most efforts at elucidating the pathophysiology of chlamydial infections have 
focused on two protein antigens (596). The first is MOMP which is almost certainly 
involved in the earliest interactions of this organism with leukocytes during the 
course of natural infection. MOMP, an immunodominant molecule, constitutes 
almost 60% of the outer membrane protein of C. trachomatis (170) and appears to 
evoke a protective humoral response to infection (636). A second protein produced 
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by pathogenic strains of C. trachomatis is the heat shock protein-60 (hsp-60), which 
induces inflammatory changes in trachoma (972). 
(1) Early cell-mediated immune response to Chlamydia 
The immune-mediated eradication of chlamydiae from the genital mucosa appears 
to occur in two distinct phases and most likely by different mechanisms (1112).  
 
Neutrophils 
One early mechanism that appears to reduce the number of organisms soon after 
infection is an influx of neutrophils.  
Shortly after the vaginal inoculation of guinea pigs with Chlamydia, neutrophils 
were found in the uterine horns and oviducts (1171). In vitro experiments have 
shown that neutrophils have the capability to destroy Chlamydiae (1182). Also in 
mice that were depleted of neutrophils by antibody treatment the number of 
organisms isolated from the genital tract were approximately 10-fold greater the day 
after infection (82). In addition, a greater number of mice that were depleted of 
neutrophils were culture positive during the first week of infection compared to 
controls.  
However, neutrophils were not critical for eradication of Chlamydiae since all mice 
were able to resolve the infection within the same time frame. Thus, neutrophils 
appear to play a role in reducing the initial amplification of C. trachomatis and 
possibly limit the spread locally within the genital tract. 
 
NK cells 
NK cells also seem to play an important role in the initial control of chlamydial 
infection.  
Tseng et al. reported that mononuclear cells isolated from the genital tract of 
infected mice demonstrated YAC cell cytotoxicity in vitro which is a measure of NK 
cell function (1431). This response peaked as early as 3 days after vaginal 
inoculation. Although the antibody-induced depletion of NK cells in mice did not 
reduce the number of pathogens isolated from the genital tract within the first week 
after infection, continued depletion throughout the course of infection resulted in 
delayed clearance of Chlamydiae.  
In experiments performed by the enzyme-linked immunospot assay, high numbers 
of cells producing IFN-γ were found in the genital tract, concomitant with resolution 
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of the infection; however, in addition, an increase in IFN-γ-producing cells which 
were CD4-negative was seen early in the infection (1431).  
Also, Hook and colleagues showed that both IL-12 and IL-18, which synergise to 
stimulate NK cells to produce IFN-γ, are produced following the infection of DCs 
and ECs by live C. trachomatis (563). 
 
DCs 
Stagg and colleagues reported the recruitment of cells with a DC phenotype in the 
genital tract during Chlamydia infection of mice (1334). These cells expressed the 
costimulatory molecules CD86 and CD40 and stimulated allogeneic T cells, 
suggesting that these mononuclear cells are a population of APCs and that they 
may play a role in clearing antigen and protecting against inflammatory disease. 
(2) Specific immune response to chlamydial infection 
The knowledge of the processes that influence the induction of an acquired immune 
response against Chlamydia within the genital mucosa is still limited.  
 
Although C. trachomatis primarily utilizes ECs to complete the developmental cycle, 
the organism can also enter other cell types such as DCs and monocytes.  
In monocytes, chlamydial EBs were found to colocalize in lysosomal compartments 
containing MHC class I molecules and, upon activation with IFN-γ, in vesicles 
containing both MHC class I and II (1043). Thus, during a chlamydial infection, the 
production of both CD8+ and CD4+ specific T cells can occur.  
In DCs, the internalized bacteria appeared in lysosomes expressing MHC class II 
molecules. These cells most likely play a role in initiating a Th1 immune response 
needed to eradicate the organism.  
Recently Zhong et al. reported that C. trachomatis infection of APCs reduced the 
ability of these cells to stimulate T cell proliferation through defects in antigen 
processing but not presentation (1586). This has been shown to be mediated via a 
chlamydial protein that induces degradation of transcription factors that control 
IFN-γ-induced expression of both MHC class I and II antigens.  
 
While the ability of Chlamydia to manipulate the host cell response to infection 
obviously is a survival advantage, it may also contribute to observations that 
immunity to Chlamydia is weak, resulting in persistent or recurrent infection. 
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CD4+ T cells 
The first studies implicating a role for T cells in clearing infection in the local genital 
mucosa were performed in nude mice (1172). Rank and colleagues showed that 
infection in nude mice was chronic and persisted over 200 days whereas normal 
mice could resolve the infection within 18 to 21 days after vaginal inoculation. 
These findings have been confirmed by showing that the transfer of CD4+ or CD8+ 
lymphocyte lines specific for chlamydial antigens could clear infection in nude mice 
where the CD4-enriched cell line was much more efficient (1165).  
 
Morrison and colleagues showed that mice lacking MHC class II molecules were 
unable to clear Chlamydia from the genital tract (971). In addition, mice with 
disrupted CD4 expression also showed significantly delayed clearance. 
 
Cain et al. investigated the local mononuclear cytokine response by examining IFN-
γ and IL-4 production (167). The biphasic appearance of IFN-γ-producing cells at 1 
and 3 weeks after infection was attributed on the one hand to NK cells at week 1 
and on the other hand to the time when T cell proliferative responses against 
chlamydial antigens and the influx of CD4+ lymphocytes were observed (682). In 
contrast, only small numbers of IL-4-secreting cells could be found throughout the 
course of infection. The dominant production of IFN-γ-producing cells was also 
observed in draining iliac lymph nodes as well as the mesenteric lymph nodes and 
spleen during the course of infection.  
 
Recently, it has been shown that a Chlamydia-specific CD4 Th2 clone is unable to 
clear organisms from the genital mucosa of nude mice for up to 2 months after 
infection (523).  
In addition, it has been found that if the immune response was manipulated to 
favor a Th2 response, the local clearance of organisms was delayed. For example, 
the absence of IL-6 during a C. trachomatis respiratory infection did prolong the 
clearance of organisms from the lung and resulted in higher titers of antichlamydial 
IgG1 antibody in the serum (1506). The authors also noted increased levels of IL-10 
in these mice and were able to restore a dominant Th1 response by administering 
anti-IL-10 during infection.  
 
Thus, from these studies it appears that a predominately Th1 CD4+ lymphocyte 
response is required to clear Chlamydiae from the local genital mucosa.  
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CD8+ T cells 
Over the past few years reports have been published examining the role of 
chlamydial-specific CD8+ lymphocytes in the resolution of genital infection.  
Cytotoxic killing of chlamydial-infected cells was demonstrated in targets 
transfected with ICAM-1 (92) and Starnbach et al. were able to demonstrate 
classical MHC class I restricted cytolysis from the spleens of infected mice (1345).  
 
IFN-γ 
However, the majority of the antichlamydial activity for both CD4+ and CD8+ 
lymphocytes is associated with the production of high levels of IFN-γ. This was 
initially demonstrated in vivo by administering anti-IFN-γ to mice prior to vaginal 
inoculation which interfered with the clearance of Chlamydia from the genital 
mucosa (1167).  
In addition, a protective CD4+ Th1 clone was shown to produce high levels of IFN-γ 
and TNF-α (593) whereas Starnbach et al. also demonstrated that the ability of a 
cytotoxic CD8 cell to eliminate Chlamydia infection was largely due to the 
production of IFN-γ in a series of experiments (683).  
 
The bacteriostatic effects of IFN-γ itself were demonstrated in murine models in vitro 
where chlamydial growth inhibition was mediated by the induction of NO (892). 
Although NO inhibits chlamydial replication in vitro and is induced following 
infection (1112), it does not contribute to the resolution of genital infection in vivo 
(592).  
Another possible role for IFN-γ in vivo may include the activation of local 
macrophages which may be necessary to stimulate antichlamydial activity from 
local Th1 lymphocytes within the genital mucosa (683).  
While IFN-γ clearly plays an important role in immune-mediated killing of 
Chlamydia in vivo, studies in IFN-γ-/- mice have revealed an additional, IFN-γ-
independent mechanism for eradication of Chlamydia from the genital tract. The 
large majority of chlamydial burden in the genital tract is cleared in IFN-γ -/- mice 
(1112) and these mice did not develop dissemination of the organism following a 
second vaginal inoculation (260). In the respiratory model, results showed that 
immunity in IFN-γ -/- mice was associated with increased levels of TNF-α and GM-
CSF in the lungs (1507). 
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Adhesion molecules 
However, not only high concentrations of cytokines as IFN-γ delivered in close 
proximity to infected cells, but also activation and cell-to-cell contact for the 
inhibition of growth by a specific CD4+ T cell clone is required (683). When 
considering the extensive surface area of the genital tract mucosa and the small 
numbers of CD4+ lymphocytes present there during infection (680), the result 
would be that immune effector cells must be directed to infected ECs in order to be 
effective at eradicating the infection. The recruitment of leukocytes into tissue sites 
depends on interactions between adhesion molecules on ECs and integrin receptors 
on the leukocytes.  
 
Predominantly CD4+ T cells with a peak at 3 weeks after infection were recruited to 
the genital mucosa following chlamydial vaginal inoculation in mice (680). Kelly et 
al. showed that in the genital tract of mice, recruitment of CD4+ cells is mediated 
through the interactions between homing receptors on CD4+ T cells such as α4β7 
and adhesion molecules ICAM-1, VCAM-1 and MadCAM-1 (524, 680). The latter 
were both temporarily induced in genital tract of mice due to chlamydial infection.  
Kelly and colleagues also reported that during Chlamydia infection, cellular 
recruitment differed in the upper genital tract, i.e. oviduct and uterine horn, 
compared to the lower genital tract, i.e. cervix and vagina (682).  
It was found that CD4+ cells were recruited mainly to the upper genital tract during 
a primary genital infection with mouse pneumonitis (MoPn), a biovar of C. 
trachomatis, whereas neutrophils and monocytes were recruited to all regions of the 
genital tract. This was unexpected given that Chlamydia initially infect ECs in the 
cervix and then ascend to the oviducts. 
The study group also discovered a differential regulation of adhesion molecules on 
endothelial cells in the lower tract compared to the middle or upper tract. ICAM-1 
was found to be expressed in the lower tract of uninfected mice; VCAM-1 and 
MAdCAM-1 were induced early after infection in the lower genital tract. In contrast, 
no adhesion molecules were expressed in the upper genital tract of uninfected mice, 
but all three were induced later in the course of infection which correlates with the 
appearance of CD4+ cells in these tissues (682). 
 
Other data suggest that the IFN-γ-inducible protein-10 (IP-10) and monokine 
induced by interferon gamma (MIG) are responsible for recruiting Th1 cells to the 
genital tract during infection. The binding of these chemokines to specific receptors 
activates integrin homing receptors on leukocytes, which in turn facilitates 
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adhesion and directed migration within the tissue parenchyma. Focusing on 
chemokines that would attract Th1 cells, it was found that protein levels of IP-10 
and MIG were elevated in upper but not lower genital tract early after infection 
(891).  
These data showing differential chemokine expression in the upper and lower 
genital tracts support increasing evidence that the inflammatory response in the 
lower genital tract may be prematurely terminated even in the presence of an active 
C. trachomatis infection. 
(3) Cytokine and chemokine response to chlamydial infection  
Several studies in vivo and in vitro have shown the release of proinflammatory 
mediators including IL-1β, TNF-α, IL-6 and IL-12 upon chlamydial infection (683). 
However, studies demonstrated that C. trachomatis can enter host ECs without 
inducing the immediate production of inflammatory cytokines (1174).  
Peak levels of IL-8 were delayed until 2 to 4 days after the initiation of infection 
suggesting that neither physical entry of C. trachomatis nor cell surface contact 
with molecules such as chlamydial LPS were capable of inducing IL-8 secretion. 
Transcription of IL-8 mRNA was also delayed and was first observed 2 hours after 
infection, most likely through the translocation of NF-kB. These data suggest that 
the initiation of the chlamydial developmental cycle is responsible for inducing IL-8 
secretion (1174).  
Other proinflammatory cytokines such as IL-1, IL-6, and GM-CSF were also 
released following chlamydial infection of EC lines as well as primary endocervical 
ECs. However, unlike other invasive bacteria, the entry of Chlamydia was not 
responsible for the cytokine release (1369).  
 
Rasmussen et al. proposed the relatively small size of infectious EBs compared to 
other invasive bacteria as one factor allowing Chlamydia to enter without 
stimulation of cellular cytokine production (1174).  
Ingalls and colleagues found that chlamydial LPS has a weaker stimulatory ability 
compared to other LPS-containing bacteria, for example gonococcal LOS (596). 
Others illustrated the ability of live Chlamydia, but not of heat-killed, to induce IL-
1β, TNF-α and IL-6 from a monocyte cell line (114). 
 
Belay et al. analyzed the dynamics of chemokine and chemokine receptor 
expression in genital mucosae during genital chlamydial infection in a murine 
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model to determine how these molecular entities influence the development of 
immunity and the clearance of infection (100).  
The study revealed an increase in the levels of expression of RANTES, MCP-1, IP-10, 
MIP-1, and ICAM-1 which are involved in the recruitment of Th1 cells after genital 
infection with the C. trachomatis agent of mouse pneumonitis. Peak levels of 
expression of RANTES, MCP-1, and MIP-1 occurred by day 7 after primary 
infection, while those of IP-10 and ICAM-1 peaked by day 21. After 6 weeks and 
resolution of infection the expression of these molecules as well as of chemokine 
receptors CCR5 and CXCR3 decreased but was upregulated again after secondary 
infection.  
 
While in vitro studies have revealed that Chlamydiae can enter ECs without 
signaling the immediate production of proinflammatory cytokines, a similar result is 
also seen in the genital mucosa in vivo.  
Peak levels of TNF-α were not seen until 5 days into the infection of C. trachomatis 
after the pathogen was inoculated into the mouse vagina (297). Overall, the local 
cytokine response appears to be weak and does not follow serum levels.  
Hedges and colleagues examined IL-1, IL-6, IL-8, IL-10, and TGF-β in genital 
secretions of women with bacterial STD. The genital secretions of women with C. 
trachomatis or N. gonorrhoeae were not consistently elevated compared to 
uninfected controls (532).  
However, increased levels of IFN-γ were found in endocervical secretions compared 
to uninfected women (51), and TNF-α expression was found in cultures of fallopian 
tubes that were infected in vitro with C. trachomatis (64).  
 
Reddy et al. reported that all Th1- and Th2-cytokines analyzed in their study, i.e. 
IFN-γ, TNF-α, IL-10 and IL-12 were upregulated. As both CD4+ and CD8+ cells 
contribute to the production of and IL-10, these results confirm again that CD4+ 
and CD8+ lymphocytes may be important for local regulation of Th1/Th2 responses 
in the genital tract during C. trachomatis infection (1179). Thus, the predominant 
cytokines produced following chlamydial genital infection in animal models are also 
found in humans. 
 
APCs play a central role in shaping the cytokine profile of an immune response to 
Chlamydia through production of IL-12, IL-18, and IL-10. Both IL-12 and IL-18 are 
important for producing Th1 responses and are induced following infection with 
Chlamydia (834). IL-12 appears to play a dominant role over IL-18 since the 
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chlamydial burden was only slightly increased following infection in IL-18 knockout 
mice. Anti-IL-12 prolongs the course of infection (1112) while IL-12 administration 
shortens infection (575). Finally, IL-10 appears to reduce the frequency of IFN-γ-
producing T cells and resulted in an increase in chlamydial burden (589).  
 
Darville et al. found that depletion of TNF-α in genital secretions early after 
infection did not alter chlamydial burden or tissue pathology following vaginal 
inoculation of guinea pigs (298). However, there was an increased influx of 
inflammatory cells in TNF-α-depleted animals. Surprisingly, earlier studies had 
found that TNF-α displays antichlamydial properties in vitro (1291). 
 
The following table shows a summary of the different immune parameters and their 
functions in primary and secondary chlamydial infection (Table 30). 
 
Immune effectors 
Role in immunity against genital Chlamydia 
infection 
Importance 
Factors of adaptive immunity 
CD4+ T cells 
Th1 cytokines (IFN-γ, TNF, IL-2) 
Eradication of infection 
Protective immunity 
Obligatory 
CD8+ T cells 
Th1 cytokines (IFN-γ, TNF, IL-2) 
Synergistic role together with CD4+ 
Contributory 
B cells/Igs  Faster clearance of infection Contributory; 
obligatory in 
reinfection? 
Factors of innate immunity 
DCs/ 
Macrophages 
Phagocytosis and antigen presentation, 
stimulation of T cells, cytokine costimulation, 
ADCC 
Obligatory 
NK cells Production of IFN-γ Contributory 
Neutrophils Reduction of amplification and focal spread Contributory 
Cytokines/ 
Chemokines 
Immunostimulation Obligatory 
Table 30: Summary of relevant immune parameters in immunity against C. 
trachomatis infection, adapted from Igietseme et al. (590)  
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(4) Persistence of chlamydial infection 
A number of studies have documented that within a year after treatment of a 
previous Chlamydia infection, individuals have persistent or recurrent infections at 
a rate of 13% to 26% (683). In fact, Burstein et al. have recently estimated that the 
mean time to reinfection is 6 to 7 months in a sexually active adolescent population 
(163).  
Batteiger and colleagues noted that nearly one third of individuals became 
reinfected with the same serovar and that this was associated with continued 
contact with the same partner (87). As an explanation, selective immune pressure 
has been postulated to induce point mutations in the MOMP which have been 
shown to abrogate the binding of antibodies to epitopes that can neutralize 
infectivity in vitro (782).  
 
Given the frequent reinfection with Chlamydia in humans, the question arises as to 
whether protective immunity against chlamydial infection can develop.  
There are several studies that support this concept. For instance, the incidence of 
chlamydial infection was significantly reduced in both women and men with a 
history of STDs (665). In addition, older women with an equivalent number of 
sexual contacts became infected less often than younger women (50). Also, 
immunosuppressed women with HIV infection had both an increased prevalence 
and risk of reinfection (695).  
However, the immunity that develops appears to last for only a short time. The rate 
of reinfection significantly increased in those individuals whose last reported 
Chlamydia infection was more than 6 months previous, as compared to those with 
more recent infection (665).  
 
Animal models of chlamydial genital infection exhibited short-term immunity 
against subsequent infection (1169).  
Using a second vaginal inoculation of Chlamydiae at various times after resolution 
of the primary infection, guinea pigs demonstrated immunity against reinfection 
with a shortened course of infection and reduced numbers of viable Chlamydiae 
when the animals were challenged 30 days later. However, if the guinea pigs were 
reinfected on day 77, the level of immunity was reduced. In addition, a protective 
response was associated with the more rapid recruitment of CD4+ cells to the 
genital tract upon reinfection (680).  
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Studies have also observed a more rapid increase in the number of venules 
expressing adhesion molecules when mice were challenged shortly after the 
resolution of infection (682).  
Peak levels of adhesion molecules were seen 7 days after a challenge infection in the 
lower genital tract, similar to the kinetics following a primary infection. In the 
oviducts and uterine tissues, however, the number of venules expressing VCAM-1 
peaked 3 days after infection compared to the peak on day 21 in VCAM-1-positive 
venules observed following a primary infection.  
A reason may be that low numbers of anti-chlamydial memory T lymphocytes 
recirculate through the genital mucosa following resolution of infection. Upon 
activation with chlamydial antigens, these lymphocytes could release cytokines and 
chemotactic factors to facilitate the rapid recruitment of CD4 lymphocytes. 
 
It is likely that cellular immunity is primarily responsible for clearing the initial 
infection; however, it appears that antibody plays a role in protection from 
reinfection.  
It was shown that IFN-γ receptor knockout mice resolved infection only after a 
prolonged time period while high levels of antichlamydial IgA and IgG antibodies 
were present in genital secretions (631). Antibodies against Chlamydia are found in 
genital secretions and serum after infection (1170) and the resolution of a primary 
infection coincides with the appearance of antichlamydial antibody in genital 
secretions.  
A few proposed antibody-mediated mechanisms of control include neutralization of 
the entry of C. trachomatis into ECs; opsonization, which enhances the uptake of 
Chlamydia by macrophages; and antibody-dependent cell-mediated cytotoxicity via 
antichlamydial IgA (683).  
A less intense infection was noted in guinea pigs that were challenged as long as 
825 days after a primary infection which was correlated to serum IgG levels but not 
IgA levels in genital secretions since IgA antibodies were undetected 75 days after 
infection (88).  
Recently, the study by Morrison and Morrison in antibody-deficient mice 
demonstrated that antibodies contribute to a high degree to immunity to chlamydial 
genital tract reinfection, and that antibody-mediated protection is highly dependent 
on CD4+ T cell-mediated adaptive changes that occur in the local genital tract 
tissues during primary infection (973).  
However, in a study by Johansson and Lycke in B cell-deficient mice, long-term 
protection in the genital tract against C. trachomatis infection is conveyed by IFN-γ-
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producing CD4+ memory T cells, which appear to be maintained in the absence of 
antibodies and local antigen deposition (629). 
 
One serious problem with repeated chlamydial genital infections is, as already 
mentioned above, tissue damage followed by tubal scarring, chronic salpingitis and 
distal tubal obstruction.  
Studies proposed the hypothesis that at least some component of the immune 
response in form of a delayed-type hypersensitivity reaction could be responsible for 
causing tissue damage.  
By characterizing the inflammatory infiltrate, Patton found only mononuclear 
infiltrates during repeated infection compared to both mononuclear and 
polymorphonuclear infiltrates after a primary infection (1098).  
Moreover, a lack of Chlamydia-specific T lymphocytes may enhance tubal 
pathology. Studies observed oviduct ectasia, hydropsalpinx, and marked acute 
inflammatory infiltrates in mice that lacked an anti-chlamydial CD4+ lymphocyte 
response (1112).  
 
Recurrent or chronic chlamydial infections, which are associated with damage to 
the reproductive tract, may result from an insufficient number of antichlamydial 
Th1 cells or possibly factors that interfere with the effector mechanisms of Th1 
cells, for example IL-10.  
Yang and colleagues found that Chlamydia was eradicated more rapidly following 
infection in IL-10 knockout mice and that antichlamydial Th1 responses were 
enhanced in IL-10 knockout mice (1555).  
IL-10 is a potent counterregulatory cytokine that suppresses Th1 immune 
responses by many mechanisms such as inhibiting IL-12 production from APCs or 
suppressing transcription of the chemokine IP-10, which attracts Th1 CD4 cells 
(683).  
Another factor that may dampen Th1 responses during Chlamydia infection is the 
antiinflammatory cytokine TGF-β which is elevated in the genital tract late in the 
course of MoPn infection in mice [207].  
 
In vitro, the production of most chlamydial components is extremely downregulated 
when C. trachomatis is in its persistent, non-replicative form. However, synthesis of 
chlamydial heat shock protein (c-hsp60) is upregulated under these conditions (93).  
Immunity to this protein which only results from a persistent infection seems to 
contribute to the development of tubal occlusion and adverse pregnancy outcome.  
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A study showed that detection of antibody to c-hsp60 did not correlate with a 
positive C. trachomatis genital culture but with tubal occlusion and PID (352, 150). 
There is a human hsp60 (h-hsp60) homologue to c-hsp60 which is expressed by 
ECs of the decidua and embryo during early pregnancy (1527). Therefore, a 
chlamydial fallopian tube infection can induce the development of autoantibodies to 
h-hsp60 and in women already sensitized to c-hsp60, the exposure to h-hsp60 will 
reactivate the c-hsp60 lymphocytes. This may lead to immune rejection of the 
embryo (1527).  
A study by Kinnunen et al. has shown that T lymphoytes derived from salpingeal 
tissues of patients with tubal factor infertility show specific reactivity with c-hsp60 
(712). However, immunizing mice with both c-hsp60 and h-hsp60 could induce IL-
10 production in mice (1562). Thus, bacterial hsp60 may trigger a Th2 cell response 
during infection, which could suppress a concurrent Th1-driven response. 
(5) Chlamydial vaccine development 
The development of a safe and protective vaccine against chlamydial infection is still 
ongoing.  
In the 1960s, a vaccine for trachoma was developed and tested in humans but the 
protection was short-lived and induced immunopathologic scarring in a few 
individuals (683).  
T cell epitopes appear to be found in association with many HLA alleles and for the 
most part are directed against nonpolymorphic constant regions of the MOMP. 
Thus, cellular immunity could be generated to nonvariable segments of the 
organism for protection against an array of serovars. Support for this approach has 
been generated in mice where infection with MoPn provides subsequent protection 
against human serovars of Chlamydia trachomatis (1164).  
 
Different routes of immunization have been examined for stimulating protective 
immune responses against chlamydial infection within the reproductive tract. 
Thereby it is possible to eliminate disturbances on immune responses coming from 
reproductive hormones, for example.  
Pal et al. have reported that Chlamydia were recovered from the upper genital tract 
of significantly more mice when infected during the luteal phase with increased 
levels of progesterone and estradiol than follicular phase (1062). Kaushic and 
colleagues, however, concluded in their study of a rat model that progesterone 
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increases and estradiol decreases susceptibility to intrauterine chlamydial infection 
(673). 
In the mouse model, various mucosal versus parenteral routes of immunization 
were compared.  
In mice which were given live Chlamydia by mucosal routes, i.e. oral, intranasal, 
and vaginal, the course of infection was significantly shortened and of less 
magnitude compared to mice injected subcutaneously with live Chlamydia (681).  
Examination of the cytokine profile produced after immunization showed a 
dominant Th2 response in the draining iliac lymph nodes following parenteral 
immunization, whereas a dominant Th1 response was noted in mice immunized via 
mucosal routes.  
Igietseme and colleagues further showed that mice first given live Chlamydia 
intranasally or vaginally had greater levels of IFN-γ in the genital tract after a 
challenge infection compared to mice immunized via a subcutaneous route (594).  
Oral immunization has been shown to elicit antibodies in other mucosal tissues, 
such as the reproductive tract and mammary glands, as well as the intestine. 
However, the intranasal route was found to produce the greatest amount of IgA and 
IgG in genital secretions for the longest period of time. For instance, both IgA and 
IgG, specific for the immunizing antigen, could be found in genital secretions 
following immunization via the nasal, oral, rectal, and vaginal routes. However, 
both the nasal and vaginal routes consistently produced the greatest increase in IgA 
and IgG compared to other routes in humans (743).  
Igietseme et al. also reported that immunization via the nasal route elicited the 
highest level of antichlamydial IgG antibody titers in the genital tract even in 
comparison with a vaginal immunization (594). Moreover, immunization by the 
nasal route has been shown to protect mice from infertility following a challenge 
infection (1063). 
 
The induction of a protective cell-mediated immune response also appears to 
depend on whether a live infection initiates the immunizing response.  
In the guinea pig model of chlamydial genital infection, protection following 
parenteral immunization was observed (1168). Chlamydia-specific IgG and IgA 
levels were comparable in the serum and genital secretions among vaginal, oral, 
and parenteral immunization routes when live EB were used. Moreover, guinea pigs 
could be protected from reinfection following a parenteral immunization with UV-
inactivated Chlamydia which is most likely due to the production of a protective 
antibody response (1168).  
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In contrast, immunization of mice with UV-inactivated Chlamydia provided no 
protection against a genital infection (681).  
 
These data show that to develop a protective vaccine many factors in addition to the 
antigen must be considered, such as route of immunization or form of antigen. A 
summary of different approaches to create a protective and safe vaccine against 
chlamydial infection shows Table 31.  
 
Immunmodulatory 
approach 
Vaccine effect Research status 
Selection of antigens with 
T and B cell epitopes 
Induction of required T and B cell 
response 
In progress 
Multisubunit vaccines 
Furnishing adequate B and T cell 
epitopes for elevated immune 
responses 
In progress 
Use of delivery vehicles 
(adjuvants, vectors) 
Boost of immune responses; 
vehicles for subunits 
In progress 
Modulation of 
cytokine/chemokine 
expression 
Upregulation of Th1 cytokines; 
downregulation of Th2 cytokines 
Experimental stage 
Modulation of 
costimulatory factors 
Induction of high T cell response Experimental stage 
Vaccine targeting to 
specific inductive sites  
Mucosal immunity Active 
Table 31: Vaccine design strategies in development against chlamydial infection, 
adapted from Igietseme et al. (590) 
c) Bacterial vaginosis 
For a normal vaginal flora after menarche, estrogen provides the conditions for 
survival of lactobacilli again which is the dominant vaginal flora in the female adult.  
There are various different species of lactobacilli with the dominant species L. 
crispatus, L. gasseri, L. jensenii and L. iners in an asymptomatic vagina (1395). The 
healthy vaginal flora is characterized by high concentrations of this Lactobacillus 
spp. (108 colony forming units/ml) and a pH of less than 4.7 (874). During 
menopause, there is a mixed flora with a considerable portion of mycoplasma and 
anaerobic bacteria (419).  
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The roles of the lactobacilli species are to produce lactate for acidification of the 
vaginal mucus, to produce bacteriocines, hydrogen peroxide, a bisurfactant and 
organic acids, and furthermore to compete with pathogenic organisms for space, 
receptors and nutrients.  
 
The vaginal epithelium and its mucus layer help to regulate the intrinsic bacterial 
and mucosal defense systems (874). The vagina is lined with squamous epithelium, 
whose thickness directly correlates to estrogen concentration. Glycogen supplied by 
the vaginal ECs supplies metabolic fuel to for the generation of lactic acid by 
lactobacilli, thus enabling a low pH. This low pH, along with adequate 
concentrations of hydrogen peroxide, controls potential overgrowth of other 
commensal flora such as Gardnerella vaginalis and Candida albicans. Apparently, a 
low estrogenization of the vaginal mucous membrane will enhance the growth 
potential of flora, which is normally encountered in small quantities in the vaginal 
mucus (419). 
 
Some decades ago, Gardner and Duke reported aspects of the so-called 
Haemophilus vaginalis-vaginitis (438) which is now renamed BV. They proposed 
Haemophilus vaginalis, which is now Gardnerella vaginalis, as the single cause for 
BV.  
 
Today it is generally known that BV significantly alters the vaginal ecosystem and a 
profuse mixed flora with anaerobic and facultative anaerobic bacteria besides 
depletion of Lactobacillius spp., especially those that produce hydrogen peroxide, is 
established. The vaginal flora in BV includes G. vaginalis, Prevotella spp., 
Mobiluncus spp., Corynebacterium spp., viridans streptococci, coagulase-negative 
staphylococci, Enterococcus faecalis, Atopobium vaginalis and Mycoplasma hominis 
(419, 874). But there is not only a qualitative, but also a quantitative change with 
bacterial concentrations about 100 to 1000 times higher than normal. Production of 
fatty acids by these anaerobic bacteria leads to an elevated pH in the vagina which 
itself promotes anaerobic growth again.  
 
BV is the most prevalent form of vaginal infection in women of reproductive age, 
affecting about 3 million women in the United States per year, and is the most 
common etiology of vaginal symptoms leading women to seek for medical care (720).  
Symptomatic BV, which only accounts for 60% of all cases, causes abnormal 
amounts of a malodorous vaginal discharge deriving from degraded vaginal mucus. 
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Symptoms for a vaginitis including vaginal pruritus, burning or dyspareunia, 
however, are rare and visible local inflammation signs are absent (969). BV is 
clinically diagnosed by the Nugent criteria which quantify the number of lactobacilli 
relative to BV-associated morphotypes (1033) or the Amsel criteria (Table 32). 
 
Vaginal pH greater than 4.5 
Homogenous vaginal discharge on examination 
Detection of fishy odor on addition of potassium hydroxide to vaginal fluid 
Presence of significant clue cells in vaginal smear (>20% of total vaginal ECs) 
Table 32: Amsel criteria for BV, of which at least three of four should be present (34) 
(1) Pathogenesis and implications of BV infection 
What influences the susceptibility to BV of some women is currently not clear.  
Prepuberty and postmenopause are rarely associated with BV which has led to the 
proposal that vaginal microbial changes may be due to hormonal variations during 
the menstrual cycle (870). It is also considered that BV is a genetically determined 
miscolonization of the vagina (969) or may be another example of an STD (970). 
 
One virulence factor in bacteria associated with BV is a haemolytic toxin produced 
by G. vaginalis. Women who lack an adequate IgA immune response against this 
toxin are said to risk BV (189).  
Another hypothesis respecting the pathogenesis is that hydrolytic enzymes degrade 
the mucin and thus damage the protective vaginal mucosa. In comparison with 
healthy women, women affected by BV are also known to have significantly higher 
vaginal concentrations of the hydrolytic enzymes sialidase and proline dipeptidase. 
Proline dipeptidase is produced by both Mobiluncus spp. and G. vaginalis. Sialidase, 
which is produced by, for instance, Prevotella spp., is thought to be an important 
virulence factor in BV pathogenesis, not only because it leads to lysis of the mucin, 
thus aiding the adherence of bacteria, but also through its ability to counteract a 
specific IgA defense against G.vaginalis toxin (193). It was furthermore suggested 
that a high sialidase activity in BV cases gives rise to a significant risk of 
prematurity. 
 
A causal relationship between BV and the acquisition of HIV has been supported by 
studies evaluating HIV genital shedding in BV and from prospective studies 
examining the risk of HIV infection associated with abnormal vaginal flora (1265). 
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Presence of BV was associated with a sixfold increase of in quantity of HIV shed 
relative to normal flora (285). 
Relations between BV and the acquisition of HSV-2 have also been reported (220).  
 
Data strongly support the fact that BV is significantly associated with adverse 
sequelae related to the upper genital tract. 
During pregnancy, BV increases the risk of preterm delivery and low-birth-weight 
children (548), first trimester miscarriage among women undergoing in vitro 
fertilization (IVF) (1163), chorioamnionitis and other infections (1305). Screening for 
BV and treatment has been considered a strategy to reduce the rate of preterm 
birth (1215).  
In nonpregnant women, BV increases the risk for posthysterectomy infections and 
PID (1500) as well as the risk for acquiring Neisseria gonorrheae or Chlamydia 
(1501).  
The correlation between BV and infection in the upper genital tract is believed to be 
due to the fact that an abundant vaginal overgrowth of BV-associated bacteria 
makes ascending infections in the genital tract more likely.  
Considering the concept of vaginal inflammation, a balanced and appropriate 
immune response is thought to be crucial to clear infectious agents through the 
production of antimicrobial agents, phagocytosis and clearance of microorganisms. 
Individuals differ in their ability to mount an inflammatory response; some are 
hyperresponders with an excessive local and systemic response, others are 
hyporesponders with the risk of an overwhelming infection (1307).  
In this context, there is a hypothesis to understand the relationship between 
changes in the vaginal flora, inflammatory response and clinical outcome. 
Hyporesponsive mothers may no be able to control microbial challenge which 
results in ascending intrauterine infection and clinical chorioamnionitis. 
Hyperresponders develop an excessive local immune response, clinical symptoms of 
vaginitis and be at risk for preterm delivery.  
To underline this hypothesis, Simhan reported that women with low concentrations 
of cytokines IL-1β, IL-6 and IL-8 in vaginal fluid in early pregnancy are more likely 
to develop chorioamnionitis than those without low concentration of these 
cytokines. Also, it is agreed that women with elevated cytokines are at risk for 
preterm delivery (1215). More data concerning the circumstances of preterm 
delivery associated with infections such as BV should be further discussed below in 
the chapter on disturbances in maternal-fetal interactions. 
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(2) Innate and specific immune responses in BV  
BV is generally regarded as a noninflammatory vaginal condition and inflammatory 
signs are rare in BV-positive women.  
Activation and recruitment of neutrophils is one of the main components of innate 
immunity in general against microbial and viral infections in the mucous 
membrane of the genitalia. However, the number of vaginal neutrophils in most BV-
positive patients is not increased with respect to healthy women (192, 195).  
The anti-inflammatory and antimicrobial SLPI, which is produced by mucosal ECs, 
is present at lower levels in vaginal fluid when BV exists (341). 
 
Also production of local proinflammatory cytokines, which was shown to be 
increased in genital tract infections with Candida or T. vaginalis (411, 1287), for 
example, was investigated in BV.  
In contrast to neutrophils, the cytokine level of IL-1β in CVS was found to be higher 
in BV-positive patients (192), which presumably indicates a host response to 
microbial products. 
In a trial of the Munich study group on 45 symptomatic BV patients and 36 
asymptomatic controls, the proinflammatory cytokines IL-6, IL-10 and the 
antiinflammatory IL-12 in vaginal secretions were measured (1471). Results showed 
no significant difference in levels of all three cytokines between the two study 
groups.  
These findings are consistent with results from other studies. Wennerholm et al. 
did not find an association between IL-6 concentrations and BV but a significant 
increase of IL-1α and IL-8 in BV-positive pregnant patients (1494). 
Mattsby-Baltzer et al. also failed to demonstrate a significant rise in 
concentrations of IL-6 and TNF-α in pregnant BV-positive women compared to 
controls whereas vaginal levels of IL-1β were increased (890). 
In a study by Yudin et al., oral and vaginal metronidazole treatment of BV-positive 
patients has been shown to reduce cervical mucus levels of IL-6 as well as IL-1β 
and IL-8 (1569). In the group of patients with persistent BV, however, the 
metronidazole treatment did not result in a cytokine reduction. 
Another recent study of the Munich study group determined the levels of the 
proinflammatory cytokines IL-1α and IL-1β, and the antiinflammatory cytokines IL-
5 and IL-10 in vaginal secretions of BV patients and healthy women (37). They 
found significantly increased levels of IL-1β and significantly decreased levels of IL-
10 in BV patients compared to healthy women.  
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IL-8 is a potent chemotactic and activating factor for neutrophils that has been 
detected in vaginal fluid of women with BV and other vaginal infections (1494). A 
recent study showed that impairment of IL-8 induction in women with BV is 
associated with low levels of vaginal IgA against haemolysin produced by G. 
vaginalis, low number of leukocytes, and high microbial hydrolytic enzyme activities 
(191). 
IL-8 does not, however, seem to be correlated with the presence of BV in the same 
distinct manner. Recent findings indicate that microbial hydrolytic enzymes could 
be responsible for dampening the expected proinflammatory response cascade after 
IL-1β increase (195). The impairment of IL-8 increase may explain the absence of 
neutrophil increase in most women exposed to a massive anaerobic vaginal 
colonization.  
Recent findings have demonstrated that low concentrations of IL-1β were associated 
with low levels of anti-G.vaginalis hemotoxin IgA in vaginal fluid of women with BV 
(190) suggesting a necessary association between the innate and adaptive immune 
responses for protection from ascent of pathogens to the upper genital tract. 
Sturm-Ramirez et al. proposed that increased IL-1β during BV could upregulate 
local HIV replication through activation of the LTR promoter region and therefore 
partly explain the mechanism how BV enhances HIV transmission (1368).  
 
A problem is that some forms of abnormal vaginal flora are neither normal, nor can 
they be called BV. Such forms of abnormal flora have been termed “intermediate 
flora” in some studies, or have been included with BV in other studies (334, 335).  
However, also Taylor-Robinson et al. proposed to make a difference between the 
classic finding of BV and an “intermediate” vaginal fluid (1403). Abnormal vaginal 
flora comprises a wide range of changes, which include not only BV but also other 
less well-characterized conditions.  
An interesting study was performed by Donders et al. which raised the question if 
inflammation really exists with BV or if it is a separate entity. They tried to exactly 
define the changes in abnormal vaginal flora to differentiate between BV and a 
vaginitis (335). In opposite to BV with no signs of local inflammation, some women 
with abnormal vaginal flora showed signs of a vaginitis including redness, pruritus 
and burning pain. This was referred to as a condition characterized by a decrease in 
lactobacilli, high vaginal pH, absent clue cells and the presence of leukocytes which 
Donders called “aerobic vaginitis”. Women with “aerobic vaginitis” were reported to 
have decreased levels of lactic acids and a local inflammatory response with high 
concentrations of vaginal IL-1β, IL-6 and LIF (334). 
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A recent work by the Munich study group investigated 102 patients with a 
symptomatic vaginal dysbiosis, similar to the picture of an aerobic vaginitis of the 
Donders study, and 50 healthy asymptomatic controls (955). In women with vaginal 
dysbiosis, the proinflammatory cytokines IL-1α and IL-1β were significantly 
increased whereas IL-2 and IL-4 were significantly lower in this group compared to 
healthy controls.  
In a study on 193 women attending outpatient clinic for vaginal discharge 
problems, vaginal swabs were investigated for pathogens, lactobacilli and 
leukocytes, as well as vaginal secretions for IL-4, IL-10 and IL-12. Preliminary 
results proposed tendencies to an association of high vaginal levels of IL-12 with 
high leukocyte numbers and a high total BV-related pathogen count, whereas low 
levels of IL-10 were correlated with high total and BV-related pathogen counts (G. 
Anton, personal communication). High vaginal IL-10 levels were therefore 
supposed to be associated with healthy women whereas high levels of IL-12 were 
positively correlated with infection and inflammation. 
3. Candidiasis 
Vulvovaginal candidiasis (VVC) is a common mucosal fungal infection caused in 
about 80-90% by the opportunistic pathogen Candida albicans, a commensal 
organism in the gastrointestinal and reproductive tracts (1323, 1324). Other 
causative agents are Candida glabrata, Candida krusei and others (915).  
It affects an estimated three out of four women at least once during their 
reproductive age and a significant percentage of those women (5-10%) experience 
recurrent VVC (RVVC) (585). An overview of different clinical forms of vaginal 
candida infection gives Table 33. 
 
Asymptomatic form Colonization, lack of symptoms 
Acute form 
Burning, itching, vaginal discharge 
Vaginal erythema and edema 
Persistent form Persistence after antifungal therapy 
Recurrent form 
Recurrence after antifungal therapy 
CRVVC: ≥4 episodes/year, caused mainly by C. albicans, but 
increasing rates of C.glabrata and non-albicans-strains 
Table 33: Different clinical forms of vaginal candidiasis 
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Several exogenous predisposing factors such as pregnancy, oral contraceptives and 
uncontrolled diabetes mellitus are known to cause acute episodes of VVC (1324). 
However, RVVC seems to be idiopathic. Chronic RVVC (CRVVC) is clinically defined 
as at least four episodes per year in the absence of any predisposing factors (408).  
 
Unlike symptomatic oropharyngeal candidiasis of HIV-positive subjects, which 
seems to be closely dependent upon both the severity of cellular immunodeficiency 
and reduced CD4+ cell counts, symptomatic VVC is common in women, regardless 
of HIV serostatus and immunodeficiency (1498). Recurrences seem to be caused by 
persistent yeast in the vagina, rather than by reinfections, as demonstrated by the 
isolation of the same karyotypically identical strains in relapses (1450). 
 
Acute VCC can be treated topically with nystatin, imidazole or amphotericin B or 
systemically with fluconazole or itraconazole (915). Antifungal therapy is highly 
effective for individual attacks of VCC and RVCC but does not prevent recurrence. 
Thus, RVVC is presumed to result from some local innate and/or acquired 
dysfunction in the normal protective immune response most healthy individuals 
acquire from early exposure to Candida albicans.  
a) Cell-mediated immunity in Candida infection 
Cell-mediated immunity by T cells and cytokines, specifically a Th1 type response, 
is considered to be the predominant host defense mechanism against mucosal 
candidiasis and is thought to play a role in maintaining the organism in its 
commensal state at those sites as well.  
This is evidenced not only by the high incidence of Candida infections in HIV-
positive persons with reduced cell-mediated immunity (397) but also by a similar 
prevalence under other conditions of T cell immunosuppression, as for example 
corticosteroid therapy (725). 
 
Several experimental studies show that Th1-type cell-mediated immune responses 
are associated with resistance against systemic and mucosal C. albicans infections, 
whereas Th2-type responses are associated with susceptibility to infection (1214).  
Recently, the murine model of VCC has been used to study host immune responses 
against C. albicans. In these models, the most important requirement for a 
persistent infection is a state of pseudoestrus (401). In the absence of estrogen 
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treatments, the infection is short-lived with a low fungal burden in the vagina (406). 
However, the local vaginal immune responses in Candida infection are not clearly 
understood so far.  
Clinical as well as experimental estrogen-dependent murine model studies 
examining C. albicans vaginitis show that although Candida-specific systemic Th1-
type responses are clinically present or experimentally induced during a vaginal 
infection, these responses appear to have no effect on the infection (405, 407).  
Further experimental studies using the murine model show that partial protection 
against infection can be achieved, but without involvement of systemic Th1-type 
cell-mediated immunity (404). Through clinical and experimental studies it has 
become apparent that the host response to a C. albicans vaginal infection is more 
dependent on local immunity than the response observed in the systemic 
circulation (405, 404).  
 
Other studies evaluated the role of local vaginal associated Th1 cell immunity. Data 
to assess vaginally-associated T cells showed no changes in the percentage or 
composition of local phenotypically distinct T cells (404) during primary or 
secondary C. albicans vaginal infection, and also showed no evidence for systemic T 
cell infiltration into the vaginal mucosa during infection (403).  
By that it can be concluded that if T cells are responsible for any host defense in 
vaginal Candida infection, they exert their protective effect without significant 
changes in number and composition.  
 
In the absence of any clear exogenous predisposing factor, the risk of clinical 
infection has therefore been correlated with a partial T cell dysregulation, which 
might be exacerbated by the hormonal balance present during the follicular phase.  
Indeed, a significant reduction in the proliferation of peripheral blood lymphocytes 
from women in the follicular phase with RVVC has been reported, following their in 
vitro stimulation with Candida cells (255). These women had a depleted T cell pool 
and, in response to Candida stimulation, showed significantly reduced IFN-γ-
production which is normally a hallmark of anti-Candida protection (1523).  
However, in at least partial contradiction with these data, clinical evidence 
demonstrated that Candida-specific cell-mediated immunity at the periphery is 
normal in women with RVVC (408) and is also remarkably similar both in HIV-
positive subjects with oral candidiasis and in HIV-negative subjects (801). 
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Experimentally, both humoral and cellular protective anti-Candida responses at 
vaginal level are totally uncoupled to those occurring at the periphery (310), 
suggesting either an immunological independence, or compartmentalization of the 
vaginal mucosa, or a differential regulation of T-cell recruitment between different 
regions of the genital tract (682). Interestingly, murine vaginal T cells are 
phenotypically distinct from T cells in the blood (409). However, Candida-specific 
cell-mediated immunity was expressed by vaginal T cells in rats immunized against 
Candida after healing a primary infection (310), and vaginal T cells, particularly the 
CD4+ subset, transferred protection to naïve rats (Santoni G et al., unpublished 
data). These apparently contradictory data raise the issue of whether the data from 
experimental models of vaginal infection can be extrapolated to human disease. 
 
In contrast to a limited response to Candida at the murine vaginal mucosa, mice 
given an experimental Chlamydia trachomatis genital tract infection exhibit a CD4+ 
T-cell infiltrate into the genital tract (680). This Th1-type response is critical for the 
resolution of infection and indicates that T cells can reach the genital mucosa and 
provide substantial protection. A study by Kelly et al. addressed whether or not a 
dual infection with C. albicans and C. trachomatis could enhance the local 
recruitment of a cell-mediated host response against C. albicans and facilitate 
clearance of the infection (679). The result was that a concurrent Candida and 
Chlamydia infection could not accelerate or modulate the anti-Candida cell-
mediated response. These results suggest that host responses to these two genital 
tract infections are independent and not influenced by the presence of the other. 
b) Cytokine responses in candidiasis 
Concerning cytokines, clinical evaluation of Th1/Th2 cytokines in vaginal lavage 
fluid of women with RVVC showed no differences in comparison to control women 
without a history of vaginitis (406).  
Taylor and colleagues therefore investigated the cytokine production associated 
with the elicitation of Th1- (IL-2, IL-12, IFN-γ) and Th2- (IL-4, IL-10, TGF-β) type 
responses in the vagina and draining lymph nodes during an experimental C. 
albicans vaginal infection in mice (1398).  
It was found that in naïve animals TGF-β1 production was at least two-fold higher 
at the protein level and ten-fold higher at the mRNA level than the other cytokines 
evaluated, while most of the Th1 and Th2 cytokines were present at extremely low 
 Immunology of the genital tract 
 II-181  
levels. These high levels of TGF-β1 were further increased as a result of 
pseudoestrus and/or infection, and furthermore, the levels of TGF-β in naïve or 
infected mice were significantly higher in the vagina compared to other areas of the 
genital tract. Finally, TGF-β1 predominated as well in the draining, but not in non-
draining lymph nodes during infection (1398).  
Of the evaluated Th1/Th2 cytokines, TGF-β1 had the greatest likelihood of 
impacting the vaginal microenvironment and the local immune response, which 
may be suggestive of the newly classified Th3-type response based on the 
predominance of TGF-β1 and the virtual absence of changes in other Th-type 
cytokines during infection (810). 
 
During the last years, especially study groups around Weissenbacher et al. and 
Witkin emphasized the importance of cytokines in vaginal mycotic infections.  
Witkin reported that patients with CRVVC showed a decreased in vitro proliferative 
response of lymphocytes compared to patients with candidiasis which showed an 
increase in vaginal lymphocytes (1525). The cause is the amplified production of 
prostaglandin E2 by macrophages which consequently inhibits production of IL-2 
and therefore the proliferation of lymphocytes, thus inhibiting a Th1 immune 
response. Due to the impaired lymphocyte responses, C. albicans can proliferate 
and initiate a clinical infection.  
Prostaglandin E2 production can arise as a consequence of a vaginal allergic 
response due to local release of histamine. The allergen could be a semen 
constituent, an environmental product or a component of C. albicans. The result of 
a vaginal allergy can thus result in the weakened immune response against vaginal 
infections (1524). Epitopes of C. albicans enolase were already detected as binding 
sites for IgE antibodies (602). 
Earlier studies already proposed allergic reactions to Candida in the sense of a local 
vaginal hypersensitive immune response and suggested an allergic cause for 
chronic and recurrent symptoms (1197, 1217).  
In patients with CRVVC, Candida-specific IgE were detected in vaginal secretions, 
which further emphasizes the theory of a local vaginal hypersensitivity (1525).  
In a study of Weissenbacher et al., 104 women with clinical symptoms of a CRVVC 
and 44 healthy controls were investigated (1489). Candida was only detected in 
cultures of about 30% of all symptomatic patients, with PCR in about 42% of all 
symptomatic patients.  
The level of IL-4, IL-5 and IL-13 were identified, but there was only detected a 
significant increase in the antiinflammatory IL-4 compared to the controls (1488).  
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In addition, prostaglandin E2, whole IgE and Candida-specific-IgE was investigated. 
Prostaglandin E2 and the Candida IgE were significantly higher in comparison with 
the control group, while whole IgE showed no significant increase.  
A further study concentrated on the comparison of 150 healthy women and 74 
women with vaginal Candida-infection with respect to IL-8 and glucose in vaginal 
secretions (486). Healthy women not only showed higher concentrations of 
physiological lactobacilli, lower levels of neutrophils and a significantly lower 
presence of gram-positive cocci but also higher titers of IL-8. With respect to 
glucose levels, there was no difference between these two groups. An explanation 
could be that higher vaginal levels of the proinflammatory IL-8 in healthy persons 
serve as expression of an activated immune state, or that IL-8 may be inhibited in 
women with vaginal infection or downregulated in a kind of feedback-mechanism. 
c) Antibody responses in candidiasis 
The efficacy of humoral immune mechanisms and the role of antibodies against C. 
albicans has been a controversial subject for decades (1134).  
It is usually assumed that antibodies play little or no role in defense against this 
infection. This is based on the fact that the disease is not more common or more 
clinically serious in subjects with Ig disorders; and that subjects with candidiasis 
often have high titres of anti-Candida antibodies in their plasma, not different from 
other uninfected subjects (859).  
 
The fact that VVC and RVVC are much more common than Ig disorders clearly 
mandates that the infection also occurs in normal antibodies responders, but 
certainly does not mean that these subjects produce the correct antibodies in the 
correct place. Protective antibodies with specificity to a limited number of yeast 
epitopes might not necessarily be produced at protective levels, and some relevant 
yeast epitopes might not be expressed constitutively (859). 
Several earlier studies reported that antibodies are not protective against 
candidiasis but in the 1960s, however, reports indicated that antibodies against C. 
albicans might be protective against experimental disseminated candidiasis (983).  
Evidence from experimental settings of rodent models suggests that antibodies 
against specific virulence factors of the fungus play an important role in protection. 
This indicates that antibodies and cell-mediated immune responses are both active 
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players in the host-fungus relationship and can contribute to the host protection 
against yeast (1134). 
In a study by the group of Weissenbacher et al., 184 symptomatic patients with 
CRRVC and 46 healthy controls were investigated for detection of vaginal Candida 
IgG and IgA antibodies and vaginal Candida in culture or PCR (Anton G, personal 
communication). In the patient group, 33% were Candida-positive in PCR or 
culture and in the control group 0%. Healthy controls were mostly negative for 
vaginal Candida-specific IgA and IgG (96% and 85%, respectively). Of the CRRVC 
patients with Candida, 70% were positive for Candida-IgG and 43% were positive 
for Candida-IgA. Therefore, the question arises if Candida-IgG is probably a better 
marker for Candida-positive CRRVC. 
 
Finally, it is important to consider the extracellular nature of the infectious agent, 
and its possession of several virulence traits, many of which are in principle 
inhibitable by suitable antibodies. Indeed, protective antibodies against well-defined 
virulence factors of the fungus have been reported. Furthermore, anti-idiotypic 
killer antibodies (KAbs) have been described that carry the internal image of a yeast 
killer toxin (KT) from a selected strain of the yeast Pichia anomala (PaKT), thus 
functionally mimicking it (859). KTs are glycosylated proteins secreted by self-
immune yeasts, which exert a microbicidal activity against sensitive 
microorganisms characterized by the presence of specific KT cell wall receptors 
(KTR). 
On the basis of previous observations, and through the exploitation of new 
molecular technologies, three different possible immunotherapeutic strategies have 
been developed based on protective antibodies, KAbs and therapeutic vaccines, as 
discussed below. 
d) Effect of reproductive hormones  
Use of oral contraceptives and hormone replacement therapy were shown to 
predispose women for VCC (1324). Clinical observations show that VVC most often 
occurs in women during the luteal phase of the menstrual cycle, when estrogen and 
progesterone levels are elevated (654). In contrast, premenarchal and 
postmenopausal women who do not receive hormone replacement therapy, rarely 
suffer from VVC (1323).  
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Estrogen and progesterone have been shown to inhibit aspects of both innate and 
acquired immunity at the systemic or local level, including Candida-specific human 
peripheral blood lymphocyte responses (654) or neutrophil anti-Candida activity 
(1024) in vitro. Furthermore, in vitro Candida-specific lymphocyte responses were 
reduced in women during the luteal phase of the menstrual cycle concomitant with 
increased serum-induced germination of C. albicans (654). 
 
Although estrogen-dependent experimental rodent models of C. albicans vaginal 
infection are used for many applications, the role of reproductive hormones and 
their limits in the acquisition of vaginal candidiasis remain unclear.  
A study by Fidel and colleagues examined the effects of estrogen and progesterone 
on several aspects of an experimental infection together with relative cell-mediated 
immune responses (401). Results showed that near-physiologic concentrations of 
estrogen were as capable as supraphysiologic concentrations of sustaining 
experimental infections induced by a wide range of C. albicans inocula.  
Additionally, it was found that a persistent infection with high rates of infection 
could equally occur if estrogen treatments were initiated several days before or after 
inoculation (401). The requirement for a maintained state of pseudoestrus was 
confirmed by the rapid clearance of the infection when the estrogen treatments were 
removed. Finally, estrogen was found to reduce the ability of vaginal ECs to inhibit 
the growth of C. albicans. In contrast to estrogen, progesterone treatment alone 
could not support an experimental vaginal infection for any significant period of 
time (401). In fact, vaginal fungal burdens in progesterone-treated animals were 
lower than those in untreated animals.  
This may have been due to a lack of or reduced influence by endogenous estrogen. 
Interestingly, progesterone had no effect on the titers of C. albicans in the vagina, 
rates of infection, or chronicity of the vaginal infection in the presence of estrogen. 
Furthermore, estrogen and progesterone treatment of mice had no effect on 
Candida-specific systemic cell-mediated immunity, i.e. in vitro proliferation of lymph 
node cells in response to Candida antigens. 
 
Taken together, estrogen is predicted to be the primary factor in the susceptibility 
to vaginitis during the luteal phase of the menstrual cycle, despite higher 
concentrations of progesterone than estrogen during that time (401). This is also 
consistent with the lack of prevalence of Candida vaginitis in women taking 
progesterone contraceptives. On the other hand, one may speculate that it is the 
peak levels of estrogen during the short ovulatory phase of the menstrual cycle that 
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precipitate the vaginal infection and that the symptomatic infection does not fully 
present itself until the luteal phase. Similarly, one would predict that despite high 
levels of progesterone during pregnancy, the high incidence of vaginitis in pregnant 
women is more likely due to estrogen. 
e) Immunotherapeutic strategies 
The first immunotherapeutic strategy is based on protective antibodies against 
immunodominant candidal antigens. Many candidal virulence factors such as 
adhesins and the enzymes aspartyl proteinases can stimulate the immune system 
to generate an immune response (169). Several studies tested antibodies against 
specific candidal proteins which were protective against natural and experimental 
disseminated candidiasis. Protective antibodies against disseminated candidiasis 
and vaginal infection were elicited by a vaccine composed of liposome-encapsulated 
C. albicans surface MANNAN (503). An IgM monoclonal antibody (mAb) specific for 
β-1,2-mannotriose, an acid-labile component of the cell wall 
phosphomannoproteins acting as an adhesin, protected normal inbred, outbred, 
severe combined immunodeficient and neutropenic mice against disseminated or 
vaginal experimental candidiasis (503). 
Passive transfer of vaginal fluids from animals clearing a primary C. albicans 
infection conferred significant protection against vaginitis in naïve rats. This 
protection was associated with the presence of both anti-mannan and anti-Sap 
antibodies, mostly of the IgG and IgA isotypes (183). However, the mechanisms of 
protection by these antibodies against Candida infection are still unclear.  
 
The second immunotherapeutic approach is based on KAbs. KAbs exert a 
remarkable candidacidal activity in vitro and confer significant immunoprotection 
against infection in systemic and mucosal animal models of candidiasis. KAbs 
functionally mimic PaKT by interacting with a putative PaKT receptor expressed on 
the yeast cell wall. The mimicry of the yeast killer phenomenon through the Id 
network has allowed the development of exclusive models of Id vaccination and 
anti-Id therapy, which could represent new approaches to the control of systemic 
and mucosal candidiasis (1135). Direct use of the toxic and instable PaKT is not 
possible but a marked systemic or mucosal immunoprotection mediated by KAbs 
has been induced by parenteral or vaginal Id vaccination using a PaKT-neutralizing 
mAb in mice and in rats (1136). 
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An active immunization with immunogenic and protective microbial antigens 
represents a hallmark strategy to prevent or fight infectious diseases. To date, no 
effective prophylactic or therapeutic vaccine has been developed against 
candidiasis, although studies are in progress in animal models (312). Because of 
the antigenic complexity of Candida, it has been difficult to define the putative 
protective antigens to be considered for an effective vaccine. Moreover, the human 
commensal nature of the fungus, and the consequent natural ‘immunization’ 
against it, poses several obstacles for the feasibility of a prophylactic vaccine. More 
realistic might be the generation of therapeutic vaccines.  
 
In a study by Han et al. it was reported that immunization with the L-mannan 
vaccine in mice induced an increased resistance to VVC (503). A recombinant form 
of the mannoprotein which was identified as the major target of T cell response in 
humans is investigated as active immunogen in mice and rats (771).  
Recently, Elahi and colleagues reported of a therapeutic vaccine in a murine model 
of oral candidiasis (360). They have used this model to identify regulatory and 
effector molecules of T cell activation as parameters of induced immunity. Oral but 
not systemic immunization with the blastospore yeast form induced clinical 
immunity with a shift in parameters of cytokine response characterised by an early 
and sustained production of both IFN-γ and IL-4 from antigen-stimulated cervical 
node T lymphocytes. 
As studies have demonstrated the importance of the Th1 cytokine pattern in the 
anti-Candida immune response and in the vaginal mucosa, suggesting a possible 
beneficial role of cytokine-anti-cytokine therapeutic strategies, a role for some 
cytokines typical of a Th1 response, has been considered. However, no evidence for 
a beneficial outcome of a pure cytokine or anti-cytokine treatment has yet been 
reported. Some antifungals, such as amphothericin B, have direct 
immunomodulatory properties (1353), suggesting that a combination of 
chemotherapy with cytokines and antibodies might have great potential for the 
treatment of RVVC. 
4. Trichomoniasis 
Vaginal infections caused by the parasitic protozoan Trichomonas vaginalis are 
among the most common conditions found in women attending reproductive health 
facilities. The prevalence of trichomoniasis in young women attending American 
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STD clinics for routine care typically approaches 25% up to 48% in certain 
populations, for example African American women (68, 1328).  
The WHO has estimated that this infection with 170 million cases per year accounts 
for almost half of all curable STDs worldwide (186). Based on WHO estimates, it is 
one of the two most common STDs in the United States with approximately 7.4 
million new cases in 2000 (186, 1487).  
Symptoms of trichomoniasis in women include vaginal discharge, odour, irritation, 
and pruritus; however, about half of all women infected with T vaginalis are 
asymptomatic (1113). The pathogenesis of T. vaginalis is not well understood, also 
in respect to factors causing symptomatic versus asymptomatic infections in 
women. The extent of the inflammatory response to the parasite may determine the 
severity of the symptoms.  
 
Although survival on fomites is documented, the organism is thought to be 
transmitted almost exclusively by sexual activity. Epidemiologically, T. vaginalis 
infections are also commonly associated with other STDs, particularly BV (322, 
613). Unlike other STDs, which have a higher prevalence among adolescents and 
young adults, the rates of trichomoniasis are more evenly distributed among 
sexually active women of all age groups, further strengthening its potential utility as 
a sensitive marker for high-risk sexual behavior. 
 
Acquisition of HIV has been associated with trichomoniasis in several African 
studies, possibly as a result of local inflammation often caused by the parasite. 
Leroy et al. found a significant difference between the prevalence of trichomoniasis 
among a cohort of HIV infected and non-infected pregnant women in Rwanda, with 
20.2% versus 10.9%, respectively (806). In a prospective study by Laga et al., 
incident trichomoniasis was significantly associated with HIV seroconversion among 
a cohort of women in Zaire in multivariate analysis (774). Buve et al. reported 
significantly higher rates of vaginal trichomoniasis among women residing in high 
HIV prevalence cities than in low HIV prevalence cities and suggested that 
trichomoniasis may be an important factor in determining rates of HIV (165). 
Moreover, trichomoniasis is associated with adverse pregnancy outcome, such as 
preterm birth and premature rupture of placental membranes, which should be 
further elucidated in the chapter on infections and preterm birth. 
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a) Innate immune responses in trichomoniasis 
Current understanding of immunity to T. vaginalis has come largely from 
observations of responses in human patients and experimentation using in vitro 
models and animal models of the related species, T. foetus.  
The host immune responses to T.vaginalis infection are reported to be usually low 
and variable. Moreover, natural infection seems to produce immunity that is only 
partially protective, since the reinfection rate of patients can be 36% on follow-up 
(1021). Factors that influence the host inflammatory response are not well 
understood but may include hormonal levels, the coexisting vaginal flora, and the 
strain and relative concentration of the organisms present in the vagina. 
(1) TLR 
While it is clear that T. vaginalis infection can induce an inflammatory response in 
the female genital tract, the type of receptors involved in host recognition of the 
pathogen has not yet been established.  
Zariffard et al. recently determined if infection with T. vaginalis activates cells 
through TLR4 (1572). Genital tract secretions from infected women stimulated TNF-
α production by cells with functional TLR4 but significantly less by cells that are 
unresponsive to TLR4 ligands. Secretions collected after clearance of infection also 
induced significantly lower responses by cells with functional TLR4. TNF-α 
responses were not reduced by Polymyxin B and did not correlate with β2-defensin 
levels, indicating that stimulation of cells was not through LPS or β2-defensin.  
These studies show that T. vaginalis infection results in the appearance of 
substances in the genital tract that stimulate cells through TLR4, suggesting a 
mechanism for the inflammation caused by this infection (1572). 
(2) The role of neutrophils 
Buchvald et al. reported that vaginal inflammatory leukocytes in 47 patients with 
urogenital trichomoniasis were almost exclusively PMNs, and their concentration 
was positively correlated with the number of trichomonads in vaginal exsudate 
(152). Also patients with a clinical picture of severe mucosal inflammation had 
significantly higher vaginal exsudate leukocyte concentrations and viability than 
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those without inflammatory signs. Groups of PMNs surrounding large trichomonads 
are able to fragment them and phagocytose the pieces (1186).  
 
Little is known about the exact mechanism of how neutrophils accumulate or 
mediate the initial inflammatory response after acute T. vaginalis infection. The 
parasite was shown to secrete proteins, for example excretory-secretory product 
(ESP), that are chemotactic to PMNs (1077).  
It is also rationally presumed that leukocyte-derived chemoattractants may be 
generated during the infection. Chemoattractants which are reported to be involved 
in the inflammatory response include leukotriene B4 and IL-8. 
Leukotriene B4 can be found in high levels in vaginal discharges of symptomatic 
patients (1286) which could be due to a release from T. vaginalis or from 
neutrophils induced by the interaction of trichomonads and humoral immunity.  
In a study by Shaio et al. results indicated that humoral immunity could further 
promote the interaction of neutrophils with T. vaginalis and augment the 
inflammatory response through the amplification of leukotriene B4 production 
(1285). Specific IgG augmented leukotriene B4 production by neutrophils, possibly 
mediated by Fcγ receptor.  
(3) Complement  
Of the known chemoattractants involved in the inflammatory response of T. 
vaginalis infection, complement components have been documented to play a role 
in the activation of neutrophils as well (1186).  
Shaio et al. reported that human neutrophils in combination with serum were able 
to kill T. vaginalis (1284). This serum was shown to have specific IgG for T. vaginalis 
which facilitates neutrophil killing by an IgG-enhanced classical component 
pathway. However, also antibody-independent alternative complement pathway 
activation provided C3 for T. vaginalis to facilitate neutrophil killing (1284).   
The importance of the alternative complement pathway in host defense against T. 
vaginalis was investigated in vitro (185). Kinetic studies using immunofixation 
following electrophoresis showed that both a strongly and weakly virulent strain of 
T. vaginalis activated murine serum C3.  
In vivo studies on mice showed that the presence of C5 is also a significant factor in 
innate host resistance to primary infection with a strongly, but not a weakly 
virulent trichomonad strain (185). Also the previous findings of Rein et al. and 
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Demes et al. suggested a role for the alternative pathway activation of complement 
and the trichomonocidal effect of menstrual blood complement (1186, 320).  
(4) Nitric oxide and RNI 
It has become increasingly clear that the oxidant-antioxidant balance is essential 
for immune cell function. Neutrophil and macrophage phagocytosis can also 
stimulate other cellular processes including the respiratory burst whereby 
increased cellular oxygen uptake results in the production of antimicrobial agents, 
killing T. vaginalis by O2-dependent mechanisms (724).  
Rein et al. detected that PMNs were able to kill T. vaginalis in vitro under aerobic 
conditions which speaks for the importance of oxidative microbicidal systems 
(1186).  
The aim of a study by Malla et al. was therefore to assess the RNI production in 
animals experimentally infected with T. vaginalis isolates from symptomatic and 
asymptomatic women (865). The mean concentration of RNI in vaginal tissue of 
mice infected with isolates from symtomatic women was significantly higher than 
that of vaginal tissue of mice infected with isolates from asymptomatic women while 
it was less in the vaginal washes and plasma of mice infected with isolates from 
symptomatic women compared to those infected with isolates from asymptomatic 
women. This may be due to different macrophage populations with different 
functional capabilities (865). However, this would suggest a possible role for RNI 
production in establishing the infection. 
b) Specific immunity in trichomoniasis 
(1) Antibodies 
T. vaginalis infection in humans results in parasite-specific antibodies which can be 
found in the serum and vaginal secretions of infected individuals.  
In earlier studies, Cogne et al. detected IgA antibodies in serum of infected patients 
correlating to their clinical status (242). The presence of systemic IgG antibodies of 
all subclasses may be related to a local response of IgG-secreting cells but may also 
represent a systemic response to released antigen.  
Wos et al. found IgG, IgM, and IgA antibodies in serum of patients (1536). Street et 
al. detected serum IgG and IgM antibodies and IgG and IgA antibodies in CVS 
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(1363). Specific antibody responses to T. vaginalis antigens in serum and specific 
local antibodies, both IgG and IgA, have also been identified in women by Alderete 
and colleagues (21, 22). 
 
The experimental mouse model of Paintlia et al. showed a significant increase in 
serum and vaginal IgA levels in mice infected with T. vaginalis isolates from 
asymptomatic women compared with mice infected with isolates from symptomatic 
women and control mice (1061). A further significant response was also observed in 
group A and group B mice as compared with the control group. This suggests that 
specific IgA antibodies might help to protect asymptomatic individuals from severe 
infection. IgA antibodies may also act as a first line of defense for immune exclusion 
of the parasite at the mucosal surface. 
 
The latest study by Yadav et al. reports anti-Trichomonas IgG, IgM, IgA and IgG 
subclass antibody responses on different post-infection days in serum and vaginal 
washes of mice infected intravaginally with T. vaginalis isolates from 15 
symptomatic and 15 asymptomatic women (1548).  
A significant increase in parasite load was observed on the 14th post-infection day 
(p.i.d.) in mice inoculated with T. vaginalis isolates from symptomatic women as 
compared to asymptomatic women, followed by reduction until the 28th p.i.d. A 
significant increase in specific IgG and in particular IgG1 and IgM responses was 
observed on the 14th p.i.d. in serum and vaginal washes of mice infected with T. 
vaginalis isolates from symptomatic women as compared to asymptomatic women. 
Significant increases in specific IgG, IgM and IgG1 responses was observed on the 
14th p.i.d. in serum samples as compared with vaginal washes of mice infected with 
T. vaginalis isolates from symptomatic and asymptomatic women, whereas no 
significant difference was observed in IgA, IgG2a, IgG2b and IgG3 antibody 
responses.  
The study indicates that specific IgG, particularly IgG1 and IgM, may be playing a 
role in establishing symptomatic infection (1548). 
 
Four antigenic surface molecules have also been implicated in the adhesion of T. 
vaginalis to vaginal ECs; their expression is being upregulated during attachment to 
host cells (53). Antibodies to these molecules protected target cells from parasite-
mediated cytotoxicity (52), suggesting that anti-adhesion immune responses could 
be important in in vivo protection against the pathogenic effects of T. vaginalis.  
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Alternatively, antibodies specific for soluble parasite molecules such as proteases, 
cytoactive molecules, or lytic factors such as phospholipases may also be protective 
(1269). However, proof of the protective nature of antibodies in eliminating infection 
or limiting pathogenesis in vivo has been hampered by lack of an adequate 
experimental animal model for vaginal infection studies.  
(2) T lymphocytes 
The study of Paintlia et al. revealed a significant increase in the population of total 
T cells, as well as CD4+ T cells in mice infected with isolates from asymptomatic 
women compared with mice infected with symptomatic isolates (1061). However, no 
significant difference was observed in CD8+ cells, whereas a significant difference 
between the two groups was noticed in the vital ratio of CD4+/CD8+. Also a 
significant increase in NK cells was observed in animals infected with isolates from 
asymptomatic women compared with mice infected with isolates from symptomatic 
women and control uninfected mice, indicating that NK cells might be playing a role 
in the pathogenesis of this disease.  
c) The role of cytokines 
The cytokine profile in vaginal cervical tissues of mice infected intravaginally with T. 
vaginalis isolates from 15 symptomatic and 15 asymptomatic women was subject of 
a study by Paintlia et al.  
They reported that the concentrations of IFN-γ and TNF-α in vaginal washes of mice 
infected with isolates from symptomatic and asymptomatic women were 
significantly higher compared to uninfected mice (1061). Between the two infected 
groups, IFN and TNF levels were higher in the group of mice infected with isolates of 
asymptomatic women.  
Significantly higher IL-2 production was observed in mice infected with isolates 
from asymptomatic women compared mice infected with isolates from symptomatic 
women or the uninfected control group. IL-4 levels were found to be significantly 
higher when results from both groups infected with isolates were compared with 
controls (1061). 
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IL-8 is found in high levels in vaginal discharges of symptomatic trichomoniasis 
patients. This cytokine has been shown to enhance antimicrobial activities of 
neutrophils by inducing neutrophil degranulation and respiratory burst.  
Shaio et al. investigated the possible role of IL-8 and showed that membrane 
components of T. vaginalis induced blood monocytes to produce large dose- and 
time-dependent amounts of this cytokine (1287). Amounts of IL-8 were higher than 
those induced by live trichomonads or ESP. Neutrophil chemotaxis was inhibited by 
a neutralizing mAb directed against IL-8 itself or partly decreased by a mAb directed 
against TNF-α, suggesting also a role for TNF-α in the release of IL-8 (1287).  
In another study of Ryu et al. it was revealed that T. vaginalis can induce IL-8 
production in neutrophils which may be mediated through the NF-κB and mitogen-
activated protein (MAP) kinase signaling pathways (1232). Live T. vaginalis 
produced higher amounts of IL-8 than ESP or T. vaginalis lysate. Moreover, GRO-α, 
another chemoattractant for PMNs, was also produced by neutrophils in response 
to T. vaginalis activation (1232). 
NF-κB is implicated in the regulation of inflammatory responses by inducing 
cytokines such as IL-12 and TNF-α and activating effector mocules of innate 
immunity including macrophages.  
In a study by Chang et al., it was investigated whether the inflammatory response 
of macrophages elicited by T. vaginalis infection required NF-κB activation (198). T. 
vaginalis induced a rapid activation of NF-κB in RAW264.7 macrophage during the 
early stage of adhesion which was not maintained but led to inhibition of the 
production of the proinflammatory cytokines. Furthermore, T. vaginalis infection 
induced a state of nonresponsiveness to subsequent stimulation with bacterial LPS 
which suggest that T. vaginalis induces an inhibitory mechanism that prevents or 
delays the immune response of host cells, thereby leading to their apoptotic cell 
death (198). 
d) Vaccination strategies 
Systemic immunization of cows with a purified surface antigen of T. foetus induced 
serum and vaginal IgG and IgA antibodies, and intravaginal boosting enhanced the 
genital IgA response to infectious challenge (253). IgG and IgA antibodies in vaginal 
secretions were associated with protection or faster clearance of infection. 
Interestingly, lymphoid aggregates in vagina and uterus in response to infectious 
challenge were demonstrated in control and intravaginally immunized animals, 
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which suggestes development of mucosal inductive sites for local IgA responses 
(253). 
Immunity has been difficult to produce in vivo, since in humans, repeated infections 
with T. vaginalis do not confer immune protection (1021). Despite this, antibodies 
can be found in the serum and vaginal secretions of infected individuals and a cell-
mediated immune response is also invoked. 
Older experimental work using subcutaneous or intraperitoneal injections in mice 
suggested that antibodies could be protective, and more recent experiments with 
immunized mice challenged by intravaginal inoculation indeed indicate some 
protection (2).  
Abraham et al. were able to induce immunity to T. vaginalis in the mouse model, 
which may lead to the development of a vaccine. Whole, live trichomonads at 
different concentrations were injected subcutaneously into mice, first with Freund`s 
complete adjuvant and then in a booster dose with the trichomonads and Freund`s 
incomplete adjuvant. The mice were given estrogen and inoculated intravaginally 
with Lactobacillus acidophilus to simulate the conditions in the human vagina; they 
were then inoculated intravaginally with T. vaginalis. Immunized mice had 
significantly less intravaginal infection and had elevated antibody levels in the 
serum and vagina compared with naïve control groups (2). Mice that had been 
infected vaginally, treated, and reinfected vaginally were not protected and did not 
mount an immune response which suggests that antigen presentation may be 
crucial for developing protective immunity.  
To date, only one vaccine, the Solco Trichovac vaccine, had been produced against 
T. vaginalis. It was prepared from inactive lactobacilli and was thought to work by 
inducing antibodies to abnormal lactobacilli and T. vaginalis without adversely 
affecting the growth of normal lactobacilli in the vagina (464). However, a lack of 
antigenic similarity between this vaccine and T. vaginalis was shown, which makes 
this cross-reaction hypothesis unlikely.  
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D. Immunology in reproductive medicine 
1. Immunology of pregnancy 
Pregnancy can be described as the symbiosis of two allogeneic individuals which 
live in intimate contact. Although the fetus provides a panel of MHC antigens 
derived from both its mother and father it is not rejected by lymphocytes from its 
mother. The maternal immune system reacts towards the foreign tissue, but it 
tolerates, supports and regulates its development instead of rejecting it. The 
formation of the placenta is efficiently controlled ensuring development of the 
embryo and fetus.  
In the course of the discovery of the MHC and it role in transplantation Medawar 
was the first to compare the immunologically privileged nature of the fetus with an 
allograft in 1953 (908). He already proposed some ideas such as the anatomic 
separation of mother and fetus, antigenic immaturity of the fetus, and maternal 
immunosuppression all of which has now been investigated and partly disapproved 
over the years. However, maternal tolerance of an allogenic fetus is a paradox that 
still remains a central theme in the field of reproductive immunology. 
 
There are many factors influencing this system which can lead to imbalances and 
pregnancy disorders such as infertility and abortion. Therefore it is essential to 
investigate the immunoregulatory processes of pregnancy to prevent and treat these 
disorders. Knowledge of the structural basis of the placenta and the immunobiology 
of the deciduas and of trophoblasts are important issues to discuss before coming 
to the disturbances in this system including preeclampsia, preterm labor or 
pregnancy loss.  
a) Immunology of fertilization 
An impending pregnancy must prepare the maternal environment to accept a 
partially foreign body, a semi-allograft, which occurs in four distinct phases (79). 
The first is the pre-fertilization period in which the egg is surrounded by the 
follicular fluid with its immunosuppressive activity (184). This may facilitate the 
following fertilization process as well as embryo development by minimizing the 
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maternal immune response to the sperm, which has been shown to express foreign 
antigens shortly after fertilization. 
 
The second phase comprises fertilization and embryo development until the Morula 
stage in which the sperm penetrates the egg and becomes immunologically invisible 
for the maternal system (79). No maternal immune reaction occurs during the 
process of egg and spermhead fusion, for as long as the egg surface membrane does 
not change its characteristics. Once this happens, the fertilized egg is rapidly 
surrounded by the zona pellucida, which wards off maternal immune cells. Further 
protection against these cells is provided by maternal cumulus cells for the first 
days after fertilization.  
 
The third phase consists of the blastocyst and pre-implantation trophoblast 
polarization after the first embryonic cell divisions when the differentiation into the 
maternal embryoblast and the paternal trophoblast starts (79). The surrounding 
zona pellucida continues to provide a major protection against the maternal 
immune system so that the development of maternal immune tolerance to the 
embryo does not take place until implantation phase, when direct embryo/maternal 
contact occurs in the uterus.  
From the immunological point of view, this is the most vulnerable time for the 
embryo which is now exposed to maternal endometrial immune cells and cytokines. 
The uterus is designed to prevent implantation except during a narrow implantation 
window in which embryonic signals help promote endometrial priming and 
maternal immune tolerance. The embryo likely plays the significant role in 
conditioning the maternal environment towards immune tolerance of pregnancy. 
The arising questions are how this maternal immune tolerance takes place, what 
embryo-derived elements are involved and where, if these mechanisms are common 
to all mammals, and how early embryo tolerance can be detected in the maternal 
organism.  
 
The developing fetus is not directly exposed to maternal blood except in the 
placenta as the newly formed organ at the fetomaternal interface. The placenta 
plays the key role in maintenance of local tolerance and allows the mother to accept 
the embryo during pregnancy. As the fetal side of the placenta, the villous 
trophoblast forms a continous barrier which physically separates the mother from 
the fetus but is exposed to maternal immunocompetent cells present in the 
circulating blood of the intervillous space. Syncytiotrophoblast and villous 
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cytotrophoblast can also be found in maternal circulation and lung providing 
additional antigenic stimuli for the mother. Trophoblast is also present in the 
decidua where they contribute to further stimulating the mother with fetal antigens. 
This physiological condition of close physical contact between maternal immune 
system and fetal cells with paternal antigens is unique and normally does not 
trigger a maternal immune reaction that would lead to fetal death. 
 
Earlier studies suggest that shortly after fertilization, certain changes that favor 
immune tolerance take place in the maternal environment, possibly due to early 
pregnancy factor (EPF) and platelet activating factor (PAF) (976, 1035).  
EPF is an immunosuppressive factor with growth-regulatory properties which 
interacts with T lymphocytes and suppresses cellular immune responses and the 
early expression of cell surface membrane IgG (1156). It was first described more 
than 20 years ago as a very early serum marker of fertilization (975) and is now 
known to be essential for the initiation and maintenance of pregnancy, displays the 
regulated production and pleiotropic function typical of many cytokines and growth 
factors.  
On the one hand, it may prevent sperm penetration and maintain a successful 
pregnancy but on the other hand, its immunosuppressive activity might cause some 
adverse impact. Studies have proved that EPF activity is detectable in serum (506), 
amniotic fluid (1585) and cervical mucus (218) of pregnant women. Therefore, EPF 
may provide wide clinical applications, such as testing the occurrence of 
fertilization in vivo, predicting the prognosis of pregnancy, and evaluating embryo 
quality in the in vitro fertilization-embryo transfer treatment (218).  
 
As these factors have since been found to be not specific to pregnancy and are 
found in a non-pregnant state as well, these factors do not appear to be critical in 
initiating maternal recognition of the embryo. Barnea postulated that unique 
embryo-derived compounds are involved in creating the unique maternal 
immunological response to the embryo (79).  
Shortly after fertilization, the viable embryo starts to emit signals that promote 
maternal recognition of pregnancy and immune tolerance. Recent studies have 
found that the cumulus cells surrounding the embryo might be able to serve as a 
relay system, because they contain active immune cells that secrete cytokines 
(1118). This proximity between the putative embryo-derived compounds and the 
maternal immune system would permit rapid diffusion of embryonic signals leading 
initially to a local immune response, followed by a systemic maternal immune 
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recognition (79). This conclusion is based on the observation that pre-implantation 
factor (PIF) peptide expression modulates but do not suppresses the maternal 
immune system, allowing the mother to maintain her ability to fight diseases.  
b) Immunobiology of the trophoblast 
As already described, the fetal-placental unit initially is a semi-allograft due to the 
paternal genetic contributions. Subsequently, there is a maternal immune reaction 
to the allogeneic pregnancy. The constituents of the maternal immune reaction to 
the allogeneic stimulus are not different from any other immune reaction and the 
allogeneic conceptus, the trophoblast, is like all other allogeneic tissue grafts.  
 
However, trophoblast is an unusual cell type (1430). It is extra-embryonic and has 
several distinctive properties such as the expression of endogenous retrovirus 
products, oncofetal proteins, and imprinted genes (953). In addition, the DNA in 
trophoblast is relatively unmethylated. All these properties could have some 
relevance in interaction with the maternal immune system (1430).  
The special characteristic, however, that distinguishes the trophoblast from other 
tissues is its ability to eliminate abortogenic maternal B cell and T cell responses. 
The trophoblast induces an immunmodulation and thus actively defends itself from 
the maternal immune attack. The presence of progesterone, and its interaction with 
progesterone receptors at the decidual level, appears to play a major role in this 
defense strategy (1159). 
 
Indeed, trophoblasts can influence the immune system during pregnancy through 
their expression of soluble and cell surface-associated immunomodulatory 
molecules.  
For example, trophoblasts secrete the indoleamine 2,3-dioxygenase (IDO), which 
limits the availability of the essential amino acid tryptophan, consequently limiting 
lymphocyte proliferation (1270). IDO is an enzyme from the tryptophan catabolic 
pathway that depletes tryptophan in local tissue environments, thereby suppressing 
proliferation of cells in the vicinity (914). LPS and the inflammatory cytokines IL-1 
and TNF-α act synergistically with IFN-γ to further increase IDO expression in 
human DCs (586) while antiinflammatory cytokines IL-4, IL-10 and TGF-β inhibit 
IDO expression (852). 
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It has been shown experimentally that cells at the maternal-fetal interface 
expressing IDO may establish local microenvironments in which reduced 
tryptophan concentration precludes T cell proliferation, thus protecting the 
conceptus from rejection (988).  
 
Clark et al. also hypothesized that regulation of the expression of CD200 plays an 
immunoregulatory role at the maternal-fetal interface (235). CD200 is another DC-
associated molecule which has been shown to contribute to the successful outcome 
of organ and tissue allografts in mice (466). CD200 is upregulated in rodent 
transplantation models where successful inhibition of rejection is accomplished, 
and is believed to signal immunosuppression following engagement of a receptor, 
CD200R. The investigation of CD200 expression in implantation sites of different 
strains of mice resulted in an elevated the abortion rate in mice due to anti-CD200, 
and infusion of a CD200 immunoadhesin reduced the abortion rate (466). CD200 
mRNA expression was demonstrated on fetal trophoblast and certain areas of 
decidua (235). Reduction in CD200 has proven essential for fgl2 prothrombinase 
triggering of abortions in the mouse model, but the mechanism behind it remain 
unclear.   
 
There is growing evidence that trophoblast cells are able to recognize and respond 
to pathogens through the expression of TLRs (4). Normal term placental tissue has 
been shown to express TLR1-10 at the RNA level (1571). Holmlund et al. 
demonstrated that term syncytiotrophoblast and intermediate trophoblast cells 
express TL-2 and TLR4 at the protein level (561). In contrast, Kumazaki et al. 
found the TLR4-positive placental cells to be term extravillous and intermediate 
trophoblasts (754). Abrahams et al. observed that TLR2 and TLR4 are highly 
expressed in first trimester placental tissues (3). The first trimester trophoblast cell 
populations expressing these receptors are the villous cytotrophoblast and 
extravillous trophoblast cells while first trimester syncytiotrophoblast cells do not 
express these TLR and this suggests that the placenta serves as a highly specialized 
barrier, protecting the developing fetus against infection.  
 
These findings suggest that trophoblast cells may interact with microorganisms 
present at the implantation site and may be able to initiate an immune response. 
The trophoblast may thus function as an active member of the innate immune 
system, as it was once proposed by Guleria and Pollard (489). 
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Trophoblast cells from term placental explants have been demonstrated to produce 
IL-6 and IL-8 following ligation of TLR2 or TLR4 by LPS (561). Activation of TLR4 by 
LPS triggers first trimester cytotrophoblast and villous trophoblast cells to generate 
a classical TLR response, characterized by the increased production of both pro- 
and antiinflammatory cytokines (3).  
 
Remarkably, in contrast to most other somatic tissues, invasive trophoblast cells 
lack not only the classical MHC class I but also MHC class II, which might be 
important in avoiding the attack of maternal T cell-mediated rejection (1158). 
Among the polymorphic classical class I molecules they only express HLA-C and 
additionally, the nonclassical HLA-E, HLA-F and HLA-G class I molecules (698). 
There also have been detected membrane-bound HLA-G1 and soluble HLA-G1 and -
G2 in extravillous trophoblast (965). 
 
Increasing evidence suggests that placentally-expressed MHC molecules may play 
an important role in modulating the innate branch of the maternal immune system. 
These molecules have several characteristics, which suggests that antigen 
presentation is not their primary function, including limited tissue expression, 
relatively short half-life at the cell surface, and limited genetic polymorphism (577).  
It is assumed that the non-classical HLA-G class I may contribute to the 
immunological mechanisms that protect the fetus against maternal alloimmune 
response (1143). HLA-G expression may promote allograft survival (1219). HLA-G 
was found to inhibit cytotoxicity by NK cells via HLA-E (696) and is thought to be 
important when considering the presence of atypical CD16+ NK cells in successful 
pregnancy and increased presence of classical CD16+ NK cells in pregnancy failure 
(230). Recent evidence suggests that soluble HLA-G1 is immunosuppressive and 
induces apoptosis of activated CD8+ T cells and downmodulates CD4+ T cell 
proliferation (794). Thus, soluble HLA-G1 could also play a role during 
implantation. 
 
In addition, the trophoblast also protects itself by expression of FasL (582). In mice, 
FasL is also expressed on uterine glandular ECs and decidual cells in placental 
trophoblasts. Predominant expression of FasL in mice is found in the uterus which 
shifts to the placenta at later gestation days during pregnancy (582). Recently, FasL 
expression was also reported in first trimester and term human placental villi (500). 
Thus, expression sites of FasL are obviously positioned to induce apoptosis in 
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maternal Fas positive immune cells, such as NK and T cells, at the fetomaternal 
interface (582). 
Ohshima and colleagues studied the relationship between FasL expression and NK 
cell infiltration in human placenta during early pregnancy (1042). The findings 
suggested that a reduction in FasL expression seems to be closely associated with 
activation and infiltration of maternal NK cells and destruction of uterine glands, 
resulting in rejection of the foetus (1042). Thus, expression of FasL in the uterine 
glands and cytotrophoblasts may play a role in the downregulation of the maternal 
immune response, thereby maintaining pregnancy at early stage. 
c) Immunology at the fetomaternal interface 
(1) Antigen-presenting cells 
APCs are often regarded as the responsible inductors of maternal tolerance against 
fetal antigens. In their function of presenting antigens to lymphocytes, it could be 
assumed that they would be ideally located at the fetomaternal interface to present 
fetal antigens in a tolerance-inducing way (660).  
 
DCs 
Especially, the presence of DCs in the maternal decidua has pointed to a biologic 
role of APCs in a maternal-fetal interaction. DCs of the pregnant human uterine 
mucosa are likely to regulate immune responses to both uterine infections and 
placental trophoblast cells (642).  
In studies on pregnant rat and mouse uteri the first hints for a possible role of 
APCs in creating a local environment prohibitive of maternal lymphocyte 
stimulation against the embryo came up.  
 
Macrophages from the rat uterus were shown to be depleted shortly after 
implantation (1385) and Hunt observed that macrophages from pregnant mouse 
uteri are immunosuppressive (579). Bulmer et al. found a high population of early 
pregnancy human decidual cells to be HLA-DR+ and concluded that these HLA-DR+ 
cells mainly belong to the macrophages (158). Later he described that macrophages 
increase premenstrually and make up to 35% of the decidual leukocytes around 
implantation (157). In their study on HLA expression by human decidual cells 
throughout gestation Lessin et al. found that 21-32% of maternal decidual cells 
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were positive for HLA class I and II molecules (808). The class II+ cells were 
identified as macrophages by the antibody staining. Mizuno et al. showed that 
isolated decidual macrophages are able to present soluble antigens in an MHC-
restricted manner but also possess some some suppressive activity for the maternal 
immune responses (952).  
However, another study showed that cultured human decidual stromal cells 
express HLA-DR and the activation markers CD80 and CD86 but not the classical 
macrophage marker CD14 and are able to stimulate allogeneic T cells (1047). In 
recent years, classical mature CD40+ CD45+ CD83+ DCs similar to those of other 
mucosal surfaces were demonstrated in human endometrium and early pregnancy 
decidua (659). CD83 has been proved as a suitable and selective cell-surface 
marker for mDCs.  
 
Also the immature precursors of decidual DCs, DC-SIGN positive HLA-DR+ decidual 
cells which also stained for CD14 and CD68 as classical macrophage markers, were 
detected (657). The maturation of CD14+ DC-SIGN+ decidual cells into CD25+ 
CD83+ mDCs upon inflammatory cytokine treatment resulted in downregulation of 
antigen uptake capacity and effective stimulation of resting T cells.  
A small population of decidual DC expressing DC11c, a marker for myeloid DC, but 
not expressing other classical leukocyte lineage markers was detected by Gardner 
et al. (439). These decidual DCs comprised about 1.7% of CD45+ cells in the 
isolates. Strbo et al. demonstrated a bidirectional cross-talk between decidual 
CD56bright NK cells and decidual CD83+ cells, resulting in activation and 
proliferative response of autologous NK cells (642). 
In experiments with mice, Blois et al. found that the majority of uterine DCs were 
of myeloid lineage and that the relative number of CD11c+ uterine cells is not 
constant during pregnancy and shows an increase occuring simultaneously with 
the decisive phase of gestation, when implantation takes place (121).  
 
Miyazaki et al. showed that decidual mDCs secrete less of the proinflammatory 
cytokine, IL-12, than blood monocyte-derived DCs and induce Th2 cells when co-
cultured with naïve CD4+ T cells, which suggests an immunosuppressive phenotype 
of decidual DCs (951). 
Yoshimura et al. studied the systemic response of DCs and their cytolytic products 
and reported that the frequency of myeloid DCs, in the early and middle stages of 
human pregnancy, was comparable with that of lymphoid DCs, while in the late 
stage of pregnancy, the frequency of myeloid DCs significantly increased (1563). 
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They also showed that in the presence of human chorionic gonadotropin (hCG) both 
peripheral blood DC subsets can be activated to respond to any invading pathogens 
that affect DC subtypes. 
Myeloid DCs can produce IL-12 and IFN-γ in response to hCG, thus IL-12 produced 
from myeloid DCs can stimulate the production of IFN-γ as a positive feedback loop, 
while lymphoid DCs might be directly activated by hCG to produce IFN-γ (308).  
 
Macrophages 
Macrophages constitute 20-30% of the decidual cells at the site of implantation and 
unlike NK cells, remain high throughout pregnancy (808). Indeed, macrophages are 
one of the major cell types in both the maternal and fetal compartments of the 
uteroplacental unit. In humans, during the first weeks of implantation, 
macrophages are found in high numbers in the maternal decidua and in tissues 
close in proximity to the placenta (940), especially in the stroma surrounding the 
transformed spiral arteries and extravillous trophoblast (963).  
 
This evidence suggests that the innate immune system is not indifferent to the fetus 
and may have a role not only in host protection to infections, but also as important 
players in the feto-maternal immune adjustment. Macrophages are also a main 
source of cytokines and growth factors and contribute to the maintenance of the 
adequate balance between Th1 and TH2 cytokines at the placental bed (963). 
 
There are also several indications that macrophages are often more closely 
associated with trophoblast than uterine NK cells, with close associations between 
macrophages and extravillous trophoblast in decidua basalis and a recent study of 
rhesus monkey decidua also highlights the close association of macrophages, rather 
than uterine NK cells with trophoblast (1316). 
Although decidual macrophages are activated in vivo, as indicated by their 
expression of HLA class II, CD11c, and CD86 (581), they have recently been 
reported to express markers such as DC-SIGN that may aid in immune evasion or 
are associated with macrophage alternative activation, a phenotypic state of 
immunosuppressive activity (467). Early in vitro studies of the suppressive 
functions of decidual cell mixtures pointed to maternal macrophage production of 
prostaglandin E2 (584). Decidual macrophages have also been shown to elicit 
reduced allogeneic and autologous T cell responses when compared to their blood 
counterparts (952). The question then arises as to how decidual APC are driven into 
immune inhibitory profiles. 
 Immunology of the genital tract 
 II-204  
Several studies have indicated that placental HLA-G as product of infiltrating fetal 
cytotrophoblast cells may suppress APC functions, but reports published to date 
fail to show that HLA-G is acting specifically at the level of the APC (900). 
Macrophages and DCs both express the HLA-G receptors, ILT2 and ILT4, which can 
suppress activation signals in order to induce immunosuppressive activities by 
APCs.  
 
The dense macrophage-infiltration at the maternal fetal interface suggests that 
these cells are also involved in specific pregnancy-associated functions, and not 
only to perform their usual immunological tasks (107). Hunt et al. have implied 
that maternal macrophages assist in the tissue remodeling necessary to 
accommodate expansion of extraembryonic tissue (583).  
Macrophages actively orchestrate apoptosis of unwanted cells during tissue 
remodeling through cytokines and the influence of hormonal factors. During 
implantation, apoptosis is important for the appropriate tissue remodeling of the 
maternal decidua and invasion of the developing embryo. Apoptosis has been 
described in the trophoblast layer of placentas from uncomplicated pregnancies 
throughout gestation, suggesting that there is a constant cell turnover at the site of 
implantation necessary for the appropriate growth and function of the placenta 
(1175, 1321). In addition, the incidence of trophoblast apoptosis is higher in third 
trimester villi compared to first trimester placenta, suggesting that increasing 
placental apoptosis may be involved in the process of parturition.  
 
However, the clearance of apoptotic bodies represents the critical step in tissue 
homeostasis, preventing the release of intracellular contents, which may cause 
tissue damage and the possibility to initiate an inflammatory reaction that may 
have lethal consequences in pregnancy (963). 
During the period of implantation and trophoblast invasion with its induction of 
apoptosis in maternal tissue, numerous macrophages are present at the 
implantation site which was originally thought to represent an immune response 
against the invading trophoblast. Instead, it is suggested that macrophage 
engulfment of apoptotic cells prevents the release of potentially proinflammatory 
and proimmunogenic intracellular contents that occurs during secondary necrosis 
(963). 
Trophoblast cells are carriers of proteins, which are antigenically foreign to the 
maternal immune system and if released, as result of cell death, may initiate or 
accelerate immunological responses with lethal consequences for the fetus. 
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Therefore, the appropriate removal of dying trophoblast cells by macrophages prior 
to the release of these intracellular components is critical for the prevention of fetal 
rejection (963). Mor et al. proposed that during normal pregnancy, the uptake of 
apoptotic cells suppresses activated macrophages from secreting pro-inflammatory 
cytokines such as TNF-α and IFN-γ and promotes the release of Th-2 type, anti-
inflammatory and immunosuppressive cytokines with protective effects on 
trophoblast survival and immunological tolerance (Figure 18). 
 
 
Figure 18: Clearance of apoptotic cells by macrophages in normal pregnancy, adapted 
from Mor et al. (963) 
Changes in the cytokine milieu, owing to elevated levels of apoptotic bodies and 
inefficient clearance, will result in a proinflammatory microenvironment that in turn 
may result in changes in trophoblast resistance to Fas-mediated apoptosis and the 
maternal immune system (Figure 19). Further explanations are to be discussed in 
the chapter on disturbances in maternal-fetal interactions later.  
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Figure 19: Proinflammatory environment by inefficient clearance of apoptotic bodies 
in complicated pregnancy, adapted from Mor et al. (963)  
(2) Leukocytes 
Already in the final part of the menstrual cycle a large number of maternal 
leukocytes can be found in the endometrium (1119). As the mucosal lining of the 
uterus is transformed from endometrium in the non-pregnant state to the decidua 
of pregnancy by the influence of sex hormones, these leukocytes further increase in 
number and are found in close contact with trophoblast. CD56+ leukocytes make 
out 70% of the immunocompetent deidual cells. The predominant type of these cells 
are uterine NK cells (46%), followed by macophages (19%) and T cells (8%), mainly 
CD8+ T cells whereas B cells are virtually absent (949). In general, cells of the 
innate immune system seem to dominate this tissue since the levels of T and B 
lymphocytes are with 1-3% relatively low (808). 
Extravillous trophoblast cells interact with maternal immune immune cells at the 
implantation sie in the decidua basalis, including the abundant NK cells, APCs and 
T cells. 
 
NK cells 
Analysis of the leukocytes in the uterus has shown that NK cells are the 
predominant population but their total number in the uterine mucosa varies 
throughout the menstrual cycle with an increase throughout the secretory phase 
and in the decidua during the early stages of gestation (829).  
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There is a massive recruitment of NK cells at the embryonic site of implantation 
which makes them the dominant cell type of maternal immune cells in the decidua 
basalis in early pregnancy (1158). As gestation proceeds, NK cell numbers decline 
and at term these leukocytes are absent (954). This reduction of uterine NK cells in 
later pregnancy remains unexplained.  
Phenotypically, decidual NK cells (CD56bright CD16- CD160-) differ from NK cells in 
peripheral blood (CD56dim CD16+ CD160+) which suggests that either decidual NK 
cells represent a distinct subpopulation of circulating NK cells or they have 
undergone some tissue-specific differentiation.  
 
After blastocyst implantation and decidualization decidual NK cells are activated 
and secrete IFN-γ, perforin and angiogenetic factors in order to control trophoblast 
invasion through their cytotoxic activity and also initiate vessel instability and 
remodelling of decidual arteries to increase the blood supply to the fetoplacental 
unit (1430). Moreover, they take part in regulation of the maternal immune 
response producing Th2- and Th3-type cytokines, which result in placental 
augmentation and local immunosuppression (233). 
 
Decidual NK cells express receptors for classical and nonclassical HLA class I which 
are expressed on the cell surface of or secreted by extravillous trophoblast. The 
extravillous cytotrophoblast attracts decidual NK cells by producing MIP-1α 
chemokines so that the HLA class I molecules on the trophoblast interact with MHC 
class I-dependent receptors present on the surface of decidual NK cells (1158).  
These receptors on decidual NK cells comprise four different families with both 
activating and inhibitory members (700). The specific ligands for most NK cell 
receptors are the only HLA molecules expressed on extravillious trophoblast, HLA-
C, HLA-E and HLA-G (1444).  
These are the KIRs for which HLA-C and HLA-G molecules are the ligands, the Ig-
like receptor ILT2 which is expressed by 20-25% of decidual NK cells and interacts 
with HLA-G, the CD160 receptor with its major ligand HLA-C which is expressed on 
a minor set of decidual NK cells, and the CD94/NKG2 receptor which binds HLA-E.  
 
However, the functions for decidual NK cells in pregnancy are still not exactly clear 
but there are some hints for a possible control of placental development and 
pregnancy maintenance. Due to the high abundance of uterine NK cells in the 
decidua in the first and second trimesters of pregnancy, and their association with 
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extravillous trophoblast cells it has been proposed that they play an active role in 
the regulation of trophoblast invasion (155).  
Results from in vitro studies have proposed the involvement of NK cell receptor-HLA 
class I interactions in the protection of the trophoblast. HLA-G antigen was thought 
to be the main factor for the protection of the fetus from decidual NK cell lysis (793).  
NK cells in decidua express a noncytotoxic phenotyp lacking CD16 and CD160 as 
the markers of cytotoxicity (1444). Although expression of granzyme A, granzyme B 
and perforin was detected in decidual NK cells, these cells had a very low potential 
cytotoxic effect on K562 target cells (155). Moreover, the extravillous trophoblast 
may not express enough triggering ligands of activating NK cell receptors such as 
NKG2D and natural cytotoxicity receptors (1158). Trophoblast cells are resistant to 
cell lysis unless decidual NK cells have been stimulated with IL-2 which is not 
present in decidua (701). However, no in situ evidence of trophoblast lysis by 
uterine NK cells in early decidua has been detected yet. Another argument is the 
exposure of decidual NK cells to progesterone. A mediator of progesterone, 
progesterone-induced blocking factor (PIBF), was shown to block decidual NK 
cytolytic activity (787).  
 
As there is considerable interest in the role of cytokines in pregnancy, attention has 
also focused on uterine NK cell cytokine production. Studies detected transcripts 
for various cytokines and growth factors including GM-CSF, TNF-α, IFN-γ, IL-10, IL-
1β, TGF-β, VEGF and LIF in decidual NK cells (1195, 1239).  
 
Uterine NK cells have also been proposed to play a role in spiral artery 
transformation. Murine studies on NK cell-deficient mice also showed abnormal 
decidual vasculature including abnormal thick spiral arteries suggesting an 
additional role in uterine vascular remodelling (275). These abnormalities could be 
reversed after injection of allogeneic NK cells. It has also been demonstrated that 
the major uterine NK cell product responsible for the spiral artery remodelling 
defects is IFN-γ (275, 57). 
 
These results may be also true in humans as decidual NK cells are closely 
aggregated around maternal spiral arteries (1430). However, much less is known 
about the mechanisms involved in spiral artery remodelling in humans but it is 
likely that they are, at least in part, different from those controlling trophoblast 
invasion. Early structural changes in decidual spiral arteries, including dilatation 
and medial disorganization, occur before cellular interaction with trophoblast, but 
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at a time when uterine NK cells are present (156). Uterine NK cells reduce in 
number after 20 weeks’ gestation when vascular changes are generally complete. 
 
Granulocytes and monocytes 
It appears that other components of the immune system, especially the innate 
immune system, are activated during pregnancy. Monocytes are activated in 
pregnancy and data showed elevated surface expression of CD11b, CD14 and CD64 
antigens on monocytes from third trimester pregnant women (841). In addition, an 
increased expression of CD11a, CD49d and CD54 on monocytes was also observed 
from pregnant women. 
 
Granulocytes from pregnant women show increased surface expression of both 
activation markers and adhesion molecules, for example of CD11b and CD64 
(1234). These cells also show increased production of intracellular ROS and 
enhanced phagocytosis, as compared with nonpregnant women. Also in the study of 
Naccasha et al. baseline intracellular ROS and oxidative burst were higher in both 
granulocytes and monocytes from pregnant women than in the control group (997).  
 
Together, these data are consistent with the idea that pregnancy is a 
proinflammatory state. However, granulocytes from pregnant women in other 
studies had reduced microbial killing activity and chemotaxis as well as a decreased 
respiratory burst activity and intracellular H2O2 production when challenged (269). 
In contrast to Sacks et al. (1234) there was not found an increase in CD11b 
expression and there was no upregulation of CD18 or downregulation of CD62L 
expression, both of which are needed for appropriate priming and activation of 
granulocytes.  
A study by Luppi et al. found that during pregnancy the percentage distribution of 
granulocytes was significantly increased, with a consequent reduction in the 
percentage of lymphocytes and monocytes as compared with nonpregnant women 
(841). Data on pregnant women followed longitudinally throughout gestation 
showed that an increase in the proportion of granulocytes and a decrease in the 
proportion of lymphocytes appear from the second trimester onward (948). 
Neutrophils are located near the placenta where they might phagocytose cellular 
debris from decidual cells killed by invading trophoblast (392).   
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T lymphocytes 
In early pregnancy, T cells comprise about 10-20% of the leukocytes in the uterine 
mucosa (1119). Their proportion, however, increases with gestational age followed 
by a decline in the term pregnant uterus. A significant increase in the frequency of 
CD8+ T lymphocytes and a decrease in the frequency of CD4+ T lymphocytes were 
evident in pregnant women (398). Furthermore, an increase in the frequency of 
CD8+ T cells was observed in pregnant women during labor together with a 
concomitant reduction in the CD4/CD8 ratio. 
Th1- and Th2-type cytokines produced by maternal T lymphocytes present at 
fetomaternal interface seem to play a role in the development of pregnancy as above 
mentioned already. In humans, the success of pregnancy seems to be associated 
with the production of IL-4, IL-10 and M-CSF by T cells (1115). Both IL-4 and IL-10 
can inhibit the development and function of Th1 cells and macrophages, thus 
preventing the allograft rejection. 
 
There is direct evidence that the pregnancy-associated hormones progesterone and 
estradiol modify the cytokine production pattern of human antigen-specific T cells. 
Progesterone is a potent inducer of the production of Th2-type cytokines and of LIF 
and M-CSF production by T cells which is mediated by IL-4 (1116). Estradiol and 
hCG have both no effect on T cell differentiation to Th1 or Th2 cells (1116). In 
summary, results suggest a hormone-cytokine-T cell network at the fetomaternal 
interface with progesterone partly responsible for the T2 switch there. Defects in 
this network can result in fetal loss.  
 
T cells have also been detected in surrounding cell masses of the oocyte during 
ovulation, the so called cumulus oopherus. In women with blocked fallopian tubes 
CD4+ T cells and macrophages were found in cumuli, but only few NK cells (1118). 
Cumulus T cells produce higher levels of IL-4 and LIF than peripheral blood or 
ovary specimen T cells. Hormones can also modulate the cytokine profile of these 
cumulus oopherus T cells. Progesterone produced by cumulus granulosa cells may 
favour IL-4 production by T cells, which in turn can produce LIF (1118).  
 
T regulatory cells 
Treg cells, representing 2–5% of CD4+ cells, are believed to be important in immune 
tolerance by maintaining natural self-tolerance and negative control of pathological, 
as well as physiological, immune responses (1243). Recently, Aluvihare et al. 
reported that in mice the absence of CD4+CD25+ Treg led to a failure of gestation 
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due to immunological rejection of the fetus, suggesting that CD4+CD25+ Treg cells 
mediate maternal tolerance to the fetus (33).  
With only the CD4+ T cell population that expresses high levels of CD25 
demonstrates regulatory function in humans, it was first reported in 2003 that 
decidual and peripheral blood CD4+CD25high T cells increased during early 
pregnancy (1258). Recently, Somerset et al. reported an increase in circulating 
CD4+CD25+ T cells during early pregnancy, peaking the second trimester and then 
declining postpartum (1325).  
Sasaki et al. reported that the population of CD4+CD25high T cells rose from 6% in 
the peripheral blood of nonpregnant subjects to 8% in normal early pregnancy 
subjects, but this elevated CD4+CD25high T cell ratio decreased to a non-pregnancy 
level in miscarriage cases (1259). They reported also that the population of 
CD4+CD25high T cells to CD4+ T cells increased to over 20% in early pregnancy 
decidua, and this population rate decreased to 6% in spontaneous abortion cases.  
 
Shao et al. have focused on a subset of Treg cells, the CD8+ regulatory T cell 
(1288), which were described originally in the intestine where they are activated by 
a combination of the nonclassical class I molecule CD1d and a costimulatory 
molecule of the carcinoembryonic antigen family (31). CD1d and a form of this 
costimulatory molecule were also expressed by trophoblasts during the early stages 
of pregnancy (1288). Furthermore, isolated trophoblasts preferentially activated 
clonal populations of CD8+ T cells. The authors suggest the possibility that, in vivo, 
CD8+ T cell subsets may have a role in regulating B cells, potentially protecting the 
fetus from deleterious antibody effects (1288). 
 
Figure 20 tries to summarize te interactions between different cells at the human 
implantation site. 
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Figure 20: A schematic representation of some of the interactions at the human 
implantation site. Trophoblast cells expressing HLA-C, HLA-G, HLA-E, and possibly 
CD1d invade into the decidua. Different leukocytes in the decidua can detect the 
presence of trophoblast through their various HLA receptors. APCs may take up 
trophoblast antigens and present them to T cells whose recognition would then result 
in the production of cytokines from the maternal immune cells. These cytokines 
contribute to controlling the immune response against trophoblast and may also 
control trophoblast invasion. ILT=immunoglobulin-like transcript; KIR=killer 
immunoglobulin-like receptor; TCR=T-cell receptor; adapted from Trundley and 
Moffett (1430) 
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(3) Complement system 
Complement activation could potentially harm the developing fetus. Recent 
evidence in murine models has implicated a deficiency of a C3 convertase inhibitor 
and C3 products in the mechanisms of pregnancy loss (1545). Additionally, fetal 
injury and pregnancy loss in experimental antiphospholipidantibody syndrome have 
been attributed to the effects of complement, mainly C5a (454). Therefore, it has 
been proposed that inhibition of the complement system is an absolute requirement 
for normal pregnancy (457).  
The placental tissue contains a fully organized complement system that is mostly 
contributed by the complement factors in the maternal blood circulating in 
placental vessels, although some components may also be produced locally. As the 
placenta as a newly formed organ undergoes the process of tissue remodelling, the 
role of the complement system in the clearing of potentially destructive debris 
products may be essential.  
 
In the placenta, deposits of complement components can be detected in 
physiological pregnancy whereas at other tissue levels there are usually seen in 
association with diseases (153). Faulk et al. were the first who documented 
complement components C1q, C4, C5, C6, and C9 in normal human placenta (381). 
These were found to be associated with some stromal cells as well as in the wall of 
fetal stem vessels and colocalized with fibrin on trophoblast plasma membranes 
and perivillous fibrin. C3d and C9, but not C4 were seen associated with 
trophoblast basement membranes, which suggested that activation pathways 
leading to complement disposition on trophoblast basement membrane and on 
perivillous fibrin may be different (1314).  
Deposits of the components were also detected on spiral arteries in normal 
pregnancy with the highest staining for C3d and C9 suggesting that the 
complement system is likely to be activated through the classical pathway (1491). A 
humoral immune response leading to complement activation may thus be involved 
in the physiological changes of spiral arteries in early pregnancy. The terminal C 
complex as the final end product of all three pathways was also found to localize in 
the fibrinoid material of basal decidua, chorionic villi stroma and in vessel walls 
(1405).  
 
Fetus protection against maternal complement activation products is achieved by 
surface expression of complement regulators that act at different steps in the 
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activation cascade (153). These regulators including DAF, MCP or CD59 are present 
in placenta about 6 weeks from gestation until term and syncytiotrophoblast is 
protected from complement attack by expressing these three regulatory molecules 
(967). CD59 is distributed on all types of trophoblast while DAF and MCP are 
preferentially expressed on giant decidual cells (154).  
The effect of complement on trophoblast is not necessarily cytotoxic and may result 
either in impairment or in stimulation of the cell function caused by the membrane 
attack complex (MAC) (153).  
 
The following shows a summary of the changes in the innate immune system 
during pregnancy (Table 34). 
 
Monocytes 
Increase in number 
Increase in phagocytosis activity 
Increase in IL-12 production 
Neutrophils 
Increase in number 
Increase in phagocytosis activity 
NK cells 
Decrease in number 
Decrase in cytotoxicity 
Decrease in IFNγ production 
Complement system Increase of C1q, C3, C4, C4d 
Acute phase proteins 
Decrease of albumin 
Increase of Caeruloplasmin / Fibrinogen / 
Globulins/alpha1-antitrypsin/clotting factors 
Table 34: Changes in innate immunity during pregnancy, adapted from Herz et al. 
(541)  
(4) Cytokines and growth factors 
The local environment of the maternal-fetal interface is characterized not only by 
the cell types present, but also by the soluble factors produced therein. A wide 
range of cytokines and growth factors is present in the decidua physiologically 
including LIF, TNF-, IFN-, IL-1, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-11, IL-12, IL-13, 
IL-15, IL-16 and IL-18 (205).  
They are able to act on lymphocytes and NK cells which express a variety of 
receptors. The production and effects of these cytokines at the implantation site is 
important for the regulation of trophoblast cell growth, differentiation and invasion 
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(1309). APCs and T lymphocytes in the maternal decidua are potentially able to 
promote the rejection of the fetal allograft, which is first mediated by the recognition 
of paternal MHC antigens by APCs and then by the activity of effector T cells via the 
release of cytokines. Therefore, changes in the cytokine production by activated T 
cells may play an important role in the immunological tolerance of the conceptus.  
 
Th1/Th2 cytokine dichotomy  
Placental and decidual tissues from normal pregnancies have been shown to 
express both pro- and antiinflammatory cytokines (1463). In normal pregnancies, 
particularly at the maternal fetal interface, antiinflammatory Th2-type cytokines 
predominate over proinflammatory Th1-type cytokines and, therefore, an 
appropriate balance between proinflammatory and antiinflammatory cytokines is 
thought to be crucial for determining the success or failure of a pregnancy (1485).  
 
The evidence for a dichotomous Th response in reproduction originated from 
murine models, which showed that pregnancy rejection is mediated by Th1-
cytokines, whereas a Th2-cytokine response confers protection (1485). There have 
been only few ex vivo studies on cytokine production in human pregnancy, which 
yielded conflicting results and were unable to detect the expected early Th1/Th2 
shift during pregnancy initially (1446).  
In 2000, a study by Lim et al. demonstrated in vivo that women with recurrent 
miscarriage exhibit primarily Th1 cytokines, whereas healthy women exhibit 
decreased Th1 cytokines and increased Th2 cytokines which suggests a potential 
role for a dichotomous Th response in the mediation of subsequent reproductive 
events (819).  
Kruse et al. were then able to detect significantly reduced IL-2, IL-18 and IFN-γ 
mRNA expression levels already during the first trimester of normal pregnancy. 
Surprisingly, the mRNA levels for IL-4 and IL-10 also declined during pregnancy but 
this reduction was only marginal. Calculating the cytokine ratios revealed a shift 
from a Th1 to a pronounced Th2-type response, which was at the highest level 
during the second trimester (750).  
 
Other studies showed that proinflammatory Th1 cytokines appear to be potentially 
harmful to pregnancy since excess production of TNF-α or IFN-γ has been 
associated with preterm delivery (180). Low concentrations of LIF, IL-4, IL-6 and IL-
10 in endometrial tissue and deciduas were described in women with multiple 
failures of implantation (789) and habitual abortions (1357). 
 Immunology of the genital tract 
 II-216  
Similarly, low levels of decidual IL-4 and IL-10 have been observed in women 
suffering from unexplained recurrent abortions and where spontaneous abortion 
has occurred during the first trimester of pregnancy (181). Moreover, a defect of IL-
4 production by decidual CD4+ and CD8+ T cells and a defect of IL-10, LIF and M-
CSF by decidual CD4+ T cells was observed in women with recurrent abortions 
(1115). IL-4, IL-5 and IL-10 were detected at the fetomaternal interface throughout 
the period of gestation in mice whereas IFN-γ was only present in the first period 
(1485). 
 
Th2 cytokine activity in pregnancy   
CD4+ T lymphocytes of Th2-activity are the source of IL-4, IL-5, IL-6, IL-10, IL-13 
and GM-CSF (99).  
Already during the luteal phase of menstrual cycle endometrial cells indicate 
increased mRNA expression for Th2 cytokines including IL-4 and IL-6 compared to 
Th1 ones such as IL-2, IL-12, and IFNγ (819). 
 
IL-4, for example, is known to be the essential antiinflammatory cytokine for Th2 
differentiation and is constantly present at the fetomaternal interface where it is 
involved in pregnancy-supporting mechanisms (365). IL-4 secreted by endometrium 
infiltrating lymphocytes stimulates production of LIF in endometrial tissue, another 
cytokine of great significance for periimplantation period as it together with TGF-β 
facilitates process of trophoblast invasion (1117), endometrial decidualization (45), 
regulates interactions between decidual lymphocytes and trophoblast and, together 
with IL-6, controls angiogenesis inside trophoblastic villi (619). 
During labor at term as well as premature labor even when the onset of 
contractions was not connected with intrauterine infection, increased concentration 
of IL-6 was found in serum, placental villi, decidua and fetal membranes (1348). 
IL-10 is crucial for survival of the fetal allograft and counteracts the effects of 
inflammatory cytokines (1128). High levels of IL-12 during pregnancy are associated 
with preterm labor, preterm birth or recurrent abortions (365). 
 
It was also found that peripheral blood lymphocytes of pregnant women in the first 
trimester secrete ‘‘in vitro’’ more Th2, i.e. IL-4, IL-10 and less Th1, i.e. IL-2, IFN-γ 
cytokines compared to nonpregnant patients (879). Also the number of IL-4 
secreting cells rises progressively in the course of pregnancy (887). Pprobably 
alloantigens localized on trophoblast are the signal for peripheral lymphocytes to 
Th2 activity which is supported by observation that in further trimester peripheral 
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lymphocytes of pregnant women differentiated to Th2 cells secreting IL-4 after 
recognition of paternal alloantigens in mixed lymphocyte culture (358).  
 
Progesterone seems to be another possible inductor of Th2 overactivity during 
pregnancy. Progesterone influences cytokine network by decreasing Th1 activity of 
TNF-α in luteal phase endometrial tissue (1117) and by inducing synthesis of TGF-β 
in endometrial cells. It stimulates lymphocytes for production of PIBF which has 
potential to intensify production of Th2 cytokines (IL-3, IL-4, IL-10) and to block IL-
12 secretion by peripheral blood lymphocytes of pregnant women (624).  
Some role in regulation of endometrial Th1/Th2 balance seems to play hCG which 
stimulated IL-6 and TNFα (1435).  
 
Th1 cytokine activity in pregnancy 
CD4+ T lymphocytes of Th1 activity produce mainly IL-1, IL-2, IL-12, IL-15, IL-18, 
IFN-γ and TNF-α (99). The significance of these Th1 cytokines on the implantation 
period was defined by examination performed on mice. Components of seminal 
plasma influenced the expression of chemokines by endometrial cells which 
activates elements of innate immunity including neutrophils and macrophages 
homing endometrial stroma and uterine cavity (628). In a local inflammatory 
reaction, activated neutrophiles secrete ROS and phagocyte cellular debris while 
activated macrophages become the most important source of Th1 cytokines IL-1β 
and TNF-α (963). Uterine cavity is cleaned from sperm elements and accompanying 
microorganisms.  
 
Th1 biased reaction produces an adequate environment for presentation of paternal 
alloantigens to maternal immunocompetent cells and it also induces changes in 
number and composition of endometrial leucocytes, activates angiogeneic and 
growth factors, rebuilds extracellular matrix, activates endothelial and stromal 
cells, thus preparing maternal tissues for embryo implantation (674). Th1 activity 
triggers endometrial leucocytes and embryo itself to produce Th2 cytokines, LIF and 
TGF-β (1503). Th1 cytokines stimulate cytolytic activity of decidual NK cells and 
lymphokine activated ‘‘killer’’ T lymphocytes which are able to restrict excessive 
trophoblast proliferation and invasion.  
Similar mechanisms have been studied during periimplantation period in humans. 
Th1 cytokines present inside the uterine milieu as a result of inflammatory 
response to paternal seminal components can stimulate trophoblastic MMP-9 (816). 
It can thus enhance its invasive properties and can mediate neoangiogenesis by 
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inducing VEGF gene transcription (1401). IL-1β together with TNF-α stimulates 
secretion of LIF which has positive impact od trophoblastic growth and 
differentiation (431). Embryonic cells are also capable to secrete IL-2 which seems 
to play a stimulating role for decidual NK cells which together with macrophages by 
secreting IFN-γ, IL-12 and TNF-α can restrict depth of trophoblastic infiltration, as 
these Th1 cytokines are potent inductors of trophoblast apoptosis (89).  
 
IL-15 is one of the critical cytokines controlling uterine NK cell cytokine production 
and cytolytic potential. Moreover, IL-15 has been implicated in differentiation and 
proliferation of uterine NK cells and plays a possible role in induction of IFN-γ 
production as a mediator in vascular remodelling during early pregnancy (785). It 
was detected in nonpregnant endometrium, decidua and placenta but also in 
uterine macrophages, stromal cells, chorion and amnion (1453).  
In a study by Kitaya et al., IL-15 was found in glandular ECs and endometrial 
stroma during the late cycle with highest levels in perivascular cells surrounding 
the decidual spiral arteries (716). Expression of IL-15 during early pregnancy is 
most prominent in endothelial cells of spiral arteries. Decidualization elevates IL-15 
levels which promote survival of pre-NK cells present in and mobilizing into the 
uterus (1453). Recent studies demonstrated that IL-15 is essential for the support 
of NK cell differentiation in the decidualizing uterus (56). IL-15-deficient mice 
revealed a complete absence of uterine NK cells, poor development of decidua and 
unmodified spiral structure of arteries.  
 
Progesterone induces IL-15 expression and therefore, when progesterone levels fall 
as a result of failing pregnancy, the manifestation of apoptotic NK cells could be the 
result of a decreasing level of IL-15 (828).  
IL-15 seems to stimulate GM-CSF production by resting CD56+ NK cells and, 
together with IL-12, induces IFN-γ and TNF-α as macrophage-activating factors 
(178). NK cells also produce MIP-1α and MIP-1β after stimulation with IL-15 which 
may be a mechanism for trafficking of additional NK cells to the site of implantation 
(122). IL-15 is essential for Th2 cytokine production by NK cells and it stimulates 
uterine NK cells production of IFN-γ and IL-10 (370).  
Concerning cytotoxicity, IL-15 was found to activate cytotoxicity by decidual NK 
cells (785). IL-15 appears to directly induce upregulation of perforin and FasL 
expression on human decidual NK cells at the fetomaternal interface suggesting 
that IL-15-activated decidual CD56+ cells use perforin and FasL-mediated against 
transformed or infected cells (124). 
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IL-18 at the fetomaternal interface is produced by the entire decidua on gestation 
day 4. In murine studies, production starts in the basal proliferative stroma 
followed by glandular cells in peri-implantation uterus and appears early in murine 
spongiotrophoblast (1057). IL-18 does not appear early in human villous 
trophoblast cells but later persists in giant extravillous trophoblast cells and rare 
activated macrophages (1421).  
IL-18 enhances innate immunity and both Th1- and Th2-driven immune responses 
(1002). IL-18 is essential for its induction of IFN-γ production from Th1 cells, NK 
cells, B cells and DCs, often in combination with IL-12 (785). IL-18 alone has the 
potential to induce IL-4 and IL-13 production by T cells and NK cells, and promotes 
a Th2-mediated response (1002). It also plays a role in regulating GM-CSF 
production and induction of IL-8 and TNF-α (785). Therefore, IL-18 at the 
periimplantation site is able to stimulate murin uterine NK cells to produce IFN-γ 
that plays a key role in vascular remodelling during early pregnancy (274). 
Therefore, IL-18 might be essential for proper vascularization of the implantation 
site.  
 
Only few studies investigated the role of IL-18 on the cytolytic potential of decidual 
NK cells. IL-18 directly upregulates cytotoxic activity of NK cells and CD8+ T cells 
and induces perforin and FasL receptor expression on NK cells (587). Tokmadzic et 
al. showed that stimulation of decidual lymphocytes with IL-18 increased perforin 
expression and perforin-mediated cytotoxicity of NK cells (1421).  
IL-18 serum levels in pregnant women also show a significant increase from first 
trimester to labor and remain at high levels until at least day 3 of puerperium (588), 
which also indicates an important role of IL-18 during implantation.  
However, there are also high serum IL-18 levels in women with implantation failure, 
fetal growth restriction or recurrent abortions (588, 609). An increased level of IL-18 
promotes strong NK cell activation and probably excessive IFN-γ production (785). It 
seems that a tight regulation of IL-18 is important for normal implantation and 
decidual remodelling in early pregnancy.     
 
Leukemia inhibitory factor 
LIF is required for implantation and embryo development. This is shown in studies 
on mice lacking a LIF gene; they are fertile but their blastocyst fail to implant and 
do not develop unless the animals are treated locally with LIF (1355). LIF is 
produced by endometrial ECs, NK cells and T cells. However, LIF expression by 
glandular epithelium is dramatically downregulated after implantation whereas 
 Immunology of the genital tract 
 II-220  
expression by leukocytes is upregulated in the decidua. Most of the LIF expression 
was assigned to NK cells but decidual NK cells in culture did not produce LIF 
(1289). Therefore, production of decidual LIF seems to be assigned to T cells. LIF 
secretion is inhibited by Th1 activity cytokines such as IL-12 and IFN-γ in vitro 
(1117).        
(5) Humoral immunity in pregnancy – asymmetric antibodies 
It has been established that the synthesis of asymmetric antibodies is increased 
under different physiopathological situations involving Th2 responses including 
pregnancy (493). These are asymmetrically glycosylated IgG molecules which are 
affected in their antigen interaction turning them into functionally univalent and 
blocking antibodies. As a consequence, they are not capable of triggering immune 
effector mechanisms.  
 
An asymmetric proportion of 10-20% of IgG molecules has been demonstrated in 
non-immune sera (173). Their existence could either be beneficial or harmful to the 
host, depending on the self or nonself nature of the antigen (493). They act as 
protective antibodies if binding self-antigens but when they are specific for the 
foreign aggressor, for example in chronic infections, they block antigens of the 
pathogen leading to its survival and chronicity (871).  
 
In murine pregnancy, antibodies with antipaternal specificity, predominantly of the 
IgG1 subclass, were detected both in serum and on the placenta (1461). In an 
analysis of the humoral immune response in pregnant females, the predominance 
of antipaternal blocking IgG antibodies was demonstrated (104). Multiparous 
women had a marked increase in asymmetric IgG in serum during the first 
trimester followed by a decrease after delivery. Antibody activity was located in both 
symmetric and asymmetric IgG in a 1:5 ratio, which indicates the prevalence of 
asymmetric antibodies in this immune response (864).  
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(6) The role of progesterone as immunomodulator in pregnancy 
The best-studied immunomodulator at the maternal-fetal interface is progesterone, 
which clearly has a role in survival of the fetal allograft (1376). Numerous studies 
have demonstrated that progesterone blocks mitogen-stimulated lymphocyte 
proliferation, improves allograft survival time and modulates antibody production 
besides affecting other phases of the immune response (1105).  
 
However, the mechanism by which progesterone exerts its immunomodulatory 
actions in reproductive tissues is unclear but may involve both direct and indirect 
actions on immune cells. The biological effects of progesterone are mediated by 
PIBF which is secreted by lymphocytes of pregnant women in the presence of 
progesterone. PIBF concentrations in pregnancy urine are related to pregnancy 
outcome as PIBF levels increased up to term in normal pregnancies whereas failed 
to increase in pathological pregnancies (1376). Therefore, PIBF concentration 
correlates with positive or negative pregnancy outcome, and premature pregnancy 
termination is predictable by lower PIBF values than normal. 
 
PIBF affects B cells and induces increased production of asymmetric antibodies 
which has a regulatory effect on antifetal immune responses during pregnancy. In 
animal experiments, blockade of the progesterone receptor resulted in reduced PIBF 
production together with a reduced amount of asymmetric antibodies and elevated 
fetal resorption rates (677). 
PIBF inhibits arachidonic acid release which results in a reduced cytotoxic NK 
activity and therefore favors a normal pregnancy outcome (1076). NK activity in 
pregnant women is inversely related to the rate of PIBF-positive lymphocytes. PIBF 
keeps NK activity at a low level both by controlling IL-12 production and also by 
inhibiting perforin liberation (786). Decidual NK cells express a high level of 
perforin; however, they have low cytotoxic activity. In vitro studies in decidual cells 
obtained from elective pregnancy termination suggest that it is PIBF that inhibits 
the cytotoxicity of NK cells via blockade of degranulation, and thus contributes to 
the low decidual NK activity (386). 
 
PIBF also alters the profile of cytokine secretion by activated lymphocytes and 
increases the production of IL-3, IL-4 and IL-10 (386). PIBF seems to induce a Th2-
type cytokine production and inhibits IL-12 production by lymphocytes, which was 
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shown to be pregnancy-protective as an increased lymphocyte IL-12 production 
correlated with pathological pregnancies and high NK activity (1378).  
 
As a summary of the last chapter, the following figure should elucidate the 
immunological requirements for the maintenance of a successful pregnancy 
described above (Figure 21). 
                                                                                                                                                                           
 Successful pregnancy 
 Fetus as a semiallograft 
 50% paternal/50% maternal 
  
 Recognition of fetal antigens on trophoblast by decidua 
  
 Protective immunmodulation 
 Upregulation of progesterone/PIBF 
 
         Increase in asymmetric       Shift of Th1-type to                Reduction in  
         antibodies                            Th2-type cytokine                NK cell activity 
                                                        production   
Figure 21: Protective immunomodulatory mechanisms associated with a successful 
pregnancy, adapted from Druckmann et al. (343) 
d) Immunology of labor 
Some of the physiological processes involved in labor seem to be mediated by 
proinflammatory cytokines suggesting that the immune privileges that the fetal-
placental unit has enjoyed during pregnancy are revoked at the time of labor. An 
inflammatory response during labor may also help to remove placental fragments 
and prepare the uterus for the pathogens that it will undoubtedly encounter during 
the immediate postpartum period (1105). In the following, the immunological 
changes during the three important processes in parturition should be briefly 
described. 
 
The process of cervical ripening appears to be an inflammatory reaction associated 
with the catabolism of cervical extracellular matrix by enzymes released from 
infiltrating leukocytes. During cervical ripening and remodelling, IL-8, IL-1β, IL-6 
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and TNF-α production were found to be increased in the human cervix (1056). IL-1β 
is produced predominantly by leukocytes, IL-6 by leukocytes, glandular ECs and 
surface ECs, and IL-8 is produced primarily by leukocytes, glandular ECs, surface 
ECs and stromal cells (1566). During labor there is an influx in the number of 
leukocytes in the cervix that is caused primarily by increased numbers of 
neutrophils and macrophages (CD68+ cells) but not T (CD3+ cells) or B cells 
(CD20+ cells) (1056).  
 
The ripening of the cervix is induced by proinflammatory cytokines in different 
ways. IL-1β and TNF-α increase the production of MMP-1, MMP-3, MMP-9 and 
cathepsin S (1480). IL-1β can act on a number of cell types to increase the 
production of cyclooxygenase (COX)-2 and prostaglandin E2, the most effective 
chemical for inducing cervical dilation in women (1105). Prostaglandin E2 may then 
further stimulate labor by increasing the production of proteinases or indirectly by 
increasing the permeability of blood vessels for leukocyte trafficking (687).  
 
Besides prostaglandin E2, IL-8 also causes neutrophils from the periphery to 
migrate towards the cervix and can activate them to release MMP-8 (neutrophil 
collagenase) and neutrophil elastase that can digest the extracellular matrix 
produced by cervical fibroblasts. Increased concentrations of G-CSF in the cervix 
during labor may also stimulate proliferation of the neutrophil subset (1274). 
Possible roles for IL-6 in the cervix could be to stimulate neutrophils, macrophages 
or other cells in the local tissues to produce additional proinflammatory cytokines 
that aid the process of cervical ripening such as prostaglandin E2 or NO (1105). Il-6 
has been used as an effective biomarker for predicting labor. 
The process of weakening and rupture of the membranes in the region that overlies 
the cervix also involves a similar proinflammatory process as in the cervix. During 
labor, the production of IL-8, TNF-α, IL-6, IL-1β, and MMP-9 increases in the 
membranes (1567, 1546) and decreases levels of TIMPs (1198). TNF-α and IL-1β 
increase the production of MMP-9 by amnion, but not chorion, explants in vitro (44). 
 
The initiation of rhythmic contractions of increasing amplitude and frequency as 
another component of labor in myometrium is also associated with these cytokine-
induced changes. Increased protein concentrations of IL-1β, TNF-α and IL-6 have 
been detected in myometrium at labor and immunolocalized to the leukocytes 
(1567). The increased concentrations of leukocytes in the myometrium during labor 
could be due to increased expression of chemokines such as MCP-1 and IL-8 that 
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are also increased during labor (1566) and may recruit macrophages and 
neutrophils to the myometrium.  
IL-1β and TNF-α stimulate arachidonic acid release, activate phospholipid 
metabolism, and increase the production of prostaglandins by the myometrial cells 
(958, 1419). These effects of IL-1β on myometrial cells are similar to the effects of 
oxytocin which also upregulates COX-2 and prostaglandin E2 production by 
myometrial cells (957). IL-1β and TNF-α can also increase the production of MMP-9 
by myometrial cells, which may be important for detachment of the placenta (1212). 
e) Disturbances in maternal-fetal interaction of the immune system 
The following chapter deals with pathological conditions during pregnancy 
including preeclampsia, intrauterine groth retardation (IUGR), preterm labor (PTL) 
and recurrent spontaneous abortion (RSA).  
There are several histological similarities between IUGR and other pregnancy 
disorders such as preclampsia and RSA which leads to a common aetiology of all 
these pregnancy disturbances (885). An increased decidual cellular immunity 
limiting trophoblastic invasion and leading to failure of placentation has been 
reported to be involved in the pathogenesis of several pathologic conditions in 
pregnancy such as spontaneous abortion, preeclampsia and IUGR. Probably 
pregnancy complications as IUGR, abruptio placentae and fetal death are all clinical 
signs of placental ischemia and inflammation (885) as the following diagram should 
illustrate (Figure 22). 
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Figure 22: Mechanism of placental development in pathological pregnancies, adapted 
from Matthiesen et al. (885) 
(1) Immunologic aspects of preeclampsia 
Preeclampsia is a placenta-dependent disorder with both local intrauerine and 
systemic anomalies resulting in maternal and fetal morbidity and mortality (885). It 
affects about 3-7% of all pregnancies (1202) and is often detected in the second half 
of pregnancy, but most probably it has its onset during early pregnancy.  
 
As histological features such as restrained trophoblast invasion, placental ischemia 
and vasculitis are similar to other pregnancy complications including IUGR and 
RSA, a common immune etiology with local subclinical inflammation at the 
placental bed and systemical immune responses in maternal circulation has been 
suggested (885).  
However, for several years there has been suggested an endothelial cell dysfunction 
as pathophysiological denominator (1203). Thus, a two-stage process is proposed 
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with an excessive maternal inflammatory response, probably against foreign fetal 
antigens, results in an impaired trophoblast invasion, a defective spiral artery 
remodelling and a reduced placental perfusion at first (1203). As a consequence, 
placental hypoxia and infarction lead to the release of inflammatory cytokines and 
placental fragments into the maternal circulation. This finally ends in systemic 
vascular endothelial disruption and eventual clinical manifestation of preeclampsia 
(317).  
 
Preeclampsia is likely, at least in part, the consequence of an abnormal maternal 
immune response to antigenic challenge by the fetoplacental allograft.  
Already in the 1970s, studies showed that histological changes in the placental 
beds of preeclamptic women resembled those of acute allograft rejection (717). 
Several epidemiological evidence also point convincingly toward an immunogenetic 
basis for preeclampsia. Although exposure to paternal antigens through a prior 
pregnancy has a protective effect against development of preeclampsia, exposure to 
new or different paternal antigens as a result of change in paternity is associated 
with an altered risk of preeclampsia (813).  
Consistent with these findings, this hypothesis of immune maladaptation contends 
that certain reproductive practices such as barrier contraception and oocyte embryo 
donation that minimize maternal exposure to seminal fluid are associated with 
increased risk of preeclampsia (1208).  
 
Macrophages 
Mor et al. proposed that in pregnancy pathologies like preeclampsia an increase in 
the levels of trophoblast apoptosis, possibly a result of infection, may initiate an 
inflammatory event that will further promote trophoblast cell death preventing 
normal trophoblast invasion, spiral arteries transformations and fetal survival 
(963).  
In pregnancies complicated with preeclampsia or IUGR, activated macrophages 
secrete proinflammatory cytokines such as TNF-α and IFN-γ and induce apoptosis 
in extravillous trophoblast. This hypothesis is supported by a recent report of 
Pijnenborg et al. who found a higher incidence of cell clusters secreting TNF-α, 
probably macrophages, in the placental bed of patients with severe forms of 
preeclampsia (1122). 
Studies of placental bed specimens demonstrated changes in the distribution of 
macrophages during pathologic conditions such as preeclampsia (1188).  
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While in normal pregnancies macrophages are located in the stroma surrounding 
the transformed spiral arteries and extravillous trophoblast, in preeclampsia 
macrophages are located within and around the spiral arteries separating them 
from the trophoblast cells.  
 
In addition, it was reported that macrophages residing in excess in the placental 
bed of preeclamptic women are able to limit extravillous trophoblast invasion of 
spiral arteries segments through apoptosis mediated by the secretion of TNF-α 
(1188). Whereas in normal pregnancies macrophages function as support cells by 
facilitating trophoblast invasion through the placental bed macrophages seem to 
function as a barrier for trophoblast invasion and differentiation by inducing 
trophoblast apoptosis and therefore preventing spiral arteries transformation in 
pathologic conditions (Figure 23). 
 
Increased trophoblast apoptosis would increase the amount of trophoblast debris, 
syncytical knots, which leak into the maternal circulation and generate a systemic 
endothelial activation as seen in preeclampsia (1256). Trophoblast debris can 
activate TNF-α and IL-12 production from moncytes in vitro, which further pushes 
the systemic immune response towards excessive inflammation instead of a normal 
immune activity.  
 
Figure 23: Difference in macrophage distribution in normal and complicated 
pregnancies with preeclampsia and IUGR, adapted from Mor and Abrahams (963) 
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Lymphocytes  
An increased number of classical cytotoxic NK cells was described in third trimester 
decidua of preeclamptic patients (1335). Preeclamptic pregnancies are also 
characterized by an increase of CD8+ decidual T lymphocyte percentage (1335). 
This would be consistent with a dominance of Th1 cytokine activation which 
stimulates NK cells and CTLs.  
 
In preeclamptic patients, the T cell activation marker HLA-DR is extremely high 
expressed on CD8+ T cells (1242). Wilczynski et al. characterized lymphocyte 
subsets in decidua of patients with preeclampsia and reported an increased 
percentage of CD3-/CD56+CD16+ NK cells and cytotoxic CD8+/CD28+ T cells and 
a decreased percentage of T CD3+, B CD19+, and suppressor/inducer T 
CD4+/CD45RA+ lymphocyte subsets (1504). Increased levels of activated/memory 
cells (CD4+CD45RO+ and CD4+CD29+) are interpreted as T cells activated by 
antigens. These changes within suppressor/inducer and cytotoxic T lymphocyte 
subsets suggest that systemic immunological deviation towards suppression seen 
during normal pregnancy is absent not only in peripheral blood but also locally in 
decidua of preeclamptic women.  
   
Cytokines 
As preeclampsia is often regarded as a syndrome of an excessive inflammatory 
response even similar to that during septic shock (1234), the question of the role of 
superantigen involement with a predominant Th1-type cytokine production has 
arised (842).  
Endothelial dysfunction in preeclampsia is found to be associated with excessive 
release of Th1 cytokines like TNF-α, IL-1, and IL-8, and the Th2 cytokine, IL-6, 
which has proinflammatory properties (1459). The imbalance of Th1- and Th2-type 
cytokines has been found in peripheral lymphocyte and placenta in preeclampsia, 
for example by Saito et al. who found increased TNF-α, IL-2 and IFN-γ in PBMCs 
from preeclamptic patients compared to controls (1242). Wilczynski et al. also 
found a shift to Th1 activity with elevated IFN-γ levels and low IL-6 and IL-10 
secretion in third trimester decidua of preeclamptic patients (1504).  
 
IFN-γ secreted by activated T cells activates specialized uterine NK cells with 
regulatory properties for physiological trophoblast invasion in decidua. IFN-γ affects 
the Th1/Th2 cytokine balance again and increases the proinflammatory potential. 
High levels of IFN-γ, together with TNF-α, can lead to apoptosis of trophoblast (954). 
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IFN-γ upregulation could also involve superantigen-like stimulation of decidual 
lymphocytes by an infectious factor (842). IL-12 stimulates the production of IFN-γ 
which activates lymphocytes and neutrophils. In an inflammatory environment, 
macrophages secrete high levels of IL-12 that stimulate IFN-γ secretion by NK cells, 
thereby inhibiting angiongenesis (1240). Increased serum concentrations of IL-12 in 
peripheral blood of preeclamptic women have been observed (296) which points to a 
local dysregulation in IL-12 production.  
 
Interestingly, Reimer et al. reported an upregulated leptin expression in placental 
tissue of preeclampsia (1185). Leptin is an obesity regulating protein that also 
induces the production of large amounts of IFN and IL-2, and decreases IL-4 
production (830).  
However, a study by Omu et al. has shown the dichotomous role of IL-4 in 
pregnancy (1048). Normotensive pregnancy was associated with high increase in IL-
4 in the first half of the pregnancy, but in the second half of pregnancy and 
puerperium, high levels of IL-4 are associated with preeclampsia. This may be a 
compensatory attempt to control or balance the effect of proinflammatory cytokines 
like TNF-α. 
In conjunction with an overexpression of TNF-α in placenta and in plasma, as it is 
observed in preeclampsia, an enhanced plasma and placental expression of IL-1 
has been reported (885). Both cytokines promote functional and structural changes 
in endothelial cells including oxidative stress, complement activation and 
microthrombosis which all are present in preeclampsia.  
 
The role of TGF-β in trophoblast invasion might be also dysregulated in 
preeclampsia (174). An increase of placental oxygen during the second physiological 
invasion normally results in a decrease of TGF-β, which prevents excessive 
trophoblast invasion. In case of hypoxia, TGF-β does not decrease which results in 
insufficient trophoblast invasion. However, Lyall et al. found no changes in 
expression of TGF-β in placenta or placental bed in preeclampsia compared with 
normal pregnancy which has put the impact of an overexpression of TGF-β on 
trophoblast invasion under question (847).  
 
Elevated levels of IL-18 in preeclampsia, especially in the HELLP syndrome, have 
been reported as well (588). IL-18 induces IFN-γ production and diverts Th1 
predominant immunity when IL-12 is present (1044).  
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IL-10 as antiinflammatory cytokine promotes the termination of Th1 rejection 
reactions against the fetal-placental unit. A deficiency in IL-10 expression in 
placenta and decidua were observed during preeclamptic pregnancy which was 
interpreted as a modified immune balance consistent with inflammatory responses 
in preeclampsia (540). However, in some preeclampsia cases there were seen high 
peripheral and placental levels of IL-10, which might be a compensatory response to 
elevated levels of IFN-γ, TNF-α, and IL-12 (992).  
 
Sakai et al. showed recently that serum levels of granulysin, a cytotoxic granule 
protein of NK cells and CTLs, were significantly elevated in preeclamptic patients 
compared to nomal pregnancies (1244). Levels were also associated with mean 
blood pressure, percentage of peripheral blood Th1 cells and Th1/Th2 ratio. Serum 
granulysin would thus be a useful marker to evaluate the Th1/Th2 balance in 
preeclampsia (1244). In the search for an early marker of preeclampsia, Eneroth et 
al. found increased expression of soluble IL-2 receptor in plasma of first trimester 
pregnancies that later developed preeclampsia (368).   
 
Other immunological mediators of endothelial cell injury 
Also important for the pathogenesis of preeclampsia are other mediators of 
inflammation such as ROS which are generally found to be increased (885). In case 
of preeclampsia, the balance between antioxidants and free radicals is disturbed. 
Free radicals and levels of lipid peroxidation are increased in preeclampsia and 
probably evoke systemic endothelial activation and increased TNF-α production 
(1468).  
Autoantibodies may also contribute functionally to vascular and placental 
dysfunction associated with preeclampsia (1402). Studies have confirmed the 
presence of higher levels of antiphospholipid as well as anti-endothelial cell 
antibodies in serum of preeclamptic women compared to controls (664). Some 
authors found that autoantibodies against angiotensin II type 1 receptor are 
present in sera of preeclamptic patients (311).    
(2) Immunology of preterm labor and preterm birth 
PTL and preterm birth, defined as labor or birth before 37 weeks gestation, is 
preceded in 30% by preterm, premature rupture of membranes (PPROM), which is 
defined as membrane rupture prior to 37 weeks gestation (1105). Previously, all 
babies that were born less than 2500 g were considered to be premature but it was 
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revealed that many of these infants were actually delivered at term but were small 
because of decreased fetal growth (IUGR).  
PTL is probably the final common pathway of a number of pregnancy complications 
due to causes such as infection, smoking or coagulation disorders (839). 
Inflammation at the maternal-fetal interface, mediated by proinflammatory 
cytokines, is considered as the main common component to these conditions, which 
results in fetal loss of immunological privileges.  
 
Infection and preterm birth 
According to literature, about 50% of spontaneous preterm births are associated 
with ascending genital tract infection (826). The earlier in pregnancy at which 
spontaneous preterm labor occurs, the more likely it is due to an infection and the 
earlier in pregnancy at which abnormal genital flora is detected, the greater the risk 
for a subsequent infective adverse outcome (781). 
Different kinds of infection significantly predispose to spontaneous preterm birth 
(Table 35). 
 
Intrauterine infection, clinical or subclinical Mostly polymicrobial 
Lower genital infection BV, Trichomoniasis 
Distant infection Periodontitis 
Table 35: Kinds of infection with examples predisposing to preterm birth 
Multiple studies have led to the hypothesis that ascending lower genital tract 
infection can result in preterm labor.  
Bacterial entry into the decidua is followed by recruitment of leukocytes and 
cytokine production which in turn leads to prostaglandin synthesis in amnion, 
chorion, decidua and myometrium and MMP synthesis by chorion and amnion 
(676). MMPs are involved in cervical ripening and degradation of fetal membranes 
while trigger of prostaglandin synthesis results in cervical dilatation, uterine 
contractions and even greater entry of microbes.  
In the following, aspecs of different lower genital infections and intrauterine 
infection should be briefly discussed. 
 
Long considered a “minor” STD with few associated complications, infection with T. 
vaginalis has recently been implicated as a cause of preterm delivery in several 
studies.  
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In a large multicenter study, trichomoniasis was significantly associated with low 
birth weight, premature rupture of membranes, and preterm delivery (259). 
Similarly, Minkoff et al. also documented a significant correlation between 
trichomoniasis and premature rupture of membranes with an incidence of this 
complication at term of 27.5% in women with trichomoniasis versus 12.8% in those 
without (950).  
A more recent randomised treatment study has, however, lent controversy to this 
area. Klebanoff et al. reported the results of a study designed to prevent preterm 
labor among women with trichomoniasis (718). Pregnant women with asymptomatic 
trichomonal infection were randomised to placebo versus treatment with 
metronidazole. Unexpectedly, women in the treatment group were found to have 
higher rates of preterm birth than those who received placebo.  
 
As mentioned above, BV increases the risk of preterm delivery and low-birth-weight 
children (548), first trimester miscarriage among women undergoing IVF (1163), 
chorioamnionitis and other infections (1305). BV is associated with a twofold 
increased risk of preterm birth, presenting the greatest risk when detected before 
16 weeks` gestation (802). 
Screening for BV and treatment has been considered a strategy to reduce the rate of 
preterm birth (1215) but recent meta-analyses revealed no reduction in overall 
preterm birth with routine screening and treatment for BV except probably for 
women with a history of preterm birth (803, 898).  
However, results from two recent trials with intravaginal or oral application of 
clindamycin in early gestation resulted in a decreased incidence of preterm birth 
suggest that early treatment of BV before 20 weeks` gestation may prevent preterm 
birth (780, 1433). 
 
Other genital tract infections found to be associated with increased preterm birth 
rate are C. trachomatis and N. gonorrheae.  
The Preterm Prediction Study found that chlamydial infection detected at 24 weeks` 
gestation doubled the risk for preterm birth (36). However, trials to treat C. 
trachomatis during pregnancy have failed to demonstrate a consistent reduction in 
preterm birth rate (875). Gonorrheae was associated with a 2.9-fold increased risk 
of preterm birth (363). 
Other vaginal colonization including Candida, U. urealyticum and group B 
streptococci have not found to be associated with increased risks for preterm birth 
(176, 258, 719).  
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Intrauterine infection was early found to be another frequent cause of PPROM and 
PTL due to pathologic studies of placentas (1230). Signs for chorioamnionitis were 
found in 94% of placentas of infants delivered at 21-24 weeks compared to 5% of all 
placentas.  
The main mechanism of this infection is ascending microbial invasion by lower 
genital tract organisms which could produce local inflammation, i.e. subclinical 
chorioamnionitis leading to PPROM, PTL and possibly preterm birth. Simhan et al. 
found a strong association of elevated vaginal pH and vaginal neutrophils with early 
third-trimester PPROM (1306). 
Depending on which laboratory technique is performed, prevalences of intra-
amniotic infection in the setting of preterm labor range from 0-24% to 30-55% (451, 
721).  
Many infections are polymicrobial. Ureaplasma urealyticum, Mycoplasma hominis, 
group B streptococci, G. vaginalis and gram-negative bacteria such as Escherichia 
coli have been identified as pathogens commonly associated with PTL (445, 1030, 
1235).  
 
Cytokines 
The administration of bacteria or bacterial products to rodents or primates during 
late pregnancy causes PTL that is preceded by increased production of 
proinflammatory cytokines including TNF-α and IL-1β. Treatment with IL-1β was 
able to mimic the effects of bacteria by causing PTL, suggesting a causal role for 
this cytokine in infection-induced PTL (71).  
Studies both in primates (478) and mice (1216) have demonstrated that 
intraamniotic or systemic maternal infusion of IL-1β readily induced preterm labor 
and delivery which suggests the possibility that fetal or maternal conditions leading 
to elevated levels of IL-1β or other proinflammatory cytokines might precede and 
predict the later occurrence of preterm labor.  
 
Many bacteria involved in ascending infection produce phospholipases A2 and C, 
proteinases and endotoxins activating placental, decidual, amnion and fetal 
membrane cells (1306). This in turn may stimulate these cells to production of 
proinflammatory cytokines and prostaglandins which play an important role in the 
initiation of parturition, especially in the cases related to chorioamnionitis. 
Cytokines such as TNF-α and IL-1β may originate from trophoblast cells as well as 
fetal or maternal macrophages as cultures of amnion, chorion, and decidual cells 
produce proinflammatory cytokines such as MIP-1, IL-6 and IL-8 in response to 
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bacteria or bacterial products (345, 346, 1187). However, it is also possible that 
macrophage-derived cytokines can act on receptors on placental cells, which 
augment the production of proinflammatory cytokines at the maternal-fetal 
interface (1105). 
 
In a further study by Perni et al. the differences between singleton and twin 
gestations in immune mediators in midtrimester amniotic fluid were investigated 
(1108). Concentrations of IL-1β, TNFα and IL-4 were increased in amniotic fluid 
from twins, which may contribute to the increased rate of PPROM and spontaneous 
preterm birth in twin populations. 
Increased concentrations of free radicals such as proinflammatory NO and 
prostaglandin E2 in amniotic fluid are also associated with intrauterine infection 
(573). Furthermore, a COX-2 inhibitor blocked LPS-induced PTL in mice (1245). 
 
Antiinflammatory effects of IL-10 and progesterone 
IL-10 may be helpful in reducing the incidence of PTL and the resulting neonatal 
morbidity.  
Administration of LPS to pregnant rats between gestation day 14 and 17 causes 
extensive IUGR, fetal death and low birth weight which is associated with increased 
production of TNF-α and NO in the placenta and increased numbers of apoptotic 
cells (1200). However, coadministration of IL-10 to LPS-treated dams improved fetal 
outcome by restoring birth weight and decreasing placental TNF-α, NO and 
apoptosis (1200). Intravenous administration of IL-10 also prevents preterm birth 
caused by intrauterine infusion of LPS in rats (1407).  
 
Progestins have also been shown to be effective in preventing PTL and delivery 
(1105). Administration of pharmacological, but not physiological levels, of 
progesterone to mice delayed PTL in response to intrauterine injection of E. coli 
(552).  
The following shows a model for the immunological mechanisms involved with PTL 
and PPROM (Figure 24). 
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Figure 24: Cascade of immunological events in the pathomechanism of PTL and 
PROM, adapted from Peltier (1105) 
(3) Immunology of fetal growth retardation 
IUGR is another main cause of perinatal morbidity and mortality. It is a 
heterogeneous condition that includes abnormal situations, most of them related to 
placental insufficiency and physiological but misunderstood events leading to 
healthy small-for-gestational-age babies (84). However, there are many reports 
studying the role of immunological mechanisms in the genesis of spontaneous 
abortion and preeclampsia, but only a few about IUGR.  
 
An increased production of antibodies and a chronic activation of the lymphoid 
system similar to those found in other placental disorders seem likely in women 
with IUGR. Selvaggi et al. found that patients with IUGR presented numbers of 
circulating lymphoid cells positive for cytoplasmatic IgM, IgG, and IgA at least 10-
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fold higher than in normal pregnancies (1272). Matthiesen et al. reported higher 
levels of B lymphocytes in women with IUGR compared to women with normal 
pregnancies (886) as well as Bartha et al. who found a higher absolute number and 
percentage of B cells in women with IUGR (83).  
There have been only a few studies on the subpopulations of peripheral 
lymphocytes in IUGR. The percentage of circulating CD4+ cells and CD4/CD8 ratio 
were found to be decreased while the percentage of CD8+ cells is increased in 
women with IUGR with respect to normal pregnancies (886, 947).   
 
Bartha et al. found in their study that serum TNF-α is increased in women with 
IUGR and placental insufficiency but normal in those with IUGR and normal 
placental perfusion (84). It was suggested that elevations of TNF-α could be a 
specific phenomenon of certain subsets of IUGR, identifying cases with placental 
dysfunction.  
Holcberg et al. reported that increased TNF-α secretion in placentas of intrauterine 
growth-restricted fetuses was related to enhanced vasoconstriction of the fetal 
placental vascular bed (560). In addition, when they perfused normal placentas 
with the vasoconstrictor angiotensin II, TNF-α production was increased which 
supports the finding of elevated TNF-α levels in cases of IUGR with increased 
umbilical artery resistance (84).  
Heinig et al. determined cytokine mRNA expression in term human placentas of 
patients with IUGR and found higher IL-1α as well as higher PDGF-A and -B levels 
compared to normal placentas but no clear correlation of these differences with 
clinical data (535). 
f) Immunologic aspects in early pregnancy loss 
Spontaneous miscarriage (abortion) occurs in 15% of all clinically recognised 
pregnancies, primarily in the first trimester, and it is the most common 
complication of pregnancy. While most are sporadic and non-recurrent, RSA, 
defined as two consecutive or more than three spontaneous abortions prior to the 
20th week of gestation, occurs in approximately 1 to 3% of women with diagnosed 
pregnancies (457). 
Approximately 50–60% of spontaneous pregnancy losses can be explained by 
chromosomal anomalies of the foetus, infectious aetiologies, maternal endocrinology 
or anatomical comorbidity, but still 40–50% remain unexplained (343). A 
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substantial portion of these unexplained cases could be attributable to an 
abnormal, abortogenic immune response of the mother towards potential antigens 
on the foetus.  
 
There is considerable evidence that pregnancy is recognised by the maternal 
immune system. For example, already 20 years ago antibodies with paternal 
specificity have been found in sera from multiparous women (96) and 
immunosuppressive activity has been described in supernatants of oocytes after 
fertilisation (303). As early as 1977, it was suggested that HLA-matching between 
parents was associated with spontaneous abortion (738), a hypothesis confirmed in 
a more recent 10-year prospective study (1038). Only these couples could have 
histocompatible fetuses, i.e. fetuses whose HLA alleles do not differ from from 
maternal alleles.  
 
To study the role of immune cells and molecules in the etiology of RSA, it would 
need placental tissue during the first trimester of human pregnancy which is clearly 
not possible (776). Various alternative approaches have been adopted instead 
including the analysis of immune cell populations and cytokines in the peripheral 
blood of women with RSA and normal fertile women either before pregnancy or at 
the time of miscarriage.  
Moreover, studies use endometrial tissue obtained from women with RSA and 
normal fertile women in the periimplantation period in the non-pregnant state, and 
placental tissue obtained at the time of miscarriage from women with a history of 
RSA, from women with spontaneous abortions and from women requesting 
terminations of normal pregnancy (776). In the following, the most important 
approaches concerning immunologic aspects in RSA are mentioned. 
(1) Complement system 
Evidence collected over the last few years suggests that dysfunction of the innate 
immune system, including uncontrolled complement activation, may cause fetal 
loss (188). Complement inhibition is an absolute requirement for normal pregnancy 
which has been demonstrated by the finding that deficiency of Crry, an intrinsic 
complement regulatory protein, in utero leads to progressive embryonic lethality in 
mice (1545).  
Although the presence of complement components in the villi and in decidua is a 
common finding in physiological pregnancy, the amount of proteins deposited in 
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these areas increases substantially in pathological pregnancies. Preeclampsia is an 
example of pathological condition associated with marked deposition of both early 
and late complement components, as reported by Sinha et al. (1314). However, 
complement is also thought to play a pathogenetic role in RSA following the 
observation that Crry deficiency in mice is associated with fetal loss and C3 
deposition (1545). There is some indication that an abnormal expression of 
complement regulators may account for the occurrence of abortions in patients with 
a history of RSA (455).  
 
The involvement of complement at placental levels is also suggested by the finding 
of increased deposition of C3 and TCC on the wall of decidual vessels in patients 
with RSA (Radillo et al., unpublished data). An interesting observation was that 
the complement activity progressively declined prior to fetal loss in about 25% of 
patients with RSA (284). The trophoblast tissue collected from 
hypocomplementemic patients was responsible for complement consumption 
through the alternative pathway and had a reduced level of DAF as compared to the 
tissue obtained from patients with normal complement activity. 
 
Beside the reduced expression of the complement regulatory molecules, antibodies 
directed against surface antigens on trophoblast may also be implicated in 
complement activation in patients with RSA (456). Antiphospholipid antibodies 
(APA) are the antibodies that are more frequently encountered in these patients and 
are dealt with in details further down in the next section. However, APA are not the 
sole antibodies found in these patients. During the screening of a large number of 
sera obtained from primary and secondary aborters that did not contain APA, 
Tedesco et al. were able to detect complement-fixing antibodies that were found to 
be cytotoxic for syncytiotrophoblasts in 10-20% of the sera (1404). 
(2) Cell-mediated immune mechanisms 
NK cells 
NK cells as the predominant leukocyte population in decidua during early 
pregnancy may play an important role in RSA when too high in concentrations 
(1111). High concentrations of classical CD56+ CD16+ NK cells have been found in 
the uterus of women with abortions (773).  
Studies have shown increased numbers of CD56+ cells among a general increase of 
various lymphocyte populations (CD4+, CD8+, CD14+, CD16+/CD56+) in the non-
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pregnant endometrium of women with RSA, and lower numbers were seen in 
women with RSA who subsequently had a live birth compared with those who 
miscarried (1153).  
This is in contrast to a flow cytometric study which showed similar numbers of 
CD56+ cells in the endometrium of women with RSA and control subjects, although 
the women with RSA did have increased numbers of endometrial CD56dim CD16+ 
cells compared with control subjects (772). However, a decreased number of 
decidual CD56+ NK cells are reported in the placental tissue from spontaneous 
miscarriages in RSA women compared with tissue from spontaneous miscarriages 
in women without RSA and women requesting termination (1150). 
 
Moreover, normal human pregnancy is characterized by low peripheral NK cell 
activity whereas spontaneous pregnancy termination is linked to increased NK cell 
activity (1377). Some women with RSA show an abnormal cellular immune 
response with a marked increase in peripheral CD56+ CD16+ NK cells (1111). 
Perricone et al. also showed increased peripheral blood NK cells, both in absolute 
and in percentage values, in RSA pregnant and non-pregnant women (1111). A 
significantly increased number of circulating CD56+ NK cells was found in RSA 
women who miscarried compared with RSA women who delivered (1365). Moreover, 
high preconceptional peripheral NK cell activity in women with RSA is found to 
associate with subsequent abortion (38). 
 
However, it is not the presence of NK cells that is detrimental to the trophoblast as 
it is able to resist NK-mediated lysis in vitro (1377). In fact, NK cells are able to 
induce trophoblast lysis and cause foetal loss if they are converted to lymphokine 
activated killer cells by IFN-γ, TNF-α and IL-2 (340). As NK cells are not only the 
target of cytokines, but also producers of proinflammatory cytokines such as IFN-γ, 
this can result in the initiation of a vicious circle.  
Interations of between trophoblast HLA-C, HLA-E and HLA-G with inhibitory 
receptors like KIR and CD94/NKG2 in NK cells normally appear to block NK cell 
cytotoxicity against trophoblast cells. A previous study has shown that NK cells in 
peripheral blood of women with RSA expressed higher levels of the activation 
marker CD69 whereas significantly less of the inhibitory receptor CD94 compared 
to fertile controls (1032).  
Ntrivalas et al. further investigated the expression of inhibitory and activating 
receptors in peripheral NK cells of women with RSA and found an imbalance with 
increased expression of CD161-activating receptor and decreased expression of 
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CD158-inhibiting receptors (1031). A similar result found Yamada et al. when 
investigating peripheral blood NK cells form women with RSA (1552).  
Recently Haviid et al. investigated the HLA-G polymorphism in couples with RSA 
and compared their results with normal fertile couples (522). Although no 
significant difference were found in the distribution of HLA-G alleles between 
controls and RSA couples, 15% of the women who aborted carried the HLA-G*0106 
allele compared to 2% of those that did not. Aldrich et al. also evaluated the role of 
HLA-G polymorphisms in 113 women with RSA and found a significant association 
with increased risk for RSA (24).  
 
Macrophages 
No significant differences have been found in the number of macrophages in first-
trimester decidua from women with RSA either with chromosomally normal and 
abnormal fetuses, or in first-trimester decidua from spontaneous abortions and 
controls (1150). However, an increase in the number of macrophages in the non-
pregnant endometrium of women with RSA, together with an increased number of 
endometrial macrophages in RSA women who subsequently miscarried compared 
with those who had a live birth has been reported (1153). 
   
Lymphocytes 
Studies have shown no differences in numbers of CD3+ T cells as the second most 
abundant population in endometrium/decidua in the peripheral blood of RSA and 
normal fertile women prior to pregnancy (1549). In contrast, one study has shown a 
significantly decreased number of CD3+ T cells in the peripheral blood during 
pregnancy in women with RSA who subsequently miscarried compared with those 
who had a live birth and normal pregnant controls (766). Two recent studies have 
investigated a subpopulation of CD3+ T cells that also express the CD56+ uterine 
NK cell marker and have shown a decrease in the number of CD56+CD3+ cells in 
the peripheral blood prior to pregnancy (1549).  
No differences in the numbers of CD3+ T cells in endometrium from RSA and 
control women have been reported (772); neither were there any differences in 
numbers of CD3+ cells in early pregnancy decidua from normal fertile women and 
women with RSA (1150) and in decidua from normal pregnancies and after 
spontaneous abortion (1448). However, a decreased number of CD56+CD3+ cells in 
the decidua of women with RSA compared with control women has been reported 
(1549). 
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T cells can also be classified according to protein components of their TCR. The 
majority of peripheral blood T cells express αβ, but γδ T cells are found in EC layers 
where they are thought to play a role in preventing the invasion of infectious agents. 
Extensive studies by Clark and colleagues have suggested that these different 
populations of T cells play important roles in successful pregnancy outcome in 
mice, with αβ cells being important immediately after implantation, and decidual γδ 
T cells being important in preventing RSA (231). In abortion-prone mice the 
production of IL-10 and TGFβ2 by Vγ1.1δ6.3 T cells, which infiltrate into the 
decidua on day 8.5, has been shown to be important in preventing miscarriage (40).  
 
In humans, the ratio of specific subpopulations of peripheral blood γδ T cells, 
Vγl4Vδl and Vγ9Vδ2, is reported to be different in pregnant women with a history of 
RSA compared with controls (1374). Although several reports have suggested the 
presence and importance of γδ T cells in the human decidua (1374), other 
investigations have shown that most human decidual T cells are αβ positive, with 
only 5 to 10% of T cells expressing γδ (1447). 
 
As in older studies (222), any significant changes in the CD4/CD8 ratio in RSA 
women were not observed (606). In a recent study 15% of RSA women had an 
increased CD4/CD8 ratio (1365). These patients had normal levels of CD4+ T cells 
but low or absent suppressor/cytotoxic CD57+ CD8+ T cells suggesting lack of 
suppression, i.e. activation.  
The activation status of both T cells and CD56+ has been investigated by 
measurement of expression of CD25 as T-cell activation marker and CD69 as NK-
cell activation marker. In a study by MacLean et al., levels of CD25 in peripheral 
blood obtained from women with RSA in the first trimester of pregnancy were higher 
than those of healthy pregnant and healthy non-pregnant women (854). An 
increased number of CD25+ cells have been shown in the first-trimester decidua of 
women with RSA with chromosomally normal fetuses compared with decidua from 
elective terminations and women with RSA with chromosomally abnormal fetuses 
(1150).  
 
During normal pregnancy, the absolute leukocyte number rises due to increased 
numbers of granulocytes with unchanged numbers of lymphocytes and monocytes 
(886). The proportion and number of B cells (CD19+) were found to be significantly 
increased in the first trimester of pregnancy in RSA women compared with normal 
pregnant controls (606). 
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Fas–FasL interaction 
The critical role of Fas/FasL interaction between activated mother`s immune cells 
and trophoblast during pregnancy leads to apoptosis of activated immune cells that 
may block alloreactive responses and prevent the pregnancy failure (1246). This 
mechanism is generally regulated by the two specific proteins bcl-2 and bax that 
can promote or inhibit apoptosis process. However, the decreased expression of bcl-
2 and increased expression of bax in the deciduas are among of the characteristic 
features of pregnancy failure in women with RSA (736). Hence reduction of Fas or 
FasL during pregnancy may be associated with fetal loss in women with RSA. 
(3) Cytokine and growth factors  
The Th1/Th2-bias 
Concentrations of Th1 type cytokines, both at the maternal-fetal interface and in 
PBMC, are higher in women with unexplained habitual abortion. A Th1 type 
reaction in the maternofetal interface mainly triggers the inflammatory response 
with increase of IFN-γ, TNF-β, IL-2 and TNF-α, which contribute to trophoblast 
toxicity and failure of pregnancy in women with RSA (545). These Th1 type 
cytokines may damage the placenta directly or indirectly via the activation of 
certain immune cells.  
In addition, Th-1 type cytokines induced NK cells and lymphokine activated killer 
cells activity whereas Th-2 type reaction triggers the secretion of noninflammatory 
cytokines (IL-3, IL-4, IL-5, IL-10 and IL-13] during normal pregnancy that promotes 
the success of pregnancy by alloantibody induction, counter inflammation and 
suppression of the NK cell activity. Th1 and Th2 cytokines are mutually inhibitory 
and a shift towards a Th1 bias tends to further downregulate Th2 reactivity (343). 
 
It has been shown that stimulation of PBMC with autologous placental cells results 
in production of Th2 cytokines by women at labor and Th1 cytokines by patients at 
spontaneous miscarriage (1159). Compared to controls, Lee et al. found that the 
secretion of the Th1 cytokine from the immune cells was increased in RSA patients, 
which was associated with trophoblast apoptosis (799). There was a positive 
correlation between apoptosis and increased IFN-γ-levels of PBMCs.  
 
These results suggest that women with evidence of Th1 immunity to trophoblast 
stimulation undergo apoptosis of trophoblast cells, offering a potential pathological 
mechanism of TH1-mediated reproductive failure (799). Higher serum levels of IL-6 
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and IL-10 were detected in women at normal delivery than in patients with RSA at 
the time of abortion, and increased concentrations of TNF-α are detected in this 
group of women with RSA compared to those with successful pregnancy (862). 
Some studies have evaluated women at the time of abortion, during pregnancy or at 
labor and these reports have also shown lower levels of IL-6 in RSA patients 
compared to healthy women (1159).  
Daher and colleagues detected significantly higher levels of IFN-γ and a trend 
toward increased TNF-α in whole blood cultures from nonpregnant RSA women as 
compared to nonpregnant controls but no significant difference in IL-6 and TGF-β1 
was detected between the two groups (290).  
Under experimental conditions, the outcome of pregnancy can also be influenced by 
modulating the cytokine balance. Administration of TNF-α, IFN-γ or IL-2 to normal 
pregnant mice caused abortion whereas anti-TNF-α reduced the resorption rate in a 
murine model of spontaneous immunologically-mediated abortion (204).  
 
IL-12 
IL-12 has been shown to be present in significantly elevated levels in the serum of 
pregnant women with habitual abortion (1509). It significantly augments the 
cytolytic activity of lymphocytes against trophoblast cells and the administration of 
IL-12, along with IL-18, to pregnant mice has also been shown to result in 
pregnancy loss (991).  
 
GM-CSF 
IFN-γ has been shown to inhibit the secretion of GM-CSF that promotes the growth 
and differentiation of the trophoblast during normal pregnancy as compared to 
pregnancy in women with RSA (1110). Studies in mice have also suggested that 
GM-CSF and CSF-1 are important in successful pregnancy outcome (1133). 
Implantation is compromised in CSF-1 mutant mice which have both a lower rate of 
implantation and fetal viability, both of which can be restored to normal by 
administration of exogenous CSF-1 (1133). Decreased expression of utero-placental 
CSF-1 mRNA has also been shown in mice with spontaneous and induced 
pregnancy loss compared with control mice (468). 
  
TGF-β 
TGF-β is produced by Th3 cells and has been suggested to play an essential role 
both in promoting and in limiting placental development (597). TGF-β2 also induces 
decidual antiproliferative activity and is reduced in deciduas from women with RSA 
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at the time of miscarriage compared to women at first trimester with legal 
pregnancy termination (798).  
Ogasawara et al. have reported significantly higher levels of TGF-β1 both in 
nonpregnant and pregnant women with RSA compared to nonpregnant and 
pregnant controls, respectively (1039). They suggested that TGF-β1 is necessary for 
pregnancy development but may also represent a risk factor for recurrent abortions.  
 
The role of TNF-α in early embryonic death 
TNF-α is synthezised throughout the female reproductive tract as well as in 
placenta and embryo practically at all stages of development (1406). Data suggest 
that this multifunctional cytokine is involved in triggering immunological pregnancy 
loss, i.e. death of embryos owing to failure of defense mechanisms preventing 
rejection of the semiallogenic fetoplacental unit (1420). 
 
The injection of TNF-α into pregnant mice resulted in embryonic death and 
moreover, in a mouse model with high incidence of embryonic death, experiments 
have revealed an elevated level of TNF-α in supernatants of decidual cell cultures 
(204).  
TNF-α also influences the preimplantation development of embryos. Embryo 
transfer studies addressing the in vivo development of blastocysts that were 
exposed to TNF-α revealed that TNF-α treatment caused a 17% decrease in 
proportion of implanted embryos and that the proportion of embryos that died after 
implantation was 40% higher in the TNF-α pretreated group compared to controls 
(1542). Results suggest that TNF-α acting on blastocysts mainly decreases their 
ability to differentiate into fetuses after implantation rather than their ability to 
implant in the uterus (1424). 
Uterine cells may also serve as targets for the toxic effect of TNF-α. Experiments in 
the mouse uterine EC line WEG-1 revealed that TNF-α had a dose- and time-
dependent cytotoxic effect on these cells while stimulating apoptosis (1068). 
Monzon-Bordonaba et al. also demonstrated that TNF-α may be involved in 
pathological processes leading to pregnancy loss by disturbing normal trophoblast 
endocrine function (961).  
 
There have also been conducted several experiments showing the involvement of 
TNF-α in the pathogenesis of stress-induced early embryonic death. An elevated 
TNF-α expression was observed in the uterine epithelium, stroma, and in giant and 
spongiotrophoblast cells of mouse placenta exposed to DNA-damaging 
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cyclophosphamide (470). In mice exposed to ultrasonic sound stress, TNF-α-
producing cells at the fetomaternal interface appeared to be activated and increased 
their TNF-α production (41). In a study with diabetic mice, there was observed a 
much higher decrease in pregnancy rate in severly diabetic TNF-α +/+ mice than in 
TNF-α-deficient mice (1425).   
 
Activation of thrombotic events 
Recent studies have suggested that the way in which Th1 cytokines bring about 
pregnancy loss is via upregulation of a newly described procoagulant, fg12. Fg12 
converts prothrombin to thrombin, which in turn leads to deposition of fibrin and 
activation of polymorphonuclear leukocytes that can destroy the vascular supply to 
the placenta (232). 
In mice, anti-fg12 antibodies completely prevent spontaneous abortion and 
dramatically reduce the effects of TNF-α and IFN-γ on abortion rates (234), while 
TNF-α and IFN-γ have been shown to upregulate the production of fg12 by both 
fetal trophoblast and maternal decidua (235). In humans, increased expression of 
fg12 in trophoblast cells from failing pregnancies with chromosomally normal 
embryos, but not in trophoblast tissue from chromosomally abnormal embryos, 
have also been reported (723).  
(4) Humoral immunity – alloimmune and autoimmune antibodies 
The majority of unexplained RSA cases is found to be associated with certain 
autoimmune and alloimmune antibodies that may play major role in the 
immunologic failure of pregnancy and may lead to abortion (1071). Indeed, 
infertility and recurrent miscarriages can be a manifestation of subclinical 
autoimmune disease, and a variety of autoantibodies have been found at increased 
frequencies in women with pregnancy failures.  
Autoimmune abortions are characterized by maternal autoimmune reactions where 
antibodies or autoreactive cell target decidual or trophoblast molecules and affect 
placental and fetal growth. Alloimmune abortions are characterized by impaired 
aternal immune reactions against paternally derived molecules on trophoblast 
resulting in rejection of the fetus. 
 
Autoimmune factors 
Autoimmune factors represent the immunologic response of the mother to a 
pregnancy that can cause fetal rejection in 30% of women with RSA (1071). 
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Recently Yamada et al. have reported different types of APA, including Lupus 
anticoagulant, anticardiolipin β2-glycoprotein IgG/IgM/IgA, anticardiolipin 
IgG/IgM/IgA, anti-phosphatidylserine prothombin IgG/IgM, and anti-
phosphatidylethanolamine IgG/IgM in women with RSA (1550).  
 
As phospholipid molecules are normal components of cell membranes holding the 
dividing cells together, the production of antibodies to phospholipid molecules may 
inhibit the development of placenta at the materno-fetal interface (1071). These 
antibodies can specifically damage the inner wall of the blood vessel, which allows 
blood cells to stick to the site of the injury and cause blood clot formation. The 
combination of blood clots and constricted blood vessels may impair blood supply to 
the fetus and placenta resulting in complete fetal demise or growth retardation in 
women with RSA (1457).  
In a study over 20 years by Makino, he observed that anti-
phosphatidylethanolamine antibodies and anti-annexin antibodies were more 
common factors in RSA patients than were anticardiolipin antibodies in terms of 
induction of recurrent pregnancy losses (863). In a study by von Landenberg et al. 
the association of IgG antiprothrombin antibodies with pregnancy loss and in 
particular early pregnancy loss in cohort of patients with antiphospholipid 
syndrome was detected (1462). 
Women with RSA of unknown etiology have a higher incidence of antinuclear 
antibodies (ANA) which indicated that there may be an underlying autoimmune 
process that affects the development of the placenta and can lead to early 
pregnancy loss (1365).  
 
Bussen et al. found that the incidence of antithyreoid antibodies (ATA) in women 
with RSA appears to be significantly increased compared to controls (164). Women 
with ATA double their risk of miscarriage as compared with women without these 
antibodies (164). Increased levels of thyroglobulin and thyroid microsomal (thyroid 
peroxidase) autoantibodies are associated with an increased miscarriage rate, and 
as many as 31% of women experiencing RSA are positive for one or both antibodies. 
Risk of fetal loss increases to 20% in the first trimester of pregnancy and there is 
also an increased risk of post-partum thyroid dysfunction. 
A high percentage of women with RSA were also shown to have anti-endothelial cell 
antibodies, which suggests that the migration of endovascular trophoblast may be 
inhibited by anti-endothelial cell antibody in women with RSA (1221). 
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Alloimmune factors 
The investigation that trophoblast expresses MHC antigens on its surface which 
when recognized by maternal immune system triggers some alloimmune 
mechanism essential for the development of maternal immunotolerance has led to 
finding that RSA of unknown etiology could be attributed to the following 
alloimmune characteristics that elicits weather the fetus will survive or reject 
during pregnancy (1071). 
 
In normal pregnancy, the maternal immune system usually recognizes the paternal 
HLA as different from its own and induces the expression of several alloantibodies 
including antipaternal cytotoxic antibodies (APCA), antiidiotypic antibodies (Ab2) 
and mixed lymphocyte reaction blocking antibodies (MLR-Bf) that may coat and 
protect the fetus from the cytotoxic maternal immune responses (1071).  
However, several investigators reported that absence or decreased expression of 
APCA (1054), Ab2 (603) and MLR-Bf (6, 1072) might lead to abortion in women with 
RSA.  
Hasegawa et al. have reported less than 8.7% APCA positivity in women with poor 
pregnancy outcome (517). Agrawal et al. have also demonstrated that APCA were 
present only in 8.5% of women with RSA as compared to 33-46% in women with 
normal pregnancy (11).  
Anti-anti HLA antibodies (Ab2) and seemingly clonotypic antibodies recognize 
alloantigens receptor on T-lymphocytes and induce the suppression in alloimmune 
response during normal pregnancy (1071). The prevalence of Ab2 in women with 
RSA as well as in women with normal pregnancy was evaluated by Pandey et al. 
(1070). They found a 30% Ab2 positivity in women with normal pregnancy as 
compared to none in women with RSA which indicated that role of Ab2 is important 
for maintenance of pregnancies.  
 
The same group also observed a similar fetoprotective effect of MLR-Bf (1069). 
Tamura et al. found MLR-Bf positivity in 82.4% women with normal pregnancy as 
compared to 10% of women with RSA (1394). They also demonstrated that a 
blocking effect of MLR-Bf was inhanced as the pregnancy progresses and once it is 
developed may also be helpful with subsequent pregnancies. A study on time-
kinetics of MLR-Bf during the course of a successful pregnancy showed maximum 
levels during the first trimester and a progressive decline through the subsequent 
trimesters and post-delivery (11).  
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Symmetric antibodies 
Approximately 80% of the IgG specifically reactive to endometrial antigens are 
symmetric antibodies which can be cytotoxic in women with habitual abortion; in 
healthy pregnant women, the percentage is much lower at approximately 25% 
(343). According to a recent study, women with a history of recurrent abortions 
have significantly lower proportions of asymmetric IgG antibodies (3% of total IgG) 
compared with healthy pregnant women (29% of total IgG), nulliparous and 
multiparous women.  
In addition, amongst antibodies reactive with endometrial antigens, recurrent 
aborters had significantly lower proportions of asymmetric antibodies than healthy 
pregnant women (351). Some investigators consider that the lower levels of the non-
precipitating asymmetric-type of antibodies in RSA patients that would allow 
immunological tolerance are the major determining factor for unsuccessful 
pregnancy (351). 
(5) The role of progesterone in recurrent abortion 
The immunmodulatory effects of progesterone in the maintenance of pregnancy 
were already described in the last chapter. Chronic exposure of immunocompetent 
maternal cells to allogenic embryonic antigens progressively increases the number 
of PR on maternal lymphocytes, whereas cases of spontaneous abortion and 
preterm labor are associated with decreased numbers of maternal PR-positive 
immune cells (485).  
A specific T cell subpopulation, the γ/δ TCR+ cell, is likely to play a role in 
recognising embryonic antigens as they are able to recognise unprocessed antigens 
without MHC (1374). In the decidua, the proportion of γ/δ TCR+ cells significantly 
increases and is under hormonal control; 90% of these cells express PRs and 
overlap to a high degree with the CD56+ population. Heyborne et al. showed that 
trophoblast recognition is TCR-dependent and is mediated by the hsp60 reactive Vγl 
subset of γ/δ T lymphocytes (542). Within this subset, specific differences in the 
ratio of Vγl4Vδl and Vγ9Vδ2 cells in peripheral blood have been detected between 
healthy pregnant women and recurrent aborters (1374). Signaling via the Vγl4Vδl 
receptor induced a Th2 response whereas activation of the lymphocytes via the 
Vγ9Vδ2 receptor resulted in increased IL-12 production and NK cell activity. 
The immunomodulatory effect of progesterone by the stimulation of PIBF, as 
mentioned above, leads to the inhibition of NK cell activity and induction of the Th2 
response, especially IL-10 (485). Both progesterone and its stereoisomer 
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dydrogesterone are thought to inhibit the activity of NK cells at the foeto-maternal 
interface in humans via PIBF. PIBF production by lymphocytes is induced by both 
progesterone and dydrogesterone in a dose-dependent manner and can be inhibited 
by equimolar concentrations of RU-486 (mifepristone) (485). The absence or 
decreased expression of PIBF during pregnancy in RSA patients may cause abortion 
(343).  
 
Inhibiting the effects of progesterone by receptor blockade, or neutralising PIBF 
effects with a specific antibody, significantly reduced the production of asymmetric 
antibodies in mice as well (1375).  
Progesterone associated endometrial proteins or placental derived glycodelin found 
in epithelial glands of endometrium, endometriotic tissues, ECs of umblical cord, 
human fallopian tube, decidua amniotic fluid, normal and ovarian tumors also act 
as immunosuppressive agent during pregnancy (1587). Low levels of these proteins 
might lead to RSA and termination of pregnancy. 
 
To conclude, the following diagram is supposed to summarize the immunological 
mechanisms leading to early pregnancy loss in women with RSA (Figure 25).  
 
 
 Spontaneous pregnancy loss   
 Fetus as a semiallograft 
 50% paternal/50% maternal 
  
 Recognition of fetal antigens on trophoblast by decidua 
  
 Allogenic immune reaction 
 Abortogenic shift 
 Insufficient upregulation of progesterone/PIBF 
 
      Increase in symmetric         Shift of Th2-type to     Increase in NK cell activity  
      antibodies                            Th1-type cytokine        Conversion of NK to LAK 
                                                       production                 cells by IL-2/TNFα 
Figure 25: Abortogenic immune mechanisms associated with pregnancy loss, adapted 
from Druckmann et al. (343)  
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(6) Influence of stress on pregnancy-related immune mediators 
Since a well-balanced interaction of nervous, endocrine and immune system is 
crucial for the maintenance of successful pregnancy, recent observations on stress-
triggered pregnancy failure have been recently reviewed by Arck (43). 
The exposure of pregnant mice to a defined stressor during the periimplantation 
period has been shown to induce neurotransmitter substance P-mediated activation 
of T cells, mast cells and macrophages in the uterus, resulting in decreased levels of 
TGF-β2 and increased secretion of TNF-α (41). 
One recent study revealed a positive correlation between increasing stress scores 
and number of decidua basalis mast cells, CD8+ T cells and TNF-α expression in 
women with RSA (42). However, no significant differences between individuals with 
lower or higher stress scores could be observed with respect to decidual CD56+ NK 
cells and CD3+ T cells. It is proposed that the increase in CD8+ decidual cells 
observed in miscarriage patients with higher stress scores may reflect an attempt to 
abrogate the imminent or present failure of pregnancy (43). 
 
Interestingly, the increase in maternal stress perception has recently been shown to 
cause a decrease of the pregnancy supporting hormone progesterone and 
subsequently PIBF (624). PIBF is produced by peripheral CD8+ T lymphocytes of 
pregnant women and recent findings on immune parameters in stress-scored 
miscarriage patients further suggest an involvement of CD8+ cells (42). 
2. Immunological infertility 
Infertility is defined as a failure to conceive after 12 months of unprotected 
intercourses (1148). The causes of infertility which affects about 18-20% of couples 
in reproductive age include endocrine, tubal, uterine, cervical, and male factors. 
Unexplained infertility occurs when no cause of infertility can be identified after full 
clinical investigation of both partners. Recent studies in humans suggest that an 
unexplained reproductive failure can be influenced by some immunological 
abnormalities, similar to the causes described for RSA (225).  
 
Immunological infertility is considered to be an incapability to conceive due to 
immunological disturbances in the reproductive tract (747). Reproductive failure 
and infertility in association with autoimmune diseases has been recognized for 
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decades but only recently has it been demonstrated that certain characteristic 
autoantibodies are involved.  
Autoantibodies, such as APA, ATA, and ANA are considered to be responsible not 
only for recurrent miscarriages and some pregnancy complications but also for 
infertility. Antisperm antibodies (ASA) which can affect the transport of sperm cells, 
the process of capacitation and acrosome reaction as well as the fertilization, post-
fertilization and preimplantation processes can also be also associated with 
reproductive failure (893).  
 
The following lines try to give an overview of the most important disorders in 
immunological infertility, the presence of ASA, anti-ovarian antibodies (AOA) and 
the group of non-organ-specific antibodies including APA. Further, the latest 
approaches in treatment options in immunological infertility and abortion are 
outlined. To start with, a short summary of immunological infertility in males is 
given. 
a) Immunological infertility in males 
Although the clear focal point of these explanations is lying on the immunology of 
the female genital tract with its entire implications, one should also consider the 
importance of influences of the male reproductive system, especially in the aspect of 
immunological infertility. Therefore, the following lines briefly discuss the basic 
facts on male genital tract immunology and on male genital tract infections as a 
possible cause for infertility. 
(1) Immunology of the male reproductive system 
The testis is one of few organs in the human body which is capable of sustaining 
foreign grafts over a period of time without evidence of rejection (526). This 
“immunological privilege” is derived from the need to prevent immune responses 
against meiotic germ cells expressing nonself antigens which first appear long after 
the establishment of self-tolerance during puberty.  
However, innate and adaptive immune responses are not generally impaired in the 
testis as proven by the capability of inflammatory responses in the testis to 
infections (529). Also immune cells are found in considerable numbers within the 
interstitial compartment of the normal human testis (359, Table 36). Following 
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macrophages which are the second most abundant cell type next to Leydig cells, 
mast cells can be found as well. There is a small number of lymphocytes whereas 
there is no clear evidence for the presence of NK cells, DCs and granulocytes.  
 
Macrophages ++ NK cells ? 
Mast cells + DCs ? 
Lymphocytes (+) Granulocytes ? 
Table 36: Immune cells in the normal human testis 
Macrophages in the testis have considered being potential effector cells activating 
innate immune responses and inflammation. Testicular macrophages also express 
MHC class II antigens indicating a capacity for antigen-presentation to CD4+ Th 
cells (529). However, their ability to produce proinflammatory cytokines such as IL-
1, IL-6 and TNF-α was reduced in rats compared to macrophages of other origin 
(690). Probably, resident macrophages in the testis mainly exert antiinflammatory 
activities (528). Similar to mast cells, macrophages also seem to be involved in the 
local regulation of testicular functions.  
Only few lymphocytes were detected in testicular tissue whereas the lining 
epithelium showed more CD8+ than CD4+ T cells and the intertubular tissue more 
CD4+ than CD8+ T cells (359).  
Immunotolerance in the testis has long been explained on the basis of the fact that 
Sertoli cells can mechanically segregate all germ cell autoantigens by means of the 
so called blood-testis barrier (1103). However, tissue barriers and mechanical 
sequestration are important but not sufficient to protect male germ cells from 
autoimmune attack as circulating antibodies and and T cells can enter and soluble 
sperm antigens can exit at the level of the rete tesis (359).  
 
The presence of an immunosuppressive activity in testicular fluid was confirmed by 
a study which showed that Sertoli cells secrete molecules capable of inhibiting 
proliferation of lymphocytes, especially B and T lymphocytes (410). These 
lymphocytes drastically reduced the production of IL-12 which shows that Sertoli 
cells contribute to the maintenance of of imunological privilege in the testis.  
Expression of FasL by Sertoli cells has also been implicated in maintaining 
testicular immune privilege. CD8+ T cells migrating into the testis are capable of 
mounting an immune response against foreign tissue grafts but undergo apoptosis 
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at an increased level via upregulation of Fas on their surface (291). However, the 
role of FasL in the immune privilege in the testis remains controversial.  
Local anergy of T lymphocytes may also play a key role. Constitutive expression of 
MHC molecules is found in the testis whereas costimulatory molecules such as 
ICAM-1, CD80 and CD86 are absent which would leave naïve T cells refractory to 
antigen-specific activation (1237).  
 
Resident macrophages as well as nonimmune testicular cells have been shown to 
produce both pro- and antiinflammatory cytokines such as IL-1, IL-6, TNF-α, and 
TGF-β even in the absence of inflammation (527). The overlap between testicular 
functions including steroidogenesis and spermatogenesis and immune regulatory 
functions of these cytokines could help to understand testicular immune privilege 
and the processes leading to inflammation-mediated damage in the testis (1267). 
Consequently, local upregulation of cytokine expression during infection or injury 
may contribute to the disruption of testicular function and fertility.   
(2) Influence of male genital tract infection on fertility 
In men, infection and inflammation of the reproductive tract including the testes 
are widely accepted as important etiological factors of infertility.  
Invasion of microorganisms into the male genital tract has been frequently shown to 
be associated with impaired sperm function and thus, persistent infertility (675). 
Pathological bacterial strains present in semen may act directly on sperm cells 
causing agglutination of motile sperm (959), reducing ability for the acrosome 
reaction (734), and also causing alterations in cell morphology.  
 
Sanocka et al. just recently described a statistically significant deteriorated semen 
volume, sperm concentration, motility, morphology and vitality in ejaculated 
samples of patients with genital tract infection with Escherichia coli, Ureaplasma 
urealyticum and Staphylococcus aureus in comparison to healthy controls (1253). 
Moreover, the inflammatory process in the genital tract may lead to deterioration of 
spermatogenesis and obstruction of the seminal tract (675), worsening 
characteristics of semen and sperm density. Microorganisms trigger a local 
inflammatory reaction, activating leukocytes and inflammatory mediators such as 
cytokines and ROS, which are known to be important in the aetiology of male 
infertility. 
In general, genital tract infection may still worsen male infertility.  
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Sanocka et al. compared the influence of bacteriospermia on the anti-oxidant 
status and proinflammatory cytokine levels in seminal plasma of infertile males 
with genital tract infection to those of fertile controls with genital tract infection 
(1252).  
Results suggested that urogenital infection in the latter phase in normozoospermic 
patients may lead to the predominance of antioxidant levels in seminal plasma, 
creating a positive environment for the recovery of complete function of sperm cells 
whereas genital tract infection in infertile patients may cause a pro-oxidant 
overbalance in semen that may additionally impair the fertilization ability of 
spermatozoa and worsen the prognosis for future fertility (1252). Also, the 
significantly enhanced IL-6 concentration in the seminal plasma of 
normozoospermic patients may indicate that normozoospermic semen recovers 
better from infection whereas in semen of infertile patients leukocytes may be an 
additional factor worsening the fertility prognosis. 
 
The impact of Chlamydia trachomatis as one of the most common STD on semen 
quality and its role in male infertility is still controversial, probably due to different 
study designs (465). It is thought that up to 50% of men infected with Chlamydia 
might be asymptomatic and in those with symptoms, the most common 
presentation is urethritis (465). Most upper genital tract infections in young men, 
including epididymitis as a cause for infertility, are also attributable to Chlamydia. 
Data suggest that a C. trachomatis infection of the male reproductive system may 
contribute to the formation of ASA (1527). Antichlamydial antibodies in women`s 
sera correlated with detection of IgA antibodies in the male ejaculate and not with 
anti-chlamydial antibodies in the corresponding men`s sera (1526). The presence of 
anti-chlamydial antibodies in semen has been correlated with the development of 
autoimmunity to spermatozoa.  
 
Overall, in vivo studies of C. trachomatis in men have provided conflicting evidence 
as to whether it is associated with reduced fertility. By contrast, in vitro studies 
show that coincubation of spermatozoa with Chlamydia causes a significant decline 
in numbers of motile sperm and results in premature sperm death possibly due to 
chlamydial LPS (361). 
It appears from the literature that there is no association between male infertility 
and genital infections caused by C. trachomatis, however, prospective longterm 
investigations regarding the fertility of men after acute infections with C. 
trachomatis are lacking (746). The effect of C. trachomatis infections on male fertility 
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seems to be related to the quality of the immune response of the host. Thus, the 
cell-mediated immunity must be study more accurately (465). No doubt exists that 
the female partners carry the main risk of chlamydial infection of the genital organs 
as C. trachomatis infection of the female genital organs may be deleterious to female 
fertility. 
 
Chronic inflammatory reactions following acute orchitis are characterized by 
multifocal lymphocytic infiltrates and tubular changes which finally result in 
complete disruption of spermatogenesis as reflected by testicular atrophy and 
persistent infertility (1268). A symptomatic orchitis due to bacterial or viral 
pathogens is considered to be rare but a high prevalence of asymptomatic testicular 
inflammatory reactions could be demonstrated among infertile men. 
 
Only few studies have investigated testicular inflammatory reactions among infertile 
males. Tissue specimen from asymptomatic patients with impaired fertility showed 
a testicular infiltration of lymphocytes in about 56% of the cases, predominantly 
CD4+ and CD8+ T cells, mast cells and non-resident CD68+ macrophages (1268). 
The degree of infiltration correlated with characteristic signs of tubular damage. 
These testicular inflammatory reactions in infertile men were associated with 
significantly reduced testicular volume and impaired spermatogenesis (1268). This 
indicates a significant disturbance of the local immunoregulation and testicular 
immune privilege. The dysbalance of locally produced cytokines towards a 
proinflammatory profile, impairment of Sertoli cell function and subsequent 
breakdown of the blood-testis barrier appear to be important features of testicular 
inflammatory reactions which finally result in deterioration of spermatogenesis and 
infertility (410). The pattern of lymphocyte infiltration and concomitant damage of 
seminiferous tubules also supports the concept that activation of autoreactive T 
cells is involved (1268).  
b) Autoimmune processes in infertility 
(1) Antisperm antibodies 
ASA are one of the main causes of immunological infertility by binding to the sperm 
membrane and impairing sperm functions and can be present in males and females 
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(554). They occur in seminal plasma, bound to the sperm surface, in blood sera of 
men and women, in cervical mucus and follicular fluid of women.  
 
The incidence of ASA in infertile couples ranges between 9 and 36% in the literature 
(126). Ten percent of infertile men show ASA in the seminal plasma or attached to 
the surface of spermatozoa, while in approximately 5% of female infertile partners 
ASA occur in cervical mucus or oviductal fluid (270). However, these antibodies are 
also present in approximately 1% to 2.5% of fertile men (533) and in 4% of fertile 
women (1049), which indicates that not all ASA cause sterility. Serum ASA are 
mainly of the IgG isotype while ASA in cervical mucus or seminal plasma belong to 
the IgA isotype (747).  
It has recently demonstrated that there is a diversity of ASA bound to the sperm 
surface, including different Ig classes of ASA, differing localization of the 
corresponding antigens for ASA, and different biological activities of ASA, in males 
(1297). Moreover, a relatively high incidence of asthenozoospermia was 
demonstrated in immunologically infertile males, and a significant effect of sperm-
immobilizing antibodies bound to the surface of ejaculated sperm on sperm motility 
was confirmed (1295). 
 
Aetiology of ASA formation 
There are several hypotheses for ASA formation in men. Theoretically, the blood-
testis barrier may be breached by a variety of mechanisms resulting in exposure of 
immunogenic sperm antigens to the immune system which could initiate an 
immune response, resulting in an inflammatory reaction and ASA formation. 
Mechanical obstruction of the genital tract may occur as a result of congenital 
abnormalities, surgical interventions, inflammation and trauma to the epididymis 
and vas deferens (128). Several reports suggest that between 50% and 70% of men 
after vasectomy subsequently have sera positive for ASA (533). Frequently, ASA also 
appear to be of idiopathic origin. ASA in the male may fulfill the criteria of an 
autoimmune disease (127). 
 
Production of ASA in women may occur in a variety of ways. Mechanical or 
chemical disruption of the mucosal layer of the female genital tract may permit 
exposure to foreign sperm antigens and, ultimately, ASA formation. It is known that 
after pelvic infection or several uterine or peritoneal inseminations with capacitated 
spermatozoa, some patients can develop antisperm antibodies (872).  
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Cunningham et al. confirmed in a study of the ASA prevalence in nulligravid 
women with various gynecologic infectious processes (283). Forty-six percent of 
women diagnosed with PID had sera and cervical mucus positive for ASA compared 
with an ASA prevalence of 20% in women who had lower genital tract infection. ASA 
also were detected in 69% of women with laparoscopically confirmed pelvic adhesive 
disease or hydrosalpinx but with no prior history of PID. 
 
ASA and fertilization 
Several studies have shown an inverse relation between the proportion of sperm 
bound by ASA and the fertilizing capability of sperm. One such study showed that 
only 14% of oocytes were fertilized if 70% or more of sperm were bound by both IgG 
and IgA antibodies; whereas a fertilization rate of 60% was observed when less than 
70% of sperm was bound with ASA (305). 
Results also imply that different ASA isotypes have different effects on fertilization 
and some ASA can act synergistically to reduce fertility. ASA of isotypes IgG, IgA, 
and IgM are all capable of binding to sperm (305). However, a study showed that 
IgG ASA on sperm correlated with a reduction in fertilization rate, whereas IgA and 
IgM ASA in female serum correlated with a decrease in fertilization rate (199).  
 
Analysis of cognate antigens of ASA 
In order to understand the relevance of ASA it is necessary to characterize the 
cognate antigens of ASA. There are direct tests to detect the presence of ASA on 
sperm such as the mixed agglutination assay, agglutination tests using donor 
sperm and tray agglutination test (538). These tests only detect the gross binding of 
antibodies to various locations on sperm and do not examine the antigenic 
specificities of the ASA.  
Moreover, ASA may have heterogeneous effects on sperm functions, obviously 
depending on their binding sites (128). They were found to affect sperm motility, 
penetration of cervical mucus by spermatozoa, acrosome reaction, interaction 
between spermatozoa and zona pellucida as well as the sperm-egg-fusion. However, 
no proper methods exist which indicate which ASA of an individual man are 
functionally relevant and which sperm antigens are associated with immunological 
infertility (128).  
The possibility exists that fertilization-related antigens may be the targets of ASA 
with an inhibitory effect on fertilization (1298). Such antigens consisted of sperm 
surface antigens including PH-20 (995), PH-30 (994), fertilization antigen-1 (FA-1) 
(662), sperm agglutination antigen-1 (SAGA-1) (327), and lactate dehydrogenase-C4 
 Immunology of the genital tract 
 II-258  
(LDH-C4) (463), and acrosomal antigens such as SP-10 (499), all found by 
immunological methods. 
 
Koide et al. investigated the cognate antigens of agglutinating ASA, which were 
obtained from the blood serum of infertile women or were mAb raised in the mouse 
against human sperm proteins. Six sperm proteins have been recognized as target 
antigens for ASA sourcing from fluids of the reproductive tract including YWK-II, 
BE-20, rSMP-B, BS-63 (nucleoporin-related), BS-17 (calpastatin) and HED-2 (zyxin) 
(735). In a study by Bohring et al. 18 proteins of the sperm membrane were 
detected as cognate antigens of ASA. Six of these proteins were identified as HSP70 
and HSP70-2, disulfide-isomerase-ER60, caspase-3 and two subunits of the 
proteasome (component-C2 and zeta-chain) (126). 
 
Effect of ASA on sperm motility and transport 
Since it is likely that ASA only bind to antigens of sperm membranes it may be 
speculated that functions of proteins with intra- and extramembranaceous parts 
may be altered by ASA to interfere with sperm motility (128).  
There are several hints that show the ability of ASA of IgG and IgA to inhibit sperm 
penetration into cervical mucus. The proportion of motile sperm with ASA 
correlated with the inhibition of sperm penetration in cervical mucus (917). 
Moreover, ASA were detected in the cervical mucus from up to 29.6% of infertile 
women immobilizing sperm and preventing passage through the cervical mucus 
(917). ASA can also impair sperm migration from the uterine cavity through the 
fallopian tubes (1296).  
 
A study examining migration of sperm through cervical mucus indicated that ASA, 
mainly IgA, directed against the sperm head, along with IgA and IgG ASA directed 
against the sperm principal piece, severely impaired the ability of sperm to 
penetrate the cervical mucus (1522). In contrast, the binding of IgG and IgA to the 
tail tip of sperm did not appear to affect the ability of sperm to penetrate the 
cervical mucus providing evidence that cervical mucus aids in the selection of the 
most fertile sperm of an ejaculate by acting as an immunological filter, preventing 
the passage of sperm coated with ASA (223).  
Impairment of sperm penetration into cervical mucus appears to be a consequence 
of the activation of the complement cascade by Ig attached to sperm surface 
resulting in cell lysis and phagocytic processes (128). This impaired penetrating 
ability, however, seems to be mediated by the effector region (Fc) portion of the Ig 
 Immunology of the genital tract 
 II-259  
molecules (611). This is also proposed by the study of Hirano et al., as a 15-kD 
protein with an amino terminus identical to that of SPLI is found in human cervical 
mucus, and this inhibits sperm transport (551). The Ig possess both an antigen-
recognition region (Fab) and an Fc that binds to various leukocytes through specific 
surface receptors (FcR). Sperm exposed to the Fab portion of IgG of ASA can swim 
through the cervical mucus, whereas those exposed to intact IgG of ASA can not 
(611). 
 
Effect of ASA on capacitation and acrosome reaction 
Evidence has emerged that ASA might prevent membrane fluidity changes needed 
for capacitation before fertilization (109). In addition, sperm incubated with serum 
containing immobilizing ASA were found to have lower rates of spontaneous and 
induced acrosome reactions than sperm that were not incubated with the serum 
(996). Furthermore, ASA can inhibit the ability of sperm to undergo spontaneous 
capacitation as an antibody raised against a human sperm protein, BS-17, 
prevented capacitation of human sperm (1486). 
 
The effects of ASA on acrosome reaction have been contradictory. ASA may have a 
variable effect on the acrosome reaction and capacitation with some ASA adversely 
altering the ability of sperm to undergo capacitation or acrosome reaction, whereas 
other ASA do not (129). A study showed that human follicular fluid contains IgG 
antibodies capable of inducing the acrosome reaction and inhibiting sperm–ZP 
binding (872). 
 
Effect of ASA on sperm-oocyte binding 
There are conflicting results about the ability of ASA to affect sperm-oocyte binding 
and it is likely that the antigenic specificity of ASA is important in their effects on 
fertilization (223). Some studies reported that binding of head-directed IgG or IgA 
ASA to sperm reduced sperm binding to human ZP (860) while other investigators 
found that ASA did not affect sperm-oocyte binding (241) or that ASA were capable 
of both stimulating and suppressing sperm-oocyte fusion (146).   
 
ASA treatment  
Several strategies are used in an effort to improve the potentially deleterious effects 
of ASA-mediated infertility resulting in improved gamete function. 
First, methods used to reduce ASA production include condoms and systemic 
corticosteroid treatment. As repeated or multiple sperm exposure to the female 
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reproductive tract results in ASA formation, condom use would decrease sperm 
exposure, resulting in a concomitant decline in ASA production (893).  
Mild inflammatory and immune system suppression with corticosteroids may also 
provide some couples with a limited benefit. In a study of 43 men with ASA-bound 
sperm, there was a statistically significant decrease in sperm-associated IgG but 
only little effect on sperm-bound IgA in the steroid versus the placebo group. 
Furthermore, in spite of a decrease in the antibody titer there was no statistically 
significant difference in pregnancy outcome between the two groups (494). 
Cyclosporine was also tested in a cohort of ASA-positive men (133). After treatment, 
a pregnancy rate of 33% was observed but due to the lack of placebo controls, no 
definite conclusions can be drawn. 
 
Second, there are methods that attempt to remove ASA already bound to sperm 
include immunodepletion, sperm washing, and IgA protease treatment (893).  
The immunomagnetic separation technique has been tried to separate the 
antibodies bound on the sperm surface but offered only limited success in isolating 
sufficient number of ASA-free sperm of good motility (418). 
There are mixed reports on simple sperm washing on ASA elution from various 
laboratories. Adeghe found that washing decreased IgG bound on the sperm 
surface (8) whereas another group did not find the similar positive effects (1511). 
 
Moreover, several studies have examined the use of assisted reproduction 
technology (ART) in treatment of ASA including intrauterine insemination (IUI), 
intracervical insemination (ICI), IVF, gamete intrafallopian tube transfer (GIFT), 
subzonal sperm injection (SUZI), and, more recently, intracytoplasmic sperm 
injection (ICSI) (893).  
IUI has been found to be useful for treatment of female and male immunoinfertility 
by circumventing problems related to sperm transport in the female genital tract 
especially, sperm passage through the cervical mucus (1013). However, in women 
having ASA in the cervical mucus, pregnancy rates after IUI were identical to 
women who did not have ASA if the male partner did not have ASA (207). However, 
the pregnancy outcome significantly improved after including the ovarian 
hyperstimulation treatment along with IUI or in some cases of male 
immunoinfertility (1013).  
In GIFT procedure, sperm and eggs are mixed in vitro and then transferred to the 
fallopian tubes for fertilization. In one study, GIFT was performed in 16 
immunoinfertile couples that achieved pregnancy rates of 43% per couple (1439). 
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This study did not include any control group, and the pregnancy rates are 
comparable with those that are reported after GIFT in patients having other 
etiologies. 
 
An analysis of data from IVF programs by Chiu and Chamley has provided a great 
amount of evidence regarding the effects of ASA in serum, semen, and follicular 
fluid as a possible cause of infertility (223). These studies generally indicate that 
couples with ASA have lower pregnancy rates in IVF trials than couples without 
ASA.  
Acosta et al. (96) retrospectively examined the combined effects of ASA and sperm 
morphology on fertilization and pregnancy rates in 85 couples with male factor 
infertility, treated with 38 cycles of IVF and 57 cycles of GIFT (5). The ASA-negative 
group had greater fertilization and pregnancy rates than the ASA-positive group. 
Interestingly, there are also studies reporting increased rates of IVF outcome 
including implantation and pregnancy rates in immunoinfertile women compared 
with women with tubal factor infertility (292). In IVF procedure, generally albumin 
instead of female partner`s serum is used as a protein source in the insemination 
medium that circumvents the antibodies if present in the female partner. Thus, IVF 
can take care of female but not male immunoinfertility (1013).   
 
ICSI is a method that may allow some couples to avoid fertilization failure 
secondary to an autoimmune mechanism. Lahteenmaki et al. treated 29 infertile 
ASA-positive couples with ICSI after 22 of them demonstrated a poor fertilization 
rate (6%) during IVF (775). After ICSI, the fertilization and cleavage rates for the 
ASA-positive group were similar to the ASA-negative group. It is notable that 46% of 
the pregnancies occurring in the ASA-positive group ended in spontaneous 
pregnancy loss compared with none in the ASA-negative group.  
A retrospective analysis of 55 ICSI cycles for 32 different couples with high levels of 
ASA-bound sperm demonstrated a significantly higher fertilization rate between the 
ASA-positive group undergoing ICSI and an ASA-negative control group undergoing 
ICSI (999). Using the ICSI procedure in immunoinfertile men, one can achieve 
higher fertilization rates than using the IVF procedure; however, the fertilized 
zygotes show higher degeneration and mortality, and decreased embryonic 
development (1013). However, compared to other methods, ICSI has been the most 
successful in treating in ASA-positive infertility (747). 
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By using hybridoma and recombinant DNA technologies as well as various 
genomics approaches, several sperm antigens have been defined from various 
laboratories that may be involved in fertilization and fertility. Naz et al. has cloned 
FA-1 and YLP12 among at least nine sperm-specific cDNAs (1014). Antibodies to 
FA-1 antigen inhibit human sperm-ZP interaction, and also block human sperm 
capacitation/acrosome reaction by inhibiting tyrosine phosphorylation.  
A study was conducted if immunoadsorption with the human sperm FA-1 antigen 
would remove autoantibodies from the surface of sperm cells of immunoinfertile 
men and thus increasing their fertilizing capacity (919). An increased immunobead-
free swimming sperm on an average of 50 and 76% for IgA and IgG ASA, 
respectively, was found. The acrosome reaction rates increased significantly and 
showed improvement in 78% of the sperm samples after FA-1 adsorption. The IUI of 
FA-1-treated antibody-free sperm resulted in normal pregnancies and healthy 
babies, indicating that the antigen treatment does not have a deleterious effect on 
implantation, and embryonic and fetal development (919).  
(2) Anti-ovarian antibodies 
AOAs form a heterogeneous group of antibodies recognizing several different 
antigenic targets such as granulosa and thecal cells, zona pellucida, oocyte 
cytoplasm, corpus luteum, as well as gonadotropins and their receptors (960). Their 
involvement in patients with patent premature ovarian failure (POF), a disorder of 
multicausal etiology leading to infertility in women, is highly likely.  
POF is defined as secondary amenorrhoea with a hypestrogenic hypergonadotropic 
serum profile in the menopausal range which finally culminates into partial or total 
destruction of the primordial follicle pool thereby leading to infertility (261). 
 
In POF patients, a variety of autoantibodies and possible target antigens have been 
reported so far, including antibodies binding to mature follicles and corpus luteum, 
termed as steroid cell antibody (SCA) (113). In the ovary, SCA immunostaining was 
preferentially localized in theca interna cells of antral follicles, but in some cases 
the granulosa layer and corpus luteum were also stained. Whereas the prevalence of 
SCAs in POF is 6.5-10% of patients, it was much higher (87–100%) in patients with 
Addison`s disease with associated POF (294).  
None of these studies showed SCAs to be present in healthy controls, and it is not 
known whether they could be detected in other ovarian pathologies. Thus, these 
antibodies seem to be highly specific to anti-adrenal autoimmunity with associated 
 Immunology of the genital tract 
 II-263  
ovarian failure (960). Moreover, in normally cycling patients with autoimmune 
endocrine disorders, the appearance of SCAs may be predictive of forthcoming 
ovarian failure (113). 
 
The localization of AOAs on cells of the granulosa layer and in oocytes, as well as 
the expression of FSH and LH receptors in granulosa cells and FSH receptors in the 
oocyte, is consistent with the hypothesis of gonadotropin receptors being antigenic 
targets for AOAs (836). However, different studies on anti-gonadotropin receptor 
antibodies suggest that the role of this type of autoantibody in human ovarian 
diseases still remains to be demonstrated (960).  
 
Only a few studies have demonstrated the existence of antibodies directed against 
gonadotropins themselves. Meyer et al. detected anti-FSH antibodies in 92% and 
anti-LH antibodies in 65% of low-responder IVF patients, but not in good 
responders (928). POF patients did not present with anti-FSH antibodies, and only 
6% of them had anti-LH antibodies (837). Haller et al. showed that patients with 
endometriosis and polycystic ovary syndrome presented with higher levels of anti-
FSH IgA and proposed anti-FSH IgA as a marker for ovarian disorders causing 
infertility (498). Most of the research on anti-gonadotrophin antibodies has actually 
been done to develop contraceptive vaccines in humans, which is discussed later 
on. 
Whether the prevalence of anti-ZP antibodies is higher in infertile than fertile 
women has been examined in numerous studies, but the results are still 
controversial. In the largest series of infertile women tested, Kamada et al. found a 
significantly higher prevalence of serum anti-ZP antibodies in patients with 
unexplained infertility than in infertility with known causes, thus indicating a 
possible aetiological significance of anti-ZP antibodies in some cases of unexplained 
infertility (655). Results of a study by Kelkar et al. indicate that 66.6% women with 
POF belonged to the autoimmune group and that ZP is an important antigenic 
determinant of autoimmune POF and that ovarian auto-antibodies circulating in 
POF patients are specific to ZP (678). 
 
Only a few studies have been devoted to antioocyte antibodies. Studies on human 
ovarian sections revealed the presence of anti-oocyte antibodies in the serum of 
33% of POF patients (295), and in another group of patients with ovarian failure 
46% had such antibodies detected by ELISA with extracts from unfertilized IVF 
oocytes (837). 
 Immunology of the genital tract 
 II-264  
(3) Non-organ-specific autoantibodies 
Presence of organ-specific auto-antibodies to testicular antigens and sperm in men, 
or antibodies to zona pellucida and endometrial antigens in women, are considered 
possible causes of infertility in a fraction of patients with unexplained infertility 
(1442).  
However, the presence of other autoantibodies, which are not particularly organ-
specific, such as APA, ATA, ANA or anti-smooth muscle antibodies (SMA) have 
recently been increasingly implicated (1442). Some investigations showed a greater 
incidence of these antibodies compared to organ-specific antibodies in infertile 
women and the association between their presence and the period of infertility 
(460).   
 
In a preliminary study by Putowski et al., 82.3% of infertile patients after repeated 
IVF failure had at least one abnormal result on autoimmune testing but no 
symptoms of autoimmune disorders (1148). Results of another study on 108 
females with reproductive failure versus a control group of 392 women showed that 
40.7% of patients’ sera and 14.8% of control sera contained one or more common 
autoantibodies with ANA and SMA most frequently detected (1184).  
 
As mentioned in the chapter about immunologic aspects in early pregnancy loss, 
APA as a heterogenous group of autoantibodies are highly associated with 
reproductive failure. Clinical criteria contain venous or arterial thrombosis, 
thrombocytopenia and recurrent fertility failure as well as the presence of serum 
IgG or IgM anticardiolipin antibodies (aCL) and lupus anticoagulant (1434). Women 
with systemic rheumatic diseases and accompanying reproductive failure have a 
high prevalence of APA, antibodies against cardiolipin and β2-glycoprotein I (765). 
The latter antibodies have been shown to have a direct inhibitory effect on the 
endothelial cells of the female reproductive tract, the early embryo and trophoblasts 
in the placenta (765).  
Evidence is also accumulating that antiphosphatidylserine antibodies (aPS) are 
particularly pathogenic to trophoblast (901). Both animal and in vitro experiments 
have shown monoclonal and polyclonal aPS and aCL to specifically destroy 
trophoblast, inhibit syncytium formation, halt hCG production and limit 
trophoblast invasion (901).   
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Mettler and colleagues demonstrated in their study that 66.7% of 123 women 
undergoing IVF had at least one pathological marker in autoimmune testing; a 
combination of pathological assays was found in 25.2% patients (927). Overall, 
32.5% of all patients had a positive titer of APA which is significantly higher than 
the estimated 2% prevalence in a healthy obstetric population.  
Würfel compared several studies on the prevalence of APA in IVF-patients (1540). 
Percentage numbers of patients tested positive for APA range between 15% and 
48%; compared to percentage of controls between 0% and 6%; however, in most 
studies there were no control groups measured.  
 
The presence of autoantibodies that are not specific to components of reproductive 
system in infertile women are viewed by some authors as an epiphenomenon rather 
than a factor playing a pathogenetic role. In this context, autoantibodies in infertile 
patients are seen as a part of generalized activation of the immune system (461), 
because in these patients, in addition to infertility-associated antibodies, some 
other classic autoimmune conditions were observed including monoclonal or 
polyclonal gammopathies, selective IgA deficiencies, and abnormalities of IgG 
subclasses (460). In addition, there is a plausible possibility that reproductive 
failure, in any of its forms, is the first clinical sign of impending autoimmune 
disease (462).  
 
In conclusion, women with reproductive failure and patients with repeated 
reproductive losses in IVF programs are a highly selected patient group with 
autoantibody abnormalities. There is a need of the immunological diagnostics in the 
group of patients with unexplained infertility. In the management of reproductive 
immunology, it is proposed to be sufficient to examine antibodies against seven 
different phospholipids in IgG, IgM and IgA, sperm and zona pellucida antibodies 
(1434).  
c) Treatment options of immunologic abortion 
Heparin plus aspirin, aspirin alone, intravenous immunoglobulin (IVIG) 
administration and immunization with allogenic lymphocytes are the most common 
treatments in women with immunological RSA.  
 
 
 Immunology of the genital tract 
 II-266  
Aspirin/heparin and steroids 
Among women with the combined problems of APA and elevated NK cells who 
become pregnant with preconception treatment, live birth rate is about 70%. The 
initial treatment of choice is usually low dose heparin and aspirin therapy (166). 
Sher et al. reported that the treatment of APA-positive women with a 
heparin/aspirin combination significantly improved the birth rate (1293). 
The other treatment option for auto-antibody syndromes is prednisolone, which 
suppresses the inflammatory process and stabilizes the cell. Particularly the 
combination of steroids and heparin is evaluated increasingly positive (1540). 
 
Intravenous immunoglobulin 
For women with RSA due to immunological reasons and failure of the 
heparin/aspirin therapy, therapy with IVIG remains a safe but still controversial 
alternative of treatment (1071). It has also been suggested for use in RSA cases with 
various serum autoantibodies which suggest autoimmunity.  
 
Several studies have shown significant benefit of IVIG treatment in women with 
recurrent miscarriages, while other studies have failed to confirm this beneficial 
effect (1366, 1540). Studies have previously shown that IVIG treatment does not 
affect the pregnancy outcome compared with placebo (226, 607). Also the results of 
the German RSA/IVIG group did not show a significant difference between IVIG 
and placebo therapy of women with RSA (1411). 
Stricker et al., however, reported a significant difference in pregnancy success rate 
between IVIG-treated and untreated groups in a study with older women with RSA 
(1365). A following study with a larger group of women confirms these positive 
results (1367).  
 
The basic effect of IVIG is to neutralize the cytotoxic effect of maternal immune 
response against the fetus (Table 37). Studies demonstrated that IVIG suppress the 
activity of APA and passively transferred blocking or antiidiotypic antibodies that 
inhibit the binding of APA to corresponding antigens (201).  
 
Suppression of lymphocyte activation Inactivation of complement 
Blocking of TCR Downregulation of NK cell activity 
Increase of suppressor T cell activity Shift of Th1/Th2 cytokines to Th2 
Table 37: Proposed mechanisms of IVIG  
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Results of a study by Graphou et al. showed at administration of IVIG in women 
with RSA influenced the Th1/Th2 lymphocyte ration (477). In alloimmune 
abortions, this effect was reflected by a shift of Th1/Th2 balance to Th2, while in 
autoimmune abortion IVIG possibly drives the Th1/Th2 ratio to a normal balance. 
Morikawa et al. demonstrated a downreguation of peripheral NK cell activity and 
subsets by massive IVIG treatment of women with RSA (968). Rigal et al. 
demonstrated that IVIG had no effect on 15 of 17 tested clusters of leukocyte 
differentiation (CD) markers used but that it downregulated adhesion molecule 
lymphocyte function-associated antigen-1 (LFA-1) and NK cells (1196).  
 
However, Jablonowska et al. showed that there were no statistical differences in 
the presence of the blocking antibodies prior to pregnancy in RSA women included 
in the IVIG trial compared with women not attending the IVIG trial and controls 
(605). Furthermore, they demonstrated that IVIG does not have long-term effect on 
T- and B cell subsets in women with RSA (606). 
 
Allogeneic lymphocyte immunotherapy 
Taylor and Faulk first reported the possibility of paternal lymphocyte 
immunotherapy for women with unexplained RSA which has become widely 
performed since then (1399). They originally based their idea of third party 
lymphocyte immunization for women with RSA on observations that renal allograft 
rejection could be delayed by third party blood transfusions while Beer et al. based 
paternal lymphocyte immunization on the belief that maternal “blocking antibodies” 
were necessary for successful pregnancy (95).  
 
The exact mechanisms of immunotherapy with allogenic lymphocytes have yet to be 
elucidated (Table 38). 
  
Induction of humoral antibodies (APCA, Ab2, MLR-Bf)  Increase of PIBF on lymphocytes 
Decrease of peripheral NK cells Increase of PR on lymphocytes 
Shift of Th1/Th2 ratio to Th2  
Table 38: Proposed mechanisms of allogenic lymphocyte immunotherapy 
Immunotherapy with leukocytes attempts to block immunological rejection of the 
fetus by exposing the mother to an overload of self or third party antigen. This is 
thought to mimic the presentation of fetal antigens during pregnancy presumably 
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illiciting maternal immunoglobulin effectors that are believed to be necessary for 
maintenance of pregnancy (1050). 
 
Some investigators suggested that paternal lymphocyte immunotherapy may act as 
immunogen to enhance the maternal immune response and to induce various 
humoral antibodies as immunological regulators for maintaining pregnancy (1073).  
Various recent studies demonstrated that paternal lymphocyte immunization in 
women with RSA induce the level of humoral antibodies like APCA (1054), Ab2 
(603), and MLR Bf (1069) that were correlated with the success of pregnancy. It was 
further suggested that the humoral antibodies APCA, Ab2 and MLR-Bf produced as 
a result of immunotherapy (1072) would mask the fetal HLA antigens and prevent 
them from being attacked by the maternal T cells.  
 
Initial reports on paternal lymphocyte immunization used the sharing of HLA 
antigens between spouses as a criterium for immunization (95). This excess sharing 
was considered to be increased in couples with RSA and responsible for the 
hyporesponsiveness which was considered to be shown by a lower incidence of 
APCA, Ab2 and MLR-Bf in RSA couples.  
The anti TCR-idiotypic antibody that has been reported to be present in the sera of 
normal pregnant women (603) would provide another mechanism for the 
immunotherapy. After immunization with paternal lymphocytes, maternal T cells 
recognizing paternal HLA antigens would expand and serve as immunogens to 
produce anti TCR-idiotypic antibodies. The anti TCR-idiotypic antibody would then 
bind specifically to the TCR and suppress the maternal immune response against 
the fetus, allowing the fetus to escape the maternal immunological attack. Thus the 
beneficial effect of this procedure has been attributed to the induction of various 
humoral antibodies that may block the mechanism of immune-rejection of the fetus 
and help in the implantation and fetal growth (603).  
In addition, this therapeutic approach also includes a specific and non-specific T 
cell suppression (882), a shift to Th2-type immunity and suppression of NK cell 
activity (767). 
Recently, Gafter et al. demonstrated that monocyte functions such as secretion of 
IL-1α, TNF-α, IL-6 and cytotoxic activity decreased whereas IL-10 and TGF-β 
increased after paternal lymphocyte immunotherapy in women with RSA (433). In 
vitro studies showed that low dose of IL-6 stimulated the asymmetric antibodies 
synthesis and a high dose decreased it suggesting that IL-6 regulates the synthesis 
of asymmetric antibodies in the trophoblast (1576).  
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Check et al. reported that lymphocyte immunization causes an increase in PIBF in 
women with RSA, which may play a significant role in the maintenance of 
pregnancy by regulating the Th2 shift (206). 
 
Of interest was the observation that immunization with third party leukocytes 
produced equally good results (1050). Thus some women would abort following 
immunization with paternal cells but successfully carry pregnancies to term and 
deliver live babies after immunization with third party lymphocytes. Such an 
observation could be interpreted to mean that the husband did not provide 
adequate antigenic repertoire for the wife to raise sufficient immunological response 
to sustain the pregnancy, a condition that was then fulfilled by the third party 
leukocyte donor. 
 
LeukoNorm CytoChemia® (LNCC) 
The leukocytic ultrafiltrate LNCC has been approved for the treatment of 
immunologically-based RSA and repetitive implantation failure (1540).  
A study by Würfel et al. investigated the treatment outcome of LNCC in patients 
with multiple failed IVF or ICSI cycles (1541). Administration of LNCC on five 
consecutive days from the day of oocyte retrieval significantly improved treatment 
results with a pregnancy rate of 55% (40% clinical pregnancies) as opposed to a rate 
of 21% in the non-treatment group. A consecutive multicenter study in Germany 
with LNCC has shown similar positive results (1540). 
 
1a, 25–dihydroxy-vitamin-D3 (VD3) 
As VD3 and its analogs were already known to be effective in the treatment of Th1-
immunity-mediated disease, Bubanovic proposed VD3 as new immunomodulatory 
agent for the treatment of women with RSA another Th1-immunity disease (151). 
The mechanism of VD3 activity, however, is not yet fully understood but it is 
thought to downregulate the production of Th1 cytokines, such as IL-2, IFN-γ, TNF-
α, IL-1, IL-6 and IL-8 as well as increased Th2 associated cytokines in T cells from 
adults. VD3 also inhibits not only IL-12-generated IFN-γ production, but also 
suppresses IL-4 and IL-13 expression induced by IL-4 (1120). As the effects of VD3 
are very similar with immunomodulatory effects of IL-10, it was believed that VD3 
could be used as local immunomodulatory drug for the treatment of RSA (151).  
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Dehydrogesterone 
Progesterone was recognised early on to be one of the most important steroids 
required for the maintenance of pregnancy, and so its stereoisomer dydrogesterone 
became a candidate for the treatment of threatened and habitual abortion (485).  
Already in the 1980s, the pregnancy-maintaining effects of dydrogesterone were 
demonstrated in ovariectomised rats (850). In a study by Raghupathy et al. on 
PBMCs of women with RSA, dehydrogesterone significantly inhibited the production 
of the Th1 cytokines IFN-γ and TNF-α and induced an increase in the levels of the 
Th2 cytokines IL-4 and IL-6 resulting in a substantial shift in the ratio of Th1/Th2 
cytokines (1161). The effect of dydrogesterone was blocked by the addition of the 
progesterone-receptor antagonist mifepristone, indicating that dydrogesterone was 
acting via the progesterone receptor. Dydrogesterone also induced the production of 
PIBF.  
Another recent study compared serum cytokine levels in women with threatened 
abortion to those of healthy pregnant controls and evaluated the impact of 
dehydrogesterone in the former group (647). Peripheral cytokine production did not 
significantly differ between the two groups before and after treatment with 
dehydrogesterone. The protective effect may therefore be manifested via PIBF rather 
than controlling cytokine production (647). 
In a controlled, randomised clinical trial, 180 women with a history of habitual 
abortions received either dydrogesterone, hCG, or no treatment until the 12th week 
of gestation (366). Dydrogesterone significantly reduced the abortion rate as 
compared with untreated controls with no increase in obstetric complications.  
3. Immunocontraceptive approaches 
Vaccines are currently being explored as a tool for for contraception. This involves 
generating a cellular or humoral immune response against antigens that are critical 
in the reproductive process and therefore interference leads to a block of fertility. 
This is achieved by linking an appropriate antigen to a foreign carrier molecule and 
when coadministered with an adjuvant causes the immune system to raise 
neutralizing antibodies. In reversible methods, fertility is regained subsequent to a 
decline in antibody response whereas an irreversible block in fertility is evident by a 
failure to regain fertility in spite of undetectable circulatory antibodies (492).  
 
There are several possible targets for immunological intervention in the female 
reproductive system (492). These can be divided into three main categories: 
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contraceptive vaccines targeting gamete production, gamete function and gamete 
outcome. 
 
For example, neutralization of the gonadotropin-releasing hormone (GnRH) activity 
in the GnRH/LH/FSH feedback control system by generating a specific antibody 
response will interfere in the production and maturation of of oocytes. At the level of 
the sperm-egg interaction, possible targets could be surface determinants on the 
gametes against which an immune response can be drawn. After fertilization, 
immunological neutralization of hCG by antibodies would result in a failure of 
blastocyst implantation. An overview gives Figure 26. 
 
 Hypothalamus 
 
Anti-GnRH                                    GnRH            Immunocontraception &    
                                                                          Immunosterilization in animals 
 Pituitary 
 
Anti-FSH                                          FSH   LH     Immunocontraception in men 
 
 Testis/Ovary 
 
 
Anti-sperm                                   Oocyte/Sperm   Immunocontraception in 
Anti-oocyte                                                             women & men 
 
 Blastocyst 
 
Anti-hCG                                         hCG               Immunocontraception in women 
                                                                             
 Implantation  
Figure 26: Stages of the reproductive cycle with possible targets for immunological 
intervention  
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a) Anti-GnRH vaccines 
GnRH is present in males as well as females; hence a vaccine against GnRH is 
usable in both sexes. GnRH by itself is not immunogenic and has to be conjugated 
to a carrier to mobilize Th cells (1009).  
Vaccines incorporating GnRH have been developed primarily for use as 
immunocontraception and immmunocastration agents in animals whereas, in 
humans, their use is primarily for the treatment of prostate cancer in man and 
various sex hormone-dependent disorders (1392). For the use in human 
contraception, however, androgen supplementation is required to maintain libido 
and secondary sex characteristics (394). 
Previous studies have already shown that passive or active immunization in order 
to neutralize GnRH leads to a block of fertility in animals (1388). Miller et al. tested 
active immunization with a GnRH-based vaccine on white-tailed deer (941). 
Treatment led to reduced fawning rates, altered estrus behavior, reduced 
concentrations of progesterone, and failure to maintain pregnancy following 
conception. Infertility lasted up to two years and was reversible, directly related to 
the antibody titer.   
Another application of a GnRH-based vaccine is to perform immunocastration 
providing an alternative to surgical castration. Hannesdottir et al. used a GnRH-
analogue conjugated to Mycobacterium tuberculosis hsp70 in mice together with two 
different adjuvants (505). With either adjuvant, all mice made sufficient antibodies 
to cause atrophy of the urogenital complex and showed significantly reduced serum 
levels of testosterone. Zeng et al. also demonstrated the efficiency of a GnRH 
vaccine in immunocastration of pigs (1577).  
 
Enough data have accumulated to conclude that the vaccines against GnRH can be 
employed in humans and in animals without side effects. Recombinant vaccines 
would be substantially cheaper to make on an industrial scale than synthetic 
vaccines. Talwar et al. reported the ability of a multimer recombinant anti-GnRH 
vaccine to cause decline of testosterone to castration level and atrophy of prostate 
of rats (1389). Some GnRH vaccines for veterinary use have already been 
commercialised (VaxstrateTM, ImprovacTM) (349, 569).  
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b) Anti-FSH vaccine 
A promising vaccine for males aims to prevent spermatogenesis by immunization 
against FSH (394). Moudgal et al. have performed successful studies in male 
bonnet monkeys in which infertility was induced by immunisation with ovine FSH 
(982).  
Therefore, a phase I clinical trial was carried out using either the ovine FSH αβ-
heterodimer or isolated ovine β-chain, purified from sheep pituitary, as the 
immunogen (981). FSH-specific antibodies were elicited in all immunized 
individuals but, unfortunately, there was no overall reduction in the sperm count in 
the volunteers due to the antibodies being of fairly low titer. Further trials are 
intended using recombinant proteins and different doses of the vaccine. 
c) Anti-sperm vaccines 
As discussed in the last chapter, several clinical studies in women have 
demonstrated that antibodies against sperm are frequently associated with 
unexplained infertility. Men and women who have infertility attributed to ASA are 
involuntarily vaccinated models to show how a sperm vaccine will work in humans. 
Sperm have both auto- and isoantigens, so they can be used for both the sexes for 
contraception. Sperm antigen vaccines are designed to cause agglutination of 
spermatozoa in the female reproductive tract, by IgG and IgA antibodies in cervical 
mucus (394). These vaccines may also be applied to males but it remains a 
challenging prospect to produce effective neutralizing antibodies in the relevant 
areas of the male reproductive tract. 
However, the whole spermatozoon cannot be used for vaccine development, due to 
the presence of several antigens on sperm cell that are shared with other somatic 
cells (1012). Therefore, a sperm antigen suitable for vaccine development must be 
sperm-specific and immunogenic, it must participate in the fertilization process and 
its surface expression should be accessible to antibody binding (332).  
 
Many studies have been performed so far on candidate antigens from male and 
female gametes in order to demonstrate their ability to induce auto and/or 
isoimmune response interfering with fertility (1009). Some of them have been 
further characterized and the complementary DNA (cDNA) encoding these antigens 
have been cloned and sequenced (1009). Notable among them are the fertilization 
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antigen (FA)-1 (1015), sperm protein (SP)-17 (796), testis-specific antigen-1 (1254), 
protein A-kinase anchoring protein (931), and sperm-associated antigen 9 (1283). 
Active immunization of female animals with some of these antigens, for example FA-
1 and SP-17, has been shown to reduce fertility in vivo. To date, the maximum 
effect so far obtained is up to 75% reduction in fertility of a single antigen in the 
mouse model (1009).  
 
In humans there are at least four sperm proteins involved in oocyte ZP binding 
(1007) so that multiple antigens may be involved in the fertilization cascade. 
Vaccination with a single antigen may also not raise enough antibody titer, 
especially in the local genital tract, to completely block fertility. At this time, there is 
no published report examining the contraceptive effect of more than one sperm 
antigen in a single vaccine formulation in any animal model (1009).  
Only a few studies have examined the effect of vaccination based on a sperm 
antigen on fertility in a non-human primate model. Vaccination with testis-specific 
lactate dehydrogenase (LDH-C4) reduced fertility in female baboons in a study by 
O’Hearn et al (1036) whereas another study interestingly reported no effect on 
fertility in female monkeys after vaccination with LDH-C4 (1422). Recently, male 
monkeys (Macaca radiata) were immunized with an epididymal protein, designated 
as epididymal protein inhibitor (Eppin) (1037). After immunization, 78% monkeys 
developed high antibody titres to Eppin and became infertile which indicates that 
anti-sperm vaccine can also be used for men. 
Several synthetic sperm peptides have also been investigated for contraception 
having caused various degrees of contraceptive effects in animal models (510, 796). 
A vaccine prepared by conjugating the synthetic YLP12 peptide with recombinant 
cholera toxin B subunit (rCTB) was tested in intranasal and intramuscular 
vaccination of female mice (1008). All vaccinated animals showed a sperm-specific 
immune response inducing some degree of inhibition of fertility while the animals 
with high antibody titres in sera as well as vaginal washings showed a complete 
block. 
Perhaps, monospecific antibodies to sperm antigens may be combined for 
immunocontraceptive purposes in the form of intravaginal sperm-specific 
spermicides (332). A first recombinant miniantibody has been already engineered to 
the tissue-specific carbohydrate epitope located on the sperm glycoform of the 
CD52 antigen (331) and shown to agglutinate human sperm cells in a tangled 
pattern (1028). 
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d) Anti-oocyte zona pellucida (ZP) vaccines 
Zona pellucida (ZP) as matrix around the oocyte is mainly composed of 
glycoproteins ZPA, ZPB and ZPC (492). It serves as docking site for species-specific 
recognition and binding of spermatozoa to the oocyte and protects the growing 
blastocysts before implantation. The glycoproteins have become promising 
candidate antigens for the development of an immunocontraceptive vaccine. 
 
Antibodies generated against ZP glycoproteins from a given species were shown to 
react to some extent with the ZP from other species and thus permit heterologous 
immunization (492). After immunization with porcine ZP, infertility together with 
follicular atresia and an abnormal hormone profile was observed in female rabbits 
(1530).  
 
Studies employing different animal models demonstrated that immunization with 
heat-solubilized porcine ZP led to a block in fertility that was likely to be due to 
ovarian dystrophy rather than a block in fertilization. It was suggested that the 
observed side effects might be due to the impurities of other ovarian-associated 
proteins that may be present in the heat-solubilized ZP preparations. The group of 
Bagavant et al. showed that monkeys immunized with highly purified porcine ZPB 
and ZPC failed to conceive in the presence of high circulating antibody titers but did 
not show any adverse effects on ovarian functions (70). 
Recombinant proteins may diminish the problems of probably contaminated ZP 
glycoproteins isolated from a native source. In a study by Govind et al. 
immunization of female baboons with recombinant bonnet monkey ZPB led to a 
reversible block of fertility (472). Ovarian histology of the immunized animals 
revealed the presence of atretic follicles with degenerating oocytes, which may 
explain failure to conceive. 
 
Also the development of live recombinant vectors encoding ZP glycoproteins has 
been started. Immunization of mice with murine cytomegalovirus as live 
recombinant vector expressing mouse ZPC has led to infertility (825).  
Another approach is the use of plasmid DNA encoding ZP glycoproteins. In a study 
by Xiang et al. immunization of mice with the plasmid DNA encoding partial 
sequence of rabbit ZPC led to inhibited fertility without any disturbances in 
folliculogenesis (1544).  
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A series of experiments demonstrated that the “oophoritogenic” T cell epitopes 
present in the zona proteins may be responsible for ovarian dysfunction often 
observed after immunization with ZP antigens (832). To circumvent the ovarian 
pathology, synthetic peptides devoid of “oophoritogenic” T cell epitopes as 
immunogens have been proposed (492). However, in vivo studies did not show 
consistent reduction in fertility (1096). 
Another approach may be to employ chimeric recombinant protein comprising ZP 
and spermatozoa antigens (797).  
e) Anti-hCG vaccine 
Two fundamentally different strategies were taken regarding the development of 
hCG-based contraceptive vaccines. In one approach the main consideration was to 
produce a vaccine that would provide an hCG-specific immune response that did 
not cross-react with the structurally-related LH. The alternative approach 
considered that such cross-reaction, if it were to occur, would not be harmful and 
therefore the prime consideration should be to produce a vaccine capable of eliciting 
high titer of antibodies (319). 
 
As probably the most promising candidate for development of an 
immunocontraceptive vaccine for females, the efficacy of hCG linked to tetanus 
toxoid (TT) was tested in various animal studies (1392). For this vaccine the intact 
β-chain was used and there was no great concern about possible cross-reaction 
with LH. 
Talwar et al. conducted a multicenter phase I clinical trial on 63 women which 
showed the presence of both anti-hCG and anti-TT antibodies (1390). However, 
antibody titers and the duration of immune response highly varied among 
immunized women.  
A more immunogenic vaccine formulation was tested in extensive phase II clinical 
trials and led to generation of anti-hCG antibodies levels enough to protect against 
conception in 80% of immunized women (1391).  
 
The other vaccine against hCG developed by Stevens et al. with support from the 
WHO Task Force on Vaccines for Fertility Regulation is based on a synthetic peptide 
based on the portion of the β-subunit of the hormone linked to diphtheria toxoid 
(DT) (1354). Potentially contraceptive antibody titers were induced in a phase I 
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clinical study which was followed by a phase II clinical trial that was abandoned 
due to unacceptable local reactions at injection sites (1009).  
The immunogenicity of a β-hCG-based DNA vaccine has also been illustrated. The 
DNA vaccine together with a C3d adjuvant led to a generation of a 9-fold higher 
antibody response compared to β-hCG alone and increased the expression of 
antigen-specific Th2 humoral immune response in mice (1477).  
f) Other vaccination strategies  
Other potential approaches for development of immunocontraceptive vaccines 
include riboflavin-carrier protein which is a major transporter of vitamin to the 
embryo across the placental barrier. Active immunization in animals with this agent 
significantly reduced fertility (9).  
 
A project by the German group of Frank et al. is aimed at the immunological 
inhibition of syncytial trophoblast fusion as a novel approach to contraception 
(422). Fusion-inhibiting recombinant antibodies were generated and used together 
with autoantibodies from patients with repetitive IVF failure that were shown to 
inhibit syncytial fusion and are expected to inhibit implantation, to generate anti-
idiotypic peptides. These peptides mimic trophoblast epitopes essential for syncytial 
fusion and are, therefore, considered specific immunogens for the generation of 
antibodies that will inhibit implantation. Of 300 anti-idiotypic peptides which were 
tested for their binding capacity to patient autoantibodies associated with repetitive 
IVF failure, habitual abortion and preeclampsia only three peptides were found to 
selectively bind to autoantibodies of patients with repetitive IVF failure and were 
considered safe and efficient enough for evaluation in preclinical and clinical 
studies required for the development of immune contraceptives (422).  
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III. Discussion 
A. General immunology of the genital tract 
The aim of this review is to summarize and evaluate the latest studies dealing with 
the subject of the immunology of the female genital tract mucosal tissue. The main 
focus is thereby first to present results concerning the basic principles of innate 
and adaptive immune mechanisms in the female genital tract.  
This distinct site had long been neglected as a subject of studies but its importance 
and specialty among the human immune system has now been noticed during the 
last years. Advances concerning the field of female genital tract immunology may 
implicate conclusions for other related research fields such as the immunology of 
genital infections and immunology of pregnancy. Especially the continously rising 
number of STDs provided the need for further investigations in this field.  
 
It is now established that the mucosal immune system is a distinct and separate 
component of the host`s immune apparatus and differs from the lymphoid tissues 
in peripheral sites which contribute to the antibody isotypes found in the blood 
circulation (762, 1266, 1423). Furthermore, regulation of the mucosal immune 
system is different than that of the systemic immune system. The mucosal immune 
system can be divided into discrete inductive sites where antigens or vaccines are 
encountered and are endocytosed, processed, and presented to B and T cells and to 
separate effector areas where immune cells actually function (1018). 
 
Protection against potential pathogens in the female reproductive tract is provided 
by a variety of measures that can be grouped into the two broad categories of innate 
and adaptive immunity.  
The innate immune system differs from the adaptive immune system in the cells 
involved, the type and specificity of receptors for antigen, the immediacy of 
response, and the nature of the response to antigenic challenge (615). Recognized 
as the first line of defense, the innate immune system functions to prevent and 
control the invasion of pathogens. It has evolved to recognize foreign structures, the 
so-called PAMPs via pattern recognition receptors of the host expressed on cells of 
the innate immune system, the TLRs. Signaling through TLRs in response to PAMPs 
involves a number of adapters and other molecules that lead to recruitment of 
immune cells as well as the production of intracellular and secreted antimicrobial 
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factors that both kill invading microbes as well as link innate and acquired 
immunity. Adaptive immunity encompasses pathogen-specific defense mechanisms. 
 
Of those mucosal surfaces in the body, the female reproductive tract has unique 
requirements for the regulation of immune protection, because it must deal with 
sexually transmitted bacterial and viral pathogens, allogeneic spermatozoa, and the 
immunologically distinct fetus (1514, 924, 779, 763). The immune system of the 
female genital tract is the least understood part of the mucosal immune system 
with respect to the origin of its immune cells, the role of tissue CTL responses and 
the induction of antibody responses, as well as the contribution of serum-derived 
versus mucosally produced antibodies. Although it is considered as a part of the 
common mucosal immune system it offers some distinct features which outlines its 
special role.  
 
A major difference between the genital tract and the intestinal tract is the 
compartmentalization of the genital mucosa. Vagina and ectocervix present with 
commensal flora whereas endocervix, uterus and fallopian tubes are sterile, lacking 
the presence of a microbial flora (630, 1151, 1512). The epithelium of the vagina 
and ectocervix therefore is required to provide a strong barrier whereas the 
epithelium of uterus and endocervix is less afflicted by microorganisms. A 
sophisticated barrier function is also given by the cervical mucus as part of basic 
innate immune mechanisms that filters bacteria but allows sperm to ascend to the 
uterus (630).  
 
By analogy to a primary immune response in the MALT, antigen reaching the 
submucosa of the vagina is taken up by APCs (373), which then migrate to draining 
lymph nodes. Once in the lymph nodes, the APCs stimulate B and T lymphocytes, 
including memory subpopulations, that enter the bloodstream via the efferent 
lymph and thoracic duct. These T and B lymphocytes migrate to the genital tract 
and, on exposure to the antigen, participate in a secondary immune response.  
In contrast to the intestinal tract, the mucosal immune system of the female genital 
tract is under hormonal control of estrogen and progesterone that regulate the 
transport of Igs, the levels of cytokines, the distribution of various cell populations, 
and antigen presentation in the genital tissues during the reproductive cycle (1512).  
 
Instead of M cells in the intestinal tract, it is likely that mononuclear phagocytes 
such as macrophages and DCs as well as genital ECs present in the vagina are 
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capable of acting as APCs and of initiating an immune response (630, 1151, 1514). 
There are lymphoid aggregates in the basal layers of the uterus comparable to the 
intestinal tract but their presence and distribution strongly varies under the 
hormonal influence.  
 
Especially the role of ECs in the female genital tract has gained a completely new 
significance. Acting as the first line of defense, ECs provide host protection in a 
number of ways that includes providing a mechanical barrier, secreting 
antimicrobial molecules, transporting IgA, processing and presenting antigen and 
communicating with underlying immune cells by secreting cytokines and 
chemokines (1151, 1512, 1514).  
Besides their role in providing a physical barrier against microbes by establishing 
tight junctions and TER (372, 1034) they have to be regarded as a genuine part of 
the mucosal immune system that recognizes antigen and leads to production of 
antimicrobials (1093, 1512, 1514, 1514).  
 
It can be concluded from different studies that uterine ECs as well as APCs in the 
uterine stroma and vagina are capable of presenting antigen which initiates an 
immune response in the female reproductive tract. Isolated uterine ECs express 
MHC class II antigen and CD40 or CD1d proteins and are able to process and 
present tetanus toxoid to T cells (375, 1470).  
Moreover, antigen presentation in the female reproductive tract is supposedly 
regulated by sexual hormones and soluble factors of stromal cells (1515, 1516). 
More recent studies demonstrated that stromal antigen presentation is regulated by 
cytokine production by ECs. In response to estrogen, uterine ECs produce TGF-β 
which suppresses underlying APCs in the stroma (1517). 
 
Various defensins have been detected in the female genital tract secretions (1152, 
1436) and seem to be regulated by cycle-associated changes in sexual hormones 
and influenced by contraceptive use (415, 707). These factors may contribute to an 
altered susceptibility to infections. In the same way, SLPI and SP-A/D production 
by uterine ECs varies due to the stage and status of the menstrual cycle (376, 704, 
809, 855) and seems to be regulated by sexual hormones as well (214, 709).  
 
However, estradiol and progesterone seem to regulate genital tract EC proliferation, 
apoptosis, secretions and effects on pathogenic microbes (1034, 1513). Several 
studies suggested that estrogen regulation of EC proliferation is mediated indirectly 
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by uterine stroma (250, 595, 1121). In experiments with uterine ECs of mice, 
estradiol decreased TER and therefore EC layer integrity whereas other sexual 
hormones had no effect (474). Uterine epithelial monolayer integrity seems to be 
directly influenced by estradiol and is ER-mediated which suggests a cycle-
dependency. Sex hormone regulation of EC function is both direct via ER in ECs 
and indirect via ER located in the underlying stromal cells (250, 278). 
Soluble factors expressed by uterine stromal cells such as HGF act as mediators of 
estrogen-induced proliferation of uterine ECs, increase of TER (473, 475) and 
regulation of EC cytokine production.  
 
Cytokines are now recognized as principal components of the complex intercellular 
communication among cells in the uterus (374, 672, 673, 674), and temporal 
release patterns during both the menstrual and estrous cycles show many to be 
regulated by sex hormones. Cytokines secreted by ECs recruit other immune cells 
such as neutrophils and lymphocytes (268, 374, 674, 1292) and could also account 
for the influx of leukocytes and lymphocytes that form lymphoid aggregates 
observed during the secretory phase of endometrium (1560). 
Concentrations of cytokines and chemokines vary in the endometrium and show 
temporal release patterns related to the menstrual cycle (880). Many cytokines and 
chemokines released by ECs peak during the late proliferative phase and at menses 
such as LIF, RANTES, MIP-1α, IL-8 (48), IL-6 (1382, 1564), TGF-β, IL-1β, and M-
CSF.  
The local production and transport of Ig in ECs in the reproductive tract is also 
influenced by the female sex hormones estradiol and progesterone (1519). Estradiol 
increases pIgR and SC expression and therefore IgA transport and IgG 
accumulation are stimulated in the uterine lumen whereas this is inhibited in CVS 
by estradiol and progesterone (918, 1519, 1520).  
 
TLRs, a family of structurally related receptors that recognize specific products of 
pathogens referred to as PAMPs as well as endogenous ligands associated with cell 
damage, have recently received growing attention in the female genital tract. They 
are present mainly on macrophages, neutrophils and DCs, but low levels of 
expression have also been observed on fibroblasts, endothelial and epithelial cells 
(1514). 
The expression of TLRs in epithelial cells from the vagina, ectocervix and endocervix 
by the detection of mRNA was reported by several authors. Fichorova et al. found 
mRNA for TLR-1, -2, -3, -5 and -6, but not -4 (395), which is partly consistent with 
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other findings of Young et al. (1567) and Pioli et al (1126). TLR1-6 and TLR9 were 
expressed by endometrial ECs whereas TLR7, -8, -10 were not detected. Results 
indicate that ECs that line the uterine lumen are sensitive to viral infection and 
exposure to viral dsRNA released from killed ECs (1262, 1263). In addition to 
releasing proinflammatory cytokines and chemokines that mediate the initiation of 
an inflammatory response and recruitment of immune cells to the site of infection, 
ECs also express β-defensins, IFN-β, and IFN-β-stimulated genes that can have a 
direct inhibiting effect on viral replication. 
 
Macrophages as another representative of APCs can be found throughout female 
reproductive tract tissues and make out about 10% of the leukocytes (459, 584). In 
endometrium, their number continously rises during menses, implantation and 
early pregnancy among other leukocyte populations such as uterine NK cells and 
neutrophils (638). In the ovary, their distribution also differs depending on the stage 
of menstrual cycle (1538).  
As mediators of phagocytosis of foreign pathogens and cellular debris, they play an 
essential role in the initiation, maintenance, and resolution of host inflammatory 
responses in the female genital tract, for example by secreting pro- and 
antiinflammatory cytokines (920). In their function as effector cells of ovarian 
function with specific localization and their presence in periovulatory human 
follicular fluid they seem to play diverse roles in the folliculogenesis, tissue 
restructuring at ovulation and corpus luteum formation and regression.  
 
It is well known that estrogen levels influence macrophage proliferation and 
function as well as cytokine production (1512) and there is high evidence that 
steroid hormones regulate the recruitment of uterine macrophages throughout the 
menstrual cycle due to regulation of cytokine and chemokine expression (318). 
Human peripheral blood monocytes and macrophages have similarly shown 
expression of both receptor isoforms, ERα and ERβ (1114, 964) whereas only one 
study detected PR (1451) Paradoxically, macrophages have also been showing an 
effect to progesterone, which could be explained by cross binding of progesterone to 
the glucocorticoid receptor (1495). 
However, recent data suggest a predominantly immunosuppressive role of estrogen 
in modulating immune responses, mediated by nuclear ERα (777). Human studies 
have demonstrated that macrophages selectively aggregate into premenstrual 
endometrial stroma, concurrent with depression of estrogen and progesterone levels 
as the result of luteolysis (639, 656). This is probably due to hormone-regulated 
  Discussion 
 III-283  
variations in cytokine and chemokine levels as the expression of macrophage 
chemoattractants MCP-1, MCP-3, FKN and MIP-1β in human endometrium is also 
increased perimenstrually (638, 926). Arici et al. have demonstrated that treatment 
of endometrial stromal cells with estradiol significantly inhibits expression of MCP-
1, which correlates with suppression of macrophage migration (48). This implicates 
that fluctuations in estrogen and progesterone levels are coincident with changes in 
the migration of macrophages to the endometrium (318). 
 
To be precise, accumulation of endometrial macrophages together with macrophage 
chemokines also occurs during the mid-secretory phase of the menstrual cycle with 
high estrogen and progesterone levels (638). Although these data are inconsistent 
with estrogen inhibition of MCP-1 expression, it is possible that regulation of MCP-1 
is mediated by estrogenic modulation of another factor, such as IL-1 (48). Estrogen 
has been shown to stimulate IL-1 mRNA and protein expression and IL-1 again has 
been shown to induce expression of MCP-1 (18).  
 
As sentinels of immune function, DCs take up microbial antigens at sites of 
infection and then migrate to draining lymph nodes to stimulate antigen-specific T-
cell activation which is induced either by pathogen invasion of mucosal surfaces or 
epithelial damage (73). 
Female genital tract LCs can be found in the epithelial layer of the vaginal and 
ectocervical mucosa of women (119), whereas DCs are predominant in the 
submucosal layers.  
 
DCs express mRNA for both ER isoforms at all stages in their differentiation. Data 
suggest that nonsteroidal anti-estrogens such as tamoxifen and also estrogen 
inhibit the differentiation of immature DCs and therefore the development of 
inflammatory Th1 responses but not via ER (737). Others showed in a ex vivo 
mouse model that estradiol promoted the differentiation of functional DCs from 
murine bone marrow precursor cells via ER (1060). This suggests a mechanism by 
which estradiol levels in peripheral tissues might modulate both the number and 
functional capabilities of DC in vivo, thereby influencing immune responses. These 
contradictory results could be explained by the cell type and species specific effects 
of estradiol or by the use of different hormone concentrations. 
 
Estrogen has also been demonstrated to increase the expression of cytokines and 
chemokines in human monocyte-derived DCs (106). Moreover, mature DCs treated 
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with estradiol had an increased ability to stimulate naïve CD4+ T cells. Collectively, 
these data implicate a role for estrogen in the regulation of DC effector function and 
suggest that estradiol plays a key role in the induction and maintenance of 
inflammatory responses. Nevertheless, further investigation of the influence of 
estrogen on DC differentiation and maturation is warranted. 
 
Considered in this context, the identification of DCs in the human reproductive 
tract has significant implications for the progression of inflammation and disease as 
well as for the maintenance of pregnancy. DCs are resident in human decidua 
(439), where they have been proposed to mediate tolerance to the conceptus as well 
as to mediate maternal immune responses to pathogens. This should be discussed 
further in the next chapters. 
 
Similarly to T cells, NK cells can utilize a variety of effector mechanisms including 
cytokine production and perforin-mediated cytotoxicity to help the host to eliminate 
pathogens and tumor cells (1051). They are able to differentiate between healthy 
cells and abnormal cells by using a sophisticated repertoire of cell surface receptors 
that control their activation, proliferation and effector functions (783). They are 
focused on recognition of MHC molecules by surface receptors KIR, Ly49 and 
CD94/NKG2 with both activating and inhibitory isoforms which distinguish 
themselves from phagocytes which rely on conserved pattern-recognition receptors 
such as TLRs (1177). Downregulation of MHC I due to infection or transformation of 
cells would alleviate inhibition of NK cell positive signaling and may result in 
initiation of cytotoxicity and cytokine production (483, 783, 784).  
However, blood and uterine NK cells also express various TLRs whose agonists are 
able to trigger IFN-γ production of NK cells (568, 749, 1512). The hypothesis is 
therefore that microorganisms may initially activate ECs which produce cytokines 
and these cytokines in combination with PAMPs will activate NK cell cytokine 
production, resulting in further activation of innate immune responses. 
 
In the female genital tract tissues, NK cells make out 10-30% of all leukocytes and 
localize to the endometrium in large numbers following ovulation, then accounting 
for almost 70% of leukocytes prior to menstruation (459, 584) which suggests the 
involvement of sex hormones in regulation of this NK cell migration. Pathological 
conditions such as gynecological malignancies and pregnancy loss are associated 
with altered NK cell numbers and activity (338, 848, 902).  
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NK cells in the uterus express CD56, CD94 and KIRs, few express CD16, and none 
express CD57 or CD8 and, unlike blood NK cells, uterine NK cells express CD9 and 
CD69 on their cell surface (370). Thus, uterine NK cells have a cell-surface 
phenotype that is unique. A large molecular study indicated that decidual NK cells 
were more similar in their gene expression profile to CD56bright NK cells than to 
CD56dim NK cells (740). 
 
The question if decidual NK cells are derived from blood NK cells which differentiate 
in the decidua or if they represent a special cell line which is produced only for the 
decidua is still not resolved. The hypothesis that NK cells in the decidua are derived 
from uterine NK cells in the endometrium at the time of implantation or from newly 
recruited blood NK cells has been favoured. NK cells isolated from nonpregnant 
endometrium and decidua may not represent different phenotypes but a rather 
continuous process of differentiation due to alterations in hormone levels and 
changes in stromal cell environment (1512). 
Concerning NK cell phenotype in other female genital tract tissues, there have been 
performed only few studies (902, 1512).  
 
Uterine NK cells have shown similar chemokine receptor expression compared to 
blood NK cells and it can be proposed that migration of uterine NK cells to the 
endometrium is induced by high expression of chemokines (598, 715, 858, 1275). 
Sentman et al. suggested that sex hormones induce specific chemokines in 
nonpregnant human endometrium that can activate NK cell migration (1275).  
 
Also decidua can produce chemokines that can recruit NK cells (504, 1180); 
however, it is not exactly clear which chemokines are involved in NK cell 
recruitment. CXCL10 induced by sex hormones in endometrium prior to 
implantation may recruit uterine NK cells whereas chemokines derived from 
trophoblast such as CXCL12 may recruit uterine NK cells to reorganize placental 
arteries and facilitate trophoblast invasion of maternal tissue (1512). NK cell 
attachment to uterine endometrium needs specific adhesion molecules. L-selectins 
and α4 integrins are important for the binding of lymphocytes (200, 392). The 
adhesion of NK cells also involves VCAM-1 which is expressed at the site of 
trophoblast invasion and might allow NK cells to migrate continuously to these sites 
(200, 392). 
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In general, NK cells as part of the innate immune system help to protect against 
infections, for example by promoting macrophage and CTL activation via Th1 and 
Th2 cytokine production (370, 634, 1052, 1107).  
In pregnancy, high numbers of decidual NK cells also seem to be involved in 
regulation and restructuring of maternal spiral arteries through production of 
angiogenic growth factors and LIF as well as in decidualization and trophoblast 
invasion (156, 815, 1512). The invading trophoblasts express HLA-G and can 
interact with the KIR receptors on uterine NK cells. Membrane-bound HLA-G has 
been shown to stimulate uterine NK cells and IFN-γ production and to suppress 
mononuclear cell effector functions (1438). NK cell-derived IFN-γ seems to be 
necessary for vascular remodelling of spiral arteries and placental formation so that 
the recognition of HLA-G on trophoblasts by uterine NK cells may be important for 
placental development. Uterine NK cell-deficient mice demonstrated failure to 
sustain decidual integrity and loss of spiral artery modifications (481). 
 
Recruitment, differentiation and activation of NK cells within the uterus seem to 
dependent from specialized CD8+ Treg cells (1288) and cytokines such as IL-15, IL-
18, IFNs, TGF-β and prolaktin (30, 209, 252, 348, 370, 387, 716, 1371). 
Uterine NK cell numbers and migration, however, are regulated by sexual hormones 
as they show cycle-dependent changes with numbers up to 70% of leukocytes in 
the late secretory phase (459, 702). Two mechanisms have been discussed as 
reason for the increase of uterine NK cells: on the one hand, in situ proliferation 
(658, 1383) and on the other hand, selective recruitment from the peripheral NK 
cell pool. However, an active recruitment of these cells to the uterus is likely to play 
a major role with data indicating that uterine NK cells are derived from blood or 
bone marrow cells and not from NK cells within the uterus (488). 
 
However, it is not exactly clear how NK cell functions are regulated by sex 
hormones. Various studies have been coming to different and partly conflicting 
results. One reason may be the different kind of tissue conducted for experiments, 
including nonpregnant endometrium as well as decidua. Estrogen has been shown 
to suppress human NK cell cytolysis in vivo and in vitro in a dose-dependent 
manner (391). Another study illustrated that men showed significantly higher NK 
cell activity in blood than women with regular menstrual cycles or women using 
oral contraceptives (1568).  
Uterine NK cells of decidual tissue do not express receptors for estradiol or 
progesterone; therefore the activity of sex hormones on NK cell function is likely 
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mediated via hormone action on other cells such as fibroblasts or ECs (539). 
However, NK cells do express glucocorticoid- and estrogen-β1 receptors which may 
be mediating steroid hormonal effects on NK cells. 
 
Considered as a first line of defense against pathogens, neutrophils follow both 
endogenous and bacterial chemoattractant signals and migrate to the site of 
infection (536, 600, 812, 1266). The presence of pathogens are detected by 
germline-encoded receptors that recognize PAMPs; human neutrophils express TLR 
2 to 10 except TLR3 (525). Pathogens are then eliminated by phagocytosis, 
microbicides or production of toxic compounds via the NADPH oxidase system 
(1512). Neutrophils themselves produce several cytokines, for example IL-1β, IL-8, 
TNF-α, TGF-β1 (182), that attract more neutrophils, macrophages and other 
immune cells helping to initiate the adaptive immune response. 
 
In the female genital tract, the highest number of neutrophils can be found in the 
fallopian tube with consistently decreasing numbers down through the lower genital 
tract (459, 1529). This seems striking as the vagina contains the most pathogens 
and one would expect the highest number of neutrophils there.  
 
As a consensus, the number of neutrophils in different female genital tract tissues 
is dependent of IL-8, a potent chemoattractant and activator for neutrophils. 
Moreover, neutrophils in the female reproductive tract seem to be regulated by GM-
CSF which can potentiate induction of neutrophil chemotaxis and regulate 
neutrophil activation (1292, 1512).  
However, despite a increased expression of IL-8 in the late proliferative phase 
around ovulation there seem to be no studies on neutrophil number variation in the 
fallopian tubes during menstrual cycle (1067, 1512). This difference and the exact 
role of neutrophils in the fallopian tubes as part of the local immune system 
remains quite unclear. Fallopian tube neutrophils compared with blood neutrophils 
expressed higher levels of the adhesion molecule CD31 and CD15. CD31 is 
increased on transmigrated neutrophils (844), which suggests that fallopian 
neutrophils have crossed the endothelial barrier and are not only part of the 
marginated pool associated with the luminal surface of blood vessels. CD15 is 
involved in the binding of neutrophils to E-selectin and P-selectin. CD15 ligation is 
reported to induce a release of granule content; the high CD15 expression may be 
important for innate immune responses in the fallopian tube. 
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Fallopian tube neutrophils have also shown lower amounts of specific granule-
associated molecules which suggests that they have undergone some kind of 
degranulation. Furthermore, they also demonstrated high levels of intracellular 
VEGF and IFN-γ (1512). As VGEF plays an important role in vasodilatation and 
vascular permeability (86) it would make a leukocyte infiltration of tissues possible.  
 
High levels of IL-8 correlate with high levels of neutrophils in the female vagina 
(192). This corresponds with the findings that neutrophils cannot cross the 
epithelial barrier unless they are under the influence of a chemokine gradient of IL-
8, for example (692). Investigating vaginal neutrophil numbers during the 
menstrual cycle, Patton and colleagues found constant numbers of neutrophils 
throughout the cycle (1098) whereas in mice neutrophil migration showed a sexual 
cycle dependency and positively correlated with MIP-2 concentrations, a functional 
IL-8 homologue (1327).  
Studies demonstrated that IL-8 production and therefore neutrophil infiltration into 
the vagina only takes place in case of vaginal epithelial infection. If infection was 
asymptomatic or did not take place, there was no neutrophil infiltration in the 
vagina (400).  
 
Neutrophils represent the highest population with 83% of all leukocytes in human 
cervical secretions (1414). Both insemination and infection of the cervix with 
increased local production of IL-8 as chemoattractant increase the number of 
neutrophils in the cervix significantly (125, 1481). 
In the uterus, a decrease in progesterone levels prior to menses is responsible for a 
rise in IL-8 production and therefore a rise in neutrophil numbers (47, 267, 1249) 
which serves to guard against infection at this time of lower epithelial defenses.  
Endometrial neutrophils also biase immune responses through production of IFN-γ 
(1559) and may play a role in endometrial breakdown through release of elastase 
and MT1-MMP (1579).  
 
Studies on ovarian neutrophils proposed that they are involved in tissue remodeling 
during the ovulatory process with high numbers in the developing ovarian follicle 
wall (144). This is also consistent with peak IL-8 concentrations in follicular fluid 
around ovulation which seem to be stimulated by FSH and LH (1225). Through the 
release of and activation of MMPs and collagenase, ovarian neutrophils seem to be 
effector cells in the process of ovulation whereby the oocyte is expelled from the 
interior of the follicle (143). In addition, the corpus luteum that remains after a 
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rupture or tearing of the ovarian wall represents an injured tissue in need of 
protection from infection which may also be an explanation for the presence of 
neutrophils in this region (1512). 
 
Findings of a study on distribution of neutrophil chemoattractants in different 
female genital tract tissues do not correlate with neutrophil recovery from tissues 
by enzyme digestion (1512). Cervical tissue should contain the greatest number of 
neutrophils as they presented with the highest amount of chemokine and IL-8 
expression. Moreover, one would expect a higher amount of microorganisms at the 
cervix than in higher regions of the reproductive tract, resulting in greater need for 
innate immune protection by neutrophils.  
 
Also with respect to adaptive immunity, the genitourinary immune system displays 
characteristic features that are distinct from those of other typical mucosal sites or 
the systemic compartment.  
 
Antigen-specific IgA, IgG and IgM antibodies and SC can be detected in the external 
secretions of the human genital tracts. The dominance of IgA in the majority of 
external secretions, such as intestinal and nasal fluids, saliva, tears and milk, has 
for decades been considered a cardinal characteristic of the humoral arm of the 
mucosal immune compartment.  
Despite highly variable information about the presence of different Ig classes in 
human female genital secretions (1467), recent findings have revealed that humane 
urine, seminal plasma and cervical or vaginal washings collected at various stages 
of the menstrual cycle contain an equal or higher proportion of IgG than IgA (556, 
566, 608, 764, 1090, 1155). However, IgG/IgA ratios ranged from 2:1 to 10:1. Such 
discrepancies seem to reflect both the differences in the applied sampling method 
and individual variability such as age and stage of menstrual cycle (1090).  
 
IgG and IgA antibodies in female genital tract secretions are in part produced locally 
by resident plasma cells and also derived from plasma, as reflected in their 
structural heterogeneity. 
IgA1 and IgA2 are found in equal proportions in the female genital tract, therefore 
resembling secretions of the lower intestinal tract (922, 925). Unique is also that 
cervical mucus contains about 70% polymeric IgA and vaginal secretions contain 
almost equal proportions of polymeric and monomeric IgA whereas plasma contains 
about 90-99% monomeric IgA and saliva 95% polymeric IgA. 
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The ratios of IgA1 and IgA2 and the predominance of polymeric IgA in cervical 
secretions indicate that much of the IgA originates from local production, not from 
plasma (764). However, the high representation of the serum monomeric form of IgA 
in the vagina clearly demonstrates that, contrary to other mucosal surfaces, the 
genital tract relies heavily on antibodies derived from serum and systemic 
immunity. Because of the intrinsic resistance of IgA2 to IgA1 proteases of many 
pathogenic bacteria, the increased proportions of IgA2 may provide functional 
advantage to certain specific antibodies (763). 
As there is a high percentage of the IgG1 subclass, IgG occurring in genital 
secretions is not only serum-derived, but also produced locally (556, 1227). 
However, the mechanisms involved in the transport of IgG into cervical secretions 
remain unclear (273). 
 
Furthermore, many immunological aspects in the genital tract besides the 
distribution and properties of immunocompetent cells, namely the proportions of Ig 
isotypes and their molecular forms are under hormonal influence (423, 1408). 
Estrogen is said to increase Ig production and drives differentiation of CD4+ helper 
T cells toward Th2 regulation whereas androgens drive differentiation of CD4+ 
helper cells toward Th1 regulation. This could partly explain higher Ig levels and a a 
stronger humoral immunity in females than males (929). 
 
The role of sex steroids in regulating immunity may be especially pronounced in the 
genital tract. Similar to the rat model (1518), both IgA and IgG peak shortly before 
ovulation with significantly higher Ig levels in women on contraceptives compared to 
other women (423, 764), which supports the general agreement that reproductive 
hormones enhance immunity via increasing Ig and expression of pIgR on uterine 
ECs (1518, 1519). 
This relationship between estrous cycle and specific antibody levels likely reflects 
the changes that occur in the female reproductive tract during the course of the 
estrous cycle. Preovulatory until the time of ovulation, or at the time of mating, the 
female genital tract is subjected to numerous pathogens (1144). In fact, sperm has 
been shown to be a vector for bacteria, whereby the bacteria attach to the tails of 
sperm as they move up the reproductive tract. The need for protection of the female 
reproductive tract against pathogens is therefore especially high during ovulation. 
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Estrogen is said to increase IgG and IgM production by PBMCs due to inhibition of 
CD8+ suppressor cells (1058) whereas another study proposed secretion of IL-10 as 
responsible for the increased Ig production (661).  
It is tempting to speculate that the effects of estradiol and progesterone on Ig levels 
and secretion are mediated indirectly by hormonal effects on CD8+ (and possibly 
CD4+) T cells, or accessory cells such as macrophages. In this regard it is 
interesting that the lymphoid aggregates found in human uterus have a central core 
of B lymphocytes surrounded by large numbers of CD8+ T lymphocytes which, in 
response to hormonal changes, would be in exactly the right anatomical location to 
regulate local antibody secretion (91). 
 
Concerning distribution of Ig-producing cells, earlier immunohistochemical studies 
by Kutteh et al. found predominantly IgA-producing cells with highest percentages 
in ectocervix and vagina (759). Later, studies using ELISPOT found at least four 
times more IgG- than IgA-producing cells (273).  
Brandtzaeg proposed that immunohistochemical studies have underestimated the 
IgG class because of interstitial staining (141). Moreover, the quantification of Ig-
producing cells is difficult to perform due to their uneven distribution. The actual 
quantities of Ig-producing cells were measured as density by number of cells/10 
low-power fields without any accurate definition of the evaluated tissue 
compartment. The endocervix was found to have the largest number followed by 
ectocervix, fallopian tubes and vagina (273, 761).  
 
Almost all of the IgA-producing cells contain J chain, a marker of the synthesis of 
pIgA. Furthermore, cells in the single-layered epithelium of the fallopian tubes, 
uterus, endocervix, and ectocervical glands express the pIgR (923), which is 
essential for the selective transport of locally produced pIgA. Thus, all the structural 
and cellular components characteristic of active transepithelial transport of pIgA 
are present. 
Among different genital tract tissues, the endocervix does not only show the highest 
number of Ig-producing cells, but also the highest percentage of J chain, SC and S-
IgA (141) which suggest that the endocervix is likely to be a focal point for mucosal 
immunity in the genital tract.  
Endometrial tissue was shown to have only few Ig-producing cells with 
predominantly IgG-producing cells (141, 759). The detection of IgA in the apical 
epithelium without presence of IgA immunocytes and the appearance of SC 
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throughout the endometrial epithelium suggest the selective external transport of 
serum-derived polymeric IgA, which was supported by staining for J chain (140).  
 
SC-expression and IgA uptake in the endometrium also seems to be dependent on 
the phase of the menstrual cycle, showing a rise from the proliferative to the mid- 
and late secretory phase (118). The same study showed that the endometrial glands 
contained significantly more of all components of the secretory immune system in 
the mid- and late luteal phase than in the early half of the menstrual cycle.  
This again confirms the thesis that steroid hormones also have a significant 
influence on the adaptive immune system in the female reproductive tract. 
 
Whereas B cells are present in low numbers in the female genital tract 
compartments, T cells seem to make out up to 50% of all leukocytes, with CD8+ T 
cells predominating over CD4+ T cells (459, 1146). The highest number of T cells 
was found in the cervical transformation zone whereas normal vaginal mucosa 
contained few T cells.  
Two studies at least found characteristic cervical and endometrial lymphoid 
aggregates consisting of a B cell core surrounded by CD8+ T cells and macrophages 
(626, 1560). Their structures presented similarities to inductive lymphoid tissue in 
various respect and as expected, they seem to be regulated in size and presence by 
sex hormones (1560). ER has proven to be present on T cells whereas the presence 
of PR on T cells remains controversial (91).  
Further studies are needed to investigate the effect of sexual hormones on T cell 
function, especially in the genital tract.  
 
It seems clear, however, that T cells throughout the genital tract are provided with 
cytolytic activity which is also hormonally regulated (1146, 1497). However, 
menstrual cycle and menopause had no apparent effect on cellular localization or 
abundance in any of the lower genital tract tissues which makes clear that the 
cervix, especially the transformation zone, is the major inductive and effector site 
for cell-mediated immunity in the lower female genital tract (1146).  
 
To sum up, analysis of the female genital tract indicates that the key cells of the 
innate and adaptive immune systems are present and functionally responsive to 
antigens; however, there is a certain degree of compartmentalization. The 
identification of TLRs in the fallopian tubes, uterus, cervix, and vagina and the 
presence of ECs, macrophages, DCs, NK cells, and neutrophils throughout the 
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reproductive tract along with their responsiveness to selected PAMPs indicate that 
the female reproductive tract has evolved to meet the challenges of STDs, while at 
the same time supporting an immunologically distinct fetal placental unit. The 
innate immune system is characterized by a significant contribution of chemokines 
and cytokines that recruit and activate immune cells as well as produce bactericidal 
and virucidal agents, which confer protection at times when adaptive immunity is 
downregulated by sex hormones. Findings suggest that the mucosal immune 
system throughout the reproductive tract is orchestrated by sex hormones so that 
immune coverage occurs in a way that confers continuous protection.  
 
The consequent link between endocrine and immune system in the female genital 
tract can also be observed during menstruation. In opposite to older theories which 
favoured the theory of vasoconstriction due to hypoxia (873), the concept of 
menstruation as the result of an inflammatory event has come up and been subject 
to several studies (413). This is mainly supported by the presence of leukocyte 
invasion and production of inflammatory markers and MMPs in the endometrium 
during the secretory phase (1249).  
 
An interesting theory proposes a first phase of endometrial vasoconstriction and 
cytokine changes induced by progesterone withdrawal (12, 686, 873, 1384). A 
second phase then involves inevitable activation of lytic and apoptotic mechanisms 
due to hypoxia which may be due to steroid hormone withdrawal or and probably is 
progesterone independent (686, 1381, 1384).  
Hypoxia, prostaglandins and cytokines such as IL-1 also stimulates local VEGF in 
endometrial stromal cells which both induces vascular permeability and acts as a 
chemoattractant for monocytes (1299, 268). 
 
During the praemenstrual and menstrual phase there is a significant influx of 
activated inflammatory cells, i.e. mainly macrophages, NK cells, eosinophils and 
neutrophils, into the endometrium comprising up to 40% of total cell number 
within the functional endometrium, possibly due to progesterone withdrawal 
affecting PR-expressing endometrial cells (471, 623, 940, 1249, 1250).  
However, most studies show a lack of evidence for PR or ER expression on 
endometrial leukocytes which suggests that effects of steroid hormones on human 
leukocytes may only be indirect (708, 1356). As glucocorticoid receptors are similar 
to PRs; it is highly likely that progesterone could act in progesterone-dependent 
tissues in a similar manner than glucocorticoids in other tissues.  
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Besides that, leukocyte migration into the endometrium is likely to be mediated by 
chemokines and cytokines such as IL-1, IL-8 or MCP-1 (105). Data propose that 
progesterone withdrawal thus can stimulate the premenstrual rise in chemokines 
IL-8 and MCP-1 (635, 639, 684, 685).  
It can be concluded from several studies that chemokines modulate the recruitment 
of leukocytes into the endometrium and their expression is stimulated by the 
withdrawal of progesterone at the end of cycle.  
 
Also the regulation of adhesion molecules responsible for leukocyte attachment 
during the menstrual cycle with a higher expression of ICAM-1 and PECAM in the 
secretory phase fits in this theory (1397, 1413). Besides entering the endometrium 
from the blood, some leukocytes, especially granulocytes, have been observed to 
proliferate in the endometrium, mostly during the secretory phase (1383). The 
question arises how inflammatory cells differentiate to different phenotypic subsets 
in the endometrium and how are they activated to release their mediators at 
appropriate time and place for menstruation.  
 
This leukocyte influx induces production of MMPs and other enzymes with the 
potential to degrade components of the extracellular matrix (1248), which supports 
the theory that MMPs play a decisive role in the breakdown of cell-cell and cell-
matrix adhesions of endometrial tissue (117).  
Most MMPs are produced by endometrial stromal/decidual cells except MMP-7 
which is an EC product and MMP-9 which is mainly produced by leukocytes 
including eosinophils, neutrophils, macrophages and some endometrial T cells 
(1209, 1248, 1580). Also MT1-MMP, perforin and elastase are produced by 
neutrophils and endometrial NK cells (1248, 1579) while mast cells with their 
proteases chymase and tryptase can activate the MMP cascade as well (623, 1249).  
 
Regulated by cytokines and steroid hormones (1178, 1249), the patterns of 
expression of MMPs during the menstrual cycles are different in normal human 
endometrium. MMP1, MMP-3, MMP-7, MMP-9 and MT1-MMP mRNA and protein 
are all substantially increased immediately prior to and during menstruation (1209, 
1579) which proposes them as the mediators of tissue breakdown at menstruation.  
 
Withdrawal of progesterone may contribute to the recruitment and activation of 
leukocytes by inducing the production of cytokines and chemokines by endometrial 
and ECs of the endometrium. Furthermore, withdrawal of progesterone may directly 
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promote MMP production by resident endometrial cells (868, 1247). Several in vitro 
studies demonstrate that progesterone is a potentially important player in 
regulation of MMPs in the endometrium. 
 
The unique immunological characteristics of the female genital tract must be 
considered in the design of vaccines for the protection against microbial diseases, 
especially against STDs. 
 
Despite the uniqueness of the female genital tract as a mucosal immune system, 
the concept of a common mucosal immune system with dissemination of activated 
immune cells from inductive sites to other distant mucosal effector sites offers great 
hopes and oppurtunities in the field of vaccine development (287). This is 
dependent on characteristic homing receptor-ligand interactions. The presence of 
adhesion molecules like ICAM-1, VCAM-1 and selectins, but not MAdCAM-1, in 
female genital mucosa was reported by Johansson et al. (626).  
This indicates that the lymphocytes which are destined to the genital tract do not 
use the MAdCAM-1-α4β7 integrin interaction used by intestinal lymphocytes, at 
least in non-inflamed tissue (1364). However, it can be proposed that, in response 
to infection, cytokines produced by genital tract ECs such as TNF-a, IL-1 and IL-6 
can induce the expression of both VCAM-1 and MAdCAM-1. 
 
Investigators have attempted to elicit secretory immunity in the genital tract by 
using different routes of immunization, i.e. vaginal, nasal, rectal and parenteral 
routes. Systemic immunization warranted some success but further studies are 
needed (272, 1227, 1410). Remote inductive site immunizations, especially by 
intranasal route or combinations of systemic and various mucosal routes, results in 
induction of sustained IgG- and IgA-mediated humoral immune responses. 
 
Numerous experiments have shown that the local instillation of various antigens, 
especially together with an adjuvant, into the vagina of experimental animals or of 
human female volunteers can result in the development of specific antibodies in the 
local secretions (1041, 1409, 1410).  
The study by Kozlowski et al. where oral, rectal and vaginal immunization 
increased levels of specific IgG in serum and specific IgA in saliva similarly but only 
vaginal immunization significantly increased both specific IgA and specific IgG in 
female genital mucosa (743, 744).  
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Generally, the levels of these responses are quite modest and moreover the 
responses are not disseminated either to remote mucosal sites or to the systemic 
compartment represented by serum antibodies. Local intravaginal immunization 
required large and repeated doses of antigen. Also the influence of the menstrual 
cycle should be taken into consideration. Furthermore, local immunization of the 
male tract is unlikely to be practicable.  
These considerations and findings sustain the notion that the genital tracts 
represent effector sites of the central mucosal immune system, but as inductive 
sites they serve only for the generation of local responses. 
 
The potential importance of rectal lymphoid tissues as an inductive site for 
stimulation of humoral immune responses in the human female genital tract is 
based on the equal distribution of IgA subclasses at both sites.  
In general, the rectal immunization route generated variable results, depending on 
the type of antigen, frequency of vaccine administration and stage of menstrual 
cycle (272, 743, 744, 745, 760). To generate long-lasting humoral immune 
responses, however, the combination of several mucosal immunization routes was 
more effective, for example oral and rectal immunization in the trial of Kutteh et al. 
(760).  
 
Animal studies also emphasized the importance of the inductive sites in the nasal 
cavity for the generation of mucosal, including genital, and systemic immune 
responses that may exceed in magnitude those induced by oral immunization 
(1227).  
Experiments on mice and women convincingly demonstrated that viral or bacterial 
antigens in combination with CTB instilled into the nasal cavity induced superior 
immune responses in local secretions as well as in saliva and female genital tract 
secretions (111, 625, 1222, 1228, 1537). Furthermore, the complicating factor of 
hormonal influences could be avoided by using the nasal route, which offers the 
additional advantage of potentially inducing high levels of specific IgG antibodies in 
the circulation, and requiring lower antigen doses.  
It was concluded that a combination of nasal and vaginal vaccination might be the 
best vaccination strategy for inducing protective antibody responses in both cervical 
and vaginal secretions, provided that the vaginal vaccination is given on optimal 
time points in the cycle (627).  
Therefore, the nasal immunization route in particular deserves further testing with 
vaccines and potential adjuvants for prevention of STDs. 
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B. Immunology of genital tract infections 
1. HSV 
Genital herpes infection remains one of the most prevalent STDs worldwide. About 
25% of sexually active adults are infected in the United States (416) and 20-35% of 
pregnant women are estimated to be HSV-2 seropositive (880). Its increasing 
prevalence (1337), the frequency of clinical recurrences and asymptomatic shedding 
(1465) as well as its link to HIV transmission (1466) emphasize the urgent need to 
develop new preventive strategies to control HSV. 
Genital herpes is more common in women than in men, with approximately one in 
four women versus one in five men having specific antibodies to HSV-2 (416). This 
gender difference suggests that the female genital tract provides a more permissive 
environment for HSV-2 infection and the establishment of latency. 
 
The role of immune factors in the control of HSV infection, especially recurrent 
lesions after viral reactivation, appears complex.  
TLR2 and TLR9 seem to be involved in cell signaling in response to HSV-1 and HSV-
2 mediating HSV-induced cytokine secretion (840, 756). The first line of defense 
against genital HSV infection then consists of mucus, normal bacterial flora, acidic 
pH and secreted proteins such as complement, defensins or SLPI. The second 
implies early virally induced responses by ECs and resident DCs, which are 
characterized predominantly by IFN production. Thirdly, there is the recruitment of 
cellular effectors including neutrophils, macrophages, and NK cells (347, 1584). 
 
Recent studies by Mascasullo et al. demonstrated the irreversible antiviral effect of 
acidic pH≤4.5 on HSV-1 or HSV-2 (880), which confirms hints of earlier studies 
(1218). Exposure to acidic pH seems to disrupt the viral envelope and prevents 
binding and invasion. The significance of these in vitro observations was confirmed 
in a murine model with the vaginal buffer AmpHora (440), which suggests a 
protective role of vaginal acidic pH against HSV infections.  
Findings suggest that CVS might contribute to innate resistance to HSV-2 and 
identified defensins as contributors to this activity (633). They may provide a 
prototype for future topical microbicides. This is also implicated in earlier in vitro 
studies on the protective effect of HNP1-4 and HD-5/6 against HSV (1557, 880). 
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However, due to a relatively low concentration of HNP 1-3 in CVL these findings 
suggest also the effects of other defensins as contributors to this activity.  
Also other genital tract proteins such as SLPI (880), lactoferrin (869) and SP-D (921) 
may play a role in innate immunity against HSV, but this has to be investigated 
further.  
Studies suggest a potential role for complement as a genital tract host defense 
against HSV besides other infectious diseases (835, 432); and HSV has evolved 
several strategies to evade immune attack by the classical and alternative 
complement pathways in inhibiting C3, for example (429).  
Less is known about the role played by MBL and the lectin pathway as a host 
defense against genital herpes infection or whether HSV also evades this 
complement pathway. 
 
The precise role played by the different DC populations in the immune response to 
HSV in the female genital tract is not clear; and, notably, differences have been 
observed for HSV-1 and HSV-2.  
HSV-1 may interfere with immune responses through infection of immature DCs 
and selective downmodulation of costimulatory molecules (932), which leads to 
delayed activation of T cells and allows more time for replication of HSV type 1 in 
epidermal cells. These findings support the notion that immature DCs respond to 
HSV challenge by impaired maturation. Further results indicate that HSV-1-
infected mature DCs are limited in their capacity to migrate to lymph nodes, thus 
inhibiting an antiviral immune response (1141). 
In a study on rhesus macaques, HSV-2 was found to induce apoptotic death, 
decreased expression of costimulatory molecules and increased release of cytokines 
by monocyte-derived DCs (1106). This coincided with HSV-2-infected DCs 
stimulating weak T cell responses. Similar effects were observed in HSV-2-exposed 
human DCs. 
 
In contrast, results from other studies suggest a previously unanticipated role for 
submucosal DCs in the generation of protective Th1 immune responses to HSV-2 in 
the vaginal mucosa (821, 1584). The observation that submucosal DCs, but not 
LCs, are the primary cells responsible for T cell priming in the draining lymph 
nodes after intravaginal HSV-2 infection is also supported by work from King et al. 
(711) and MasCasullo et al. (880).  
Further studies are ongoing to define better the role that DCs play in mucosal 
response to HSV infection in the genital tract. 
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The exact role of NK cells and neutrophils in genital HSV infection is elusive.  
Studies in mice have shown a potential role of NK and NK T cells in immunity 
against genital HSV-2 (58) and the role of NK cells in innate immune responses 
against HSV-2 in humans also seems essential (293). However, because NK cell 
deficiencies involve other immune functions, it is difficult to determine the precise 
role played by NK cells in these cases. 
Studies on lymphocyte-deficient mice implicated that their impaired innate 
resistance to HSV-1 is not dependent on NK cells (497) but due to the differences in 
these study models one probably cannot transfer these results to human HSV-
infection. 
Murine studies suggest that neutrophils may not be critical for primary HSV 
infection (946) but somehow help in virus clearance from the genital mucosa after 
primary infection. The mechanisms by which neutrophils mediate antiviral activity 
are not well understood but may implicate release of antiviral cytokines or ROI/RNI 
(880, 182). 
 
Despite the recognition that innate immunity provides the first line of defense 
during both primary and recurrent HSV infection and plays a critical role in 
preventing infection and in limiting viral replication, the specific factors such as 
antimicrobials and TLRs that contribute to the mucosal response in the female 
genital tract have only recently begun to receive attention. 
Further studies are needed to provide a better understanding of the contribution of 
specific components of mucosal immunity and the mechanisms by which virus may 
evade these immune strategies. Defining this activity is crucial, as these factors 
might be exploited in the development of microbicides.  
Susceptibility and immune responses to STDs including genital HSV-2 infection are 
profoundly affected by sex hormones. Studies have already indicated that intake of 
oral contraceptives influences susceptibility to candidiasis, HSV-2, HIV-1, and 
chlamydial infections in women (876). 
 
Interestingly, previous studies have shown that mice are susceptible to intravaginal 
HSV-2 infection primarily during the diestrous phase of the estrous cycle (1086). 
Thus, treatment of mice with progesterone which maintains the mice at a diestrus-
like stage is often required for consistent intravaginal infection with HSV-2.  
However, the precise mechanism by which progesterone treatment increases the 
susceptibility to intravaginal HSV-2 infection is unknown. It is suggested that this 
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is due to diminishing thickness and increased permeability of the vaginal epithelial 
layer during diestrus with high progesterone levels (604).  
Kaushic et al. demonstrated that progesterone (Depo-Provera) treatment of mice 
led to a 100-fold increase in susceptibility to genital HSV-2 compared to untreated 
mice at diestrous phase (671). Further, longterm effects of Depo-Provera treatment 
included reduction in protective immunity to HSV-2. This study highlights the 
immunosuppressive role of Depo-Provera and also demonstrates that the thickness 
and gross morphology of the vaginal epithelium alone cannot account for the 
susceptibility to HSV-2 infection.  
 
As another possible mechanism for the increased susceptibility to HSV-2 at the 
diestrous phase it can be hypothesized that APCs are less abundant in the vagina 
during the susceptible diestrous phase and more abundant during the resistant 
estrous stage. However, analysis of the distribution of the DCs during the estrous 
cycle revealed that these cells are abundantly present in the epithelium of mice at 
diestrus, whereas they are only sparsely present in the basal layer of the vaginal 
epithelium in estrus (1584), which suggests that the distribution of the APCs per se 
does not account for the susceptibility to virus infection at different stages of the 
estrous cycle.  
 
Finally, it is possible that the virus entry receptors are expressed differently during 
the hormonal cycle and that the relevant receptors are expressed only during the 
susceptible stages. Interestingly, nectin-1, the major co-receptor for HSV entry in 
the genital tract, is expressed in the epithelium of the mouse vagina only during the 
stages of the estrous cycle in which mice are susceptible to vaginal HSV (821). 
Limited clinical studies suggest that asymptomatic HSV viral shedding is not 
related to contraceptive use or menstrual cycle (145). Moreover, nectin-1 is 
expressed throughout the menstrual cycle in human beings (821). 
Further studies are needed to elucidate the relationship between mucosal 
immunity, the hormonal environment, and response to HSV challenge. 
 
Extensive studies have demonstrated that in HSV-2, as in many other viral 
infections, both antibodies and cell-mediated immune responses in the systemic 
and mucosal compartments contribute to protection against infection and to 
clearance of infected cells. However, the majority of studies have been performed on 
mice due to ethical and methodologic limitations. 
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Several basic indications show the greater importance of T cell responses than the 
persistence of neutralizing antibodies in recurrent infections. AIDS patients have 
longer prevalences of herpetic lesions (1301) and mice depleted of CD4+ and CD8+ 
T cells prior to genital HSV-2 infection shed virus for a prolonged period, confirming 
a role for T cells in virus clearance (1087).  
 
Early murine studies of the immunology of HSV infection suggested that IFNs and 
macrophages were an important part of the initial immune response and that the 
most important protective specific T-lymphocyte response was that mediated by 
CD8+ lymphocytes. However, immunohistology of biopsies of human recurrent 
herpetic lesions revealed a sequence of immune cell infiltration beginning with 
CD4+ lymphocytes and macrophages in the first 2 days around the infected 
epidermal cells which also develop strong HLA-DR expression (281). This was 
followed by an influx of CD8+ lymphocytes, which normalized the balance between 
CD4 and CD8 lymphocytes. The CD4/CD8 ratio is not restored to that of the blood 
until after 2 days, indicating an early CD4+ and a later CD8+ lymphocyte influx 
(281).  
 
Several studies have demonstrated that Th1 CD4+ T cells are necessary and 
sufficient to provide protective immunity to HSV-2. Murine studies on the local T 
cell response indicate that CD4+ and Th1-like cells dominate in number in genital 
lymph nodes and secretions after intravaginal HSV inoculation and suggest a 
predominant role for CD4+ T cells in anti-HSV-2 immunity (944, 753). 
Further, it was shown that the CD4+ T cell-meditated protection was linked to their 
ability to secrete IFN-γ (509, 281).  
 
The mechanism of the Th1-mediated protective immunity to HSV-2 likely involves 
several pathways. It is possible that CD4+ T cells are involved in the direct killing of 
HSV-infected ECs, as these effector cells are rapidly recruited to the sites of 
secondary infection (1086). IFN-γ has also been shown to act on vaginal ECs to 
restore MHC class I expression and up-regulate MHC class II expression (1427), 
which may contribute to the recognition by CD4+ effector T cells. Alternatively, IFN-
γ could exert protection by activating macrophages and neutrophils for enhanced 
phagocytosis of infected cells, resulting in the secretion of TNF-α and the release of 
NO. Finally, IFN-γ secreted during the secondary viral challenge may also be 
important in the recruitment of memory and effector lymphocytes to the infected 
vaginal epithelium (1091).  
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Antigen-specific T cells have been detected in the uterine cervix of women with 
genital HSV-2 infection where CTL activity was both associated with CD4+ and 
CD8+ T cell populations (732). This is consistent with the finding that clearance of 
HSV-2 skin lesions correlated with the infiltration of CTLs of both CD4+ and CD8+ 
phenotypes (731). Recent studies concerning the specificity of CTLs indicate that 
CD8+ T cells from genital herpes lesions recognize viral tegument and immediate 
early proteins as their targets (729). 
The importance of CTL-mediated clearance of HSV is evidenced by yet another 
immune evasion mechanism employed by the virus. Its genome encodes the ICP-47 
gene product, which can bind and block the TAP complex to prevent assembly f 
MHC class I peptide and antigen presentation to CD8+ T cells (1424, 544). 
 
Women with symptomatic genital herpes have antibodies to HSV-2 of both IgA and 
IgG isotypes, as well as IgM in CVS (59, 60, 894) and in serum (519). External 
secretions including cervical mucus contain both IgG and IgA antibodies, but these 
differ in their specificity for various HSV-2 antigens (60). Moreover, cervical anti-
HSV IgA antibodies either free or with SC as S-IgA also differ with respect to their 
levels and specificities for various HSV-2 antigens, suggesting origin from 
circulation as well as by local production. 
Remarkably, nearly all specific viral antibody in vaginal mucus in HSV-immune 
mice was of the IgG isotype whereas S-IgA seems to contribute little to protection 
(1079, 943, 1082, 1085). However, these observations did not eliminate the 
possibility of contribution of vaginal IgA in immune protection against HSV-2, since 
ELISA titers of specific antibodies do not necessarily predict functional virus 
neutralization (1092). 
The importance of IgG in HSV immunity is also evidenced by the immune evasion 
mechanism employed by the virus. The HSV gE and gI together comprise a high 
affinity Fc receptor expressed by infected cells for the purpose of absorbing and 
inactivating anti-HSV IgG (998). 
 
The role of antibodies in protection of the female genital tract against HSV-2 could 
be seen controversial.  
Anti-HSV mAb failed to protect against vaginal challenge infection and specific 
antibody was not detected in vaginal secretions after parenteral immunization that 
produced high antibody titres in serum (896). Immunity against vaginal HSV-2 
infection was comparable in intact and IgA-deficient mice and only little vaginal 
specific S-IgA was detected after local immunization in the vagina (1082, 1088). 
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Kuklin et al. reported that intranasal immunization of mice with recombinant 
vaccinia virus produced high titers of specific IgG and IgA in the vagina but failed to 
prevent epithelial infection (753).  
These results would suggest a protective immunity in vaginal mucosa which is 
mainly based on T cells which was underlined by other experiments as well (945, 
1310).  
Passive transfer of serum IgG from immune mice diminished a vaginal challenge 
infection even though mean antibody titer in vaginal secretions of mice was only 8% 
of that measured in actively immunized mice (1082). Purified IgG from vaginal 
secretions of immunized mice neutralized HSV-2 in vitro. The protective effect of 
HSV-2 specific antibodies has also been demonstrated by passive intravaginal 
immunization shortly before HSV-2 challenge given by the same route (1496, 1575). 
  
The importance of B cells and antibody-mediated protection in vaginal HSV-2 
infection was shown in B cell-deficient mice. In contrast to intact mice, these 
animals displayed diminished immunity to intravaginal challenge as well as 
increased viral shedding (1088). Antibody is supposed to mainly act early during 
immune resistance to challenge infection, whereas cell-mediated immunity 
primarily acts later. An early role for antibody is consistent with the presence of 
neutralizing IgG in vaginal secretions of immunized mice (1082) whereas memory T 
cells, on the other hand, require several hours to secrete substantial amounts of 
IFN-γ in the vagina in response to the challenge antigen and may require even 
longer developing cytolytic activity (1091).  
 
Differences in study designs and experimental procedures may be responsible for 
different results. The route of immunization also influences antibody-mediated 
protection. Secreted antibody is relatively more protective in vaginally immunized 
mice than in parenterally immunized mice as local immunization leads to 
accumulation of plasma cells and antibody in the vagina (1083).  
 
The conclusion may be that herpetic lesions show all the hallmarks of the 
predominantly Th1-pattern, with the induction of MHC class II on epidermal cells 
being particularly prominent. IFN-γ has a critical role within the lesion in up-
regulating MHC classes I and II on infected cells, in activating macrophages and in 
preventing the spread of epidermal infection by the virus in synergy with IFN-α. 
Destruction of infected cells and the induction of antiviral immunity within adjacent 
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uninfected cells are complementary activities of early CD4 and late CD8 lymphocyte 
infiltration within the lesion. 
This indicates that recurrent disease is prevented by virus-specific Th1 immunity, 
most notably by IFN-γ, and its ability to enhance the innate immunity. Treg cells 
and Th2 cytokines such as IL-10 downregulate this immune profile, thereby 
allowing for unimpeded replication of reactivated virus and recurrent disease. A Th2 
pattern leading to neutralizing antibody production may prevent cell-to-cell 
transmission of the virus. 
 
Alternative immunologic treatment options have gained attention during the last 
years.  
The IRM Resiquimod is said to initiate immune cells such as DCs and macrophages 
to produce Th1 immune responses via cytokine production (942) and may therefore 
be suitable for treatment of genital herpes. Animal models and phase II studies 
showed quite promising effects in delaying genital herpes recurrency (112, 1333); 
however, phase III clinical trials were suspended due to the lack of efficacy of 
resiquimod gel in recurrent genital herpes lesions (1333). It may have a comeback 
as a vaccine adjuvant for viral infections that require a strong Th1 immune 
response.  
A similar effect with induction of vaginal Th1-type cytokines and increase of B and 
T cells in genital lymph nodes was demonstrated by vaginal application of CpG ODN 
in mice and ginea pigs (507, 1149).  
The purpose of a study by Kwant et al. was to determine whether intravaginal 
immunization with recombinant glycoprotein B (rgB) of HSV-2 plus CpG ODN can 
induce specific immunity and protect against genital HSV-2 challenge (769). Mice 
immunized with rgB+CpG had higher levels of anti-gB IgA and IgG in the vaginal 
washes and serum compared to mice immunized with rgB alone. Mice immunized 
with rgB +CpG showed higher survival and lower pathology scores following genital 
HSV-2 challenge than mice immunized with rgB+non-CpG ODN or rgB alone.  
 
Gallichan et al. showed that intranasal immunization with CpG ODN plus rgB of 
HSV-1 resulted in significantly elevated levels of specific anti-gB IgA antibodies in 
vaginal washes that remained high throughout the estrous cycle (434). Additionally, 
dramatically elevated numbers of specific IgA-secreting cells were present and 
persisted in the genital tract in response to intravaginal HSV-2 challenge. Strong 
CTL responses were observed locally in the genital tissues of both CpG and non-
CpG ODN-immunized mice following intravaginal HSV-2 challenge. Interestingly, 
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mice immunized intranasally with rgB plus CpG ODN, but not non-CpG ODN, were 
significantly protected following intravaginally HSV-2 challenge. In conclusion, 
these results indicate that intranasal immunization with CpG ODN plus protein 
mediates immunity in the female genital tract capable of protecting against a 
sexually transmitted pathogen. 
McCluskie et al. recently compared the efficacy of CpG ODN and resiquimod for 
topical immunotherapy of intravaginal HSV-2 infection in mice and demonstrated 
efficacy for CpG ODN but less so for resiquimod (895). Intravaginal administration 
of GpG ODN resulted in a strong local but weak systemic immune response, as 
determined by the levels of chemokines as IP-10 whereas intravaginal 
administration of resiquimod resulted in high levels of plasma IP-10 and weaker 
local immune responses. 
These findings provide a basis for further intervention studies of the efficacy of CpG 
ODN in humans. 
 
Vaccination to prevent HSV infection, or to reduce reacitivation frequency and 
severity, would reduce morbidity, the risk of dissemination to newborns and the 
risk of HIV acquisition. Vaccines may be sought for two independent purposes; 
prophylaxis in uninfected individuals and therapy in already infected.  
History of HSV vaccine development goes back for almost 80 years. HSV vaccines 
may be divided into the two groups of live or inactive vaccines. Live vaccines contain 
organisms capable of at least limited replication in vivo, whereas inactive vaccines 
are incapable of replicating. The vaccines may be further subdivided into the 
categories: attenuated HSV vaccines (912), replication-limited HSV vaccines (904), 
vaccines consisting of live nonpathogenic replicating vectors engineered to express 
HSV gene products, inactivated HSV vaccines (689, 1490, 881), subunit vaccines 
(1336, 956), and nucleic acid (plasmid) vaccines (136, 449). 
 
Many types of vaccines have been evaluated in clinical trials of immunogenicity and 
prophylactic or therapeutic efficacy (339, 689, 1490, 881, 758, 1315, 1360, 1361, 
1339). Some of the early vaccines either showed low immunogenicity, safety flaws or 
appeared immunogenic but the trial design then precluded interpretation of 
efficacy. 
 
The only randomised clinical trials of a vaccine against genital herpes showing 
efficacy so far, are those with the HSV-2 glycoprotein-D-alum-MLP vaccine of 
GlaxoSmithKline (1339, 1338). These studies demonstrated that the vaccine was 
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over 70% effective in preventing genital herpes disease, but only in women who 
were negative for both HSV-1 and HSV-2 before receiving the vaccine. The vaccine 
was shown to induce both gD-specific neutralizing antibodies and a Th1 cell-
mediated immune response.  
 
Another vaccine containing HSV-2 glycoprotein B2 and D2 together with the 
adjuvant MF59 failed to show long-term efficacy in preventing HSV acquisition; 
HSV disease was not reported as an endpoint in these trials (254). 
Interestingly, the HSV-2 antibody titers did not differ between vaccinated, 
uninfected and vaccinated, finally infected individuals which suggests that 
neutralizing antibody alone is not sufficient to protect against genital HSV-2 
infection and that the vaccine failed to induce critical cell-mediated immune 
responses against HSV-2 infection. Possible explanations for the loss of efficacy 
could be that the protective immune response was only short time or that initial 
protection was lost with frequent exposure to the virus (1339). 
Also the adjuvant used in both vaccines may be critical in facilitating the induction 
of protective immune responses as the MF59 adjuvant induces a Th2-pattern of 
response (1313), whereas the MPL adjuvant induces a Th1-pattern of cytokine 
response.  
 
The difference between herpes disease and herpes infection is crucial in interpreting 
the studies (495). The primary endpoint of the GSK study was the occurrence of 
genital herpes disease and no distinctin was made between HSV-1 and HSV-2 as 
causes. As HSV-1 is responsible for a a high rate of primary genital herpes, 
recipients may be protected against disease caused by either virus. 
An effective HSV-vaccine might mimic the immunological process underlying the 
phenomenon that previous HSV infection protects against HSV disease by reducing 
its severity. It appears that in HSV-1 seropositive, HSV-2 seronegative persons, the 
GSK vaccine provided no additional protection over their presumed HSV-1 induced 
immunity.  
There might also be hints in statistical analysis of the GSK studies that the study 
was insufficiently powered to detect a difference in infection rates between placebo 
and vaccine (495). Also the significantly different results in efficacy for men and 
women rise questions. 
To evaluate all this further, a larger phase III study of 7550 females with the GSK 
vaccine is currently ongoing. 
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However, the development of an effective vaccine against genital herpes seems to be 
under way. If it is ideal to protect the public from rising rates of genital herpes 
remains speculative. Further areas of investigation should include the route of 
immunization and suitable adjuvants.  
2. HIV 
Women comprise an alarming number of newly diagnosed cases of HIV infection 
(1531, 571). Worldwide, 70 to 80% of HIV-1 infections are transmitted through 
heterosexual contact, and the majority from male to female. Nonetheless, only one 
in 200 to one in 1000 encounters results in productive infection which emphasize 
the effectiveness of structural and cellular barriers to virus entry (479). 
 
As the genital tract mucosa is the site of initial contact with HIV-1 for the vast 
majority of exposed individuals, study of the virus from the genital tract is critical 
for the development of vaccines and therapeutics. Therefore, a better understanding 
of the immunological mechanisms in the genital tract mucosa occurring during HIV 
infection is essential. During the last years, significant progress has been made in 
understanding anti-HIV immunity in the vagina by using the SIV/rhesus monkey 
model of heterosexual HIV transmission (937).  
Dysregulation of the immune system of the body is seen in association with HIV 
infection, with a fall in the CD4+ lymphocyte count and a reversal of the CD4/CD8 
ratio now being well recognized systemic manifestations of infection. However, 
alterations in mucosal immunity in the presence of HIV infection have been clearly 
documented in both the gut (617) and the lungs (10) whereas in contrast, the 
female lower genital tract has not been as extensively studied. 
 
During sexual intercourse, free HIV virus and virus-infected cells in semen are 
deposited within the vagina (1101). Understanding the mechanism of HIV-1 
transmission within the female genital tract requires definition of the cellular 
targets for infection, and whether susceptibility to infection varies under different 
hormonal and inflammatory conditions.  
 
Several reports have identified DC, resting and activated memory CD4+ T cells, and 
macrophages as the earliest cell populations to become positive for SIV- or HIV RNA 
following a non-traumatic exposure to the virus (491, 574).  
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As mentioned, the cervicovaginal mucosa contains a complete set of immune cells 
including APCs, CD4+ and CD8+ T cells and B cells. Cervical biopsies from HIV-
positive women have shown significantly reduced levels of LCs but increased 
numbers of macrophages as well as an increased proportion of activated 
macrophages (13) suggesting that local mechanisms of T-cell activation are in place. 
Although in chronically HIV-1 infected women, T cells, macrophages, and LCs in 
cervical tissue are infected with HIV-1 (1137), analysis of lymph nodes in HIV-
infected men indicates that active virus replication occurs in activated and resting 
CD4+ T cells (1583).  
However, there are no in vivo data to indicate the cell types that first become 
infected in the reproductive tract of women.  
In the SIV-rhesus monkey model, there are controversial data on which cells are 
first infected during sexual transmission. Zhang et al. proposed CD4+ T cells as the 
first cells to become infected after intravaginal inoculation of SIV (1583) whereas Hu 
et al. demonstrated the presence of SIV RNA in DCs shortly after intravaginal 
exposure of SIV (574). 
 
One problem in studying HIV-1 transmission in humans is the lack of a suitable in 
vitro model. Gupta et al. used a cervical tissue-derived organ culture model which 
seems suitable to provide the natural tissue architecture and identified memory 
CD4+ T cells as the first cells that became infected during HIV-1 transmission 
across the cervical mucosa (491). This would imply a higher replication of HIV in T 
cells which would allow the virus to expand and get transferred to DCs. DCs are 
considered important target cells in HIV infection and transmission, as the cell 
surface receptor DC-SIGN is thought to be one of the receptors to bind and 
internalize virus prior to its transmission to lymph nodes where the infection would 
be passed to CD4+ T cells (333).  
Although HIV can be recovered from the vagina of women who have had a total 
hysterectomy, most genital virus arises from the cervix and possibly the upper 
genital tract (378, 251). Studies on leucocyte populations in the human cervix 
showed leucocytes in the squamous mucosa and submucosal stroma to be 
predominantly T lymphocytes and DC which both did not vary in numbers or 
distribution during the menstrual cycle (1138). 
Due to the findings of Pudney et al. with the cervix and especially the 
transformation zone as the major inductive and effector site for cell-mediated 
immunity in the genital tract, it would also speak for the cervix as primary infection 
site of HIV-1 (1146). 
  Discussion 
 III-309  
Expression of HIV receptors and coreceptors is likely to correlate with susceptibility 
to viral infection. In defining if the ectocervix or the uterus serves as first site of HIV 
infection, the studies by Yeaman et al. on expression of HIV receptors CD4 and 
GalCer and coreceptors CCR5 and CXCR4 in the female genital tract have given 
important clues. 
 
It has been shown that HIV-1 infects viable tissue sections and isolated cells from 
both the lower and upper female genital tract suggesting that both ECs and 
submucosal leukocytes may be targets for initial HIV-1 infection (571).  
HIV-1 strains that utilize the CXCR4 chemokine receptor (X4) for infectivity are able 
to undergo reverse transcription, integration, viral DNA transcription and viral 
release whereas viral strains that utilize CCR5 (R5) do not undergo these early 
replicative events and are only released unmodified from these cells (570).  
Endometrial ECs were shown to express all four receptor types and altered 
expression of these receptors as a function of menstrual cycle stage could serve to 
either enhance or inhibit HIV-1 infection (1561).  
It also seems probable that chemokine receptors, by virtue of their selective binding 
to HIV-strains X4 or R5, play a role in the selective uptake and transmission of 
virus within the genital tract (61). Results indicated that uterine ECs could 
preferentially bind R5 strain during the proliferative phase whereas during the 
second hal of the cycle they may be more susceptible to X4.  
 
In contrast, there was a lack of CCR5-, CXCR4- and CD4-expressing cells 
accessible to HIV in the lumen of the ectocervix (1561). Results suggest that HIV 
infection of cells in the ectocervix could most likely occur through GalCer and CCR5 
which were both expressed on ectocervical ECs throughout the menstrual cycle. 
 
Thus, on the basis of findings of HIV-1 infection and HIV-1 receptor and coreceptor 
expression on uterine ECs, it appears that in comparison to the ectocervix, the 
uterus is a more likely first site for infection and transmission of virus after vaginal 
intercourse.  
In the uterus, HIV-1 transmission could involve secretion of newly synthesized 
infectious virus from the uterine ECs, or viral transmission by cell-to-cell contact 
between the infected EC and a susceptible leucocyte. In contrast, the lack of CD4, 
CCR5 and CXCR4 expression on ectocervical ECs and the inability of these cells to 
develop a productive infection by HIV-1 (324) suggest that HIV-1 transmission in 
the ectocervix it is more likely to occur through the gradual release of infectious 
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unmodified virus that is then able to infect susceptible submucosal leucocytes. An 
alternative mechanism of HIV infection of the lower female genital tract involves the 
transcytosis of endosome-internalized HIV through the epithelium barrier, without 
EC infection (558). 
It is also known that mutations in chemokine receptors markedly reduce the 
likelihood of acquiring HIV infection following exposure to virus. The well-described 
deletion in CCR5 has been shown to protect against HIV transmission among 
discordant couples (115). 
 
One of the most important barrier functions to HIV transmission seems to be an 
intact and healthy vaginal and cervical epithelium with a normal microbial flora and 
low levels of inflammation. Disruptions to the genital epithelium, which can be 
induced either by agents in contraceptives or microbicides or infectious agents, 
enhance HIV transmission. Growing evidence suggest that not only the presence of 
STDs but also BV supports HIV transmission in the genital tract (28). Enhanced 
recruitment of activated immune cells, disruption of the epithelium barrier, 
reduction of Th and CTL function, which are all associated with STDs, may 
contribute to this STD-mediated enhancement of HIV detection in the female genital 
tract (27).  
 
Concerning other innate immune responses to HIV infection in the genital tract 
there have not been enough studies to concretely evaluate these mechanisms at 
this site.  
Newer studies may implicate a role for antimicrobials such as defensins and SLPI in 
controlling HIV infection within the genital tract. Higher SLPI concentrations in 
vaginal fluid samples correlate with a reduced rate of perinatal HIV transmission 
(1123) and SLPI blocks HIV infection of macrophages via annexin II (907, 849). 
Hormonal regulation of SLPI together with its anti-HIV activity may also be 
important factors in the susceptibility of women to HIV infection. 
HBD1-4 also seems to be involved in innate immune responses to HIV infection in 
the genital tract. Promising findings underline their possible role (1476, 1539, 
1157, 138); however, more studies have to further elucidate the role of 
antimicrobials in HIV immunity in the female genital tract. 
 
Immature DCs express CCR5 and CXCR4 as well as DC-SIGN and have been 
demonstrated to be one of the immune cell species which are infected with HIV-1 
(1317, 442). However, they are infected with lower efficiency than CD4+ T cells and 
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macrophages. In contrast, mature DCs do not efficiently replicate the virus and may 
therefore represent an important reservoir of latent virus infection (1317).  
 
One can speculate that several functional impairments of DCs and other APCs 
including inability to stimulate T cell proliferation (420) and a reduction of DCs and 
NK cells may contribute to impaired elimination of infected cells (420). However, 
further studies need to be done to evaluate these findings and if they can also be 
transferred to the genital tract mucosal immune system.  
It has been proposed that HIV binds to DC-SIGN on DCs in the genital tract and is 
internalized into nonlysosomal compartments where it retains infectivity, then 
transported to lymph nodes and presented to T cells. However, DC-SIGN is not 
expressed on LCs, the most superficially located DCs. It seems likely that there are 
other types of HIV receptors expressed by DCs (1432). 
 
It might be expected that humoral immune responses to mucosally encountered 
HV-1 would result in the predominance of S-IgA anti-HIV-1 antibodies. Instead, it is 
known from several studies that anti-HIV-1 antibodies are present in the vaginal 
secretions of infected individuals and anti-SIV antibodies in vaginal secretions of 
infected rhesus macaques with IgG as the major isotype (939, 833, 101). IgA 
antibodies are either absent or present at low levels. This is also the case in urine, 
intestinal fluid, saliva, and tears.  
The relative contributions of serum-derived and locally produced antibodies needs 
further study. However, there is evidence that at least some of the anti-HIV-1 IgG 
antibodies are locally produced (938).  
Recently, it has been demonstrated that plasma-derived IgG antibodies were 
functional in the prevention of vaginally induced SIV infections in monkeys (67). 
Thus, there is hope that intensive systemic active immunization with relevant HIV-1 
antigens may provide long-term protection against genitally encountered HIV-1 
infection. 
There is also clear evidence of cellular antiviral effector function in the female 
genital tract. HIV-specific CD8+ CTL are present in the cervicovaginal mucosa of 
infected women as well as anti-SIV CTL in vaginal and cervical epithelium of rhesus 
macaques (993, 938, 1281, 827). Elevated numbers of CD8+ cells seen in the 
ectocervix of HIV-1 women demonstrates the active recruitment of nonresident 
CD8+ lymphocytes rather than an expansion of the resident intraepithelial 
population. 
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Increased proportions of these CD8+ cells in the ectocervix are activated; however, 
as elsewhere, these cells do not appear to be capable of mounting an adequate 
immune response to the virus. Mucosal CD8+ T cells may be functionally impaired 
relative to those in the blood, both in terms of lytic activity and IFN-γ production 
(13, 906).  
 
In the uterus, CD8+ T cells were found to be noncytolytic during the secretory 
phase and CTL activity is higher in postmenopausal women than in premenopausal 
women (571). One could postulate that this would lead to a higher viral 
susceptibility at the uterine level during the secretory phase.  
Furthermore, the decrease in percentage of CD4+ T cells typically seen in HIV-
infected persons is also detectable in in the lamina propria of the genital tract in 
monkeys (1352) and humans (13). 
The relative importance of local HIV-specific antibodies and CD8+ CTL immune 
responses is presently not exactly clear. Animal models suggest that virus-specific 
CD8+ T cells together with adequate help of CD4+ T cells can efficiently suppress 
replication of SIV and HIV-1 and slow down disease progression (807). Antibodies 
play an impotant role in controlling most viral infections, but HIV envelope proteins 
are variable and evade a neutralizing antibody response.  
 
Studies also show a significant effect of proinflammatory cytokines on replication 
and spread of HIV. IL-2, TNF-α, IL-1, and IL-6 can upregulate HIV replication, 
whereas INF-α, TGF-β, IL-10, MIP-1α, MIP-1β, and RANTES can downregulate HIV 
(380). The balance between HIV-inducing and HIV-inhibiting cytokines may impact 
the viral load in the mucosa and subsequently, the sexual transmission of the 
virus. 
 
Levels of the cytokines TNF-α, IL-1β, MIP-1α, IL-6 and IL-10 were found to be 
significantly elevated in genital secretions of HIV-infected women compared to 
healthy controls (102, 35, 271). HIV-1 therefore leads to an induction of 
proinflammatory cytokines in the genital tract mucosa.  
These results parallel reports demonstrating increased concentrations of Th2-type 
cytokines, IL-6 and IL-10, in the systemic circulation and at mucosal surfaces of 
HIV-positive adults (239, 1045). It also corresponds to reports of increased IL-10 
mRNA expression in cervical biopsy specimens from HIV-positive patients compared 
with those from HIV-negative patients (1045). Moreover, this parallels findings of 
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increased levels of these cytokines in serum and digestive tract mucosa in HIV 
infected persons (103, 1189). 
 
As these cytokines are present in CVS in healthy women as well, they could 
enhance HIV replication as soon as the virus enters the vagina. This hypothesis is 
in keeping with the higher risk of male-to-female transmission in case of female 
genital tract infection or inflammation, a situation likely associated with increased 
local production of proinflammatory cytokines.  
Data indicate that concomitant infection of the genital tract with HIV and other 
viral, bacterial, or protozoan pathogens influences the local concentrations of some 
immunoregulatory cytokines, as for example IL-10 (271).  
In adults, systemic IL-10 concentrations increase with HIV disease progression 
(326). Most of the patients in the Crowley-Norwick-study had CD4+ T cell counts 
>400/µL and the increased IL-10 concentrations were detected in female 
adolescents who had been infected relatively recently, suggesting that the local 
immunoregulatory mechanisms of the cervix are altered early in the course of 
infection, long before systemic CD4+ T cell counts decline (271). 
 
The impact of the menstrual cycle on genital tract shedding of HIV is controversial. 
Studies reported that there are correlations between cervicovaginal HIV-1 RNA 
levels and phase of menstrual cycle or serum levels of progesterone and estrogen 
(1183, 108). However, other studies were unable to detect a menstrual cycle pattern 
to HIV genital tract shedding (978). Variation in assay methods, other influencing 
factors and different number of women sampled in studies may account for this 
discrepancy.  
Recent studies using the SIV-macaque model of vaginal infection indicated that 
progesterone implants enhanced HIV transmission, presumably by thinning of the 
vaginal wall (878), whereas estrogen inhibited HIV infection, inversely, by 
thickening of the vaginal wall (1320). 
 
Expression of HIV-1 receptors and coreceptors in the female genital tract varies as a 
function of menstrual-cycle stage, suggesting that sex hormone levels may influence 
a women`s susceptibility to HIV-1 infection (1561). This variation in receptor 
expression suggests that receptors are regulated by estradiol and progesterone and 
that a woman`s susceptibility to HIV infection may vary due to this hormonal 
regulation of HIV receptor expression.  
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Increased vaginal cytokine levels during menses of HIV-positive women (26) may be 
correlated with the increased numbers of granulocytes and macrophages in the 
genital mucosa at menses (102) which in the case of HIV may be hyperactivated, 
leading to enhanced cytokine production. 
 
In summary, HIV-1 infection leads to a dysregulation of the immune system of 
genital tract mucosa (Table 39). As in the periphery, HIV-1 infection causes the 
disruption of CD4/CD8 ratio in the cervical mucosa (13). The increased CD8+ T 
cells are predominately primed/memory T cells, however, these CD8+ T cells are 
functionally impaired, as indicated by decreased or lack of perforin and TIA-1 
(cytolytic granule-associated protein) expression (13). In the systemic compartment, 
HIV infection leads to an alteration in the cytokine pattern, most prominent in 
advanced stage of HIV disease. Likewise, in the CVL of HIV-positive women, 
proinflammatory cytokines are enhanced and at least one study, using mRNA in 
situ hybridization techniques, pointed to a shift towards Th2 cytokines (IL-4, IL-5, 
IL-10), which were significantly higher among HIV-positive women than HIV-
seronegative women (1045). LCs are lost or decreased in the cervical epithelium of 
HIV-positive women (1045), which may be caused by direct HIV infection of LCs or 
redistribution of these primed LCs to lymphoid tissues. Plasma cells are also 
reduced from the submucosa of HIV-positive women (1045), which may account for 
the impaired local production of IgA (101). 
HIV infection in women is often associated with chronic viral infection, candidiasis, 
syphilis, pelvic inflammatory disease, and bacterial infections. These conditions are 
seen in the genital tract before any manifestation in the periphery, which suggests 
that breakdown in the genital mucosal immune system may occur before immune 
system dysregulation (13). 
 
Dysregulation of the immune system in the HIV-infected female genital mucosa  
T lymphocytes 
Increase in CD8+ T cells 
Decreased perforin/TIA-1 production in CD8+ T cells 
Shift in CD4+/CD8+ ratio 
DCs Reduced levels 
Igs 
Decrease in plasma cells 
Decrease in S-IgA production, predominance of IgG 
Cytokines Increased production of proinflammatory cytokines (e.g. IL-6, IL-10) 
Table 39: Features of immune system dysregulation in the female genital tract caused 
by HIV infection 
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That some individuals become HIV positive after a single virus exposure whereas 
others remain resistant to repeated challenge indicates that there are factors 
beyond simple viral contact with particular mucosal cells. Sex hormones and 
cytokine levels in the environment of the virus and target cells may influence 
infectivity. 
There is the hypothesis that in frequently HIV-exposed but uninfected individuals, 
HIV-specific mucosal antibody responses may exist and play a role in resistance to 
HIV. It has been published that HIV-1-resistant sex workers show the presence of 
HIV-specific IgA in their genital secretions (670) whereas other studies described 
the absence of HIV-specific antibodies in genital secretions of HIV-resistant sex 
workers (337). So far, a condition that mimics the reports of HIV infections that 
produce genital anti-HIV antibodies without exposures of a systemic immune 
response could not be reproduced in monkeys (938). Seronegative sex workers also 
have higher frequencies of CD8+ T cells in the cervical mucosa than in blood 
whereas HIV-infected individuals have higher CTL responses in blood than in 
mucosal tissues (668) which would again suggest a more important role for cell-
mediated responses in the immunity against HIV. 
A vaccine that can elicit strong antiviral immunity may provide protection for 
heterosexual HIV-1 transmission. Further trials of anti-HIV vaccines should include 
an analysis of potential genital mucosal immune responses induced by the vaccine 
candidates. 
3. HPV 
Worldwide, cervical carcinoma is the second leading cause of death from cancer in 
women after breast cancer. The precursor of squamous cervical carcinoma known 
as CIN is generally diagnosed in younger women, reflecting that it requires a 
median of 15 years before invasion occurs (867).  
HPV can be considered the most prevalent STD, but infections remain 
asymptomatic in about 75% (1417) and will regress spontaneously in most cases 
(549). It is now generally accepted that persistent HPV infection of the cervix is 
responsible for the development of cervical dysplasia and cancer. 
Specifically, the high-risk HPV types 16, 18, 31 and 45 among others account for 
more than 80% of the cases of HPV-associated HSIL and cervical carcinoma (1340, 
1359) while low-risk HPV types such as HPV 6 and 11 cause benign genital warts.  
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The differences in oncogenicity between high and low-risk HPV result from their 
different ability to integrate the host DNA and to cause genetic instability. After 
penetrating epithelium through microabrasions virions infect the stem cells at the 
basal ECs layers (1059). They replicate their DNA episomally using their own non-
structural proteins E1 and E2 and the cellular machinery.  
In benign and low-grade cervical lesions, the HPV DNA is maintained in an 
episomal, non-integrated state (572). The expression of E6 and E7 delays cell cycle 
arrest and differentiation, which favours the thickening of the epithelium. The 
integration process observed during the progression of CIN associated with high-
risk HPV usually disrupts the E2 region, resulting in an enhanced expression of E6 
and E7 after integration of the episomal DNA into the host`s DNA. Binding of E6 to 
the host`s p53 and E7 to Rb, respectively causes uncontrolled cell proliferation 
(210, 691) and finally, oncogenic transformation of the cell follows (1417). 
 
Although a very high percentage of women are positive for HPV-16 (555), most HPV 
infections are subclinical in immunocompetent patients or manifest intermittently 
as self-limiting warty lesions. A small but medically important fraction of the lesions 
will progress to HSIL, cervical carcinomas-in-situ, and if left untreated, to invasive 
and metastatic carcinomas (899). Thus, infection with oncogenic HPV types is a 
necessary but not a sufficient cause of cervical cancer, other risk factors probably 
include smoking, genetic factors, cervical inflammation and immune-system 
dysfunction (1418). 
Cervical carcinogenesis includes HPV infection, viral persistence, progression to 
precancer lesions and invasion. HPV persistence and progression involve a complex 
interaction between viral and host factors, such as viral variants, viral load, 
susceptibility genes, immune response against HPV and molecular events 
associated with progression.  
The host immune response is essential for restraining both HPV infections and 
HPV-related cervical cancer. In women with pre-invasive cervical neoplasia the 
spontaneous regression of lesions occurs in 30% up to 65% of cases (867, 1260), 
indicating a role for a successful immune response to HPV infection.  
 
However, HPV does not provoke strong immune responses (328) and especially the 
cancer-associated HPV types employ distinct immune-evasion mechanisms (427).  
There is no cytolysis or cytopathic death as a consequence of HPV replication and 
therefore no release of the proinflammatory cytokines and little local or systemic 
presentation of HPV antigens to the immune system by professional APCs (755, 
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1351). The viral proteins E6 and E7 halt apoptosis until viral replication in the 
differentiating KC is completed and the KC proceeds to its natural death far from 
the sites of immune activity. The low levels of HLA I and II of KCs further cause a 
resistance to CTL-mediated lysis (427) whereas HPV-infected KCs might resist CTL-
killing as well by producing proteins that interfere with CTL-lytic mechanisms (238, 
1319) or by inducing apoptotic cell death in the CTLs themselves (1570). As a 
consequence, HPV infection is not accompanied by inflammation resulting in 
persistent infectons as the host remains ignorant of the pathogen for long periods.  
Other immunsuppressive mechanisms include the subversion of IFN responses by 
interfering with IFN signaling pathways (78, 814, 1016) and downregulation of other 
immune factors by E6/E7 proteins such as IL-18 (224), TGF-β2 (1017) and MCP-1 
(722). 
Thus, activity of E6 and E7, and partly E5 (171, 1578) provides the molecular basis 
for promoting viral persistence and avoiding innate immunity and the consequential 
activation of adaptive immunity. 
 
Invasive cervical carcinoma cells further evade immune response and CTL-mediated 
killing by HLA downregulation (248, 1199), IL-10 production (980), predominant 
Th2 polarity instead of a Th1 response (1294) and therefore induction of anergic or 
Treg cells (379) and downregulation of signaling components of the TCR such as 
CD3-zeta (739). Studies also propose a role for FasL expression in cervical 
carcinoma which allows the tumor cells to evade host immune surveillance (663)  
Moreover, the number of LCs in CIN lesions is reduced (1454) and they are not 
activated by HPV-VLP (384) or uptake of HPV capsids as DCs (385).  
In addition, changes in tissue architecture by downregulating E-cadherin 
expression through E6 modulate LC contact with HPV not allowing optimal antigen 
capture or activation necessary for the initiation of anti-viral T cell responses (884).  
This could probably result in an inefficient primary immune response which also 
delays the activation of the adaptive immune response in HPV infection (1342, 
1418). The host APCs are exposed to low levels of viral proteins in a non-
inflammatory milieu for a prolonged time period and, as a result, local immune 
non-responsiveness may be established in the infected mucosa.  
In this HPV antigen-tolerant milieu, host defenses become irrevocably 
compromised, and HPV antigen-specific effector cells are either not recruited to the 
infected area and/or their activity is downregulated. Thus, if during a persistent 
HPV infection there is deregulation of high-risk HPV E6 and E7 with increased 
protein expression, and this does not result in an armed effector cell-mediated 
  Discussion 
 III-318  
immune response, HPV-mediated progression to HSIL and invasive carcinoma are 
unobstructed. 
 
The investigation of the role of natural immunity to HPV infection is problematic as 
HPV infections can be transient and often asymptomatic. Studies have been carried 
out largely on patients with established HPV-associated disease and have focused 
on the oncogenic HPV types, in particular responses against the viral transforming 
proteins, E6 and E7, the only viral antigens constitutively expressed in transformed 
cells. Also studies have focused on systemic rather than mucosal immunity, so a 
substantial component of the host response against HPVs could be missed (867). 
 
Circumstantial evidence suggests a role for both the humoral, e.g. antibodies to 
capsid proteins, and cellular immune system, e.g. CTLs versus oncogenes, in the 
clearance of HPV infections. Neutralizing antibodies may be an effective way of 
preventing early viral infection and spread, but cell-mediated immune response 
virally may mainly be important in the resolution of infection and associated 
disease. 
HPV infections induce both systemic and local humoral immune responses 
manifested by the presence of IgG and IgA antibodies to HPV-associated antigens. 
Although low levels and frequencies of anti-HPV antibodies are present in serum 
and CVS of apparently healthy women, women with cervical cancer present these 
antibodies at higher levels and frequencies (131, 316, 342, 714, 1020, 1257, 1452, 
1456, 1478).  
Increased local levels of HPV-specific IgG in vaginal washes of women with cervical 
cancer indicate a local inflammation, perhaps due to invasive tumor growth that 
results in transudation of IgG from plasma to the vaginal secretion. Observations 
indicate that infection of the genital tract mucosa by HPV preferably induces 
immune responses at the mucosal site of infection rather than in the systemic 
compartment. 
It is not clear whether these antibodies in CVS were locally produced or a result of 
leakage from the blood (1418). Also the role of anti-HPV S-IgA which has been 
detected in CVS of healthy controls and HPV-infected patients remains unclear (76, 
496).  
 
There are also some observations relevant to development and persistence of 
humoral responses to HPV. 
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HPV-specific local antibodies are apparently induced several months after the initial 
HPV infection (496) and the persistence of these antibodies is dependent on the 
concomitant HPV presence (1302). Konization of CIN lesions was shown to be 
followed by a gradual decline in serum and cervical mucus antibodies (362). 
Mucosal IgG and IgA also display different kinetics of appearance and persistence in 
cervical mucus. IgA responses are more frequent and reflect current HPV infection 
whereas IgG appears to parallel the development of cervical lesions (1257). 
Moreover, local IgA responses are elicited earlier than IgG responses with rare 
detection of IgG in preclinical HPV infection. 
Measurement of serum antibodies to HPV 16/18 antigens E6 and E7 does not 
appear to be useful for the prognosis of cervical cancer (800, 1303). Similarly, local 
HPV-16 VLP-specific IgA and IgG responses do not correlate with viral clearance in 
patients with CIN and healthy women (131, 1452). Rather, the mucosal HPV-16 
VLP-specific IgA and IgG responses reflect current HPV infection and development 
of cervical lesions (1257). 
Results suggest a selective downregulation of local HPV-specific IgA responses in 
women with cervical cancer (1020). Gene expression profiling also indicated 
downregulation of genes associated with Ig synthesis including gene encoding the 
heavy chain of IgA2 in cervical tumor tissue as compared to that in the normal 
tissue of the same patient. 
Previously, it was also reported that the number of IgA plasma cells infiltrating 
invasive cervical carcinoma was altered when compared to normal cervix specimens 
(356). 
This was supported by data obtained from cytokine analysis. Th2 type cytokines, 
including IL-4, IL-5, and IL-10, that play important roles in B-cell differentiation 
and subsequent Ab production, were not detected in the vaginal washes.  
 
Increased incidence of HPV persistence and HPV-asociated malignancies in 
immunosuppressed individuals strongly suggests a decisive role for cell-mediated 
immune mechanisms (32, 390). Furthermore, the regression of HPV-induced warts 
is associated with lymphocytic infiltration of both CD4+ and CD8+ T cells in both 
patients with genital warts (245) and animal papillomavirus models (1273) whereas 
non-regressing warts are characterized by a lack of immune cells. Moreover, there 
are cytokines such as IL-12, TNF-α, and IFN-γ which are characteristic for a Th1-
based immune response in regressing warts (245, 1343).  
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Cell-mediated responses comprise both CD4+ and CD8+ T cells which take part 
directly as CTL or indirectly as Th cells for CTL or antibody production in HPV 
immunity. In almost all studies of cell-mediated immunity against HPV, peripheral 
blood rather than local T cells have been used (307, 314, 643, 644, 1001, 1000, 
1022, 1343, 1565) due to the low yield of T cells from surgical removed cervical 
cancer tissue and the low availability of relevant cervix tissue.  
 
Studies have shown a correlation of in vivo immune responses and the regression of 
CIN lesions and clearance of HPV (565). In humans, regression of cervical 
neoplastic lesions was associated with cell-mediated responses to specific HPV 16 
E6 and E7 (643, 644), and persistene of HPV infection was reported to be correlated 
with a lack of CTL responses to HPV 16 E6 (307, 1001). 
This is also consistent with trials on vaccination against HPV E6 and E7 in 
experimental animals which induced cell-mediated immunity. A regression of skin 
papillomas in rabbits (792) and tumors formed by HPV16 E7-transformed cells in 
mice (778) has been observed. 
 
Studies suggest a relationship between T cell responses against HPV and cervical 
disease, with a decreased response in cancer patients and an increased response in 
women with high-grade CIN and viral persistence (314, 643, 644).  
Other studies also showed serological T cell responses against HPV in healthy 
controls (846, 845, 1441). It is not clear if these results represent in vitro artefacts 
or memory responses based on a prior exposure to HPV.  
 
However, only a limited number of prospective studies have been carried out. 
Obviously, failure to develop effective cell-mediated immunity to clear or control 
infection results in persistent infection and, in the case of the high-risk HPVs, an 
increased probability of progression to HSIL or invasive carcinoma. 
Therefore, there is the need of further studies on T cell responses in longitudinal 
studies and at the sites of disease.  
 
Latest studies indicated that a majority of both patients with cervical lesions and 
healthy persons display HPV16 L1 peptide-specific type 1 T-cell responses with a 
similar magnitude (1441). These responses were covering a broad range of peptides 
within L1 which suggets that during persistent or repeated exposure to HPV16 L1 
the immune system maximizes its efforts to counter the viral challenge. Unlike type 
1 T cell responses against HPV 16 E2 and E6, type 1 T cell immunity against L1 
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does not correlate with health or disease. This is in contrast to the previous finding 
that such patients lack such type 1 T-cell immunity against HPV16 early antigens 
E2 and E6 (307).  
Lately, Steele et al. investigated T cell responses to the HPV16 proteins E6, E7, E4, 
L1 and L2 in women with CIN or cervical carcinoma directly ex vivo (1347). The 
frequency of CD4+ responders was far lower among those with progressive disease, 
indicating that the CD4+ T-cell response might be important in HPV clearance. 
CD8+ reactivity to E6 peptides was dominant across all disease grades, inferring 
that E6-specific CD8+ T cells are not vitally involved in disease clearance. 
 
Concerning the production of cytokines by CD4+ T helper cells, a study found 
decreased level of IL-2 production but elevated levels of IL-4 and IL-10 in patients 
who had extensive HPV disease compared with those suffering from localized HPV 
disease or healthy controls (238).  
Production of cytokines that mainly enhance potentially protective cell-mediated 
immunity is defective in women with extended HPV disease. Moreover, a 
pronounced shift from type 1 to type 2 cytokine production is associated with more 
extensive HPV infection. This suggests a shift towards the T-cell production of 
cytokines associated with the suppression of cell-mediated immunity.  
Another study showed a significant IL-2 production against HPV peptides in 
patients with CIN and persistent HPV infection, as well as to a significantly lesser 
extent in patients with cervical cancer which suggests a correlation between IL-2 
responses and disease (315). 
 
It is widely expected that a vaccine that would prevent HPV infection, which is 
mediated by antibodies at the site of infection, and restrict the spread of HPV from 
infected KCs, which depends on the induction of CTLs, would greatly reduce the 
incidence of cervical cancer and associated mortality. This is especially important in 
developing countries where screening, early diagnosis, and treatment of 
precancerous lesions is not available (641, 1417). 
 
Two main types of HPV vaccines are currently being developed: prophylactic 
vaccines to prevent HPV infection and associated diseases, and therapeutic 
vaccines to induce regression of precancerous lesions or remission of advanced 
cervical cancer. The prophylactic vaccines are focused on the generation of 
neutralizing antibodies mainly against L1 whereas in therapeutic chimeric vaccines, 
the targets are E6 and E7, which have no share epitopes with human cellular 
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proteins; therefore, the risk of inducing an autoimmune response is theoretically 
eliminated (1349). 
 
DNA-free VLP synthesized by selfassembly of fusion proteins of the major capsid 
antigen L1, or of both L1 and L2, induce a strong humoral response with 
neutralizing antibodies (713). VLPs are thus the best candidate immunogen for HPV 
vaccine trials. 
 
At present, several prophylactic vaccines have been developed and tested in clinical 
trials with proming results (63, 371, 512, 513, 742, 1456). Two pharmaceutical 
companies, GlaxoSmithKline and Merck, have been the major forces in research 
and development in prophylactic HPV vaccines to date with two randomized 
controlled trials published with highly promising proof-of-principle results (512, 
742). 
The present trial results show a good safety profile and an almost universal 
induction of high titers of virus-specific antibody by VLP-based vaccines. Further 
follow-up is needed to see whether the antibody levels remain after decades or 
whether booster vaccination is needed but encouraging data on HPV VLP L1 
vaccines suggests only a slight decline in the high serum antibody titers over a 6-to-
8-month evaluation period (1417). 
Vaccine efficacy was 100% in preventing acquisition of persistent HPV infection in 
both studies. Both also showed encouraging results concerning prevention of CIN 
but these trials had not been designed with sufficient power to detect reductions in 
CIN incidence. Demonstration of efficacy in preventing high grade CIN is the 
objective of much larger, phase III trials, which are currently ongoing in different 
populations. Moreover, evidence from randomized controlled trials has been 
obtained only for monovalent (HPV 16) and bivalent (HPVs 16 and 18) vaccine 
candidates.  
Based on the successful HPV16/18 L1 VLP vaccine pilot efficacy trial, which 
established 100% efficacy against persistent HPV16/18 infection, GlaxoSmithKline 
Biologicals is currently accomplishing phase III trials on 28,000 persons of this 
prophylactic HPV vaccine (1417). These studies aim to extend the findings in the 
prevention of high-grade CIN associated with HPV16/18 infection. The efficacy trial 
is conducted over 48 months as a double-blind, multicenter, controlled study in 
adolescent and young adult females vaccinated according to a 3-dose schedule. The 
company also has plans to bring a tetravalent vaccine (with VLPs of cancer-
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associated HPV types) into the development phase once it completes the clinical 
development for its bivalent HPV 16/18 vaccine candidate. 
Another multicenter phase III study by Merck & Co with several thousand women is 
currently carried out to prove efficacy of a quadrivalent HPV vaccine (HPV types 6, 
11, 16, and 18) (640, 1342). 
 
However, there also have to be mentioned some important aspects which have to be 
regarded developing a HPV vaccine.  
Levels of specific antibodies in the human female genital tract which are likely to be 
an important determinant of vaccine efficacy might be influenced over the course of 
the menstrual cycle. Experiments raise the possibility that the HPV16 VLP vaccine 
might be less effective during the peri-ovulatory phase (1004). 
One has to consider the preferred delivery route for vaccine administration in order 
to induce effective mucosal immune responses (1349). Obviously, a single dose with 
mucosal delivery would be the preferred route for vaccine delivery; if nasal or oral 
delivery can induce antibodies still has to be further investigated but also showed 
encouraging results so far (1003). An alternative route of administration that avoids 
parenteral injection while inducing mucosal immunity might also facilitate vaccine 
implementation in some settings, and partially overcome the substantial variation 
in HPV16 antibodies at the cervix seen in ovulating women.  
The choice and the number of HPV types included in the vaccine is an important 
issue as there are geographic differences in the prevalence of HPV types involved in 
CIN and cancer. In order to be effective for at least 80% of the population, the 
vaccines should theoretically consist of VLPs of the four or five most common types 
of HPV of that country or region but combining multiple types in one vaccine may 
be problematic (989, 1417). A pentavalent vaccine with VLPs of HPV types 16, 18, 
45, 31, and 33 would potentially prevent 83% of all cervical carcinomas whereas a 
heptavalent vaccine that also included types 52 and 58 could potentially prevent 
87% of the overall cervical cancer burden internationally (989).  
Whether such a polyvalent vaccine would result in immunological equivalence such 
that each component virus-like particle induced an antibody response that 
correlated with protection is unclear.  
Finally, all trials to date of HPV vaccines have enrolled women, but genital HPV 
infections are mainly sexually transmitted and men will also need to be vaccinated 
if the whole population is to develop immunity. 
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In infected patients, targeting already infected basal cells that do not express capsid 
antigens remains a major challenge. Therefore, vaccine chimeric VLP vaccines are 
being developed, which contain not only structural viral L1 or L2 proteins but also 
functional E-proteins (1059). In preclinical data, these chimeric VLP vaccines 
elicited both neutralizing antibodies to the VLP and T-cell responses to L1 and E7, 
and could therefore be prophylactic and therapeutic (28). 
 
Therapeutic vaccines consisting of E6 and/or E7 have been tested in patients and 
have proven to be safe and effective against benign warts, however have had limited 
therapeutic effect so far in cases of cervical cancer (425). 
In general, there are several broad categories of therapeutic vaccine strategies: 
chimeric VLPs, peptides, proteins, nucleic acid–based, and cell-based. 
The major challenge in infected patients remains the targeting of already infected 
basal cells that do not express capsid antigens. Therefore, chimeric VLP vaccines 
with structural viral L1 or L2 proteins and functional E-poteins are being developed 
(986). Therapeutic vaccination strategies based on using chimeric VLP (288, 1341), 
chimeric capsomeres (458) or chimeric HPV VLP immune complexes (383) have 
been investigated in animal models or clinical trials and may be effective in 
generating an immune response against HPV-induced diseases such as cervical 
cancer. 
There are only few animal studies and preliminary clinical trials performed with 
either peptide-based (25, 389, 984) or protein HPV vaccines (426) so that there 
cannot be concluded if they are an alternative yet. 
Finally, various attempts to develop DNA vaccines are currently in progress, which 
tend to be more effective in the generation of both humoral and cellular protective 
immunity responses. Polynucleotide and recombinant viral vaccines encoding non-
structural viral proteins show therapeutic efficacy in animal models and are 
candidate immunotherapies for established low-grade benign genital infections 
(299, 502, 822, 962, 1277).  
 
Despite the current enthusiasm about future prospects of preventive HPV vaccines, 
limitations concerning restricted coverage to only a few HPV types, expenses, 
potential barriers to wide availability and acceptability in both developed and 
developing countries, and the potential epidemiological shift of HPV disease to 
currently less frequent types and variants, have to be taken into consideration. 
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4. Gonorrhea 
Gonococcal infection caused by Neisseria gonorrheae remains a major global health 
problem with more than 60 million cases reported annually worldwide. Teenagers 
and young adults are at high risk for infection, which is unsettling in view of the 
increased risk associated with gonorrhea for infection with HIV-1. 
In contrast to the inflammatory response generated predominately with gonococcal 
infection of the male urethra, 50-80% of women with lower genital tract N. 
gonorrhoeae infection are asymptomatic (1330). Infection spreads to the upper 
female genital tract in up to 45% of patients, possibly causing PID with serious 
complications including tubal scarring (1330). 
 
Gonococcal pilus binds to CR3 present on the ectocervix and endocervix, 
positioning the bacterium at the cervical cell surface where complement 
concentrations would be expected to allow efficient opsonization for the subsequent 
intimate adherence of iC3b and gonococcal porin to the I-domain (353). Activation 
of the alternative complement pathway results in C3b deposition upon gonococci; 
C3b is inactivated to form iC3b. 
Ascension to the upper female genital tract is then mediated by both host and 
gonococcal factors that are subject to cyclic environmental changes occurring 
within the female genital tract. The LHr present on the endometrial and fallopian 
tube epithelia mediates the interaction of gonococci with the upper female genital 
tract (1331). 
 
Gonococci possess numerous surface antigens including LOS, porin, Opa, Rmp and 
pili, which enable a high grade of antigenic variation. 
Adherence to mucosal ECs, the initial step in pathogenesis, is mainly determined by 
pili and Opa which bind CD46 and CEACAM, respectively (1229). The expression of 
Opa proteins and the penetration of EC membrane by porin facilitates invasion of 
nonciliated mucosal ECs through endocytosis. 
These virulence factors together with the high heterogeneity and adaptability with 
repeated phase and antigenic change may be a way to downregulate the functional 
immune response of the host. 
 
Other mechanisms of N. gonorrheae to evade the host`s immune response are the 
resistance to complement-mediated bacteriolysis and the production of IgA1 
protease. However, the relevance of data concerning complement-mediated 
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bacteriolysis for the reproductive tract with its relative complement deficient setting 
is not known.  
 
IgA1 protease was detected in vaginal washes from patients infected with N. 
gonorrhoeae by its ability to cleave IgA1 (120) although Hedges et al. did not 
identify characteristic cleavage fragments of IgA1 protease in cervical mucus or 
vaginal wash samples (530). 
These results suggest that IgA1 protease does not play a significant role in the 
pathogenesis of uncomplicated gonococcal infections within the lumen of the lower 
female genital tract. As all of the clinical isolates of N. gonorrhoeae infecting the 
patients produced IgA1 protease in vitro one could propose that N. gonorrhoeae may 
not be present in the lumen or on the mucosal surface in sufficiently high numbers 
(530). This hypothesis is supported by the lack of significant local immune or 
cytokine responses in women infected with N. gonorrhoeae. Therefore, the lack of 
detectable IgA1 protease activity in cervical mucus, in addition to the lack of local 
host responses, may simply be due to small numbers of bacteria at that site. 
In addition, LAMP-1 on ECs is cleaved by neisserial IgA1 protease (820) which may 
contribute to intracellular gonococcal survival and facilitate escape from antibodies 
and complement. 
 
In addition to its potential ability to avoid the effects of an immune response, N. 
gonorrhoeae apparently does not elicit strong humoral immune responses during 
uncomplicated genital infections. Yet, the immunology of gonococcal infections in 
the genital tract has not been extensively studied so far. 
Analysis of cervical secretions obtained from uninfected women and from women 
infected with the gonococcus revealed that a significant antibody response is not 
generated with uncomplicated infection (531). Further support for this idea is found 
in the work of Hedges et al. who found that women with gonococcal cervicitis did 
not exhibit elevated local levels of IL-1, IL-6, and IL-8 (532). In contrast, Fichorova 
et al. have reported increased IL-1, IL-6, and IL-8 expression in similar studies 
performed with immortalized vaginal and cervical epithelia (396). The release of 
inflammatory cytokines by the cervical epithelium in response to N. gonorrhoeae 
infection therefore remains under question. 
 
Results indicate that while there are some minor systemic and local antibody 
responses associated with uncomplicated gonococcal infection in females, the 
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antibody levels are lower than with other mucosal infections and concomitant 
infection neither alters total Ig nor antigonococcal antibody levels. 
There has not been observed any clear indications of immune memory toward 
gonococci as evidenced by the failure of previous exposure to this organism to 
generate more pronounced antibody responses (531). It is unlikely that the poor 
antibody responses in both male and female patients to N. gonorrheae is simply due 
to an absence of known inductive sites in the genital tract, since female patients 
with rectal infections did not show any marked enhancement of the antigonococcal 
responses.  
Latest studies have shown that expression of Opa protein results in downregulation 
of proliferative T cell responses to gonococcal antigens, and eiher downregulation or 
increased apoptosis of CEACAM1-expressing B cells (134, 1075). 
The production of an effective vaccine against N. gonorrheae should be an important 
goal, also due to increasing antibiotic resistance but there is still minimal success 
despite a long list of potential candidate proteins. Latest approaches with intranasal 
immunization in mice with gonococcal transferring binding receptor proteins have 
shown promise due to induction of local and systemic antigen-specific IgA and IgG 
antibodies (1142), which is also consisting with earlier trials with gonococcal outer 
membrane preparations or other bacterial antigens in the mouse model (1127, 
1226). 
5. Chlamydia 
Chlamydia trachomatis, an obligate intracellular bacterial pathogen, is a major 
cause of STDs worldwide with 90 million new cases per year and a prevalence 
reaching 25% (1543, 683). Women are disproportionally affected because of their 
increased risk to develop postinfection complications. Chlamydial infections of the 
lower genital tract of women are frequently asymptomatic in their acute form (187), 
but can progress to the upper genital tract causing PID, postinfection scarring and 
finally tubal factor infertility (1527). 
 
To picture the immune mechanisms contributing to the resolution of chlamydial 
infection and protection of reinfection, it is important to consider the unique 
developmental cycle of the pathogen in ECs (90, 1527). Protective immunity might 
include responses directed at the infectious EB, such as neutralizing antibody, or at 
infected cells, such as CTLs or ADCC.  
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Despite progress in the past decade, the current understanding of mucosal 
immunity to this pathogen in the human host remains limited. Most of current 
knowledge comes from studies in women or female animal models.  
 
Several studies show that innate immune responses are evoked following 
chlamydial infection which is evidenced by the accumulation of phagocytic cells 
including neutrophils at the site of infection (1171).  
Experiments with neutrophil-depleted mice suggest that these cells may play a role 
in reducing the initial amplification of C. trachomatis and possibly limit local 
spreading within the genital tract (82) but neutrophils appear not to be critical for 
eradication of Chlamydiae.  
NK cells also seem to play an important role in the initial control of chlamydial 
infection as they are not only responsible for the production of IFN-γ early in the 
course of chlamydial genital tract infection but are also, via IFN-γ, a significant 
factor in the development of the Th1 CD4+ response and in the control of the 
infection (1431). 
Clearance of chlamydial infection and protection against inflammatory disease in a 
mouse model appeared to be associated with recruitment of MHC class II APCs with 
a DC phenotype into uterine tissue early in infection (1334). 
 
As a result, innate immunity is likely to be essential in shaping the adaptive 
immune response but alone is unable to resolve genital chlamydial infection. 
Humoral and adaptive immune responses are also mobilized during chlamydial 
infection and are thought to contribute substantially to protective immunity. Study 
of the infection in both animal models and naturally acquired infection in humans 
suggest that protective immunity is provoked (50, 665, 695). Moreover, individuals 
with a previous chlamydial infection show reduced risk of acquiring a chlamydial 
STD, and immunity to reinfection is partial and of limited duration (665). A 
proportion of women who had not received antimicrobial therapy were shown to 
resolve infection (1078). Brunham et al. also reported a short-term and serovar-
specific immunity against chlamydial infection in female sex workers (148). 
 
However, a number of studies have documented the high rate of recurrences of 
Chlamydia infections in humans (87, 163, 665, 683) and animals (680, 682, 1169). 
Studies all conclude that some form of short-term protective immunity does develop 
against chlamydial genital infection in humans but natural production of solid, 
long-term immunity appears to occur only after multiple infections.  
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The contribution of the humoral arm of the specific immune response appears 
controversial but one could propose a minor role for anti-chlamydial antibodies in 
protective immunity.  
Murine studies provided evidence that delayed appearance of anti-chlamydial IgA 
antibodies in CVS correlated with a delay in the resolution of infection (971). 
Women with anti-chlamydial IgA antibodies in CVS shed significantly fewer 
infectious chlamydiae than women without IgA in CVS; this effect was not observed 
with high serum antibodies (149). Moreover, the presence of these IgA in CVS seems 
to accelerate the clearance of infection with antibiotic therapy (282). 
Equally convincing results from murine models put forward the hypothesis that 
antibodies are not required for protective immunity against Chlamydia. B-cell 
deficient mice have been shown to resolve chlamydial genital tract infection equally 
effective than normal mice (632). The presence of anti-chlamydial IgA in mouse CVS 
alone seems to be insufficient to resolve infection (631) which clearly points to a 
synergistic role of antibody and cell-mediated immunity in protection (629). 
 
However, a recent study by Morrison et al. shows that immune serum and 
Chlamydia-specific mAbs have a profound impact on immunity to chlamydial 
genital tract reinfection (973). Although the mechanisms by which antibody protects 
is not understood, the protective efficacy of antibody is highly dependent upon 
CD4+ T cell-mediated adaptive changes that occur within the genital tract tissues 
after primary infection. 
Extensive studies of the immune mechanisms the control chlamydial infections in 
the mouse female genital tract have provided evidence that cell-mediated immunity 
is essential in resolving infection and protective immunity (1172, 1165). Th1-type 
CD4+ cells are the main effectors in the resolution of genital infection and clearance 
of challenge infections whereas CD8+ lymphocytes are neither sufficient nor 
necessary to confer optimal levels of protective immunity (523, 629, 594, 680, 683, 
1165, 1506). However, immune CD8+ T cells can confer a limited level of immunity 
to naïve mice and display measurable cytotoxicity for Chlamydia-infected cells in 
vitro (92, 1345). 
Results of Belay et al. demonstrated that genital chlamydial infection is associated 
with a significant induction of chemokines and chemokine receptors that are 
involved in the recruitment of Th1 cells into the site of infection (100). Expression of 
RANTES, MCP-1, MIP-1α, IP-10 and ICAM-1 as well as of CCR5 and CXCR3, known 
to be preferentially expressed on Th1 and DCs was upregulated during chlamydial 
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infection of mice and decreased after clearance of infection, suggesting an infection-
driven regulation of expression. 
Further data not only demonstrated the necessity of CD4+ cells in the resolution of 
chlamydial infection but also showed that fewer numbers of CD4 lymphocytes 
delayed clearance of organisms from the local genital mucosa (971). Consequently, 
a critical number of antichlamydial CD4+ cells appeared necessary to eradicate 
infection.  
 
This is also consistent with the postulated interactions between Chlamydia and 
genital tract DCs. Although recognition of chlamydial antigens on genital ECs by 
CD4+ and CD8+ T cells has not been demonstrated (1084), recognition of antigens 
that have been processed by DCs is very likely. Following phagocytosis of 
Chlamydia by DCs in the genital tract of immune animals and processing of 
chlamydial antigen in the MHC II pathway, CD4+ Th1 memory cells are probably 
located in the mucosa where they rapidly begin to secrete IFN-γ. Several authors 
had originally suggested that mainly genital ECs present chlamydial antigen to T 
cells (417, 1345). 
 
The key for understanding cell-mediated immunity to chlamydial genital infection 
lies in defining the mechanisms by which lymphocytes traffic to the genital tract. 
The recruitment of leukocytes into tissue sites depends on adhesive interactions 
between adhesion molecules on ECs and integrin receptors on the leukocytes. 
However, the role of homing molecules in the recruitment and retention of 
lymphocytes to genital tract mucosa, which lacks the organized lymphoid 
structures present in the gut, has not been defined. 
Kelly et al. showed that in the genital tract of mice, recruitment of CD4+ cells is 
mediated through the interactions between homing receptors on CD4+ T cells such 
as α4β7 and adhesion molecules ICAM-1, VCAM-1 and MadCAM-1 (524, 680). They 
also reported that during Chlamydia infection in mice, cellular recruitment differed 
with CD4+ cells mainly recruited to the upper genital tract, whereas neutrophils 
and monocytes were recruited to all regions of the genital tract (682). This 
correlated with an upregulation of all three adhesion molecules in the upper genital 
tract during the course of infection. 
Remarkably, the mucosal addressin MAdCAM-1 is not expressed by human female 
genital tract tissue (626). 
Some investigators tried to identify the antigen specificity of the B cells that traffic 
to the sites of human mucosal chlamydial infection. IgG- and IgA-secreting B cells 
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with specificity for chlamydial MOMP, hsp-60, and a chlamydial plasmid encoded 
protein accumulate at sites of chlamydial genital tract infection (448). 
 
Moreover, there is strong evidence indicating that IFN-γ is a major effector 
mechanism of the cell-mediated immune response. 
The majority of the antichlamydial activity for both CD4+ and CD8+ lymphocytes is 
associated with the production of high levels of IFN-γ (167, 593, 683, 1167). Direct 
evidence for rapid IFN-γ secretion in Th1-immune mice after vaginal challenge with 
Chlamydia has been reported (629). 
Besides some minor mechanisms of cytotoxicity such as perforin-mediated lysis 
(1443), it is proposed that IFN-γ is a primary mechanism for eradication of 
Chlamydia by CTL and CD4+ T cells. However, IFN-γ has also bacteriostatic effects 
on Chlamydia via NO (892, 1112), at least in vitro (592).  
 
It was demonstrated that C. trachomatis can enter host ECs without inducing the 
immediate production of inflammatory cytokines such as IL-1, IL-6, IL-8, TNF-α, 
and GM-CSF, probably due to the small size of infectious EB, a weak stimulatory 
ability of chlamydial LPS (297, 532, 596, 1174, 1369).  
Therefore, these data show that Chlamydia can enter host ECs without inducing a 
vigorous proinflammatory immune response until the developmental cycle is 
completed. At that time, cell lysis causes the release of IL-1α and the induction of 
other proinflammatory cytokines. It also appears that Chlamydia can further 
manipulate cells to enhance their survival by inhibiting apoptosis of infected cells 
through the caspase-3 pathway, which also occurs after initiation of the 
developmental cycle (377).  
Recently Zhong et al. reported that C. trachomatis infection of APCs reduced the 
ability of these cells to stimulate T cell proliferation through defects in antigen 
processing but not presentation (1586). This has been shown to be mediated via a 
chlamydial protein that induces degradation of transcription factors that control 
IFNγ-induced expression of both MHC class I and II antigens.  
While the ability of Chlamydia to manipulate the host cell response to infection 
obviously is a survival advantage, it may also contribute to observations that 
immunity to Chlamydia is weak, resulting in persistent or recurrent infection. 
 
Therefore, C. trachomatis appears to initiate its developmental cycle in vivo without 
immediately alerting the immune system. Possibly, the delayed induction of early 
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inflammatory mediators may be a survival mechanism that evolved to protect the 
developmental cycle from immune-mediated disruption. 
 
One serious problem with repeated chlamydial genital infections is tissue damage 
followed by tubal scarring, chronic salpingitis and distal tubal obstruction.  
Recurrent or chronic chlamydial infections, which are associated with damage to 
the reproductive tract, may result from an insufficient number of antichlamydial 
Th1 CD4+ cells (1112) or possibly factors that interfere with the effector 
mechanisms of Th1 cells, for example IL-10 (683, 1555) or TGF-β [207].  
Also neutrophils or their products might play a significant role in tubal pathology 
and infertility since they have the potential to cause damage through the release of 
proteinases and hydrolases. Furthermore, neutrophils primed by exposure to 
cytokines such as GM-CSF, IL-8, and TNF-α can release large quantities of ROI and 
granule enzymes upon activation with soluble immune complexes (357).  
In addition, a shift from a Th1-dominated response to a mixed Th1/Th2 response 
may further dampen antichlamydial responses (974). Unfortunately, cytokines 
characteristic of Th2 responses are associated with increased collagen deposition, a 
measure of fibrosis (559), which may contribute to reproductive tract dysfunction. 
In contrast, IFN-γ inhibited this process (559).  
Immunity to chlamydial protein hsp60 which is upregulated during persistent 
infection (93) seems to contribute to the development of tubal occlusion and adverse 
pregnancy outcome (352, 150, 1562).  
There is a human hsp60 (h-hsp60) homologue to c-hsp60 which is expressed by 
ECs of the decidua and embryo during early pregnancy (1527). Therefore, a 
chlamydial fallopian tube infection can induce the development of autoantibodies to 
h-hsp60 and in women already sensitized to c-hsp60, the exposure to h-hsp60 will 
reactivate the c-hsp60 lymphocytes. This may lead to immune rejection of the 
embryo (1527).  
The immunologic components that contribute to the production of tubal pathology 
may also be associated to many factors including the genetic background of the 
individual. Another question is whether individuals become reinfected with the 
same serovar or perhaps develop persistent infections.  
Although the large majority of women infected with Chlamydia are effectively 
treated and reinfection commonly occurs, it is difficult to document persistence in 
vivo. However, some less prevalent serovars, such as serovar I, J, K, and H, show 
increased rates among those with repeat infections (309). More studies are needed 
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to understand whether these serovars have an increased ability to escape recall 
responses against Chlamydia or these organisms can persist in a latent state. 
 
A major challenge in designing anti-chlamydial vaccines is to develop an 
immunization regimen capable of inducing and retaining a mucosal Th1 CD4+ 
response in order to foster long-term protective benefits. This type of immunity 
would help to resolve infections rather than prevent them and could therefore 
influence the consequences of asymptomatic infections ascending from the cervix. 
 
Vaccine research is still ongoing and several vaccination methods have been 
described that target antigens into the endocytic MHC II pathway of DCs and elicit a 
Th1-type CD4+ immunity. These include immune stimulating complexes (ISCOMS) 
(591), alphavirus vectors (344), opsonized liposomes (1276), and conjugation of 
antigen to lysosome-associated membrane protein-1 (Sig/LAMP-1) (212). The 
antigens that would be the most effective targets for a Th1 cellular immune 
response have not been identified, but chlamydial MOMP is a suitable candidate 
(591).  
Concerning the route of immunization, data from murine models show that 
immunization via mucosal routes, i.e. oral, intranasal, and vaginal, induced greater 
levels of IFN-γ, induced a dominant Th1 response and limited the course and 
magnitude of infection when compared to subcutaneous immunization (681, 594). 
Moreover, both specific IgA and IgG could be found in genital secretions following 
immunization via the nasal, oral, rectal, and vaginal routes. However, both the 
nasal and vaginal routes consistently produced the greatest increase in IgA and IgG 
compared to other routes in humans (594, 743). 
The induction of a protective cell-mediated immune response also appears to 
depend on whether a live infection initiates the immunizing response (681, 1168).  
6. BV 
BV is the most common adverse alteration of the vaginal flora, with a prevalence of 
about 10-60% in different populations (1229). It is characterized by a depletion of 
vaginal lactobacilli accompanied by an overgrowth of a mixed vaginal flora of 
anaerobic and microaerophilic species in large number, mainly G. vaginalis, 
Prevotella ssp., and Mobiluncus spp. among others (419, 874).  
BV is associated with several adverse pregnancy outcomes such as preterm birth, 
low birth weight, and spontaneous abortion (548, 1163, 1305, 1215), and increased 
  Discussion 
 III-334  
susceptibility to HIV and HSV-2 (1265, 285, 220). Studies also raised suspicion that 
there is a correlation between BV and CIN or cervical carcinoma (329). 
 
It seems clear that there is an increased risk of incurring infections such as HIV 
and HSV-2 in the presence of an abnormal vaginal microbiota (1265, 285, 220, 
1278) and it may be speculated that it is due in part to the fact that vaginal acidity 
falls as lactobacillus levels decline and this circumstance benefits the survival of 
other microorganisms (1278).  
A further factor arising from the decrease of the lactobacilli is a corresponding 
decline in production of H2O2, which has an antimicrobial effect (547, 1278).  
Since SLPI has been shown to inhibit HIV infection in vitro, it has been suggested 
that low levels of SLPI in conjunction with a BV-positive status might contribute to 
the risk of contracting HIV.  
Furthermore, some anaerobes associated with BV augment expression of HIV in T 
cells in vitro, which might enhance the amount of HIV shedding or activate these T 
cells to further support viral transmission (518).  
Studies showed that genital mucosal fluids from women with BV are potent 
stimulators of leukocytes, eliciting secretion of TNF-α and expression of mRNA for 
both TLR4 and TLR2 (1573). Thus, findings suggest that TNF-α levels in genital 
mucosal fluids from women with BV would be higher than those in women with 
normal flora. Stimulation of cells through TLR 2 and TLR4 with microbial products 
stimulates HIV expression through stimulation of TNF-α secretion or direct 
activation of NF-κB and subsequent binding of NF-κB to the HIV promoter (369). 
Therefore the secretion of TNF-α and mRNA expression of TLR2 and TLR4 by genital 
mucosal fluid of women with BV could play a role in mediating adverse effects of BV 
in HIV transmission.  
This is also consistent with the studies by Sturm-Ramirez et al. (1368). 
Proinflammatory cytokines such as IL-1 and TNF-α were found to be elevated in BV 
patients. As these cytokines could upregulate local HIV replication by activating NF-
κB in the LTR-promoter region of HIV, this could partly explain the mechanism by 
which this risk factor enhances HIV transmisssion. 
 
A characteristic of BV is the absence of strong inflammatory signs that accompany 
other vaginal conditions caused by pathogens. The vaginal mucosa appears neither 
red nor inflamed and characteristic symptoms for a vaginitis including vaginal 
pruritus, burning or dyspareunia, however, are rare (969). 
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The number of vaginal neutrophils is not statistically higher in BV-positive women 
than in women with normal vaginal flora, which is astounding due to the massive 
microbial colonization (192, 195). A subgroup of BV-positive patients actually 
shows high numbers of neutrophils together with a 10-fold increase in 
proinflammatory cytokine concentrations when compared to the subgroup with low 
numbers of neutrophils. This implies that some women with BV do experience a 
strong activation of the innate response. 
In addition, other innate immune factors, such as the antimicrobial SLPI, are 
decreased in BV-positive women (341). The concentration of neutrophil defensins is 
also not increased in BV (72). 
 
Proinflammatory cytokines IL-1α and IL-1β are released by phagocytes which are 
stimulated by bacterial surface antigens and trigger an inflammatory reaction by 
activating T helper cells.  
The cytokine level of IL-1α and IL-1β in CVS is higher in BV-positive patients 
whether pregnant or not (37, 192, 890, 1494). Furthermore, there is a correlation 
between a gradual disruption of the lactobacillus dominance and a gradual increase 
of IL-1α and IL-1β (192). This shows that the innate immune system is reacting 
strongly and trying to fight abnormal microbial colonization, although most BV 
positive women do not show any inflammatory signs.  
However, increased levels of IL-1α seem to be associated with pregnant BV patients 
(1494, 1569) whereas studies in non-pregnant BV patients have not shown elevated 
IL-1α levels (37). Thus, there may be a difference in the response of the local 
immune system during pregnancy. 
 
IL-1β is a master cytokine inducing several chemokines, especially IL-8. IL-8 is a 
potent chemotactic and activating factor for neutrophils that has been detected in 
vaginal fluid of women with other vaginal infections such as trichomoniasis (1287). 
It also has been demonstrated that the numbers of neutrophils in BV-positive 
patients and in healthy women are associated with levels of IL-8 (192). 
IL-8 does not, however, seem to be correlated with the presence of BV in the same 
distinct manner as IL-1β (192). The BV microbial flora seems to produce virulence 
factors that specifically inhibit IL-8 more than IL-1β. The resulting low IL-8 levels 
may be responsible for the low counts of vaginal leukocytes and for the clinically 
observed absence of inflammatory symptoms in most women with BV. 
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Specific bacterial proteases could be responsible for the IL-8 degradation in BV 
(191). Another possibility is that neutrophils as IL-8-producing cells could be 
impaired by microbial virulence factors, such as G. vaginalis cytolysin. 
 
There is no significant difference in IL-6 levels in the cervical mucus sampled from 
healthy vaginas and that from BV-positive vaginas, also in pregnant women (890, 
1471, 1494). Analyses of cervical mucus from pregnant women tend to show a rise 
of IL-8, though not as high as for IL-1α (1494). In pregnant women, BV can 
probably result in the induction of a local immune response mediated by IL-1α and 
IL-8.  
As IL-6 is expressed in endometrial ECs, the absence of an IL-6 response in BV may 
be because the mucosal ECs are not triggered by BV-associated bacteria or their 
components to secrete IL-6 above the constitutive levels (889). 
Nonetheless, oral and vaginal metronidazole treatment of BV-positive pregnant 
patients has been shown to reduce cervical mucus levels of IL-6 as well as IL-1β 
and IL-8 (1569). In the group of patients with persistent BV, however, the 
metronidazole treatment did not result in a cytokine reduction, possibly due to a 
persistence of bacterial endotoxin. 
 
Anti-inflammatory IL-10 inhibits activation of Th1 cells thereby suppressing cell-
mediated immunity. Concerning this cytokine, there are inconsistent results.  
The Munich study showed no significant difference in vaginal IL-10 levels of BV-
patients compared to healthy women (1471) whereas Cohen et al. showed higher 
IL-10 levels in CVS of BV patients compared to controls (243). They suggested that 
higher IL-10 levels in CVS of BV patients may be another mechanism to increase 
susceptibility to HIV infection. In another study, vaginal levels of IL-10 were 
significantly higher in healthy controls as compared to BV patients (37) probably 
speaking for a suppression of cell-mediated immunity in healthy subjects. This is 
also consistent with results of a further study where high vaginal IL-10 levels were 
supposed to be associated with healthy women compared to patients with vaginal 
discharge (G. Anton, personal communication). 
These differences may be caused by recruitment of different patients into the 
studies. 
 
Some evidence points to microbial hydrolytic enzymes, sialidases and prolidases, 
and toxins as factors that degrade human Igs and thus impair the immune 
response. So far, the only characterized specific adaptive immune response in BV is 
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IgA antibody against the hemolysin produced by G.vaginalis. Levels of these vaginal 
IgA antibodies are positively associated with IL-8 and IL-1β concentrations and are 
inversely related to microbial enzyme activity (191). Cauci et al. also proposed an 
association between levels of IL-1β and anti-G.vaginalis hemolysin IgA in vaginal 
fluids (190) suggesting a parallel induction of innate and specific immune 
responses. High levels of anti-G.vaginalis hemotoxin IgA in BV-positive pregnant 
women appear to be protective against adverse pregnancy outcomes whereas BV 
with high prolidase and sialidase activity was associated with a higher risk for low 
birth weight (194). 
 
All bacterial species associated with BV, with the exception of Mobiluncus spp., 
appear in small quantities in the flora of healthy vaginas, but they increase 
considerably in the vaginas of women with BV. BV might well be an endogenous 
infection since microorganisms associated with BV are shown to have their natural 
habitat in the gastrointestinal tract (562).  
The pathogenetic mechanisms that lead to BV among a subpopulation of women 
are still unknown. The consequences of any interaction between different species of 
bacteria are not clear. All in all, however, it seems that an increased level of 
proinflammatory cytokines in conjunction with a disruption of the vaginal flora does 
not evoke an inflammatory effect in the usual clinical sense, but that it nonetheless 
is a host response to a growing potential threat. 
One could propose that the condition of BV can be considered as a mucosal 
immunity disorder or genetically determined miscolonization of the vagina resulting 
in the lack of an adequate immune response aginst the intruding microorganisms. 
Another option would be that the prevalence of certain bacteria would inhibit the 
local host response.  
 
It seems to be important to clearly differentiate between the prevalence of BV with 
its typical clinical picture on the one hand (34), and the state of bacterial dysbiosis 
on the other hand which is more precisely characterized as a dysbalance of the 
vaginal flora.  
Studies have investigated an abnormal vaginal flora, but concentrated on BV 
instead of taking also in account other foms of a dysbalaned vaginal flora. These 
forms have been classified either as “intermediate” flora or assigned to the group of 
BV or normal vaginal flora, respectively (334, 335). 
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However, there exist forms of an abnormal vaginal flora, which neither can be 
classified as normal or correspond with the clinical picture of BV, but could then be 
classified as bacterial dysbiosis. Donders et al. have termed those forms as aerobic 
vaginitis to clearly seperate them from BV (334, 335).  
Women with abnormal vaginal flora showed signs of a vaginitis including a yellow 
discharge, redness, pruritus and burning pain. This state was characterized by a 
decrease in lactobacilli, high vaginal pH, absent clue cells and the presence of 
increased aerobic bacteria and leukocytes (334). This should be clearly separated 
from BV which shows another clinical picture and is characterized by a different 
immunologic response. 
Women with vaginal dysbiosis were reported to have decreased levels of lactic acids 
and a local inflammatory response with high concentrations of vaginal IL-1β, IL-6 
and LIF (334), which is also consistent with the results of the Munich study group 
(955). The increase of IL-1β is indirect proportional to the decrease in lactobacilli. 
Vaginal IL-1β also increases in BV, but significantly more (8-fold) in aerobic 
vaginitis. 
Studies by Spandorfer et al. have also found an association of an abnormal vaginal 
flora with elevated cervical levels of IL-1β (1329). Concentrations of 
proinflammatory cytokines in an abnormal vaginal flora could be higher due to 
bacterial release of LPS and endotoxins (890). 
Elevated IL-1β was also demonstrated in patients with cervical dysplasia which was 
more often in women with an abnormal vaginal flora compared to women with 
normal vaginal flora (98). IL-1β could be responsible for stimulation of HPV 
replication, similar to HIV. 
Also the concentration of neutrophil defensins is increased in patients with 
“intermediate” flora whereas in BV they are not (72). 
 
The immunoregulatory cytokines IL-2 and IL-4 were found to be significantly lower 
in the group with a symptomatic vaginal dysbiosis compared to healthy controls 
(955). This could also be due to bacterial proteins and proteases which have been 
shown to inhibit cytokine release (1508). The production of prostaglandin E2 by 
monocytes also inhibits IL-2 production, which was proposed as one important 
factor in recurrent vaginitis by Witkin (1525). An inihibition of the cytokine 
response results in incompetent effector functions of the immune response 
stimulating further bacterial growth and the prevalence of symptoms. Possible 
therapeutic interventions in vaginal dysbiosis such as an immunostimulation 
through IL-2 are implicated but need further study. 
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However, if bacterial dysbiosis can be considered a separate entity or a state of 
transition to BV, remains unclear. There has to be reached a consensus about the 
diagnostics and classifications of vaginal flora to better define different states of 
abnormal vaginal flora which also has important implications for therapy.  
Further studies to differentiate the effects of BV and aerobic vaginitis on the 
outcome of pregnancy are needed as well. They might solve the problem of 
inconsistent results concerning the fact that some studies have found no 
association between BV and pregnancy outcome whereas others did. 
7. Candida 
Candidal vaginitis is a common mucosal infection principally caused by the 
opportunistic yeast-like fungus Candida albicans (915, 1323, 1324). While an 
estimated 75% of women will experience VVC in their lifetime, another 5-10% have 
RVVC (585). Whereas acute VVC has several known exogenous predisposing factors 
(1324), RVVC is usually defined as idiopathic.  
Antifungal therapy is highly effective in acute VVC and individual attacks of RVVC 
(915), but it does not prevent recurrence. The question is therefore, if susceptibility 
to RVVC results from an immune dysfunction or deficiency.  
 
Results of studies on women with RVVC during the last decades have been 
conflicting as to whether any deficiency in cell-mediated immunity was present but 
the consensus was that no deficiency in either cell-mediated immunity or antibody 
response was observed (408). This is consistent with the fact that HIV-infected 
women do not acquire VVC more often than HIV-negative women and the systemic 
T cell responsiveness was similar in HIV-positive women with or without 
symptomatic VVC (801) 
It is obvious that innate and adaptive humoral and cellular immune mechanisms 
are involved in the host defense against C.albicans infections, but they exert their 
functions site-specific. Innate immunity by PMNs and macrophages seem to 
dominate protection against systemic candidiasis which results from the high 
incidence of systemic candidiasis in neutropenic patients (1224).  
There is now evidence that human and animal vaginal ECs may represent an 
important innate anti-Candida host defense mechanism (1025). Interestingly, a 
recent study in humans showed that while the vaginal EC anti-Candida activity was 
not different at the various stages of the menstrual cycle, it was significantly 
reduced in women with a history of RVVC (81). Thus, reduced EC anti-Candida 
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activity may represent, in part, a local immune deficiency associated with RVVC. 
Other innate immune cells such as DCs and macrophages have not been studied 
during vaginal Candida infections. 
 
The efficacy of humoral immune mechanisms and the role of antibodies against C. 
albicans have been controversial and speak for a subordinate role of antibodies in 
VCC (1134). Especially Candida-IgA has been said to have a protective role. 
Candida-specific antibodies also induced by the commensal presence of Candida 
(859) have not been associated with protection against infection (408) while other 
reports indicated that antibodies against C. albicans might be protective against 
experimental disseminated candidiasis (310, 983).  
Similar to other studies (402), a recent study found higher levels of Candida-specific 
IgA, IgG1, and IgG4 in those with symptomatic VVC (306). The authors suggested 
that the increase in antibodies may indicate a role in fungal clearance. However, 
similar to previous studies showing similar findings, the increase in antibodies 
correlated with increased rather than decreased fungal burden, and the study was 
not designed to examine an endpoint of clearance. Thus, it would appear that the 
antibodies are induced in response to the organism, but there is no evidence of any 
role in clearance or protection.Instead, it is equally possible that the antibodies 
actually contribute to the pathogenesis.  
 
Actually, the role of Candida-IgE is considered to be an important one.  
Earlier studies already proposed allergic reactions to Candida in the sense of a local 
vaginal hypersensitive immune response and suggested an allergic cause for 
chronic and recurrent symptoms (1197, 1217, 1525). This was confirmed by the 
study of Weissenbacher et al. who showed significantly higher prostaglandin E2 
and Candida-IgE levels in vaginal secretions of women with CRVVC compared to 
healthy controls. As epitopes of C. albicans enolase were already detected as 
binding sites for IgE antibodies (602), this results in a further proposal of a local 
allergic immune response in CRVVC. Current diagnostic and therapy should be 
reconsidered. 
 
A further study concentrated on the comparison of 150 healthy women and 74 
women with vaginal Candida-infection with respect to IL-8 and glucose in vaginal 
secretions (486). Healthy women not only showed higher concentrations of 
physiological lactobacilli, lower levels of neutrophils and a significantly lower 
presence of gram-positive cocci but also higher titers of IL-8. With respect to 
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glucose levels, there was no difference between these two groups. An explanation 
could be that higher vaginal levels of the proinflammatory IL-8 in healthy persons 
serve as expression of an activated immune state, or that IL-8 may be inhibited in 
women with vaginal infection or downregulated in a kind of feedback-mechanism. 
 
Candida-specific cell-mediated immunity, acquired by exposure to Candida as a 
commensal early in life, has been considered the predominant host defense 
mechanisms against mucosal Candidiasis. Specifically, resistance to infection has 
been considered associated with a Th1 response whereas susceptibility to infection 
is associated with Th2 responses.  
Several observations have led to this conclusion. Individuals with impaired T cell 
function, including those with HIV infections, are particularly prone to Candida 
infections (397, 725). Clinical studies on RVVC as well as several investigations with 
estrogen-dependent murine models of VVC led to the suggestion that Th1-type CMI 
plays a critical role in anti-candidal protection at the vaginal level (310, 402, 406, 
408, 1214, 1398). 
 
However, studies from mouse models of vaginal candidiasis and clinical studies on 
women with RVVC have revealed a general lack of protection by local or systemic 
adaptive immunity (404, 405, 407, 1534). 
The general lack of a role for systemic or local adaptive immunity against vaginal 
candidiasis is postulated to be due to multiple putative immunoregulatory 
mechanisms that prohibit more profound adaptive immune responses in the vagina 
rather than a simple lack of immune reactivity or protective effects.  
There are experimental and clinical evidences that support immunoregulation or 
tolerance against Candida at the vaginal mucosa.  
Mice deficient of δ-chain TCR are more resistant to experimental vaginitis than WT-
mice, suggesting a tolerance role for vaginal γ/δ T cells that are in higher numbers 
compared with the circulation (1533). Vaginal tissue homogenates in mice showed 
high constitutive concentrations of the immunoregulatory cytokine TGF-β, which 
were increased further in vaginally infected mice together with low levels of other Th 
cytokines (1398). Third, Candida-specific T cells with appropriate homing receptors 
for infiltation into the vaginal mucosa are reduced during a vaginal Candida 
infection in mice despite the upregulation of reciprocal adhesion molecules on the 
vaginal epithelium (1535). Moreover, PMNs, which have significant killing activity 
against C. albicans in vitro and are often observed in vaginal lavage fluid of infected 
animals, are not effective against Candida in the vaginal environment (403). 
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One report using a live challenge model in humans revealed a possible paradigm 
shift for factors associated with susceptibility and resistance to candidal vaginitis 
(400). Of women with no history of vaginitis only few became symptomatic with 
vaginitis or even colonized. In contrast, inclusion of women with documented 
infrequent episodes of VVC resulted in significantly higher rates of symptomatic 
infection, with the remaining women becoming asymptomatically colonized. 
Interestingly, protection occurred in the absence of any evidence of inflammation or 
an inflammatory response, whereas those with symptomatic infection had a heavy 
vaginal cellular infiltrate consisting entirely of neutrophils. Furthermore, a high 
neutrophil infiltration score correlated with higher fungal burden. 
Therefore, symptomatic infection appears associated with a hyperresponse by 
neutrophils rather than a deficiency in adaptive immunity, whereas resistance to 
infection appears to be associated with a noninflammatory innate presence rather 
than an adaptive cell-mediated response. This would change the paradigm for host 
defense against VVC away from adaptive immune dysfunction and toward 
dichotomous roles for innate immunity in both resistance and susceptibility to VVC 
(399).  
 
Although there are significant efforts to develop a vaccine for Candida infections 
(503, 183, 1136, 360), no effective prophylactic or therapeutic vaccine has been 
developed against candidiasis so far. One should pose the question if a vaccine 
against vaginal Candidiasis is useful as women with VVC or RVVC are not generally 
immunosuppressed. Candida-specific antibodies and cell-mediated immunity are 
present locally and systemically and if immunoregulation acts to prevent more 
profound adaptive immunity, a vaccine would not be suitable to overcome this 
(399). It may be better to seek other immunotherapeutic strategies to overcome 
immunoregulation. 
8. Trichomonas 
Trichomonas vaginalis, a parasitic protozoan, is the cause of trichomoniasis, a STD 
of worldwide importance. It is estimated that 170 million cases occur each year, 
making trichomoniasis the most frequent nonviral STD (186). 
It is not only associated with classical symptoms of vaginitis or cervicitis but also 
with other STDs such as BV or gonorrheae (322, 613), adverse pregnancy outcome 
(259, 950), and an increased susceptibility to HIV (806, 774, 165). However, about 
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half of all women infected with T. vaginalis are asymptomatic (1113) and in males, 
the infection appears usually to be asymptomatic.  
The existing literature provides little information on the host and parasite factors 
leading to symptomatic or asymptomatic T. vaginalis infection in women. The 
existence of two types of T. vaginalis strains, each differing in its morphological 
characteristics and intrinsic virulence has been suggested (20). 
 
Observations may indicate that innate immunity involving chemotaxis and 
subsequent influx of neutrophils is much more important than acquired immunity 
in controlling infections with T. vaginalis, since neutrophils are the predominant 
inflammatory cells found in vaginal discharges in response to infection. Higher 
vaginal leukocyte concentrations were directly correlated with both the severity of 
mucosal inflammation and the number of trichomonads in vaginal exsudates (152, 
1186).  
 
Little is known about the exact mechanism of how neutrophils accumulate or 
mediate the initial inflammatory response after acute T. vaginalis infection.  
It may be hypothesized that trichomonads in the vagina after acute infection secrete 
proteins like ESP which have a chemoattractant effect on neutrophils (1077). These 
neutrophils can be further stimulated by T. vaginalis to produce chemokines such 
as IL-8 and GRO-α, mediated through the NF-κB and MAP-kinase signaling 
pathways (1232).  
IL-8 is found in high levels in vaginal discharges of symptomatic trichomoniasis 
patients. T.vaginalis-membrane components have been shown to induce blood 
monocytes and neutrophils to produce IL-8, probably with the help of TNF-α (1287). 
IL-8 has been shown to enhance antimicrobial activities of neutrophils by inducing 
neutrophil degranulation and respiratory burst.  
However, a study by Chang et al. found that during prolonged T. vaginalis 
adhesion, later proinflammatory production of TNF-α and IL-12 was suppressed, 
accompanied by inhibition of NF-κB activity suggesting that T. vaginalis may inhibit 
the NF-κB activity of macrophages (198). 
 
In vitro experiments showed that T. vaginalis selectively adhered to human vaginal 
ECs and exerted their cytopathogenic effects (452). It is possible that IL-8 
production is induced in vaginal ECs early in infection when the vaginal ECs are 
activated with T. vaginalis - Candida and Neisseria gonorrheae have been reported 
to induce IL-8 production by vaginal ECs early in infection as well (1346, 396). 
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These may subsequently induce more infiltration and recruitment of neutrophils by 
chemotaxis at the reaction site. Finally, the neutrophils are thought to cause 
continued inflammation in vaginal tissue. 
 
Another leukocyte-derived chemoattractant, which may be generated during the 
infection either by release from T. vaginalis or from neutrophils induced by 
interaction of trichomonads and humoral immunity, is leukotriene B4. 
Leukotriene B4 can be found in high levels in vaginal discharges of symptomatic 
patients (1286) and appeared be further augmented by IgG antibodies promoting 
the interaction of neutrophils with T. vaginalis and augment the inflammatory 
response through the amplification of leukotriene B4 production (1285). 
 
Complement components have been documented to play a role in the activation of 
neutrophils and therefore in the inflammatory response to T. vaginalis infection as 
well (1186). Shaio et al. were able to show that both a IgG-enhanced classical 
component pathway activation and an antibody-independent alternative pathway 
activation provide C3 to facilitate neutrophil killing of T. vaginalis (1284). Earlier 
studies have already suggested an essential role for the alternative pathway 
activation of complement (185, 1186, 320).  
T. vaginalis seems to have taken advantage of a niche in which little complement is 
present as cervical mucus is surprisingly deficient in complement (321). Menstrual 
blood represents the only source of complement available to the vagina and has 
appreciable complement-mediated cytotoxicity toward T. vaginalis, and although a 
reduction in parasite concentration is seen during menses, trichomonal infection 
persists even after menses (320).  
It was also found that iron was a contributing factor in complement resistance. 
Demes et al. found that fresh isolates of T. vaginalis differ in their susceptibility or 
resistance to complement-mediated lysis in serum (321). It appears that 
complement-resistant fresh isolates become susceptible to complement after 
prolonged in vitro cultivation, which is consistent with the hypothesis that 
phenotypic variation allows the trichomonad to avoid lysis by complement. 
Resistance to complement is dependent upon a high concentration of iron (23), a 
nutrient which is indeed abundant during menses. It seems that iron upregulates 
the expression of proteases, which have been found to degrade the C3 portion of 
complement on the surface of the organism; this allows the organism to evade 
complement-mediated destruction (23). 
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Nitric oxide and other ROS/ROI produced by immune effector cells such as 
macrophages are important cytotoxic mediators in microbial infections. The 
synthesis of nitric oxide by macrophages also results in antimicrobial activity 
against another protozoan, Leishmania major, which was regulated by the cytokines 
TNF and TGF controlling parasite survival or killing via IFN-γ (480).  
In a study by Malla et al., the mean concentration of RNI in vaginal tissue of mice 
infected with T. vaginalis isolates from symptomatic women was significantly higher 
than that of vaginal tissue of mice infected with isolates from asymptomatic women 
(865). However, it was less in the vaginal washes and plasma of mice infected with 
isolates from symptomatic women compared to those infected with isolates from 
asymptomatic women which may be due to different macrophage populations with 
different functional capabilities (865). This would suggest a possible role for RNI 
production in establishing the infection. 
A recent publication by Yadav et al. strongly supports this hypothesis (1547). Mean 
RNI concentration was significantly higher in leukoctes and vaginal washes of 
asymptomatic women as compared to symptomatic women, and was also higher in 
samples of infected as compared to healthy women. This suggests that RNI may 
have a role in limiting T.vaginalis infection in asymptomatic women.  
 
Human infection with T. vaginalis does not appear to induce a state of protective 
immunity, as repeated infections occur without less intensity or duration (1021). 
Serum from infected subjects show high concentrations of IgG, IgM and IgA 
antibody to trichomonads, and specific IgG and IgA are present in cervicovaginal 
washes from women with acute trichomoniasis (242, 1536, 1363, 21, 22). A 
significant increase in the specific IgA antibody response was detected in serum 
samples and vaginal washes of T. vaginalis-infected women (1290). 
However, similar to their local counterparts, circulating antibody levels also differ 
and appear to have no function in helping the host to get rid of the infection. 
Although an association between the presence of local antibody and low parasite 
counts has been postulated, there is no conclusive evidence to suggest that the 
presence of IgA antibodies is specifically related to the immune response to T. 
vaginalis.  
 
IgA antibodies may otherwise act as a first line of defense for immune exclusion of 
the parasite at the mucosal surface. Greater serum and vaginal IgA responses and 
increased IFN-γ, IL-2 and TNF-α have been reported in mice infected with 
T.vaginalis isolates derived from asymptomatic women than those from 
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symptomatic women suggesting that specific IgA antibodies might help to protect 
asymptomatic individuals from severe infection (1061). A higher concentration of 
proinflammatory cytokines may also lead to a greater activation of macrophages 
which would result in a greater RNI production again. 
 
Several trichomonad antigens appear to be important for these responses, including 
α-actinin (7), adhesins (916), and the newly detected TV44 via an IgA mAb (987). 
Multiple signaling pathways seem to be functional for distinct surface proteins of T. 
vaginalis, and T.vaginalis responds during infection both to environmental cues like 
iron and to adherence to vaginal ECs by up- and downregulating expression of 
genes (752). Also Candida albicans undergoes both up- and downregulation of 
surface proteins after host cell contact (217).  
However, despite the first report describing IgA mAb reactivity to a surface protein 
of T.vaginalis, the protective role of IgA in recognition of surface protein 
immunogens in trichomoniasis is poorly understood. IgA has been associated with 
with resistance to a number of other mucosal pathogens, such as Chlamydia 
trachomatis or mycobacteria (1064, 1210).  
 
It is proposed that also IgM and the balance between different IgG subclasses 
influences the clinical outcome of infection. IgM and IgG1 antibody response was 
found to be predominantly higher in serum and vaginal washes of mice infected 
with symptomatic isolates as compared with asymptomatic isolates, whereas no 
significant difference was observed in the other IgG subclasses (1548). 
 
However, T.vaginalis possesses several mechanisms for evading host responses. 
Provenzano and Alderete have reported that numerous proteases secreted by T. 
vaginalis degrade IgG, IgM, and IgA, which allows the organism to survive the 
antibody response (1145). 
 
The presence of parasite-specific IgG and IgA responses also indicates priming of Th 
cells, although the relevant antigens are largely unknown, as are the exact effects of 
antibodies on the parasites. Paintlia et al. detected a significant increase in the 
population of total T cells, as well as CD4+ T cells in mice infected with isolates 
from asymptomatic women compared with mice infected with symptomatic isolates, 
but no difference in CD8+cells (1061). Also a significant increase in NK cells was 
observed in animals infected with isolates from asymptomatic women compared 
with mice infected with isolates from symptomatic women and control uninfected 
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mice, indicating that NK cells might be playing a role in the pathogenesis of this 
disease.  
An increase in CD4+ T cells in mice infected with isolates from asymptomatic 
women appears to be beneficial; it suggests that these cells have a role in the 
elimination of T. vaginalis from their mucosal surface. Clearance of T. vaginalis in 
these animals correlated well with development of anti-IgA antibodies. The results 
on cytokine production in the study of Paintlia et al. also suggest that the Th1 type 
of response might play a role in the elimination of T.vaginalis. 
 
While it is clear that T. vaginalis infection can induce an inflammatory response in 
the female genital tract, the type of receptors involved in host recognition of the 
pathogen has not yet been established. A recent study shows that T. vaginalis 
infection of women is associated with the presence in the genital tract of a 
substance either produced by T.vaginalis or by genital tract cells as an innate 
immune response to infection, that interact with TLR4 (1572).  
Interestingly, however, ECs from normal human vagina, ectocervix, and endocervix 
do not appear to express TLR4 and consequently do not respond to LPS, but do 
express mRNA for TLR1, -2, -3, -5, and -6 (395). Findings therefore suggest that 
ECs in the genital tract would not be stimulated during infection with T. vaginalis 
and a severe inflammatory response is initially avoided until the migration of 
leukocytes into the genital tract would establish an inflammatory response since 
neutrophils, monocytes, and macrophages express TLR4.  
It may be relevant that in many cases, T. vaginalis infection is relatively 
asymptomatic until menses although numbers of T. vaginalis organisms decrease at 
this time (320). Thus, the initiation of symptoms correlates with the introduction of 
leukocytes into the lower genital tract from the upper genital tract and likely come 
into contact with T. vaginalis organism. 
 
Finally, prospects for vaccine development have been enhanced by the finding that 
estrogen-treated mice coinfected with Lactobacillus acidophilus can be imunized 
subcutaneously against vaginal challenge with T.vaginalis, whereas infection alone 
does not confer protective immunity (2). 
The Solco Trichovac vaccine against T. vaginalis, which was prepared from inactive 
lactobacilli and was thought to work by inducing antibodies to abnormal lactobacilli 
and T. vaginalis without adversely affecting the growth of normal lactobacilli in the 
vagina, showed a lack of antigenic relatedness between the Solco Trichovac 
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lactobacilli and several strains of T.vaginalis (464). Furthermore, antiserum to 
L.acidophilus failed to inhibit trichomonad cytoadherence or host cell killing (19). 
 
In conclusion, the findings suggest that both the humoral and cellular immune 
responses might contribute to the varied symptomatology in trichomoniasis-infected 
patients, thereby reducing symptoms to asymptomatic levels. Periodic changes in 
immune competence, perhaps induced by parasite-derived products, might be 
responsible for an increase in parasite numbers leading to increased epithelial 
damage and inflammatory response. 
However, the current understanding of immunity to T. vaginalis remains 
unsatisfactory, and it is not clear whether acquired immune responses are required 
for protection and, if so, what role is played by acquired immunity in containing or 
eliminating infections. Although there is some evidence that protection may be 
achieved by immunization of laboratory animals, strong protective immunity does 
not seem to follow natural infection in humans.  
A recent study of patients infected with T. vaginalis and HIV indicated no evidence 
of increased levels or longevity of parasite infection in these patients compared to 
those in patients infected with T. vaginalis but not HIV (286). These observations 
may indicate that innate immunity involving chemotaxis and subsequent influx of 
neutrophils is much more important than acquired immunity in controlling 
infections with T. vaginalis. 
C. Immunology in reproductive medicine 
1. Immunology of normal pregnancy 
Maternal tolerance of her semiallogenic histoincompatible fetus during pregnancy is 
still a unique physiological phenomenon contradicting many of the generally 
established rules. From the immunological point of view, pregnancy is a balancing 
act of tolerance toward the fetus on the one hand and functional immunodefense on 
the other hand. 
Studies have demonstrated that the maternal immune system recognizes the semi-
allogeneic fetus, but that it remains in a quiescent state. The potential mechanisms 
underlying this phenomenon are likely to be complex and may involve several 
complementary or overlapping pathways to favor reproductive success. Knowledge 
of the immunoregulatory processes of pregnancy is necessary to understand and 
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treat a variety of disorders, which may lead to infertility, premature events or 
preeclampsia.  
 
The constituents of the maternal immune reaction to the allogeneic stimulus are 
not different from any other immune reaction and the allogeneic conceptus, the 
trophoblast, is like all other allogeneic tissue grafts.  
Anatomically, placental trophoblasts occupy a unique position at the interface 
between mother and child. These epithelial cells possess several intriguing features 
that suggest a role for these cells in preventing fetal rejection. The extra-embryonic 
trophoblast has several distinctive properties such as the expression of endogenous 
retrovirus products, oncofetal proteins, and imprinted genes and its DNA is 
relatively unmethylated (953, 1430). Moreover, it eliminates abortogenic maternal B 
cell and T cell responses through immunmodulation, probably through 
progesterone (1159). 
 
Indeed, trophoblasts can influence the immune system during pregnancy through 
their expression of soluble and cell surface-associated immunomodulatory 
molecules. For example, trophoblasts secrete IDO, which limits the availability of 
the essential amino acid tryptophan, consequently limiting lymphocyte proliferation 
and protecting the conceptus from rejection (988, 1270). Pregnant mice exposed to 
an IDO inhibitor rejected allogeneic but not syngeneic fetuses. IDO may not only 
inhibit T-cell proliferation but also be bactericidal by this mechanism (1270). The 
DC-associated signaling molecule CD200 is also expressed on fetal trophoblast and 
decidua (235). It was already found essential for induction of allograft tolerance in 
mice (466) by signaling immunosuppression and experiments in mice support the 
hypothesis that CD200 plays an unknown immunoregulatory role at the maternal-
fetal interface in maintaining pregnancy (235, 466).  
There is also growing evidence that trophoblast cells are able to recognize and 
respond to pathogens through the expression of TLRs, especially TLR2 and TLR4 (3, 
561, 754). This suggests that the placenta serves as a highly specialized barrier 
protecting the fetus against infection and that trophoblast cells themselves initiate 
an immune response characterized by promotion of cytokines such as IL-6 and IL-8 
(3, 4, 489, 561). As it has been found that TLR4 ligation promotes cytokine 
production, while ligation of TLR2 induces apoptosis in first trimester trophoblast 
cells it was suggested that a pathogen may directly promote the elevated 
trophoblast cell death via TLR2 observed in a number of pregnancy complications 
(4). TLR2-mediated trophoblast apoptosis, therefore, may provide a novel 
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mechanism of pathogenesis by which certain intrauterine infections may contribute 
to conditions such as preterm labor or preeclampsia. 
 
Moreover, trophoblasts express little or no classical MHC class I (HLA-A, -B, and -
C), but do express a number of nonclassical MHC class I molecules. Examples 
include HLA-E, -F and -G, which can modulate the innate immune response and 
prevent NK and NKT cell-mediated cytotoxicity (230, 696, 698, 965, 1143, 1158, 
1219). Additionally, trophoblasts have been recently shown to express the 
nonclassical MHC class I molecule, CD1d, on the surface of first-trimester human 
trophoblasts (137). 
Also the apoptosis-inducing molecule FasL is expressed by placental trophoblast 
(582) and by first trimester and term human placental villi (500) inducing apoptosis 
in maternal Fas positive immune cells, such as NK and T cells, at the fetomaternal 
interface (1042). A reduction in FasL expression seems to be closely associated with 
activation and infiltration of maternal NK cells and destruction of uterine glands, 
resulting in rejection of the foetus (1042). Thus, expression of FasL in the uterine 
glands and cytotrophoblasts may play a role in the downregulation of the maternal 
immune response, thereby maintaining pregnancy at early stage. 
 
During four phases of the fertilization period maternal immune responses are 
minimized by different mechanisms, for example protection of the egg through the 
follicular fluid with its immunosuppressive activity (184), the ZP or maternal 
cumulus cells (79).  
The implantation phase with direct embryo/maternal contact in the uterus is 
probably the most vulnerable time for the embryo which is now exposed to maternal 
endometrial immune cells and cytokines. The uterus is designed to prevent 
implantation except during a narrow implantation window in which embryonic 
signals help promote endometrial priming and maternal immune tolerance.  
Post fertilization, immune tolerance is possibly promoted by the 
immunosuppressive EPF and PAF (976, 1035, 1156). EPF is non-specific and 
detectable in serum (506), amniotic fluid (1585) and cervical mucus (218) of 
pregnant women but also in non-pregnant women which makes its use as a marker 
for evaluation of pregnancy not very helpful. 
 
How this maternal immune tolerance takes exactly place, what embryo-derived 
elements are involved and where, if these mechanisms are common to all mammals, 
and how early embryo tolerance can be detected in the maternal organism are still 
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are still unanswered questions. Barnea postulated that unique embryo-derived 
compounds are involved in creating the unique maternal immunological response to 
the embryo (79, 1118). His study group favors PIF as modulator of the maternal 
immune system, allowing the mother to maintain her ability to fight diseases. 
Coulam and Barnea have found that the presence of PIF activity in maternal serum 
within 4 days after embryo transfer indicates a >70% chance of successful 
pregnancy outcome whereas the absence of PIF activity indicated that pregnancy 
would not develop in 97% of cases (Coulam and Barnea, unpublished data). 
 
In the following, results from studies concerning immune cells at the feto-maternal 
interface during normal pregnancy and their actions are summarized and 
evaluated.  
 
APCs such as DCs and macrophages are often regarded as the responsible 
inductors of maternal tolerance against fetal antigens (660).  
Studies in mice or rats and humans showed that the population of APCs in the 
decidua of pregnancy comprises classical macrophages, classical mature DCs 
(CD83+), immature or intermediate macrophage/DC-like cells (CD83-) and myeloid 
DCs (121, 157, 158, 439, 579, 657, 659, 660, 808, 900, 952, 1047, 1385). However, 
the exact functions of decidual APCs are unclear. Specialized APCs may present 
fetal antigens from the invasive trophoblasts to the maternal immune system which 
leads to a state of tolerance. Decidual APCs are able to either acquire functions of 
classical mDCs that can activate T cells or rest in an immature state which likely 
induces tolerance (843). Cytokine studies show that decidual mDCs secrete less IL-
12 than blood monocyte-derived DCs and induce Th2 cells when cocultured with 
naive CD4+ T cells, which suggests an immunosuppressive phenotype of decidual 
DCs (951). Recent studies found a significantly higher number of mDCs in human 
decidual tissue from abortions than in normal pregnancies which leads to 
speculations that mDCs may play a role in recurrent abortions (62). 
 
CD11c+ CD86+ DC-SIGN+ macrophages are with 20-30% of the decidual cells one 
of the major cell types in both the maternal and fetal compartments at the site of 
implantation and unlike NK cells, remain high throughout pregnancy (581, 808, 
940, 963). They are closely associated with trophoblast (1316) and it is proposed 
that they contribute to the feto-maternal immunesuppressive adjustment via 
cytokines and growth factors (467, 963) and prostaglandin E2 production (584). 
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However, there is limited knowledge about how decidual APC are driven into 
immune inhibitory profiles. 
Concerning macrophage function, they seem to be involved in essential tissue 
remodeling by clearance of apoptotic trophoblast cells during implantation and 
embryo development and thus preventing an extensive inflammatory reaction (107, 
583, 963, 1175, 1321). Mor et al. stated in their hypothesis that the uptake of 
apoptotic cells suppresses activated macrophages from secreting proinflammatory 
cytokines such as TNF-α and IFN-γ and promotes the release of Th-2 type, anti-
inflammatory and immunosuppressive cytokines with protective effects on 
trophoblast survival and immunological tolerance (963). Changes in the cytokine 
milieu, owing to elevated levels of apoptotic bodies and inefficient clearance, will 
result in a proinflammatory microenvironment that in turn may result in changes 
in trophoblast resistance to Fas-mediated apoptosis and the maternal immune 
system.  
 
The number of endometrial leukocytes continously increases with beginning of 
pregnancy (1119). 46% of the decidual CD56+ leukocytes are uterine NK cells, 19% 
are macophages and 8% are T cells, mainly CD8+ T cells, whereas B cells are 
virtually absent (808, 949) which means that cells of the innate immune system 
seem to dominate this tissue. 
Decidual NK cells are the predominant maternal immune cells in early pregnancy 
(1158), declining again later until they are absent at term (954). This reduction of 
uterine NK cells in later pregnancy remains unexplained. Death by both apoptosis 
and necrosis has been proposed for the loss of uterine NK cells in the late stages of 
mouse pregnancy (757) but no information is available regarding the fate of the 
cells in human pregnancy (155). 
Results of studies which have compared the distribution of uterine NK cells between 
decidua basalis, which underlies the placenta and is infiltrated by trophoblast, and 
decidua parietalis, which lines the remainder of the uterine cavity, have been 
inconsistent. Some have reported increased numbers of uterine NK cells in decidua 
basalis and considered this to support a role in the control of trophoblast invasion 
(1312) but others have failed to detect any difference in the different decidual areas 
(Scaife, Bulmer, Robson, Searle, Innes, unpublished data).  
However, the possibility of a functional difference between the two sites has not 
been considered in detail. Since uterine NK cells express receptors for the non-
classical HLA antigens expressed by extravillous trophoblast, contact with 
trophoblast in decidua basalis could lead to altered function such as a differing 
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cytokine profiles and increased IFN-γ levels have been reported in decidua basalis 
(1463). 
 
Phenotypically, decidual NK cells (CD56bright CD16- CD160-) differ from NK cells in 
peripheral blood (CD56dim CD16+ CD160+) which suggests that either decidual NK 
cells represent a distinct subpopulation of circulating NK cells or they have 
undergone some tissue-specific differentiation. There are also morphological 
differences between CD56bright NK cells in decidua and those present in low 
numbers in peripheral blood. All the peripheral CD56bright NK cells are small and 
agranular whereas those in decidua are mostly large granular lymphocytes (699). 
However, decidual NK cells can change into classical CD16-expressing cells after IL-
2 stimulation which can result in cytotoxicity and an alloimmune reaction (701). 
Women with recurrent abortions have high numbers of NK cells of the conventional 
CD16+ CD56+ type in the uterus (1448).  
This underlines the possibility that decidual NK cells exert different functions with 
the priority of tributing to placental development and pregnancy outcome. In direct 
contact with the trophoblast, they can produce cytokines involved in the control of 
trophoblast invasion, trophoblast differentiation, decidual artery remodeling and 
placental augmentation (57, 155, 156, 233, 275, 1430). 
 
The function of decidual NK cells is regulated by a balance between activating and 
inhibitory signals provided by their receptor repertoire upon recognition of specific 
ligands, most of which are HLA molecules (HLA-C, HLA-G, HLA-E) expressed on 
invading trophoblast (700, 1158, 1444). These are the KIRs for which HLA-C and 
HLA-G molecules are the ligands, the immunglobulin-like receptor ILT2 which is 
expressed by 20-25% of decidual NK cells and interacts with HLA-G, the CD160 
receptor with its major ligand HLA-C which is expressed on a minor set of decidual 
NK cells, and the CD94/NKG2 receptor which binds HLA-E. Varla-Leftherioti 
suggested that among the different interactions of NK receptors with their specific 
couterparts on trophoblast, the inhibitory KIR-HLA-C interactions appear to be 
those mainly involved in the functions of an NK cell-mediated allorecognition 
system in pregnancy (1444). 
 
Several mechanisms have been suggested for this regulation of pregnancy including 
cytotoxicity, local cytokine production and induction of trophoblast apoptosis. There 
is strong evidence that decidual NK cells are unlikely to play a role in cytotoxicity. 
The general consensus of different studies is that the cytotoxic activity of uterine 
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NK cells is reduced compared with peripheral blood NK cells (155, 701, 787, 793, 
1158, 1444). 
The functional importance of uterine NK cell cytokine and growth factor production 
in normal pregnancy is currently not known (1195, 1239). The cytokine profile of 
uterine NK cells does, however, appear to differ dependent on the phenotype of the 
surrounding cells, such as HLA-G expressing cells. Altered production of IFN-γ has 
been reported in decidua basalis compared with decidua parietalis (1463) and van 
der Meer et al. have reported increased production of IFN-γ and VEGF by uterine 
NK cells in response to HLA-G (1438).  
Current interest is directed towards the role of uterine NK cell-derived cytokines, 
particularly IFN-γ, in the control of trophoblast invasion by a non-cytotoxic 
mechanism and remodelling of uterine spiral arteries in the first half of normal 
pregnancy (155). These cytokines may influence trophoblast growth since their 
receptors have been found in human trophoblast cells (634). In the placental bed of 
uncomplicated pregnancies during early gestation up to 30% of the extravillous 
trophoblast cells are undergoing apoptosis and many of these apoptosing 
trophoblast cells are surrounded by uterine NK cells (330). A possible explanation 
for this may be that the trophoblast cells which undergo apoptosis recruit uterine 
NK cells after apoptosis has been initiated (155). If uterine NK cells regulate 
trophoblast invasion then the most likely mechanism by which this occurs is 
mediated by uterine NK cell cytokine secretion. Also cytokine production by 
decidual NK cells might play a role in the defense against viral spreading to the 
fetus in case of uterine infection, for example, secreted IFN-γ might control 
cytomegalovirus spreading (1158).  
 
Pregnancy presents itself as an inflammatory condition. Study results generally 
demonstrate an increased number of granulocytes in pregnancy compared to 
nonpregnant women (841, 948). An increased expression of surface CD11a, CD11b, 
CD14, CD49d, CD54 and CD64 on monocytes in pregnant women further supports 
the hypothesis that the innate immune system is activated during pregnancy (841). 
Available data on granulocyte activation during pregnancy are contradictory with 
some studies showing increased surface expression of both activation markers and 
adhesion molecules, for example of CD11b and CD64 (1234), and an increased 
production of intracellular ROS and enhanced phagocytosis (997). Other studies 
showed no upregulation of activation markers and reduced microbial killing activity 
and chemotaxis of granulocytes (269).  
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T cells comprise about 10-20% of the leukocytes in the uterine mucosa and 
continously increase during pregnancy until a decline at term (1119) with rising 
CD8+ and decreasing CD4+ T cells, respectively (398). Recently, the importance of 
decidual CD4+CD25+ Treg cells with their increasing numbers during pregnancy in 
mediating maternal tolerance to the fetus has become clear (33, 1243, 1258, 1259, 
1325).  
However, the factors regulating CD4+CD25+ Treg cells are largely unknown. Data 
suggest that estrogen promotes maternal tolerance to the fetus by increasing the 
number of CD4+CD25+ Treg cells (1129). Decidual CD4+CD25high T cells express a 
high frequency of intracellular CTLA-4 and 5–7% of these cells express surface 
CTLA-4 (1259), suggesting that decidual CD4+CD25high T cells are stimulated by 
some antigens such as fetal antigens. Because antigen stimulation by DCs induced 
the surface expression of CTLA-4, these activated CD4+CD25high Treg cells should 
mediate maternal tolerance to the fetus (1241). Recently, Sindram-Trujillo et al. 
reported that labor is associated with a decrease of CD4+CD25+ cells in decidua, 
suggesting that the disappearance of the CD4+CD25+ T cell population may 
contribute to the induction of labor, although the study did not explicitly investigate 
CD4+CD25high cells (1311). 
 
Interestingly, CD4+CD25+ Treg cells express TLR4, 5, 7 and 8 (175). Recent data 
showed that microbial induction of the Toll pathway, partly mediated by 
inflammatory IL-6, blocks the suppressive effect of CD4+CD25+ Treg, allowing 
activation of pathogen-specific adaptive immune responses (1094). Recently, Yang 
et al. reported that DC-based tumor vaccines ablate tumor-specific T cell tolerance 
only after removal of CD4+CD25+ Treg cells (1556). However, to ablate tumor-
specific T cell tolerance in the presence of CD4+CD25+ Treg cells by DC-based 
tumor vaccines, persistent TLR signals are required to reverse CD4+CD25+ Treg-
mediated CD8+ T cell tolerance.  
These data suggest that chronic inflammation in recurrent spontaneous abortion, 
preterm labor and preeclampsia might disturb the suppressive effects of 
CD4+CD25+ Treg cells resulting in induction of fetal rejection responses (1241).  
 
Taken all together, decidua is a highly complex tissue containing unique, highly 
specialized leukocyte subpopulations for each stage of gestation that may play a 
role in determining the nature of local immune responses at the fetomaternal 
interface. The specific leukocyte composition is controlled at the level of cell 
trafficking with different expression of cellular adhesion molecules involved in 
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leukocyte recruitment which has been demonstrated in the mouse (751). Switches 
in vascular specificity or partial loss of microenvironmental specialization during 
the second half of mouse development result in dramatic changes in leukocyte 
populations recruited to the fetomaternal interface.  
Studies showed a generalized activation of peripheral blood leukocytes in third 
trimester normal pregnancy, which is not reflected in the leukocyte populations 
within the decidua (841). Although a Th2 phenotype predominates within the 
decidua during pregnancy, this is not the case in the peripheral circulation. As the 
vast majority of maternal-fetal interactions during gestation occur within the uterus 
it is not surprising to find a discrepancy in the phenotype of leukocytes between the 
two compartments. 
 
Future studies are needed to get a more integrated understanding of how these 
different cell types in the decidua interact with each other and with trophoblast to 
create the correct environment for implantation to be a success from both the 
maternal and the fetal perspectives. 
 
However, the observation that NK cells and macrophages, and not T and B cells, 
comprise the major population of leukocytes in the uterus lends support to the idea 
that implantation is likely to involve an innate immune system that is distinct from 
that seen in clinical organ transplantation, where rejection is mediated by cells of 
the specific immune system, T and B cells.  
Pregnancy is characterized by the enhancement of the innate immune system and 
suppression of the adaptive immune response (541, 1233). There are accumulating 
evidences in support of this view, for example an increased number of granulocytes 
in maternal blood as well as phenotypic and metabolic changes in granulocytes and 
monocytes including increased expression of adhesion molecules, baseline 
intracellular reactive oxygen, and oxidative burst (997). Moreover, an increased 
concentration of acute phase proteins such as fibrinogen, clotting factors or 
globulin (246) and a shift of the Th1- to Th2-type cytokine profile (205).  
 
Moreover, placental tissue in physiological pregnancies contains a fully organized 
complement system with components C1q, C3d, C4, C5, C6, and C9 detectable (153 
381, 1314). As the placenta as a newly formed organ undergoes the process of 
tissue remodelling, the role of the complement system in the clearing of potentially 
destructive debris products may be essential. Uncontrolled complement activation 
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is prevented in successful pregnancy by the three regulatory proteins DAF, MCP 
and CD59 positioned on the surface of trophoblasts (153, 455, 457, 967).  
 
Deposits of the components were also detected on spiral arteries in normal 
pregnancy with the highest staining for C3d and C9 suggesting that the 
complement system is likely to be activated through the classical pathway (1491). A 
humoral immune response leading to complement activation may thus be involved 
in the physiological changes of spiral arteries in early pregnancy. The terminal C 
complex as the final end product of all three pathways was also found to localize in 
the fibrinoid material of basal decidua, chorionic villi stroma and in vessel walls 
(1405).  
However, the exact way of complement activation in placenta has not been clarified. 
Potential local activators including cellular and tissue debris could be responsible 
(153). Another study demonstrated that normal pregnancy is associated with 
activation of the complement system as determined by increased maternal plasma 
C3a, C4a, and C5a concentrations remaining high from 20 weeks to term gestation 
(1194). 
 
Th1- and Th2-type cytokines produced by maternal T lymphocytes present at 
fetomaternal interface also seem to play a decisive role in the development in 
pregnancy (205, 1309, 1463). Successful pregnancy seems to be associated with the 
predominance of antiinflammatory Th2-type cytokines over proinflammatory Th1-
type cytokines (1463, 1485).  
Murine models and human studies showed that pregnancy rejection or 
complications are mediated by elevated Th1-cytokines and decreased levels of Th2 
cytokines (180, 181, 789, 1115, 1357), whereas an increased Th2-cytokine 
response and decreased levels of Th1 cytokines confers protection (750, 819, 1485). 
It is currently believed that for the continuous normal development of pregnancy 
production of proinflammatory cytokines such as, IL-2, TNF-α and IFN-γ is 
suppressed, whereas production of antiinflammatory cytokines such as IL-4, IL-6 or 
IL-10 is enhanced. Therefore, the conception of Th2 overbalance during pregnancy 
has been a paradigm for immunology of reproduction for many years, while Th1 
activity has been presented as unwanted component.  
However, the broadening knowledge of immunological mechanisms working for 
successful pregnancy and birth of the viable fetus brings nowadays the necessity to 
verify the ‘‘Th2-phenomenon’’ (1485) in favour of conception of ‘‘Th1–Th2 
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cooperation’’ (203) in which Th1 type activity is no longer only destructive 
component of physiological pregnancy. 
 
This fine-tuned cytokine balance between Th1 and Th2 seems to be regulated on 
the intracellular signaling level which is regulated again by a complex of cytokines 
and other factors, for example the JAK/STAT system (1128). Intracellular signals 
from cytokine receptors are mostly transduced via the Janus kinases (JAK) and 
signal transducers and activators of a transcription (STAT) system. Only little is 
known, however, about the specific intracellular signals in decidual lymphocytes 
during pregnancy that may support fetomaternal tolerance. Important regulators of 
cytokine signals in lymphocytes are the suppressors of cytokine signaling (SOCS) 
which are constitutively expressed in naïve T cells (1128). They have also been 
detected in gestational tissues and their differential regulation is associated with 
the onset of labor, but there is no information about their role in decidual 
lymphocytes in pregnancy so far (123). 
 
CD4+ T lymphocytes of Th2-activity are the source of IL-4, IL-5, IL-6, IL-10, IL-13 
and GM-CSF, while CD4+ T lymphocytes of Th1 activity produce mainly IL-1, IL-2, 
IL-12, IL-15, IL-18, IFN-γ and TNF-α (99). 
IL-4, known to be the essential antiinflammatory cytokine for Th2 differentiation 
(365), IL-6 (1348), and IL-10 (1128) are constantly present in high numbers at the 
fetomaternal interface where they are involved in pregnancy-supporting 
mechanisms (365).  
It was also found that peripheral blood lymphocytes of pregnant women in the first 
trimester secrete ‘‘in vitro’’ more Th2, i.e. IL-4, IL-10 and less Th1, i.e. IL-2, IFN-γ 
cytokines compared to non-pregnant patients (879). Also the number of IL-4 
secreting cells rises progressively in the course of pregnancy (887). Probably 
alloantigens localized on trophoblast are the signal for peripheral lymphocytes to 
Th2 activity which is supported by observation that in further trimester peripheral 
lymphocytes of pregnant women differentiated to Th2 cells secreting IL-4 after 
recognition of paternal alloantigens in mixed lymphocyte culture (358).  
 
Studies on mice and humans showed that Th1 activity triggers endometrial 
leucocytes and embryo itself to produce Th2 cytokines, LIF and TGF-β, activates 
angiogenic factors (1401) and endothelial cells, thus preparing maternal tissues for 
embryo implantation (674, 1503). Th1 cytokines stimulate cytolytic activity of 
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decidual NK cells and lymphokine activated killer T lymphocytes which are able to 
restrict excessive trophoblast proliferation and invasion (89).  
 
IFNs, especially upon GM-CSF stimulation, can be secreted by cyto- and 
syncytiotrophoblast. All isoforms of IFNs are present in human placenta, mostly in 
extravillous trophoblast, but also in villous syncytiotrophoblast (1100). They play a 
role of immunomodulators as they can decrease proliferative activity of maternal T 
and B lymphocytes (1463) as well as they cause soluble HLA shedding from the 
surface of trophoblastic cells. Soluble HLA functions as immunosuppressive factor 
for maternal macrophages and cytotoxic lymphocytes (1231). IFNs can also increase 
expression of HLA-G molecules on cytotrophoblast (1463), augment Th2 cytokines 
production, i.e. IL-6, GM-CSF in endometrial stroma and, together with IL-12, IL-
15, IL-18 and VEGF, influences local angiogenesis in uterus (275).  
These facts lead to the hypothesis that Th1 activity plays important role in 
promotion of Th2 response, regulation of placentation process, defense against 
infections and initiation of delivery. Together with Th2 activity it is necessary 
component of immunological reactions during pregnancy (1503). 
 
Th1 cytokines also play a positive role for initiation of labor at term (1503). In the 
sera of delivering women, raised concentrations of IFN-γ and IL-1β were observed 
(159). Th1 cytokines stimulate decidual prostaglandins which are responsible for 
the onset of uterine contractions (1132). Proinflammatory cytokines together with 
mechanical stimuli induce IL-8 production, whose concentration in cervical mucus 
is positively correlated with the progress of cervical ripening and opening (45). 
 
IL-15 and IL-18 are critical cytokines controlling uterine NK cell cytotoxicity by 
upregulation of perforin and FasL expression on human decidual NK cells and 
cytokine production such as GM-CSF, IFN-γ, TNF-α, MIP-1α and MIP-1β (124, 122, 
178, 370, 587, 1421, 785). Moreover, IL-15 has been implicated in differentiation 
and proliferation of uterine NK cells and plays a possible role in induction of IFN-γ 
production as a mediator in vascular remodelling during early pregnancy with its 
highest expression in perivascular cells surrounding the decidual spiral arteries 
(56, 716, 785, 1453). Progesterone induces IL-15 expression and therefore, when 
progesterone levels fall as a result of failing pregnancy, the manifestation of 
apoptotic NK cells could be the result of a decreasing level of IL-15 (828).  
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Similarly, decidual IL-18 enhances innate immunity and both Th1- and Th2-driven 
immune responses via induction of IFN-γ/IL-4/IL-8/IL-13/GM-CSF production 
from T cells, NK cells, B cells and DCs (785, 1002). It might also be essential for 
proper vascularization of the implantation site (274).  
However, there are not only high serum IL-18 levels in pregnant women but also in 
women with implantation failure, fetal growth restriction or recurrent abortions 
(588, 609). An increased level of IL-18 promotes strong NK cell activation and 
probably excessive IFN-γ production (785). It seems that a tight regulation of IL-18 
is important for normal implantation and decidual remodelling in early pregnancy. 
A special role in trophoblast invasion (1117, 1355), endometrial decidualization 
(45), and angiogenesis inside trophoblastic villi (619) is also considered for T cell 
production of LIF (1289). 
 
It has been demonstrated that Th2 cytokines increase the proportion of asymmetric 
antibodies, which are unable to activate effector immune mechanisms such as 
complement fixation, clearance of antigens and phagocytosis (493). It also has been 
established that their synthesis is increased under different conditions involving 
Th2 responses such as pregnancy (104, 864).  
Experiments showed that IL-6 is the main responsible factor for the glycosylation of 
asymmetric IgG molecules and therefore regulates the quality of the humoral 
immune response during pregnancy (172). Gutierrez et al. then hypothesized that 
during pregnancy, in context of a predominant Th2 immune response, the quality of 
IgG antibodies synthesized is modified by IL-6 of placental origin (493). If the IL-6 
levels secreted by placental cell or normal, there is a preferential synthesis of 
asymmetric glycosylated antibodies which have a blocking activity and participate 
in the protection of the fetal antigens whereas if IL-6 levels are abnormal there is a 
predominance of aggressive antibodies (493). 
 
Another factor regulating immune responses during pregnancy in several ways is 
progesterone. It can induce the production of Th2-type cytokines (386, 1378) and of 
LIF and M-CSF production by T cells which is mediated by IL-4 (1116, 1118). 
Moreover, it can decrease Th1 activity of TNF-α in luteal phase endometrial tissue 
(1117) which is both at least partly regulated by increased levels of PIBF (624). As 
urine PIBF concentrations are positively related to pregnancy outcome it could be 
used as one possible marker for predicting pregnancy outcome (1376).  
In summary, results suggest a hormone-cytokine-T cell network at the fetomaternal 
interface with progesterone partly responsible for the T2 switch there. Defects in 
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this network can result in fetal loss. Numerous studies have also demonstrated that 
progesterone via PIBF blocks mitogen-stimulated lymphocyte proliferation, improves 
allograft survival time, reduces NK cell cytotoxicity and modulates antibody 
production besides affecting other phases of the immune response (386, 677, 786, 
1076, 1105, 1376).  
 
What has become clear from investigations is that labor and the post-partum period 
also involves an inflammatory reaction with induction of proinflammatory 
cytokines. The process of cervical ripening is characterized by an influx of 
neutrophils and macrophages, i.e. cells of the innate immune system, and 
increasing production of IL-8, IL-1β, IL-6 and TNF-α in the human cervix (1056, 
1566). An inflammatory response during labor may also help to remove placental 
fragments and prepare the uterus for the pathogens that it will undoubtedly 
encounter during the immediate postpartum period (1105).  
 
These cytokines induce cervical dilatation by production of MMP-1, MMP-3, MMP-9 
and cathepsin S (1480) as well as by increasing production of COX-2 and 
prostaglandin E2 (1105). Furthermore, IL-1β downregulates the expression of TIMP-
2, an endogenous inhibitor of MMP-2, which can digest the collagen and elastin 
fibers in the extracellular matrix of the cervix to further increase cervical 
compliance (1480). Prostaglandin E2 may then further stimulate labor by 
increasing the production of proteinases or indirectly by increasing the permeability 
of blood vessels for leukocyte trafficking (687). NO, another proinflammatory 
mediator that is increased at term, may also contribute to vasodilation in order to 
facilitate leukocyte trafficking (687). 
Increased levels of G-CSF, IL-8 and IL-6 stimulate neutrophils to release more 
proinflammatory cytokines and neutrophil elastase that can digest the extracellular 
matrix produced by cervical fibroblasts. (1274, 1105). These cytokines could be 
used as markers for predicting labor. 
The same proinflammatory cytokines and MMP-9 also stimulate the rupture of the 
membranes above the cervix (44, 1567, 1546). Increased collagenase activity can 
then weaken the strength of the membranes and lower their threshold for rupture.  
Stimulation of amnion and chorion cells with IL-1β and TNF-α also increases the 
production of prostaglandin E2 via COX-2 (1131).  
Prostaglandin E2 may then either cause increased production of MMP-9 (903) or it 
could cross the membranes to stimulate cervical ripening in the cervix or stimulate 
contractions by the myometrium. Hormones and cytokines associated with labor 
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such as cortisol, TNF-α and IL-1β, have been shown to inhibit the production of the 
enzyme 15-hydroxyprostaglandin dehydrogenase by chorion and trophoblast, which 
may contribute to increased prostaglandin production during labor (1095).  
 
The initiation of rhythmic contractions in myometrium is also associated with 
increased number of leukocytes and changes induced by these proinflammatory 
cytokines (1566, 1567). IL-1β and TNF-α stimulate arachidonic acid release, 
activate phospholipid metabolism, and increase the production of prostaglandins by 
the myometrial cells similar to oxytocin effects (957, 958, 1419). IL-1β and TNF-α 
can also increase the production of MMP-9 by myometrial cells, which may be 
important for detachment of the placenta (1212). 
IL-6 has no effect on prostaglandin production by myometrial cells (1419) and is 
unable to stimulate myometrial contractions. However, this cytokine may play a 
role in labor by increasing the expression of oxytocin receptors on myometrial cells 
(1176) and like IL-1β, it can also increase oxytocin secretion by myometrial cells 
(428).  
 
The post-partum period of about one year has been considered as a time for 
immunological recovery from the profound immunological changes of pregnancy. 
The immunology of the post-partum period is often viewed as a restoration of 
Th1/Th2 balance, which has been useful, but not the only explanatory model in 
explaining autoimmune diseases such as rheumatoid arthritis as Th1-driven 
diseases which remit during pregnancy but exacerbate during the post-partum 
period (482). 
Delivery is associated with increased serum levels of inflammatory cytokines such 
as IL-6 and IL-1 (256). The early post-partum period is also characterized by 
upregulatory inflammatory responses. Both Th1 and Th2 ex vivo cytokine 
production rise during the post-partum compared to pregnancy, with increased 
Th1/Th2 ratios observed through post-partum months 1 to 12 (1300). Watanabe et 
al. found increased levels of Th cells, CTLs and NK cell subsets with weak 
cytotoxicity (CD16+ CD57+) in the first months post partum (1479). An increase of 
suppressor T cells and CD5+ B cells followed during month 7 to 10 post partum 
which may also be related to the postpartum aggravation of autoimmune diseases 
(1479). The three immune activation markers neopterin, soluble IL-2 receptor, both 
elevated during allograft rejection or autoimmune disorders, and soluble CD8 
antigen were found elevated at delivery and post partum (162). In a recent study by 
Groer et al. every serum cytokine measured and all proinflammatory macrophage 
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and acute phase proteins (TNF-a, IL-6, CRP, and neopterin) are higher in post-
partum mothers along with a higher lymphocyte proliferative response and the 
secretion of higher levels of S-IgA (482).  
 
All these data suggest a broad state of immune activation and an upregulated 
general and mucosal immunity whose functions are unclear at this time. One can 
speculate that innate inflammatory activation is both protective and related to the 
stage of uterine involution. There is increased risk for maternal uterine 
contamination during birth, and the endometrium is protected from infection by 
activated macrophages. Uterine involution is associated with myometrial shrinkage, 
elimination of microorganisms, and repair and restoration of the endometrium 
which is also associated with both apoptosis and proliferation. This process 
probably involves inflammatory and immune mediators (482).  
2. Disturbances in maternal-fetal interactions 
Pathological conditions during pregnancy including preeclampsia, IUGR, PTL and 
RSA are some of the leading causes of maternal and fetal morbidity and mortality 
worldwide. Latest studies suppose a common etiology for these pregnancy disorders 
as they are characterized by similar histological features (885). The endpoint of all 
disorders may be placental ischemia and inflammation due to an inadequate 
trophoblast invasion and defect remodelling of spiral arteries.  
 
Studies on the etiology of IUGR are rare compared to the other pregnancy disorders. 
Results propose an activated state of the immune system with higher serum levels 
of B lymphocytes and antibodies as well as CD4+ T cells (83, 886, 947, 1272) as 
compared to healthy pregnancies  
Concerning cytokine levels, Bartha et al. found in their study that serum TNF-α is 
increased in women with IUGR and placental insufficiency but normal in those with 
IUGR and normal placental perfusion (84) suggesting that elevations of TNF-α could 
be a specific phenomenon of certain subsets of IUGR with placental dysfunction. 
This was supported by the study of Holcberg et al. who reported a correlation 
between increased placental TNF-α secretion and an abnormal placental perfusion 
due to vasoconstriction of the fetal placental vascular bed (560). The study of 
Walther et al. detected serum autoantibody against the angiotensin type 1 receptor 
in a high percentage of pregnant women with preeclampsia and IUGR (1472). This 
autoantibody may be causative for pathological uteroplacental perfusion and thus 
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be associated with distinct types of pregnancy disorders rsulting from impaired 
placental development.  
Further studies have to be undertaken if it could serve as an early marker for these 
disorders. 
a) Preeclampsia 
Preeclampsia, the occurrence of acute hypertension during pregnancy, is still a 
leading cause of maternal and fetal death worldwide affecting about 3-7% of all 
pregnancies (1202). To date, there is no reliable, costeffective screening test for this 
disease, and there are also no widely accepted or proven measures for primary 
prevention. 
Its histological signs comprise restrained trophoblast invasion, vasculitis, 
thrombosis and placental ischemia which resembles features of other obstetric 
complications like IUGR, RSA or abruptio placentae. The question is if these 
separate clinical entities might have a common immunological etiology (885).  
 
Current hypotheses regarding its etiology focus on maladaptation of immune 
responses and defective trophoblast invasion. Researchers suppose that an 
excessive maternal inflammatory response directed against foreign fetal antigens 
results in shallow trophoblast invasion, defective spiral artery remodelling, and 
placental infarction which results in the release of proinflammatory cytokines and 
placental fragments into the systemic circulation and finally in endothelial 
activation (1203). An abnormal maternal immune response in the sense of an acute 
allograft rejection was already implicated in earlier studies (717). A recent paper by 
Feinberg presents the thesis of a minimal excess of placental immune complex 
production versus removal as the cause of a proinflammatory autoamplification 
cascade of trophoblast apoptosis and oxidative stress, culminating in clinical 
preeclampsia (388).  
 
For years, there have been discussions on the question of primiparity versus 
primipaternity in the etiology of preeclampsia (202, 911). For some researchers, 
preeclampsia is associated with the first pregnancy, with oxidative stress as the 
main cause of vascular defects. For others, it may be associated with the first 
pregnancy with a particular father.  
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The first occurrence of preeclampsia, or its recurrence in primiparous women, 
seems to be associated with a change of partner (1207, 1208). Furthermore, its 
incidence is inversely correlated with the duration of sexual cohabitation (1206). In 
other studies oral sex seemed to be protective; a possible immunological 
explanation may be that both local and, more important, systemic tolerance can be 
obtained by oral administration of an antigen. 
Although exposure to paternal antigens through a prior pregnancy has a protective 
effect against development of preeclampsia, exposure to new or different paternal 
antigens as a result of change in paternity is associated with an altered risk of 
preeclampsia (813). 
Certain reproductive practices that minimize maternal exposure to seminal fluid are 
associated with increased risk of preeclampsia which include barrier contraception, 
brief sexual cohabitation, nonpartner donor insemination, oocyte embryo donation, 
absence of preconceptual oral sex, or intracytoplasmic sperm injection with 
surgically obtained sperm (1208). Thus, an accumulating body of epidemiological 
evidence points convincingly toward an immunogenetic basis for preeclampsia. 
 
Perhaps the greatest barrier to enlighten the etiology of preeclampsia is the still 
incomplete understanding of the immunological basis for normal pregnancy. The 
success of human reproduction depends on the ability of the mother and fetus to 
control allogeneic immune responses through multiple, overlapping mechanisms, 
while maintaining the capacity to mount defense against infectious organisms 
(726). Evidence suggests that site-specific suppression, whereby maternal immune 
responses are controlled locally at the maternal-fetal interface, plays a fundamental 
role (726).  
As mentioned above, in normal pregnancy, the ratio of proinflammatory Th1 to 
suppressor Th2 lymphocytes is shifted toward the suppressor phenotype, which is 
believed to facilitate maternal immune tolerance of the fetus by suppressing activity 
of the cytotoxic Th1 cytokines, which are capable of attacking the fetal allograft and 
impairing trophoblastic invasion (1240, 1485).  
Studies revealed that endothelial dysfunction in preeclampsia is found to be 
associated with excessive release of Th1 cytokines like TNF-α, IFN-γ, IL-1, IL-2 and 
IL-8 found in PBMC and placenta as well as a deficiency in IL-10 (540, 885, 1242, 
1459, 1504).  
High levels of IFN-γ, together with TNF-α, can lead to apoptosis of trophoblast (954) 
which makes them major contributors to many of the local and systemic changes 
that characterize preeclampsia. Studies of Mor et al. and Pijnenborg et al. propose 
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that activated macrophages in the placental bed secrete TNF-α and IFN-γ, inducing 
trophoblast apoptosis (963, 1122). These macrophages show characteristic changes 
in distribution compared to normal pregnancies and are located within and around 
the spiral arteries separating them from the trophoblast cells (1188). Instead of 
facilitating trophoblast invasion through the placental bed macrophages seem to 
function as a barrier for trophoblast invasion and differentiation by inducing 
trophoblast apoptosis and therefore preventing spiral arteries transformation in 
pathologic conditions (1188).  
Increased trophoblast apoptosis would increase the amount of trophoblast debris, 
syncytical knots, which leak into the maternal circulation and generate a systemic 
endothelial activation as seen in preeclampsia (1256). Trophoblast debris can 
activate TNF-α and IL-12 production from monocytes in vitro, which further pushes 
the systemic immune response towards excessive inflammation instead of a normal 
immune activity.  
 
Consistent with that, Reimer et al. reported an upregulated leptin expression in 
placental tissue of preeclampsia (1185) which could partly explain the production of 
large amounts of IFN and IL-2, and decrease of IL-4 production (830).  
The search for useful markers in preeclampsia have brought up serum granulysin 
for evaluation of Th1/Th2 balance by Sakai et al. (1244) and soluble IL-2 receptor 
in plasma by Eneroth et al. (368), which has to be further evaluated. 
 
Despite the fact that there is a shift to a Th1 response in preeclampsia, 
accompanied by a systemic inflammatory response, there is also a marked systemic 
inflammatory response in normal pregnancy and the Th1/Th2 paradigm has been 
put into question as too simplistic (1485). The state of preeclampsia could be seen 
as an exacerbation of the inflammation during normal pregnancy as the paper of 
Redman and Sargent does (911, 1181). They demonstrated that the first signs of a 
systemic inflammatory cytokine response characteristic of pregnancy begin before 
implantation, and deduce that its origins may not necessarily involve immune 
recognition of the fetal allograft. Their data show that the predominant changes are 
in NK and NKT cell populations, whereas T lymphocytes show minimal or no 
changes. These changes are observed especially for IL-18, which is interesting since 
there is a Th1 storm in fulminant preeclampsia characterized by excess IL-18 which 
with IL-12 stimulates IFN-γ secretion and creates a vicious loop (1181). 
They then presented data suggesting the systemic stimulus triggering the innate 
immune system is due to the circulating fetal cells in maternal blood, plus the 
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release of placental debris from syncytiotrophoblast (1181). This shedding of 
syncytiotrophoblast microparticles is increased in preeclampsia; and these 
syncytiotrophoblast microvillous membrane particles increasingly bind to maternal 
DCs. They likely interact with TLRs, and thus trigger Th1 cytokine production. 
 
Preeclampsia is also characterized by systemic changes in the distribution of 
lymphocyte populations in peripheral blood. Sakai et al. investigated CD4+CD25+ 
Treg cells, and the ratio of CD4+CD25bright/CD4+ cells is markedly decreased in 
preeclampsia cases compared to normal pregnancy subjects and even nonpregnant 
controls (911). Also there is a general consensus that there are increased levels of 
activated/memory cells (CD4+CD25RO+ and CD4+CD29+) and decreased levels of 
naïve/suppressor cells (CD4+CD45RA+) (885, 886) whereas there is a switch to 
naïve/suppressor T cells in normal pregnancy.  
A possible explanation might be that antigens have activated these T cells in 
preeclampsia, indicating inflammatory activity. Reports also characterized 
lymphocyte subsets in decidua of patients with preeclampsia and reported an 
increased percentage of CD3-/CD56+CD16+ NK cells and cytotoxic CD8+/CD28+ T 
cells and a decreased percentage of T CD3+, B CD19+, and suppressor/inducer T 
CD4+/CD45RA+ lymphocyte subsets (1335, 1504). Systemic immunological 
deviation towards suppression seen during normal pregnancy is absent not only in 
peripheral blood but also locally in decidua of preeclamptic women. Moreover, it is 
consistent with the dominance of Th1 cytokine activation in preeclampsia which 
stimulates NK cells and CTLs.  
 
Some investigators have proposed that preeclampsia represents a defect in 
immunological masking that normally allows trophoblast cells to evade maternal 
immune recognition. Lim et al. already described a dysregulation of the expression 
of HLA-G and MMP-9 on human trophoblast in preeclampsia (818). Dekker et al. 
suggested in their hypothesis that lower expression of HLA-G on trophoblast could 
result in local IFN-γ- and NK cell upregulation which may be the main factors for 
pregnancy failure in preeclampsia (317). Defects in the immunosuppressive 
functions of HLA-G contributing to the control CD4+ and CD8+ T cell activity in 
preeclampsia may alter the local cytokine profile which is normally controlled by T 
cells (795). 
Kim et al. evaluated the expression pattern of TLR4 and TLR2 at the fetomaternal 
interface, the placental bed, both in normal and complicated pregnancies (694). 
TLR4 protein expression was found to be increased in interstitial trophoblasts of 
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patients with preeclampsia which suggests that dangerous host or microbial signals 
at the feto-maternal interface, which are recognized by trophoblasts through TLR4, 
may play a key role in creating a local abnormal cytokine milieu leading to the 
development of preeclampsia. 
 
To conclude, preeclampsia is based on a cascade of complex immunological events 
originating from placenta. During normal pregnancy, trophoblast cells interact with 
uterine NK cells, modifying their cytokine repertoire which results in cellular 
homeostasis and angiogenesis. Preeclampsia is characterized by the inability of the 
trophoblast to accomplish this. Trophoblast apoptosis prevents adequate 
trophoblast invasion into decidua and results in defect remodelling of spiral 
arteries, hypoxia, placental ischemia and an excessive inflammatory reaction. 
Leakage of increasing amounts of placental fragments and cytokines into the 
maternal circulation and a systemic endothelial activation lead to the clinical signs 
of preeclampsia.  
Important for future studies are the further identification of these complex immune 
factors, perhaps with the help of animal studies, and to discover possible early 
markers for preeclampsia. Treatment options of preeclampsia which are still 
focused on signs like hypertension could be widened with respect to modification of 
immune responses (388). 
b) Preterm labor and preterm birth 
PTL and preterm birth, defined as labor or birth before 37 weeks gestation, is the 
major cause of perinatal mortality and morbidity in the developed world. It is 
preceded in 30% by PPROM, which is defined as membrane rupture prior to 37 
weeks gestation (1105).  
Infection is considered as the most significant cause of spontaneous PTL and 
preterm birth in up to 50% of all cases (826, 839). Inflammation at the maternal-
fetal interface, mediated by proinflammatory cytokines including TNF-α and IL-1β 
(345, 346, 1105, 1187), is considered as the main common component and can be 
caused by intrauterine infections, lower genital infections or distant infections such 
as periodontitis in pregnancy (781). Animal studies showed that treatment with IL-
1β was able to mimic the effects of bacteria and induced PTL, suggesting a causal 
role for this cytokine in infection-induced PTL (71, 478, 1216).  
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Recent human studies have demonstrated that fetal carriage of a polymorphism in 
the IL-1 receptor antagonist gene was associated with elevated second-trimester 
intraamniotic IL-1β levels and an increased rate of spontaneous preterm birth 
(1521) as well as a history of spontaneous abortions (1109). The group of Kalish et 
al. also demonstrated that fetal carriage of polymorphisms in genes coding for IL-1 
receptor antagonist (649), IL-4 (651), and TNF-α (650, 856), as well as a maternal 
IL-4 polymorphism (651) was associated with PPROM and preterm birth in 
multifetal gestations. This is a promising area for future research.  
 
However, recent findings also indicate that midgestation maternal immune 
hyporesponsiveness, as represented by low cervicovaginal concentrations of various 
proinflammatory cytokines, constitute an increased risk for subsequent preterm 
delivery among women with lower genital tract pathological microflora (1308). 
Kalinka et al. reported in their study that the highest risk of preterm delivery was 
observed among women with low cervicovaginal concentrations of IL-1α and IL-1β; 
lower but still elevated risk was found for women with genital tract infection and 
low cervicovaginal levels of IL-6 and IL-8 (648). The increased risk for preterm 
delivery was found only in the group of women with lower genital tract infection 
who had low cervicovaginal concentrations of proinflammatory cytokines. The latter 
condition may also imply a lower reactivity of the maternal immune system that 
should normally result in diminishing the growth of pathological bacteria in the 
genitourinary tract (648). Probably, pregnant women with no adequate, i.e. hypo- or 
hyperimmune responses, are at risk for subsequent infection-related preterm birth. 
 
Intrauterine infections are mostly subclinical (1230) and polymicrobial with 
Ureaplasma urealyticum, Mycoplasma hominis, group B streptococci, G. vaginalis 
and gram-negative bacteria such as Escherichia coli as the most common pathogens 
associated with PTL (445, 1030, 1235). Depending on which laboratory technique is 
performed, prevalences of intraamniotic infection in the setting of PTL range from 0-
24% to 30-55% (451, 721). The main mechanism of this infection is ascending 
microbial invasion by lower genital tract organisms which could produce local 
inflammation caused by proinflammatory cytokines and prostaglandins (676, 1306), 
i.e. subclinical chorioamnionitis leading to PPROM, PTL and possibly preterm birth 
(1306). Important to mention is also the higher probability of respiratory distress, 
sepsis and cerebral palsy in preterm infants due to fetal inflammatory responses in 
cases of clinical chorioamnionitis (721).  
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Once intraamniotic infection is diagnosed, the standard care is administration of 
intravenous antibiotics and delivery regardless of gestational age (721). However, a 
recent meta-analysis assessing 11 trials among 7428 patients in PTL with intact 
membranes showed that overall use of antibiotics did not decrease preterm birth or 
perinatal morbidity (710). Routine administration of antibiotics to women with 
preterm labor and intact membranes is therefore not recommended as there are no 
clear improvements in neonatal outcomes.  
 
Trichomoniasis has recently been associated with a significantly increased risk of 
PPROM and preterm delivery in several studies (259, 950). Surprisingly, the 
randomized study of Klebanoff et al. reported an even increased risk of preterm 
birth in patients with asymptomatic trichomoniasis who were treated with 
metronidazole (718). A possible explanation may be that dying trichomonads could 
release inflammatory mediators that trigger PTL. 
 
The results of this study may be difficult to extrapolate to the clinical care of the 
pregnant woman with trichomoniasis as only women with asymptomatic infections 
were included in the study and much higher doses of metronidazole were used than 
is the standard of care. It is possible that the latter in some manner had an impact 
on preterm birth rates. It is also possible that women with symptomatic 
trichomoniasis may have a different response to treatment than women with 
asymptomatic infection as a result of organism burden or host factors.  
Similar results with increased low birth weight and a trend towards increased 
preterm birth were reported from a recent randomized trial from Uganda (693). 
Further studies may be warranted to resolve the conflicting findings. Only 
symptomatic trichomoniasis should therefore be treated during pregnancy (721). 
 
Also BV is associated with a twofold increased risk of preterm birth among other 
pregnancy complications, presenting the greatest risk when detected before 16 
weeks` gestation (548, 802). This implies a critical period during early gestation 
where pathogens can ascend the genital tract.  
 
The results of treatment trials for pregnant women with BV have been inconsistent. 
Two meta-analyses revealed no reduction in overall preterm birth with routine 
screening and treatment for BV (803, 898). In both studies, however, oral BV 
treatment led to a decrease in PPROM and low birth weight in a subgroup of 
patients with a history of preterm birth.  
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In the study by Lamont et al., treatment of low-risk women with BV with a 
intravaginal clindamycin cream resulted in a decrease of preterm birth (780). 
Another trial with oral clindamycin showed similar results (1433). Different in those 
two trials compared to others was that all patients were enrolled and treated before 
22 weeks of gestation which suggests that early treatment of BV may be the key to 
prevention of preterm birth.These results have to be proved in high-risk populations 
such as women with prior preterm delivery.  
 
Other vaginal colonization including Candida, U. urealyticum and group B 
streptococci have not found to be associated with increased risks for preterm birth 
(176, 258, 719) whereas infection with C. trachomatis or N. gonorrheae doubled the 
risk for preterm birth (36, 363). 
 
Future treatment options against PTL and the resulting neonatal morbidity could 
include the antiinflammatory cytokine IL-10 or progesterone as animal studies 
showed (552, 1105, 1200, 1407). IL-10 may function by decreasing LPS-stimulated 
IL-1β that could prevent the induction of COX-2 and ultimately lead to decreased 
prostaglandin E2 in the gestational tissues (147). Furthermore, IL-10 blocked IL-1β-
induced PTL in rhesus monkeys, probably mediated by a decrease in prostaglandin 
E2 production (1236). In women with a history of preterm birth, the weekly 
injection of synthetic progestin, 17α-OH progesterone-caproate, significantly 
reduced the rate of delivery at 30, 32, or 37 weeks gestation (913).  
c) Early pregnancy loss 
The physiology of human reproduction, including the immune mechanisms that 
permit pregnancy, is extremely complex and inefficient. Spontaneous abortion is 
with 15% of all clinically recognised pregnancies the most common adverse 
reproductive outcome in women. A highly sensitive C-terminal peptide of hCG assay 
for pregnancy indicates that an additional 20% of conceptions terminate as “occult 
losses” before pregnancy is detected clinically (1502). 
RSA is defined as two consecutive or more than three spontaneous abortions prior 
to the 20th week of gestation and occurs in approximately 1 to 3% of women with 
diagnosed pregnancies (457). 
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Generally, the causes of spontaneous abortion are classified as genetic, 
endocrinologic, anatomic or microbiologic. After excluding those etiologies, however, 
still 40-50% of all cases remain unexplained (343). A probable explanation for those 
cases is that recurrent reproductive wastage had occurred as a result of 
immunologic failure.  
Clinical observations suggest that genetic and immunologic disparity could be a 
factor in fecundity. This theory is based on earlier clinical observations, as for 
example a change of partner can sometimes solve the problem (97) or women who 
have had RSA reject their partner`s skin graft less quickly (77). As the HLA system 
is the basis of this disparity, the immunologic hypothesis suggests that HLA-
sharing induces a weaker tolerance response which leads to rejection of the fetus. 
Studies have shown that fetuses whose HLA alleles do not differ from maternal 
alleles are more likely to be aborted than histoincompatible fetuses (738, 1038).  
 
Concerning evaluation of research in this field, there have to be mentioned some 
general problems. It is likely that there is more than one immune cause of RSA, 
which may include recognition of paternal antigens on the feto-placental unit by the 
maternal immune system followed by destruction of the fetus, although actual 
evidence for this in humans is limited. A population of women with unexplained 
RSA is likely to comprise subsets with RSA of different etiologies.  
As most published studies only involve a small number of women it is possible that 
some differences are also due to the fact that different populations of women with 
RSA have been selected. This is inevitable because the recruitment of patients is 
difficult.  
One of the problems in understanding the underlying etiology of this immune 
failure is that the mechanisms by which the fetus is protected from the maternal 
immune system during normal pregnancy are not fully understood. 
 
Immunological rejection of the fetus due to recognition of paternal antigens by the 
maternal immune system, resulting in abnormal immune cells and cytokine 
production, is postulated to be one cause of unexplained pregnancy loss. To study 
the role of these immune cells and molecules in the etiology of RSA, it would need 
placental tissue during the first trimester of human pregnancy which is clearly not 
possible (776).  
Various alternative approaches have been adopted instead including the analysis of 
immune cell populations and cytokines in the peripheral blood of women with RSA 
and normal fertile women either before pregnancy or at the time of miscarriage. 
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Moreover, studies use endometrial tissue obtained from women with RSA and 
normal fertile women in the periimplantation period in the nonpregnant state, or 
placental tissue obtained at the time of miscarriage from women with a history of 
RSA, from women with spontaneous abortions and from women requesting 
terminations of normal pregnancy (776).  
 
While the study of placental tissue might appear to be the best approach, there are 
difficulties, particularly with respect to components of the immune system, in 
determining whether observed differences are due to proinflammatory events as a 
consequence of the miscarriage.  
One must also emphasize the importance of compartment, i.e. either peripheral 
blood, endometrium or decidua in which the cells and molecules are measured, and 
the timing of the sampling, both with respect to the menstrual cycle and pregnancy. 
Both has critical relevance for the interpretation of results. The measurement of 
factors such as cytokines in peripheral blood may have little significance as this 
compartment is far removed from where the important interactions are taking 
place. In addition, the peripheral blood cell population is considerably different to 
that in the endometrium and decidua. The timing of sampling is also important, 
both with respect to the point in the menstrual cycle and pregnancy and whether it 
is at the time or just after miscarriage, as both of these factors will affect the 
expression of these cells and molecules. 
 
Recurrent miscarriage is normally defined as a loss of three or more miscarriages, 
but some studies also include women with only two miscarriages. In addition, the 
timing of the fetal loss may differ between studies and may result in the study of 
different populations. It must not be neglected as well that immune mechanisms 
responsible for infertility which is further discussed in an extra chapter and early 
pregnancy loss might overlap. 
Moreover, there is a tendency to extrapolate directly from animal models, 
particularly those of rodents, to humans, and this has led to assumptions of 
mechanisms for which the evidence is incomplete.  
Lastly, it has recently been suggested that the importance of chromosomal 
abnormalities in RSA has been vastly underestimated (1154). Karyotyping of the 
fetus is also important, and should be carried out in future studies so that 
miscarriages which result from chromosomally abnormal pregnancies can be 
considered separately from those resulting from chromosomally normal 
pregnancies.  
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Concerning NK cells as the predominant leukocyte population in decidua during 
early pregnancy, there are partly inconsistent results in patients with RSA.  
Whereas normal human pregnancy is characterized by a decreasing peripheral NK 
cell activity during first trimester, several studies have shown increased numbers of 
CD56+ NK cells in the peripheral blood of women with RSA either prior to or during 
pregnancy compared with healthy fertile nonpregnant or pregnant controls (38, 
766, 1111). A significantly increased number of circulating CD56+ NK cells was also 
found in RSA women who miscarried compared with RSA women who delivered 
(1365) and other studies have also shown that levels of peripheral blood CD56+ 
cells both prior to and during pregnancy can predict pregnancy outcome in women 
with RSA (262).  
However, another study by Yamamoto et al. has shown no differences in the levels 
of peripheral blood CD56+ CD16+ NK cells in normal pregnancies and missed 
abortions with normal and abnormal chromosomes (1553) 
 
In contrast to the increased numbers of CD56+ cells in peripheral blood, a 
decreased number of decidual CD56+ NK cells are reported in the placental tissue 
from spontaneous miscarriages in RSA women compared with tissue from 
spontaneous miscarriages in women without RSA and women requesting 
termination (1150). Vassiliadou and Bulmer reported a decreased cytotoxic 
capability of decidual CD56+ NK cells in placental tissue from spontaneous aborters 
(1447), though women with RSA were not included in this study. 
The fact that there appears to be decreased numbers of CD56+ cells in the decidua 
and increased numbers in the endometrium could be due to the presence of two 
different populations of CD56+ cells, either CD16+ or CD16- (776). The increased 
number in the endometrium could be due to CD56+, CD16+ cells as suggested 
previously while the decreased number reported in decidua could be the CD56+, 
CD16- population, which is supported by the study showing increased numbers of 
CD16+ cells in early pregnancy deciduas of women with RSA (367). 
 
Studies have shown increased numbers of CD56+ cells among a general increase of 
various lymphocyte populations (CD4+, CD8+, CD14+, CD16+/CD56+) in the non-
pregnant endometrium of women with RSA, and lower numbers were seen in 
women with RSA who subsequently had a live birth compared with those who 
miscarried (773, 1153). This is in contrast to a flow cytometric study which showed 
similar numbers of CD56+ cells in the endometrium of women with RSA and control 
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subjects, although the women with RSA did have increased numbers of endometrial 
CD56dim CD16+ cells compared with control subjects (772).  
However, the latter report suggested that CD3+ cells were the major leukocytes 
within the endometrial leukocyte population, both in women with RSA and fertile 
controls. This is in disagreement with numerous in vivo immunocytochemical 
studies and suggests that flow cytometry may not be the best means of studying 
these endometrial leukocyte populations (776). 
 
These results suggest that there are alterations in the CD56+ population of 
leukocytes in women with RSA but whether these are increased or decreased 
depends on whether peripheral blood, first-trimester decidua or periimplantation 
endometrium is analysed (776). There are many reports that support a relationship 
between elevated peripheral NK cell numbers and/or activity and RSA which means 
that an abnormal increase in peripheral NK cell parameters prior to conception and 
during early pregnancy is causally associated with RSA. Recent studies further 
suggest that a divergence of the specific NK cell repertoire in peripheral blood might 
be related to the etiology of RSA (1031, 1032, 1552). Therefore, it is proposed that 
women with alloimmune abortions have a limited inhibitory NK cell receptor 
repertoire resulting in the recognition of trophoblast HLA class I molecules by 
decidual NK cells. The relationship between uterine NK cell populations and RSA is 
still unclear. 
 
Results concerning the numbers of CD3+ T cells as the second most abundant 
population in endometrium and decidua in RSA patients are also partly 
inconsistent.  
Studies showed no differences in numbers of CD3+ T cells in peripheral blood of 
RSA and normal fertile women prior to pregnancy (1549); others a significantly 
decreased number of CD3+ T cells in the peripheral blood of pregnant women with 
RSA who subsequently miscarried compared with those who had a live birth and 
normal pregnant controls (766). When investigating the CD56+ subpopulation of 
CD3+ T cells a decrease in the number of CD56+CD3+ cells in the peripheral blood 
prior to pregnancy was shown (1549).  
Similarly, no differences in the numbers of CD3+ T cells in endometrium and early 
pregnancy decidua from RSA and control women have been reported (772, 1448, 
1150) whereas a decreased number of CD56+CD3+ cells in the decidua of women 
with RSA compared with control women has been reported (1549). 
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Thus, although there appear to be no differences in the total T cell numbers in 
women with RSA, there may be differences in subpopulations of T cells which may 
be important. This is also suggested by studies investigating the relationship 
between prevalence of protein components of their TCR and RSA (40, 231, 1374, 
1447). 
In a study by Jablonowska et al. they investigated lymphocyte subsets in 
peripheral blood of women with history of unexplained RSA during the first 
trimester of pregnancy and found significant changes in T cell subpopulations in 
pregnant RSA women (606). Interestingly, the proportions of T helper/memory cells 
(CD4+CD45RO+), T-killer/effector cells (CD8+ S6F1+), and HLA-DR positive T cells 
(CD3+ HLA-DR+), all markers of T cell activation, were increased compared with 
normal pregnant controls. In contrast, the T-suppressor/inducer population (CD4+ 
CD45RA+) was decreased compared with normal pregnant controls. 
Thus, RSA women reveal the opposite phenotype compared to the state of 
suppression/non-activation during normal pregnancy, indicating that women with 
RSA have an activated immune system during pregnancy (854). However, it is not 
known whether this aberration in T cell subsets is pathogenetically involved in RSA, 
or whether it represents an epiphenomenon (606). Also the proportion and number 
of B cells (CD19+) were found to be significantly increased in the first trimester of 
pregnancy in RSA women compared with normal pregnant controls (606). 
 
Studies in rodents, carried out by Wegmann and colleagues during the early 
1990s, have provided strong evidence that successful pregnancy is associated with 
a predominant Th2 cytokine profile, and that Th1 cytokines are detrimental to 
pregnancy (1485) and recent data from human experience confirm that. More 
recently, it has been suggested that even in mice the Th1/Th2 hypothesis 
represents an oversimplification of the situation, and the importance of other 
cytokines has been acknowledged (205). 
 
The evidence for an abnormal Th1 cellular immune response with higher levels of 
IFN-γ and lower levels of IL-6 and IL-10 to reproductive antigens in women with 
RSA seems convincing (545, 799, 862, 1159). PBMCs from women with RSA 
produce TNF-α and IFN-γ in response to stimulation from trophoblast cell extracts, 
while cells from healthy nonpregnant women and men produced IL-10 (546).  
Similar studies have also shown decreased production of IL-4, IL-5, IL-6 and IL-10 
and increased production of IFN-γ, IL-2, TNF-α and TNF-β in supernatants of 
phorbol-12-myristate-13-acetate-stimulated PBMCs obtained from women with RSA 
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at the time of miscarriage compared with stimulated PBMCs obtained during the 
first trimester of ongoing pregnancies in women with a normal reproductive history 
(1160).  
However, a recent study of cytokine production by peripheral blood cells of women 
with RSA taken during early pregnancy before miscarriage, has shown opposite 
effects with increased IL-4 and IL-10 and decreased IFN-γ in women with RSA (85). 
In contrast to other studies, the results of this study are not complicated by 
comparing results from blood samples taken with and without miscarriage and 
during the first trimester of pregnancy and at birth, both of which are likely to affect 
cytokine production. 
 
There is also some evidence for differences in endometrial and decidual Th1 and 
Th2 cytokine production in RSA patients (819, 1115), and in particular decreased 
production of cytokines such as IL-4, IL-6 and IL-10. However, although the cells in 
this study originated from the decidua, they underwent considerable in vitro 
manipulations before cytokine measurement (1115). In addition, the T cell 
population from which these clones were derived comprises only a small percentage 
of cytokine-producing cells in the decidua. 
 
TNF-α with its elevated levels in RSA patients is proposed to play a central role in 
triggering immunological pregnancy loss and implantation failure (204, 1420, 1424, 
1542). It might have a toxic effect on blastocyst and uterine cells (1068) and is 
involved in the pathogenesis of stress-induced early embryonic death as 
experiments with mice showed (41, 470, 1425). Recently, there is also the 
hypothesis that LIF as another proinflammatory cytokine may be involved in 
mediating TNF-α-induced stress-induced early embryonic death (1426). LIF 
knockout mice were shown to produce normal blastocysts but implantation of the 
embryos did not occur (1355). When transferred to wild-type pseudopregnant 
recipients, the blastocysts can implant and develop. These results suggest that the 
implantation failure in LIF-deficient mice was not due to some defects specific to the 
embryos but to those arising in the uterus which resulted in the total loss of its 
receptivity.  
There is the possibility that LIF signaling may be affected due to alterations in TNF-
α expression. Observations showed that LIF must be expressed in the uterus at the 
right time and at the right level, with activated receptors and signaling pathways, to 
guarantee a successful implantation (216). Data reported that a sustained 
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increased TNF-α expression in the reproductive tract of females exposed to stress 
can alter the temporal pattern of LIF expression (216). 
 
As already mentioned, there has been an increased interest in newly identified 
cytokines such as IL-12, IL-15, IL-16, IL-17 and IL-18 in relation with RSA. 
Elevated serum levels of IL-12 and IL-18 were found in RSA patients who 
miscarried compared to healthy or delivering RSA women (1509, 1510). IL-12 is 
known to be a Th1-inducer cytokine and IL-18 can synergize with IL-12 in the 
induction of Th1 immune response resulting in pregnancy loss (991). 
The endometrium of women with RSA also expresses elevated levels of IL-13 and IL-
15 which might induce a proliferative response in decidual NK cells and augment 
their cytolytic activity (209). These findings await further investigation.  
The role of other cytokines and growth factors have also gained interest. Decreased 
levels of CSF-1 (468, 1133), GM-CSF (1110, 1133) and TGF-β2 (798) in patients 
with RSA compared to healthy women seem to be associated with pregnancy failure. 
However, there are too few studies to evaluate the role of these cytokines exactly. 
 
Similar to the case of unexplained infertility, a high percentage of unexplained RSA 
cases is found to be associated with certain autoimmune and alloimmune 
antibodies that may play major role in the immunologic failure of pregnancy and 
may lead to abortion (1071).  
A variety of autoimmune antibodies have been found at increased frequencies in 
women with recurrent pregnancy failures as for example different types of APA, 
including Lupus anticoagulant, anticardiolipin β2-glycoprotein IgG/IgM/IgA, 
anticardiolipin IgG/IgM/IgA, anti-phosphatidylserine prothombin IgG/IgM, and 
anti-phosphatidylethanolamine IgG/IgM (863, 1462, 1550), as well as a higher 
incidence of ANA (1365), ATA (164) and anti-endothelial cell antibodies (1221). 
 
Investigators also reported the absence or decreased expression of the protective 
alloantibodies APCA (11, 517, 1054), Ab2 (603, 1069, 1070) and MLR-Bf (6, 1072, 
1394) in patients with RSA which might attribute as another cause to RSA of 
unknown etiology. However, there are also several studies which reported that 
MLR-Bf does not play protective role in the maintenance of pregnancy, for example 
by Jablonowska et al. who observed that blocking antibodies have no predictive 
value for the pregnancy outcome in RSA patients (605). 
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There are some other interesting approaches concerning further immunological 
explanations of unexplained RSA which should also be mentioned but still need 
further evaluation.  
A fully active complement system is present in the placenta and protects both the 
fetus and the mother against infectious and other toxic agents. As fetal tissues are 
semi-allogeneic and alloantibodies commonly develop in the mother, the placenta is 
potentially subject to complement-mediated immune attack at the feto–maternal 
interface with the potential risk of fetal loss. Uncontrolled complement activation is 
prevented in successful pregnancy by the three regulatory proteins DAF, MCP and 
CD59 positioned on the surface of trophoblasts (455, 457).  
Excessive complement activation in the placenta places the fetus at risk for growth 
restriction or death. The embryonic letality observed in Crry-deficient mice supports 
the critical role of the complement regulatory proteins in preventing complement-
dependent fetal loss (1545). There is some indication that an altered complement 
regulation can cause and may perpetuate complications of pregnancy in women, for 
example in RSA patients (188, 284, 455), although the data need to be confirmed 
and extended. What is clear is that antibody-induced complement activation can 
overcome the protective function of the complement regulatory proteins and may be 
responsible for tissue damage. This situation is encountered in several patients 
with RSA associated with the presence of APAs (456). 
 
On the other hand, there is the lower ratio of asymmetric/symmetric IgG antibodies 
in women with RSA compared to healthy women (351). Some investigators consider 
that the lower levels of the non-precipitating asymmetric-type of antibodies in RSA 
patients that would allow immunological tolerance are the major determining factor 
for unsuccessful pregnancy. This still has be investigated further.  
 
The immunmodulation of progesterone and the antiabortive effect of PIBF are also 
part of the immunological theory behind RSA. In recurrent spontaneous aborters 
and women showing clinical symptoms of threatened preterm pregnancy 
termination, PIBF expression and the percentage of PIBF+ lymphocytes and PR+ 
immune cells was found to be significantly lower than in healthy pregnant women 
(343, 485, 1374). PIBF which is stimulated by progesterone leads to the inhibition 
of NK cell activity, enhancement of asymmetric antibody production (1375) and 
induction of the Th2 response, especially IL-10 (485).  
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Interestingly, also stress has been shown to influence number of decidual mast 
cells, CD8+ T cells and TNF-α expression in women with RSA (41, 42, 43). Also the 
expression of PIBF was decreased by a higher maternal stress perception (624). 
Psychotherapy has also been reported to result in successful pregnancy outcome in 
patients with a history of RSA in one study (1362). Furthermore, relaxation therapy, 
another strategy to improve stress-management, has been shown to decrease 
peripheral levels of TNF-α (1483). Therefore, women with recurrent pregnancy loss 
who received psychological counselling may have a better power to manage stress, 
resulting in decreased levels of abortogenic Th1 cytokines, such as TNF-α (43).  
 
To conclude, improper immune responses and an unbalanced cytokine network 
may be related to implantation failures, pregnancy loss and obstetric complications. 
The presence of elevated Th1/Th2 cell ratios, high concentrations of Th1 cytokines 
secreted by PBMC, elevated NK cell cytotoxicity and levels, and emergence of 
various autoantibodies are supporting evidence. The underlying immunopathology 
still need to be investigated but recent data have brought up the induction of 
procoagulant fg12 by Th1 cytokines as one probable mechanism (232, 234, 235, 
723). 
3. Immunology of infertility 
Approximately 10-20% of couples suffer from infertility, defined as unprotected 
intercourse for 12 months without conception (1148). In addition, recurrent 
pregnancy loss, generally defined as three or more consecutive pregnancy losses 
before 20 weeks gestation, may occur in as many as 2% of child-bearing women. A 
thorough evaluation of the infertile couple will demonstrate no explanation for 
infertility in approximately 10% of cases, whereas the evaluation of RSA will 
demonstrate no cause in as many as 60% of cases. 
This “unexplained” reproductive failure can be influenced by some immunological 
abnormalities, similar to the causes described for RSA (225); therefore, the term 
immunological infertility has been created (747).  
Both reproductive failure and infertility in association with immunological 
disturbances has been recognized for decades but only recently has it been 
demonstrated that certain characteristic autoantibodies seem to be involved.  
 
Recent attention has focused on a range of immunological tests for the infertile 
couple based on the hypothesis that a portion of unexplained infertility and results 
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from immune-mediated reproductive failure (1434, Table 40). The immunological 
tests purport to identify autoimmune abnormalities, i.e. APA, ATA, ASA or more 
generalized immune defects, i.e. a NK cell dysregulation, which are postulated to 
cause reproductive failure.  
 
Antiphospholipid antibodies (anticardiolipin, antiphosphatidyl antibodies) (APA) 
Lupus anticoagulant 
Antisperm antibodies (ASA) 
Antithyroid antibodies (ATA) 
Antinuclear antibodies (ANA) 
Anti-smooth muscle antibodies (SMA) 
Embryotoxicity assay 
NK cells 
Table 40: Immunological tests in fertility practice 
However, this has to be seen critical due to several reasons.  
Precise mechanisms by which these alloimmune or autoimmune disorders 
contribute to infertility remain to be established. Furthermore, there is considerable 
variability in the methodologies utilized, the validity, and the standardization for 
many of the mentioned tests (652). Similarly, the interpretation of test results is 
inconsistent. Moreover, the rationale for good testing in clinical practice should 
include the ability to secure a diagnosis and to guide clinical decision-making and 
treatment plan. 
 
Presence of organ-specific auto-antibodies to testicular antigens and sperm, or 
antibodies to ZP (655, 678) and endometrial antigens (113, 960), are considered 
possible causes of infertility in a fraction of patients with unexplained infertility 
(1442).  
Except for some cases of POF, the relationship between anti-ovarian autoimmunity 
and reproductive failure remains controversial (960). It is even more difficult to 
ascertain a causal relationship between AOAs and other ovarian pathologies, 
especially infertility, in patients who have not yet presented with clinical signs of 
ovarian failure. Currently, several studies suggest a possible role of autoimmunity 
in these cases of recurrent reproductive failure, but the levels of evidence are low 
maybe due to the multiplicity of antigenic targets in the ovary. 
ASA are present in infertile male and female (126, 270, 1295) as well as in fertile 
individuals (533, 1049) indicating that there are not necessarily causing infertility.  
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Causes for ASA formation include trauma, surgery (128, 533) and gynaecologic 
infections (283, 872) in both sexes. 
ASA are considered to be one of the main causes of immunological infertility by 
binding to the sperm membrane and impairing sperm functions (554). They have 
been shown to reduce fertilization rates (305), decrease sperm motility (128, 917, 
1296, 1522) and may inhibit capacitation and acrosome reaction (109, 996, 1486). 
 
Methods used to reduce ASA production include condoms (893) and systemic 
corticosteroid treatment whose effects are ambiguous (494). Separation and 
washing techniques (8, 418, 1511) are not very promising as well. Concerning ART 
in treatment of ASA-positive infertility, the most capable procedure seems to be ICSI 
(747, 999, 1013) compared to IUI (207), GIFT (1439) and IVF (1013). However, it is 
difficult to compare the different techniques as there have not been sufficient well-
controlled data. 
 
To conclude, there is not enough evidence to support the use of systemic 
immunosuppressive methods to treat ASA. However, there are promising animal 
data that suggest that ASA formation may be prevented by prompt antibiotic 
treatment in the case of suspected genital tract infection in men (893). The use of 
ART in many couples with ASA and unexplained infertility is beneficial because it 
minimizes impaired gamete recognition and fusion. 
 
However, the presence of other autoantibodies, which are not particularly organ-
specific, such as APA, ATA, ANA or SMA have recently been increasingly implicated 
in immunological infertility (460, 1442). Both aPS and antibodies against β2-
glycoprotein have been shown to be directly pathogenic to trophoblast (765, 901). 
Several studies on infertile patients after repeated reproductive failure showed that 
40 to 80% had at least one abnormal result in autoantibody testing (927, 1148, 
1184, 1540). However, several studies had no control group measured and if they 
did, autoantibodies were also observed in control sera but at lower percentages 
(1184, 1540). 
The association of APAs with RPL (1550) has led investigators to explore a role for 
such antibodies in unexplained infertility. The thrombogenic nature of these 
antibodies has been postulated to interfere with implantation, placentation, and the 
normal vascular perfusion of the developing embryo. 
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Data on the prevalence of APA in infertile patients must be interpreted based on the 
numbers of autoantibodies tested, the availability of assay controls, the use of non-
standardized test modalities, patient inclusion criteria and variable ranges selected 
to distinguish normal from abnormal test values. The prevalence of serum APAs in 
the general population has been reported to be 1-3% (364) Taylor et al. reported 
increased ACA levels in 17% of infertile patients versus 6% of the control group 
(1400). When restricting analysis to fertility patients being treated with IVF, the 
prevalence of APA was consistently higher (6–38%) than in control populations 
(when available) consisting of normal parous women (highest prevalence 3.5%) 
(652).  
The consistent observation has been an increased prevalence of APA in the infertile 
population, especially demonstrated in IVF patients. The essential question has 
been whether these autoantibodies cause infertility or IVF failure, or simply 
represent serum markers associated with infertility.  
Similar results have also been obtained from studies on the prevalence of ATA, ANA 
or SMA (446, 447) in infertile patients but it remains difficult to draw conclusions 
due to small patient numbers and lack of control groups. 
Therefore, the use of APA testing in fertility practice is not clear by current data, as 
well as there is no compelling evidence that testing for ANA, ATA, or SMA in routine 
clinical practice is relevant to the diagnosis or treatment of otherwise unexplained 
infertility. 
 
There is also increasing evidence that an abnormal immunophenotype including a 
high NK cell count may be one of the causes of recurrent abortion and repeated 
fertilization failures.  
A study by Fukui et al. showed that an increased blood NK cell cytotoxicity level 
was associated with recurrent failed implantation after IVF treatment (430). 
Beer et al. reported that there were not live births in the group of women with 
multiple failed in IVF cycles and women with the history of RSA which had the 
percentage of blood NK cells 18.0% or higher (94). Risk factors for immunologic 
implantation failure associated with a negative pregnancy test after IVF reported in 
the literature have included APA, ANA, and ATA, embryotoxic factors detected by an 
embryotoxicity assay, and elevated levels of circulating NK cells (645). 70% of 
women with IVF failure had at least one risk factor.  
More recent studies have focused on elevated CD69 expression on NK cells as being 
associated with RSA and infertility of unknown etiology (263). As described by 
Thum et al., CD69 is a triggering molecule on activated NK cells that is capable of 
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inducing cytotoxicity and stimulating cytokine production (1415). In this study, 
women with high CD56dimCD16+CD69+ in peripheral blood had reduced 
implantation rates and higher miscarriage rates. 
 
Taken together, the results of the multiple investigations suggest that there are 
alterations in the NK cell population in women with RSA or infertility. However, 
whether NK cells are increased or decreased depends on whether peripheral blood, 
endometrium or first-trimester decidua is analyzed and the timing of sampling with 
respect to menstrual cycle or pregnancy (776). Data fail to distinguish if the 
difference in activity and number of NK cells is a cause or effect of reproductive 
failure.  
Further studies, however, are needed to investigate if the composition of NK cells is 
critical in implantation and what might be the options for intervention aimed at NK 
cells in reproductive failure as discussed further down. 
 
 
Different approaches in therapy of immunological infertility and recurrent 
miscarriage have been used and evaluated. Before effective treatment can be 
instituted, the cause of pregnancy loss must be determined. Once this has been 
determined, the most suitable therapy can be recommended and applied.  
The most common include heparin plus aspirin, aspirin alone, IVIG administration 
and immunization with allogenic lymphocytes. There should be no doubt, that 
immunotherapy seems to be an effective treatment of women with the history of 
RSA and combined immune abnormalities. Recently, Jerzak et al. have used 
heparin/aspirin, aspirin alone, steroids, IVIG and alloimmunization or combined 
therapy for the treatment of women with RSA, where he observed 80.5% success 
rate in immunized women (622). 
 
Without doubt, the most experience exists with a combination therapy of low 
molecular weight heparin and aspirin in women with repetitive implantation failure. 
Especially, in women with APA and RSA, it is currently the most recommended 
treatment form (1416, 1540). Several studies show the effectiveness of this therapy 
(166, 1293), also compared to aspirin alone (1162). This therapy may not only be 
effective, but also less costly, and logistically simpler to provide than other 
treatment options. Possible side effects such as decrease in bone density due to 
heparin could be neglected (69).  
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Würfel also reported an increasing role of steroids, above all prednisone, in the 
treatment of recurrent implantation failure, especially together with heparin (1540). 
His experience showed a clear benefit in patients with a high autoimmune activity, 
as presented by high numbers of NK cells or an increased Th1/Th2 ratio. However, 
there also have been plaebo-controlled studies showing that prednisone and aspirin 
was not effective in promoting live birth and even increased the risk of prematuity 
(788). To evaluate this correctly, more data from placebo-controlled, randomized 
studies seem to be necessary.  
 
The use of IVIG may be restricted to patients with RSA despite conventional 
treatment with heparin/aspirin (1071, 1416). It has also been suggested for use in 
RSA cases with various serum autoantibodies which suggest autoimmunity or a 
high increase in NK cell numbers indicating high autoimmune activity (1540).  
 
However, IVIG therapy still remains controversial. In some trials with IVIG, the lack 
of a control group made it impossible to evaluate the apparently favourable effect 
(768, 1365, 1367). So far, there have been published several placebo-controlled 
trials studies on IVIG therapy with over 300 treated RSA patients. Of those studies, 
only two showed a possible significant benefit of IVIG treatment in women with 
recurrent miscarriages (227, 261), while other studies have failed to confirm this 
beneficial effect compared to placebo treatment (228, 607, 1411, 1350). Results 
from trials showing a positive effect of IVIG present a live birth rate between 60-
85%.  
 
A lack of standardization of IVIG trial design has made their comparison virtually 
impossible and contributed to the ongoing controversy over IVIG therapy. Major 
differences were found in patient selection and timing of IVIG regimens. Generally, 
an evaluation of IVIG therapy may be difficult as different authors propose different 
indications or no exact indication for IVIG. Patients from different populations with 
different diagnoses are included in the study groups, making the comparison of 
results almost impossible. Trials differed in the numbers of previous miscarriages 
and in the number of patients with RSA after one birth. Concerning treatment 
protocols, the trials show great diversity with regard to starting time of treatment, 
number of infusions and amount of IVIG given. 
Moreover, additional therapies including aspirin/heparin are often added, and the 
number of patients included in the studies might be too low to detect any 
significant effect of IVIG. 
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Searching for possible reasons, a review showed that factors associated with 
successful use of IVIG were an older mean patient age, initiation of IVIG therapy 
prior to conception and repeated intervals of IVIG during pregnancy (1366).  
 
IVIG exhibits a documented effect in many immunological disorders. 
Immunomodulation by IVIG is thought to result from passively transferred blocking 
or anti-idiotypic antibodies (201), downregulation of B cell function, inhibition of 
complement activation (477, 968), reduction of NK cell activity (968, 1196) and shift 
of Th1/Th2 ratio to Th2 (477). However, studies detected no statistical differences 
in the presence of the blocking antibodies prior to pregnancy in RSA women treated 
with IVIG compared to controls (605). The long-term effect of IVIG on T and B cell 
subsets in women with RSA also seems unsure (606).  
It seems obvious that IVIG are capable of reducing high concentrations of NK cells 
in peripheral blood with a short and long-term efficacy. This was confirmed in a 
recent study by Perricone et al. (1111). The same group also supposed a positive 
effect of IVIG on GM-CSF levels (1110) which are usually very low in pregnant RSA 
patients  
 
Appropriate patient selection and valid timing of IVIG administration seem to be 
crucial factors that determine the success of this treatment. IVIG therapy appears 
to be safe and effective especially for older women with recurrent failure of natural 
or IVF-induced pregnancy or recurrent aborters with elevated NK cell activity. 
Monthly administration of low-dose IVIG initiated prior to conception and 
continuing through the end of the second trimester of pregnancy appears to be the 
optimal treatment regimen. 
IVIG has been associated with some undesirable side effects (1551); it is costly and 
the long term effects of its use remain to be confirmed. Further experiments should 
be carried out with large sample sizes both for experimental and placebo treatments 
and more exactly defined patient groups and IVIG regime. 
 
Immunotherapy with allogenic leukocytes attempts to block immunological 
rejection of the fetus by exposing the mother to an overload of self or third party 
antigen. This is thought to mimic the presentation of fetal antigens during 
pregnancy presumably illiciting maternal Ig effectors that are believed to be 
necessary for maintenance of pregnancy (1050). 
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Various recent studies demonstrated that paternal lymphocyte immunization in 
women with RSA induce the level of humoral antibodies correlating with the 
success of pregnancy like APCA, Ab2 and MLR Bf (1054, 603, 1069). 
 
Würfel pointed at the fact that the effect of this therapy seems to be rather 
inspecific and independent of HLA-sharing (95) as HLA-investigations in several 
studies indicated. Benefits of this therapeutic approach rather seem to be a short-
term suppression of NK cell activity and numbers, a decrease in Th1/Th2 ratio and 
a increase of PR on lymphocytes (767, 433, 206). Progesterone also decreases NK 
cells in peripheral blood. 
 
Data on the efficacy of this immunotherapy remain controversial with several of the 
published results of randomized allogenic lymphocyte immunotherapy for women 
with RSA showing no significant effect whereas others do. The problem is on the 
one hand, that most of the trials with positive results have been non-randomized 
and clinical data were not complete. On the other hand, it was suggested that there 
are some other factors such as the number of previous miscarriages, presence of 
prior live births, and time of conception after immunization and patient`s age which 
may also influence the outcome of pregnancy. 
 
Pandey et al. recently preformed a meta-analysis of various randomized and non-
randomized clinical trials for lymphocyte immunization in women with RSA (1073). 
Women with RSA who received paternal lymphocytes were considered as study 
group and those who received autologous lymphocytes, third party lymphocytes and 
normal saline were considered as control group. Comparing the success rate in 
pooled data of trials, a success rate of 67% in paternal lymphocytes immunized 
women with RSA under study group as compared to 36% success rate in women 
with RSA of control group was found.  
 
These data showed the efficacy of paternal lymphocyte immunotherapy as a 
therapeutic approach for the treatment of women with RSA (1073). However, 
despite these promising numbers, the point of the small sample size and lack of 
control groups in several studies has to be made. Moreover, women randomized to 
immunotherapy tended to be older and reported to be at higher risk of RSA than 
those randomized to control groups. 
The use of allogeneic lymphocyte immunization using partner or third party 
leukocytes in new meta-analyses of the Cochrane databases was found to be 
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associated with an odds ratio of 1.23 (12 trials on 641 women) and 1.39 (3 trials on 
156 women), respectively (1139). Both thus provided no significant effect over 
placebo in improving the live birth rate, similar to IVIG with an odds ratio of 0.98. 
Three authors independently evaluated randomized, placebo-controlled studies with 
well-defined treatment criteria and patients.  
In addition, lymphocyte immunotherapy has been associated with some adverse 
side effects such as erythrocyte sensitization, thrombocytopenia and IUGR among 
others (1050). 
 
They have also come up other treatment options for immunological infertility such 
as dehydrogesterone, VD3 and the leukocytic ultrafiltrate LNCC. Present situation 
shows that they all have to be evaluated differently. 
LNCC has been approved for the treatment of immunologically-based RSA and 
recently also for repetitive implantation failure (1540) and placebo-controlled, 
single- and multicenter studies have shown positive results (1541). 
VD3 is thought to influence the Th1/Th2 ratio but its mechanisms are not 
completely understood (1120). The proposal to use it as an effective immunotherapy 
in women with RSA has to be evaluated in well-controlled studies first. 
A similar effect is aligned to dehydrogesterone (1161) which acts through PR and 
also showed to induce production of PIBF (647). Studies on animals and humans 
indicate its pregnancy-maintaining effects (850, 366).  
However, there is still a need for more controlled, blinded and randomised clinical 
trials in order to draw firm conclusions as to the usefulness of dydrogesterone in 
women with a history of recurrent miscarriage. 
4. Immunocontraceptive approaches 
A continuing population explosion and unintended pregnancies continue to pose 
major public health issues worldwide. The world population currently increases by 
1 billion every 12 years; 95% of this growth takes place in the developing nations.  
In the USA, half of all pregnancies are said to be unintended, which results in more 
than 1 million elective abortions annually (484).  
Better education regarding women`s health issues and enhanced contraceptive 
development are necessary to impact this problem. Contraceptive vaccines may 
provide viable and valuable alternatives to the presently available methods of 
contraception. 
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The molecules that are currently being explored for development of 
immunocontraceptives either target gamete production, such as anti-GnRH and 
anti-FSH vaccines, gamete function, such as anti-sperm and anti-oocyte ZP 
vaccines, and gamete outcome, such as anti-hCG vaccines (1009). 
 
A GnRH-based vaccine would be usable in both sexes and as its primary structure 
is largely conserved in mammals, rodents can be employed as a homologous model 
for efficacy and safety. Enough data have accumulated to conclude that 
immunosterilizing GnRH-based vaccines can be effectively employed in various 
animal species without side-effects (505, 941, 1389, 1577).  
However, generating antibodies against GnRH may have wide-ranging consequences 
leading to a block in the secretions of pituitary gonadotropins and may therefore 
not be acceptable for fertility inhibition in humans. For example, the inhibition of 
testosterone secretion complicates the potential use of GnRH vaccines in man 
where androgen supplementation would be required in order to maintain secondary 
sexual characteristics and libido (394). 
Also the main research field concerning application of anti-GnRH vaccines in 
humans is not contraception, but the treatment of prostate cancer and other 
estrogen-dependent conditions.  
Concerning anti-FSH vaccines, early clinical trials on males have not proven to be 
as successful as expected after quite encouraging results in monkeys (981, 982). 
One has to remark that it has still not been confirmed that spermatogenesis in 
humans is dependent on FSH (1238). 
 
The revelation that ASA are frequently associated with unexplained infertility 
prompted several researchers to identify the immunocontraceptive potential of 
spermatozoa-specific antigens.  
It has to be considered that the selection of a certain sperm antigen for the 
development of a contraceptive vaccine is limited by its specificity, participation in 
the fertilization process and its potential to induce a high sperm-specific antibody 
titer in the genital tract (332). 
As no single predominant target of polyclonal ASA but a number of sperm proteins 
have been identified (796, 931, 1015, 1254, 1283), an effective 
immunocontraceptive vaccine would be probably consisting of several specific 
antigenic epitopes included in a single formula.  
Active immunization studies on animals with some of these antigens, for example 
FA-1 and SP-17, has been shown to reduce fertility in vivo (1009). To date, no single 
  Discussion 
 III-390  
antigen has been shown to cause a 100% fertility reduction in the mouse model 
which may be due to the inherent nature of the model and the involvement of 
multiple antigens in the fertilization cascade. Another reason may be that 
vaccination with no single antigen has raised enough antibody titer, especially in 
the local genital tract, to completely block fertility. 
However, it is interesting to note that several studies have observed a complete 
block of fertility in a few mice after immunization with a single antigen. It is 
possible that these animals develop a high cell-mediated immune response besides 
antibody response that also has a deleterious effect on sperm or oocyte function.  
Immunization with several antigens does cause induction of cell-mediated immune 
response and production of cytokines such as TNF-α and IFN-γ (1010) which have 
deleterious effects on sperm and embryos (1011). Thus, to enhance the efficacy of a 
vaccine, it may be important to induce both the cell-mediated as well as humoral 
immune responses.  
DNA vaccination may provide a solution but a DNA vaccination approach has not 
been examined for a sperm antigen (1009). In other systems, it has already been 
reported that DNA vaccination favours memory and cell-mediated response rather 
than effector B-cell response (791). 
To conduct phase I and II multicenter clinical trials in a quality-controlled manner, 
the antigens have to be either recombinant or synthetic molecules. Synthetic sperm 
peptides (510, 796, 1008) were already tested in animals with ambiguous results. 
Perhaps monospecific antibodies to sperm antigens may be combined for 
immunocontraceptive purposes in the form of intravaginal sperm-specific 
spermicides (332). A first recombinant miniantibody has been already engineered to 
the tissue-specific carbohydrate epitope located on the sperm glycoform of the 
CD52 antigen (331) and shown to agglutinate human sperm cells in a tangled 
pattern (1028). The S19 mAb was shown to immobilize sperm in the presence of 
complement, agglutinates sperm, and blocks sperm interaction with the zona 
pellucida.  
The functional findings and the demonstration of the male reproductive tract-
specificity of the S19 epitope on the CD52 glycoprotein serve as further indications 
that both the S19 mAb and its unique carbohydrate cognate epitope are strong 
candidates for vaccine development (1029). 
 
Due to fact that ZP glycoproteins play a critical role in successful fertilization, they 
have become promising candidate antigens for contraceptive vaccines.  
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First, porcine ZP glycoproteins became the antigens of choice because of their 
immunological cross-reactivity with the ZP of various species including humans. 
However, ZP glycoproteins from a native source may be contaminated with other 
ovarian-associated proteins as shown in animal studies (1530), which may be 
prevented by the use of highly-purified porcine ZP (70) or recombinant proteins 
(472).  
Further approaches include the use of live recombinant vectors, DNA vaccines or 
synthetic peptides (825, 1544, 492)  
Despite of quite promising results, there is the need for long-term active 
immunization studies, before these ZP glycoproteins can be considered for human 
application. 
 
Finally, the most promising candidate for development of an immunocontraceptive 
vaccine for females is hCG as it is synthesized pregnancy-specific after fertilization 
and judged crucial for the establishment and maintenance of pregnancy at east 
during the first weeks of gestation.  
After extensive and promising animal studies with hCG linked to TT, clinical trials 
have led to variable antibody titers among women (1390). A more immunogenic 
formula finally resulted in the induction of sufficiently high antibody titers in 60-
80% of the immunized women of a phase II trial (1391).  
This vaccine against hCG is the first and only birth control vaccine to go through 
phase II efficacy trials successfully. It is devoid of side-effects showing no bleeding 
irregularity, and women keep ovulating normally, produce their own sex hormones 
and have regular menstrual cycles. The fact that luteal phase did not lengthen in 
vaccinated women provided confirmation that anti-hCG antibodies prevent 
implantation of the embryo onto the endometrium; interception is therefore before 
the onset of pregnancy. However, the degree of efficacy is highly satisfactory for 
vaccines against infectious diseases but a birth control vaccine has to be effective in 
about 90-95% of recipients in order to be acceptable. 
A similar approach employing another anti-hCG vaccine was abandoned due to 
adverse side effects after promising animal and phase I studies (1009). 
Therefore, there is still the need to improve immungenicity of this hCG vaccine by 
incorporating more adjuvants using other carrier proteins instead of TT. Pilot 
studies have shown that the conjugation of β-HCG to various peptides not only 
enhances the quantum of immune response compared to β-hCG conjugated to TT 
but also assures antibody response in mice of different genetic background (490). 
Furthermore, cross-reactivity with LH has to be reduced. 
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The application of contraceptive vaccines in humans still needs further 
investigation and development. The identification and use of novel target candidates 
that are crucial for gametogenesis, fertilization and implantation will take more time 
and effort. Another major challenge will be to increase the immunogenicity of 
contraceptive vaccines to generate antibody levels in 100% of the recipients.  
Furthermore, it is unlikely that a clearly defined common length of protection can 
be obtained. 
One could also argue that systemic immunisation is not an appropriate, effective or 
reliable means of eliciting an optimal immune response in the female reproductive 
tract. Alternative routes of immunisation, which are likely to promote mucosal 
immune responses in the reproductive tract, for example nasal immunisation, may 
offer an effective and acceptable approach to human immunocontraception in the 
future. 
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IV. Summary-Zusammenfassung 
The objective of this work was to systematically review and discuss recent studies 
and articles dealing with the subject of the immunology of female genital tract 
mucosal tissue.  
The emphasis hereby lies on the evaluation of studies concerning the basics of 
female reproductive immunology, research on immunology of the most important 
genital infections and vaccination strategies, immunologic principles at the 
fetomaternal interface during normal pregnancy and its complications as well as on 
immunologic data on infertility and immunocontraception.  
 
It is now established that the mucosal immune system is a distinct and separate 
component of the host`s immune apparatus and differs from the lymphoid tissues 
in peripheral sites. Furthermore, despite some common features, the female genital 
tract mucosal system displays some distinct characteristics which outlines its 
special role.  
Analysis of the female genital tract indicates that the key cells of the innate and 
adaptive immune systems are present and functionally responsive to antigens; 
however, there is a certain degree of compartmentalization within the tract. The 
identification of TLRs in the fallopian tubes, uterus, cervix, and vagina and the 
presence of ECs, macrophages, DCs, NK cells, and neutrophils throughout the 
reproductive tract along with their responsiveness to selected PAMPs indicate that 
the female reproductive tract has evolved to meet the challenges of STDs, while at 
the same time supporting an immunologically distinct fetal placental unit. To meet 
these diverse challenges, innate and adaptive immune system in the female genital 
tract are precisely regulated not only by a network of cytokines and chemokines, 
but also by the sex hormones estrogen and progesterone.  
 
Understanding the specialty of the genital tract immune system is of critical 
importance, because STDs are and will be a major worldwide health problem. 
Despite extensive efforts, only limited success has been achieved in dealing with a 
growing list of STDs.  
The role of immune factors in the control of genital viral and bacterial infections 
appears complex and needs further studying, also with respect to creating vaccines. 
Despite the recognition that innate immunity as the first line of defense and 
adaptive immunity, especially Th1 immune responses, play a critical role in 
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preventing infection and in limiting viral replication, factors such as antimicrobials 
and TLRs that contribute to the mucosal response in the female genital tract have 
only recently begun to receive attention. Further studies are also needed to 
elucidate the relationship between mucosal immunity, the hormonal environment, 
and response to pathogen challenge. More data must be collected on the 
mechanisms of immune evasion by several pathogens such as HSV, N. gonorrheae 
or Chlamydia. While considerable information can be obtained from animal 
experiments, important differences in the physiology of reproduction and the 
immune sytem result in the need for studies in humans. 
 
Further knowledge on female tract immunology will also impact on immunological 
approaches to contraception, immunological infertility and the immunological 
aspects of pregnancy. This does not only involve new options for diagnostics but 
also for treatment of pregnancy complications such as preeclampsia, preterm birth 
and early pregnancy loss as well as for infertility. 
Pregnancy involves maternal tolerance of the semiallogenic histoincompatible fetus 
and is characterized by the enhancement of the innate immune system and 
suppression of the adaptive immune response, probably with progesterone as the 
important regulator. In opposite to normal pregnancy, improper immune responses 
and an unbalanced cytokine network may characterize implantation failures, 
pregnancy loss and obstetric complications. These are the presence of elevated 
Th1/Th2 cell ratios, high concentrations of Th1 cytokines, elevated NK cell 
cytotoxicity and levels, and emergence of various autoantibodies. 
These immunological approaches needs to be investigated and evaluated further 
with respect to widening of treatment options by modification of immune responses. 
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Das Ziel dieser Arbeit war es, eine systematische Literaturübersicht über die 
aktuelle Studienlage zum Thema „Immunologie im weiblichen Reproduktionstrakt“ 
zu erstellen. 
Die Schwerpunkte liegen dabei zunächst auf der Zusammenfassung und Bewertung 
von Studien, die die Grundlagen zur Immunologie der Scheide beschreiben. Des 
weiteren soll ein Überblick über die Forschung hinsichtlich der Immunologie der 
wichtigsten Genitalinfektionen und neuesten Impfstrategien gegeben werden. 
Aktuelle Studien zu den immunologischen Grundlagen der normalen 
Schwangerschaft, Schwangerschaftskomplikationen sowie Infertilität und 
Immunokontrazeption werden zusammengefasst und diskutiert. 
 
Es gilt heute als gesichert, dass das Immunsystem der Schleimhäute einen 
eigenständigen und unabhängig funktionierenden Teil der menschlichen 
Immunabwehr darstellt und sich von der systemischen Immunabwehr vielfach 
unterscheidet. Das Immunsystem des weiblichen Reproduktionstrakt weist zudem 
noch einige spezielle Merkmale auf, die seine Sonderstellung unterstreichen.  
Untersuchungen des weiblichen Genitaltrakts deuten an, dass die Schlüsselzellen 
der angeborenen und erworbenen Immunität vorhanden sind und auf Antigene 
reagieren, auch wenn es gewisse Unterschiede zwischen einzelnen Kompartmenten 
gibt. Die Identifizierung von TLRs in Eileiter, Uterus, Zervix und Vagina sowie das 
Vorhandensein von für ausgewählte PAMPs empfängliche Epithelzellen, 
Makrophagen, dendritische Zellen, natürliche Killerzellen und neutrophile 
Granulozyten im gesamten Reproduktionstrakt unterstreicht, dass der weibliche 
Genitaltrakt sich sowohl den immunologischen Herausforderungen durch sexuell 
übertragbare Krankheiten stellen, als auch gleichzeitig die immunologische 
Abstoßung des Fetus während einer Schwangerschaft verhindern kann. Um diese 
vielfältigen Aufgaben zu gewährleisten, wird das angeborene und erworbene 
Immunsystem im weiblichen Genitaltrakt sowohl durch ein Netzwerk an Zytokinen 
und Chemokinen als auch durch die Sexualhormone Östrogen und Progesteron 
genauestens gesteuert. 
 
Die immunologische Sonderstellung des weiblichen Genitaltrakts ist von besonderer 
Bedeutung im Hinblick auf die stetig wachsende Bedeutung von sexuell 
übertragbaren Krankheiten weltweit. Trotz intensiver Forschung ist der Erfolg in 
der Behandlung einer stetig wachsenden Zahl von sexuell übertragbaren 
Erkrankungen begrenzt. 
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Die Bedeutung von Immunfaktoren in der Kontrolle von viralen und bakteriellen 
Genitalinfektionen erweist sich als komplex und bedarf weiterer Erforschung, 
besonders im Hinblick auf die Entwicklung von Impfstoffen. Trotz der Erkenntnis, 
daß angeborene Immunität als erste Abwehrlinie und erworbene Immunität, 
insbesondere eine Th1 Immunantwort, eine entscheidende Rolle in der 
Infektabwehr im weiblichen Reproduktionstrakt spielen, sind Einflüsse durch 
antimikrobielle Faktoren oder TLRs erst seit kurzem Gegenstand der Forschung. 
Weitere Untersuchungen hinsichtlich der Beziehung zwischen Immunität, 
hormonellen Einflüssen und der Antwort auf Pathogene sind notwendig. Zu 
Mechanismen von verschiedenen Pathogenen wie HSV, N. gonorrheae oder 
Chlamydia., der Immunabwehr zu entgehen, müssen ebenfalls weitere Daten 
erhoben werden. Obwohl Tierexperimente beachtliche Informationen liefern, 
erfordern erhebliche Unterschiede in der Reproduktionsphysiologie und des 
Immunsystems zwischen Tier und Mensch weiterführende Studien am Menschen. 
 
Erkenntnisse über die Immunologie des weiblichen Genitaltrakts beeinflussen 
ebenso die Forschung über Immunokontrazeption, immunologische Infertilität und 
die fetomaternale Immunität während der Schwangerschaft. Dies beinhaltet nicht 
nur neue Möglichkeiten in der Diagnostik, sondern auch neue Therapieoptionen für 
Schwangerschaftskomplikationen wie Präeklampsie und Frühgeburtlichkeit oder 
Infertilität. 
Schwangerschaft bedeutet den Schutz des semiallogenen histoinkompatiblen Fetus 
vor Attacken des mütterlichen Immunsystems und ist charakterisiert durch eine 
Aktivierung des angeborenen Immunsystems und Supprimierung der adaptiven 
Immunantwort, was vermutlich durch das Hormon Progesteron mitgesteuert wird.  
Im Gegensatz zur normalen Schwangerschaft wird vermutet, dass Infertilität, 
Schwangerschaftsabbruch und geburtshilfliche Komplikationen durch 
unangemessene Immunantworten und ein Ungleichgewicht an Zytokinen 
gekennzeichnet sind. Dazu zählen unter anderem eine erhöhte Th1/Th2 Zellratio, 
hohe Konzentrationen von Th1 Zytokinen, erhöhte Spiegel und Zytotoxizität der 
natürlichen Killerzellen, sowie das Auftreten von verschiedenen Autoantikörpern. 
Diese immunologischen Erkenntnisse bedürfen weiterer Studien, um neue 
Therapieansätze durch Modulation der Immunantwort zu entwickeln. 
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V. Abbreviations 
aCL Anticardiolipin antibodies 
aPS Antiphosphatidylserine antibodies 
Ab2 Antiidiotypic antibodies 
ADCC Antibody-dependent cellular cytotoxicity 
AIDS Acquired immunodeficiency syndrome 
ANA Antinuclear antibodies 
APA Antiphospholipid antibodies 
APCA Antipaternal cytotoxic antibodies 
APC Antigen-presenting cell 
ART Assisted reproduction technology 
ASA Antisperm antibodies 
ATA Antithyreoid antibodies 
BV Bacterial vaginosis 
CD Cluster of differentiation 
cDNA Complementary DNA 
CEACAM Carcinoembryonic antigen-related adhesion molecule 
CIN Cervical intraepithelial neoplasia 
COPV Canine oral papillomavirus 
COX Cyclooxygenase 
CpG Cytosine-phosphatidyl-guanine 
CRVVC Chronic recurrent vulvovaginal candidiasis 
CTB Cholera toxin B subunit 
CTL Cytotoxic T lymphocytes 
CVL Cervicovaginal lavage 
CVS Cervicovaginal secretion 
DC Dendritic cell 
DHEA Dehydroepiandosterone 
DISC Disabled infectious single cycle 
dMPL Deacylated monophosphoryl lipid 
DNA Deoxyribonucleic acid 
DT Diphtheria toxoid 
EB Elementary body 
EBV Epstein-Barr Virus 
EC Epithelial cell 
ECP Eosinophil cationic protein 
EGF Epidermal growth factor 
EPF Early pregnancy factor 
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Eppin Epididymal protein inhibitor 
ER  Estrogen receptor 
ESP Excretory-secretory protein 
GALT Gut-associated lymphoreticular tissue 
GalCer Galactosyl ceramide 
G-CSF Granulocyte colony-stimulating factor 
FA Fertilization antigen 
FasL Fas-ligand 
FKN Fractalkine 
FSH Follicle-stimulating hormone 
GIFT Gamete intrafallopian tube transfer 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
GnRH Gonadotropin-releasing hormone 
GRO Growth-related oncogene 
HBD Human β-defensin 
HCC Hysterectomy for cervical cancer 
hCG Human chorionic gonadotropin 
HD Human defensin 
HEV High endothelial venules 
HGF Hepatocyte growth factor 
HIV Human immunodeficiency virus 
HLA Human leukocyte antigen 
HMC Human mast cell line 
HNP human neutrophil peptide 
HSIL High-grade squamous intraepithelial lesion 
hsp Heat shock protein 
ICAM Intercellular adhesion molecule 
ICI Intracervical insemination 
ICP Infected cell protein 
ICSI Intracytoplasmatic sperm injection 
iDC Immature DC 
IDO Indoleamine-2,3-dioxygenase 
IEL Intraepithelial lymphocyte 
IFN Interferon 
Ig Immunoglobulin 
IGF Insulin-like growth factor 
IL Interleukin 
IP IFN-γ-inducible protein 
IRM Immune response modifier 
ISCOM Immune-stimulating complex 
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ITAM Immunoreceptor tyrosine-based activation motif 
ITIM Immunoreceptor tyrosine-based inhibitory motif 
IUGR Intrauterine growth retardation 
IUI Intrauterine semination 
IVF In vitro fertilization 
IVIG Intravenous immunoglobulin 
JAK Janus kinase 
KAb Killer antibody 
KC Keratinocyte 
KGF Keratinocyte growth factor 
KIR Killer cell Ig-like receptor 
KTR Killer toxin receptor 
LAMP Lysosomal-phagosomal protein 
LC Langerhans cell 
LCR Long control region 
LDH Lactat-dehydrogenase 
LH Luteinizing hormone 
LHr Lutropin receptor 
LIF Leukaemia inhibitory factor 
LOS Lipooligosaccharide 
LPS Lipopolysaccaride 
LSIL Low-grade squamous intraepithelial lesion 
LTR Long terminal repeat 
M cell Membranous EC 
MAdCAM Mucosal addressin cell adhesion molecule 
MALT Mucosa-associated lymphoreticular tissue 
MAP Mitogen-activated protein 
MBL Mannose binding lectin 
MBP Major basic protein 
MCP Monocyte chemoattractant protein 
mDC Mature DC 
MHC Major histocompatibility complex 
MIF Macrophage inhibitory factor 
MIG Monokine induced by IFN-γ 
MIP Macrophage inflammatory protein 
MLR-Bf Mixed lymphocyte reaction blocking antibodies 
MT-MMP Membrane-type matrix metalloproteinase 
MOMP Major outer membrane protein 
MoPn Mouse pneumonitis 
mRNA Messenger ribonucleid acid 
  Abbreviations 
 V-400  
NADPH Nicotinamide adenine dinucleotide phosphate 
NALT Nasal-associated lymphoreticular tissue 
NF-κB Nuclear factor-κB 
NK cells Natural killer cells 
NO Nitric oxide 
ODN Oligodeoxynucleotide 
Opa Outer membrane protein 
ORF Open reading frame 
PAF Platelet activating factor 
PaKT Pichia anomala killer toxin 
PAMP Pathogen-associated molecular pattern 
PBMC Peripheral blood mononuclear cells 
PDGF Platelet-derived growth factor 
PECAM Platelet cell adhesion molecule 
PIBF Progesterone-induced blocking factor 
p.i.d. Post-infection day 
PID Pelvic inflammatory disease 
PIF Preimplantation factor 
pIgR Polymeric immunoglobulin receptor 
PK Protein kinase 
PMN Polymorphonuclear neutrophil 
POF Premature ovarian failure 
PPROM Preterm premature rupture of membranes 
PR  Progesterone receptor 
PTL Preterm labor 
RANTES Regulation upon activation, normal T cell expressed and 
secreted 
rCTB Recombinant CTB 
Rb Retinoblastoma gene product 
RB Reticulate body 
RES Reticuloendothelial system 
Rmp Reduction modifiable protein 
RNA Ribonucleic acid 
RNI Reactive nitrogen intermediates  
ROI Reactive oxygen intermediates 
RSA Recurrent spontaneous abortion 
RVVC Recurrent vulvovaginal candidiasis 
S-IgA Secretory IgA 
SC Secretory component 
SCA Steroid cell antibodies 
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SLPI Secretory leukocyte protease inhibitor 
SMA Anti-smooth muscle antibody 
SP Sperm protein 
SP-A Surfactant protein A 
STAT Signal tranducers and activators of transcribtion 
STD Sexually-transmitted disease 
SUZI Subzonal sperm injection 
TAP Tracheal antimicrobial peptide 
 Transporter associated with antigen presentation 
TCR T-cell receptor 
TER Transepithelial resistance 
TGF Tumor growth factor 
Th cells T helper cells 
TIMP Tissue inhibitor of metalloproteinase 
TK Thymidine kinase 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
Treg T regulatory cell 
TT Tetanus toxoid 
VAP Vascular adhesion protein 
VCAM Vascular cellular adhesion molecule 
VLP Virus-like particle 
VVC Vulvovaginal candidiasis 
WHO World Health Organisation 
WT Wild-type 
ZP Zona pellucida 
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